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ABSTRACT 
 
It is widely accepted that A-beta (A) generated from amyloid precursor protein (APP) 
oligomerizes and fibrillizes to form neuritic plaques in the Alzheimer’s disease (AD) brain, yet little 
is known about the contribution of APP preceding AD pathogenesis. Our data presented here 
suggest that APP has a functional role in cell cycle regulation and proliferation.  First, we demonstrat 
that APP is pathologically phosphorylated at Thr668 and that P-APP localizes to the centrosomes.  
Furthermore, P-APP is proteolytically processed in a cell cycle -dependent manner to generate its 
pathogenic metabolites.  Using Stable Isotope Labeling by Amino Acids in Culture (SILAC) and 
mass spectrometry analyses, we also show that expression of APP results in the expression of 
proliferation-associated proteins and the phosphorylation of proteins associated with cell cycle 
regulation and transcription.  Here, we demonstrate that APP expression and oligomeric Aβ42 elicit 
Ras/ERK signaling cascade and glycogen synthase kinase3 (GSK3) activation. Both ERK and 
GSK3 are known to induce hyperphosphorylation of tau and of APP at Thr668, and our findings 
suggest that aberrant signaling by APP facilitates these events. Supporting this notion, analysis of 
human brain samples show increased expression of Ras, activation of GSK3 and phosphorylation of 
APP and tau, which correlate with A levels in the AD brains. Furthermore, treatment of primary 
rat neurons with A recapitulate these events and show enhanced Ras-ERK signaling, GSK3 
activation, upregulation of cyclin D1, and phosphorylation of APP and tau. The finding that A 
 xv 
induces Thr668 phosphorylation on APP, which we show enhances APP proteolysis and Aβ 
generation, denotes a vicious feed-forward mechanism by which APP and Aβ promote tau 
hyperphosphorylation and neurodegeneration in AD.  Based on these results we hypothesize that 
aberrant proliferative signaling by APP plays a fundamental role in AD neurodegeneration and an 
inhibition of this would impede the mitotic catastrophe and neurodegeneration observed in AD. 
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CHAPTER 1:  AN INTRODUCTION TO ALZHEIMER’S DISEASE1 
 
1.1. Neuropathology of Alzheimer’s Disease 
 1.1.1. The History of Alzheimer’s Disease 
  1.1.1.1. The Historical Concept of Dementia 
 The description of senility in aged people dates back to antiquity and has been well 
documented throughout recorded history.  An understanding of dementia has evolved for over 4000 
years and began as a simple observation of the elderly to the clinical and pathological features that 
we know today.  Around 2000 BCE, ancient Egyptians were the first to document the observation 
that memory deficits were a possible consequence of aging (Boller and Forbes, 1998).  While there is 
evidence that senility is an antiquated concept, it was not until 7th century BCE that legal records 
highlighted the prevalence of dementia in society at that time.  It is likely that age related cognitive 
regression in this time was fairly common as records of amended laws by the ancient Greek Judge 
Solon took into account memory loss in advanced age as an impairment when regarding legal 
documents and wills (Berchtold and Cotman, 1998).  In the 5th and 4thcenturies BC, the Greek 
physician Hippocrates reasoned that cognitive decline was an unavoidable result of old age and this 
notion was later supported by the Greek philosophers Plato and Aristotle (Halpert, 1983).   
                                                          
1 Portions of this chapter has been legally reproduced under the Creative Commons Attribution (CC-BY) license and are 
utilized with the permission of the publisher. See Appendices B and C.  Kirouac L, Mathew M. and Padmanabhan, J. 
(2015) Interplay between Inflammation and Cell Cycle Deregulation in Alzheimer's Disease. JSM Alzheimer's Dis 
Related Dementia 1. 
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 For centuries, the correlative observation between age and memory loss was upheld.  It was 
not until the 13th century that the organ responsible for cognition was identified.  Through empirical 
methods, the Franciscan friar Roger Bacon not only identified the brain as the seat of cognition 
(previously attributed to the heart and diaphragm by ancient Greeks and Egyptians), he also mapped 
memory to a central ‘ventricle’ in the brain (Feldman, 2007).  Bacon was the first to suggest a disease 
process that affected the brain in the elderly and, consistent with his predecessors, he regarded old 
age as the home of forgetfulness (Roman, 2003).    Later in 1797, the father of modern Psychiatry 
Philippe Pinel, coined the term ‘dementia’ and was the first to provide a clinical description of the 
behavior associated with the mental disorder (Boller and Forbes, 1998).  By the mid 1800’s, British 
neurologist Samuel Wilks recognized dementia as a disease of the brain.  Wilks examined the brains 
of individuals with senile dementia and found the gross anatomical hallmarks of Alzheimer’s disease 
we recognize: substantial cortical atrophy and enlarged ventricles (Rose, 2012).  
 It is likely that dementia has existed as long as mankind.  The concept of dementia, however, 
evolved over centuries from a simple antiquated description of aged behavior to a recognized 
disease with broad clinical implications. 
  1.1.1.2. The Discovery of Alzheimer’s Disease 
 In 1901, a 51 year old woman by the name of Auguste Deter came under care of the 
German physician, Alois Alzheimer at a Frankfurt hospital (O'Brien, 1996).  Prior to admission, 
Deter’s husband had noticed a sharp decline in her mental health over a period of eight months with 
disturbed sleep pattern, memory loss, agitation and aggression (Hippius and Neundorfer, 2003).  
Upon examination, Dr. Alzheimer documented spatial and temporal disorientation, erratic behavior, 
impaired comprehension, memory deficits and aphasia (Dahm, 2006).  Tellingly, Alzheimer reports 
Deter to have remarked on her mental state, “I have lost myself” (Maurer et al., 1997).  In 1903, 
Alzheimer relocated to the Royal Psychiatric Clinic in Munich to join the renowned psychiatrist of 
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the time, Emil Kraepelin (Dahm, 2006).  During this time Auguste’s health progressively worsened 
and on April 8, 1906 Alzheimer received news that his patient had died (Maurer et al., 1997).  
Following her autopsy, Alzheimer received Deter’s brain for pathological analysis.  Upon 
examination of the brain, Alzheimer noticed substantial atrophy of the cerebral cortex and widening 
of the sulci (Shampo et al., 2013).    Histopathological alterations in the brain tissue were also 
revealed.  Alzheimer described a neuron with “several fibrils” with “characteristic thickness and 
peculiar impregnability” and within the cortex “numerous small military foci” comprised of 
“peculiar material” (Alzheimer et al., 1995).  These observations would later become known as 
neurofibrillary tangles and neuritic plaques.  On November 3, 1906, Alzheimer presented his novel 
findings in a talk entitled On a peculiar disease of the cerebral cortex  at the 37th meeting of South-West 
German psychiatrists in Tübingen, Germany (Dahm, 2006).  Alzheimer later attended to three 
additional patients with symptoms similar to Auguste Deter and found that the post mortem brains 
shared the pathologies he had noted previously:  neurofibrillary tangles and neuritic plaques.  In 
1910, Kraepelin published the 8th edition of his textbook Psychiatrie A where he introduced the term 
Alzheimer’s disease and described the clinical, anatomical and histopathological features of the 
degenerative condition we know today.           
 1.1.2. Epidemiology of Alzheimer’s Disease 
 Modern medicine in recent times has resulted in prolonged human life; increasing the 
population of elderly individuals.  Alzheimer’s disease (AD), being an age-related disorder, has 
emerged as the nation’s most important health and socioeconomic problems of the present.  
Currently, AD is recognized as the most common form of senile dementia and is ranked 6th in 
leading causes of death in the United States.  There are an estimated 5.4 million Americans living 
with AD and it is projected that by 2050, this number will nearly triple (Association, 2016).  The 
progressive nature of the disease ultimately leads to widespread synaptic dysfunction and neuronal 
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loss in cortical regions of the brain responsible for memory and cognition.  Alzheimer’s disease is a 
devastating diagnosis: there is no cure and prognosis is poor.  The implications of AD extend 
further than the individual as it is often financially and mentally devastating for patient caregivers.  
In 2015, caregivers provided 18.1 billion house of unpaid care, resulting in an economic loss of over 
2 billion dollars.  Further, in 2016 it is estimated that the national healthcare costs associated with 
AD will come to 236 billion dollars (Association, 2016).  As the aging population in America 
continues to rise, Alzheimer’s will become an unavoidable fiscal concern.   
  1.1.2.1. Prevalence  
 The occurrence of Alzheimer’s disease is strongly associated with increase in age.  Data from 
the 2010 U.S. Census corroborates this correlation.  The prevalence, or existing cases of AD, is 
about 11 percent in individuals aged 65 and older and this percentage jumps to 32 percent (roughly 
one-third) in individuals aged 85 or older (Hebert LE, 2013).  AD also appears to be more prevalent 
in woman.  Approximately two-thirds of Americans diagnosed with Alzheimer’s are woman (Hebert 
LE, 2013) and this discrepancy is thought to be due to longer life expectancy amongst females.   
  1.1.2.2. Incidence  
 The incidence, or risk of developing AD increases with age.  In 2016, there will be an 
estimated 63,000 new cases of AD in individuals aged 65 to 74, 172,000 new cases in individuals 
aged 74 to 84, and 241,000 new cases among individuals aged 85 and older (Association, 2016).  It is 
clear that the incidence rate for Alzheimer’s disease increases exponentially with age, especially in the 
7th and 8th decades of life.   
 1.1.3. Clinical Presentation of Alzheimer’s Disease 
 The clinical presentation and progression of Alzheimer’s disease spans a wide continuum 
that varies between individuals.  The rate of decline is variable between individuals and while the 
average length of survival upon diagnosis of AD is approximately 5 to 8 years, some patients can live 
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with the disease for up to twenty years (Walsh et al., 1990, Bracco et al., 1994).  Clinically, the disease 
is divided into three stages- pre-symptomatic, mild cognitive impaired (MCI) and late AD (LAD).  It 
is thought that the cognitive deficits associated with these stages directly reflect the underlying 
pathology in the brain (Nelson et al., 2009, Braskie and Thompson, 2013).  Recent evidence 
suggests, however that AD pathology develops in the brain decades before the clinical onset of the 
disease (Jack et al., 2010).  Recognized as the prodromal period of AD, MCI presents itself in the 
patient with memory deficit, language impairment, and executive function decline.  The deficits in 
this stage are subtle and often do not interfere with normal daily function.  As the disease 
progresses, symptoms worsen and there is marked cognitive and behavior changes and individuals 
become increasingly dependent on caregivers.  Episodic, semantic and procedural memory are 
affected, language and communication become impaired, and the patient is likely to become agitated 
and sometimes aggressive.  Typically at the terminal stage of the disease, patients succumb to 
opportunistic infection.            
 1.1.4. Neuropathological Hallmarks  
 From a neuropathological perspective, the gross anatomy of the AD brain exhibits 
significant cortical atrophy with widened sulci, shrunken gyri and ventricular enlargement (Unger et 
al., 1991).  On a microscopic level, there is widespread neurodegeneration and neuronal loss 
accompanied by reactive gliosis within the cerebral cortex (Villemagne, 2016).  The most striking 
histopathological change, however, is the formation and deposition of two proteins that are central 
to the disease:  tau and amyloid beta (Aβ).  
  1.1.4.1. Amyloid Plaques 
 Amyloid plaques are extracellular lesions found in the AD brain that consist of insoluble Aβ 
peptide.  Aβ, first isolated from amyloid deposits in the brain tissue and cerebral vasculature of AD 
and Down’s syndrome patients (Glenner and Wong, 1984a, Masters et al., 1985a, Masters et al., 
6 
 
1985b), is a ~4kDa (38 to 43 amino acids) peptide that is derived from the proteolysis of the 
Amyloid Precursor Protein (APP) (Dyrks et al., 1988).  Several species of this peptide exist, however 
a number of studies have found that the Aβ40 and Aβ42 species are the most abundant species 
found within the amyloid plaques (Kang et al., 1987, Mori et al., 1992, Miller et al., 1993, Roher et 
al., 1993a, Roher et al., 1993b).  Under normal conditions, Aβ is secreted in its soluble form into the 
interstitial fluid of the brain (Cirrito et al., 2003), however, under pathogenic conditions it 
precipitates to form insoluble aggregates that deposit predominantly throughout the cerebral cortex.   
   Amyloid plaques are heterogeneous in nature, varying in both size and morphology.  While a 
number of morphologically distinct types of plaques have been described, these are typically 
categorized into two groups based on positive or negative staining with Thioflavin-S and Congo red 
(Serrano-Pozo et al., 2011):  diffuse and dense-core.  Diffuse plaques are thought to be the primary 
pathogenic event in AD, as its appearance precedes other distinct AD neuropathological changes 
(Mann and Esiri, 1988, Mann et al., 1988, Mann, 1989).  Many believe these diffuse plaques progress 
over time to form dense-cored plaques, however this has never been proven.  Diffuse plaques 
account for the majority of Aβ deposits found within the AD brain (Ikeda et al., 1989a, Ikeda et al., 
1989b) and are composed of non-fibrillar, amorphous Aβ deposits that are less than 20μM in 
diameter (Kawai et al., 1992).  Diffuse amyloid plaques are Congo red and Thioflavin-S negative, but 
stain well with antibodies to Aβ (Castellani et al., 2010).   Dense-cored plaques are spherical lesions 
measuring approximately 10 to 50μM in diameter (Castellani et al., 2010), with a core comprised of 6 
to 10 nm wide filaments (Glenner and Wong, 1984b) arranged in a cross β sheet secondary 
configuration (Kirschner et al., 1986, Kirschner et al., 1987) that stains with Thioflavin-S and Congo 
red.  These plaques are typically surrounded by dystrophic neurites and reactive gliosis and 
accompanied by synaptic loss (Castellani et al., 2010).   
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  1.1.4.2. Neurofibrillary Tangles 
 Tau is a microtubule-associated protein that binds to microtubules through discrete 
microtubule-binding repeat domains (MTBRs) and is involved in microtubule assembly and 
stabilization (Drubin and Kirschner, 1986).  Tau is primarily regulated through phosphorylation of 
serine-proline and threonine-proline motifs in the MTBR region (Mazanetz and Fischer, 2007), 
however, tau can also be regulated by post-translational modifications such as glycosylation, 
ubiquitination, glycation, polyamination, nitration, truncation and aggregation (Gong et al., 2005, 
Pevalova et al., 2006).  A normal level of phosphorylation is required for tau function and in 
physiological conditions there are 2-3 moles of phosphate per mole of tau (Ksiezak-Reding et al., 
1992, Kenessey and Yen, 1993, Kopke et al., 1993).  When tau becomes hyperphosphorylated, 
however, it results in reduced affinity for microtubules, thus affecting its function in microtubule 
stabilization and cytoskeletal organization.  Moderate hyperphosphorylated tau (4-6 moles of 
phosphate per mole of tau) results in sequestration of normal tau and under pathogenic conditions, 
an even higher hyperphosphorylated status of tau (10 moles of phosphate per mole of tau), which 
leads to self-aggregation and formation of filaments (Buee et al., 2000, Gong and Iqbal, 2008).  In 
AD, hyperphosphorylated tau proteins form characteristic paired helical filaments (PHFs) which 
aggregate and form filamentous intraneuronal inclusions known as neurofibrillary tangles (NFTs).  
The intraneuronal NFTs are found in the neuronal soma and apical dendrites and upon death of the 
tangle bearing neuron, results in an extraneuronal “ghost” NFT (Serrano-Pozo et al., 2011).   
 Phosphorylation of tau at specific sites impacts its biologic and pathogenic function.  In vitro 
kinetic studies identified two phosphorylation induced conformational states of tau:  one state in 
which hyperphosphorylated tau can sequester normal tau and another state in which it is able to self-
assemble into filaments (Alonso Adel et al., 2004).  Phosphorylation of tau at Ser199, Ser202, 
Thr205, Thr212, Ser235, Ser262 and Ser404 allows for binding of normal tau and further 
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phosphorylation at Thr231, Ser396, and Ser422 is favorable for self-aggregation (Alonso Adel et al., 
2004).   
 It is thought that the altered phosphorylation of tau is due to the loss of dynamic regulation 
of tau by various kinases and phosphatases under pathogenic conditions.  Studies over the years 
have identified numerous kinases that are able to phosphorylate tau including glycogen-synthase 
kinase-3β (GSK-3β), cyclin-dependent kinase 5 (cdk5), mitogen activated protein kinase (MAPK), 
cAMP-dependent protein kinase (PKA), Jun N-terminal kinase /stress-activated protein kinase 
(JNK/SAPK), and calcium/calmodulin-dependent kinase II (CaMK-II) (Lovestone and Reynolds, 
1997, Jenkins et al., 2000, Ferrer et al., 2001, Barrachina et al., 2005, Ferrer et al., 2005, Mazanetz 
and Fischer, 2007).  The hyperphosphorylated status of tau is also supported by the reduce activity 
of protein phosphatases (Iqbal et al., 2005).  Compromised phosphatase activity identified in the AD 
brain includes phosphoseryl/phosphothreonyl-protein phosphatase types 1 (PP1), 2A (PP2A) and 5 
(PP5) (Gong et al., 1993, Gong et al., 1995, Gong et al., 2004). 
 The precise mechanisms by which tau exerts its neurotoxic effects are debated.  One 
predominant theory is that the highly phosphorylated form of tau detaches from microtubules, 
promoting dynamic instability and disassembly of the microtubule and resulting in defective axonal 
transport (Alonso et al., 1996, Mandelkow et al., 2003, Cuchillo-Ibanez et al., 2008).  This, in turn, 
would lead to transport defects and inappropriate distribution of cellular components and ultimately, 
cell death.               
  1.1.4.3. Anatomical Progression of Pathology 
 The post-mortem AD brain is diagnostically confirmed by concurrent amyloid plaque and 
neurofibrillary tangle pathology.  Yet, the temporal evolution of these pathologies and their 
correlation to the cognitive impairment associated with AD are not fully understood.  Amyloid 
pathology is thought to be the first and central lesion in AD, accumulating up to 25 years prior to 
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the onset of clinical symptoms (Hatashita and Yamasaki, 2010, Jack et al., 2010, Bateman et al., 
2012).   Plaque load, however, is only weakly correlated to the degree of cognitive deficits.  
Temporally, tau pathology is secondary to amyloid plaque deposition, however the amount and 
distribution of NFTs closely parallels the severity and duration of the disease (Arriagada et al., 1992, 
Bierer et al., 1995, Giannakopoulos et al., 2003, Ingelsson et al., 2004).  Interestingly, both lesions 
differ in distribution and progression in the brain.  
 Amyloid plaque deposition is thought to be a descendent progression (Figure 1.1) that 
begins in the neocortex and, over time, extends into the subcortical regions (Jucker and Walker, 
2011).  In 2002, Dietmar Thal proposed five distinct stages of amyloid progression in AD.  In the 
beginning of the disease (Stage 1), amyloid deposition is typically found in the neocortex, followed 
by deposits in the entorhinal cortex, hippocampal formation, amygdala and other allocortical regions 
(Stage 2).  Next, plaque deposition progresses to the subcortical nuclei (Stage 3) and then to the 
brainstem structures (Stage 4).  In the final stage (Stage 5), amyloid can be found in the pons and the 
molecular layer of the cerebellum (Thal et al., 2002).  
 Neurofibrillary tangle pathology progresses through the brain in a highly predictable manner 
(Figure 1.1) which was first described Braak and Braak in 1991 and later used to define the 
clinicopathological progression of AD (Braak and Braak, 1991).  Braak and Braak distinguished six 
stages of disease progression based on the anatomical location and severity of tau pathology (Braak 
and Braak, 1991, 1995).  These stages are subdivided into three anatomical regions- transentorhinal 
(Stage I-II), limbic (Stage III-IV) and isocortical (V-VI) that correlate to clinical progression from 
pre-clinical to MCI and finally, LAD.  According to Braak staging, NFTs first appear in the 
transentorhinal cortex (Stage I) followed by progression to the CA1 region of the hippocampus 
(Stage II).  Next, tau pathology extends to the limbic regions such as the subiculum of the 
hippocampal formation (Stage III) and the amygdala, thalamus and claustrum (Stage IV).  At these 
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stages, dementia manifests itself clinically.  As pathology worsens, NFTs spread to isocortical areas 
(Stage V). In the final stage (Stage VI), tau tangles are found extensively throughout all regions of 
the brain (Braak and Braak, 1991, 1995, Serrano-Pozo et al., 2011).   
 
Figure 1.1.  The anatomical progression of neuritic plaques and neurofibrillary tangles.  Neuritic plaques first 
appear in the neocortical regions of the brain and then descend to the allocortex and subcortical 
regions.  Neurofibrillary tangles, however, being in the transentorhinal cortex and progress through 
the limbic regions and finally, to interconnected neocortical brain regions (Jucker and Walker, 2011).  
 
 
1.2. The Amyloid Precursor Protein 
 1.2.1. The Amyloid Precursor Protein Gene Family 
 The human amyloid precursor protein was first isolated, cloned and sequenced in 1987 
(Kang et al., 1987).  Subsequently, the gene encoding human APP was mapped to chromosome 21 
and found to be highly conserved in evolution (Goldgaber et al., 1987a, Robakis et al., 1987, Tanzi et 
al., 1987).  The human APP gene consists of at least 18 exons that span ~240 kilobases (Yoshikai et 
al., 1990, Lamb et al., 1993) (Figure 1.2).  A number of APP isoforms exist due to alternative splicing 
of exons 7 and 8 which encode the 56 amino acid Kunitz Protease Inhibitor (KPI) domain and the 
19 amino acid OX-2 domain, respectively (Sandbrink et al., 1996).  APP is expressed in a number of 
different tissues throughout the body and the most abundant isoforms are APP695 (exons 1-6 and 9-
18), APP751 (exons 1-7 and 9-18) and APP770 (exons 1-18) (Barber, 2012).  The two longer isoforms 
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of APP, APP751 and APP770, are ubiquitously expressed and differ from APP695 as they contain exon 
seven that encodes the KPI domain (Rohan de Silva et al., 1997).  The longest isoform, APP770 
contains both the KPI and the OX-2 domains.  The APP695 isoform is the predominant isoform 
expressed in the brain.  All of the major isoforms contain a 40 to 43 amino acid Aβ sequence that 
spans part of exons 16 and 17 (Meraz-Rios et al., 2014) and produce a protein with multiple modular 
domains, including a single transmembrane region (Barber, 2012). 
 
Figure 1.2.  The human APP gene structure.  The human APP gene spans 18 exons (represented by 
boxes) on chromosome 21.  Alternative splicing results in several isoforms which are named 
according to their length in amino acids.  The most common isoforms are APP695, APP751 and 
APP770.  All of these isoforms contain the Aβ sequence region that comprises part of exons 16 and 
17.  APP751 contains the KPI domain (box in orange), while APP770 contains both the KPI and OX-2 
(box in blue) domains.  The isoform predominantly expressed in the brain, APP695, contains neither 
the KPI nor the OX-2 domains. 
 
 
 Two other proteins have also been identified to be part of the APP gene family due to high 
sequence homology with APP; APP-like protein-1 and -2 (APLP1 and APLP2) (Wasco et al., 1992, 
Wasco et al., 1993).  Similar to the APP protein, the alternative splicing of APLP2 can produce a 
number of isoforms (Sandbrink et al., 1996), while the APLP1 gene produces only a single transcript 
(Daigle and Li, 1993).  The APLP1 and APLP2 genes are mapped to chromosomes 19 and 11, 
respectively (Wasco et al., 1993, von der Kammer et al., 1994) and they share ~40-50% amino acid 
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sequence identity with APP (Walsh et al., 2007).  Both APLP1 and APLP2 undergo proteolysis that 
is similar to APP, however both molecules lack the Aβ sequence (Cousins et al., 2015).  Expression 
profiles also differ between the two APP-like proteins; APLP2 is ubiquitously expressed throughout 
the body while APLP1 expression is restricted to the nervous system (Slunt et al., 1994, Lorent et al., 
1995). 
 Overall, the similarities of the APP gene family in amino acid sequence and domain 
structure, as well as overlapping brain expression profiles, suggest that these proteins have similar 
and possible redundant biological roles.     
         
 1.2.2. Protein Structure  
 Members of the APP family are all type I transmembrane glycoproteins that are comprised 
of modular domains including a large extracellular N-terminal domain, a membrane spanning 
domain and a short cytoplasmic C-terminal domain (Goldgaber et al., 1987b).  APP, APLP1 and 
APLP2 share high sequence homology in their E1 and E2 extracellular domains (Figure 1.3).  The 
E1 domain has two subdomains:  a heparin-binding (HBD)/growth factor-like (GFLD) domain, a 
copper binding domain (CuBD) and a zinc binding domain (ZnBD)(Gralle and Ferreira, 2007).  
Likewise, the E2 domain can be subdivided into a second heparin binding domain and a random 
coil (RC) sequence.  Along with the KPI domain (present only in APP770, APP751 and APLP2), an 
acidic region containing aspartic and glutamic acid residues links the E1 and E2 domains (Figure 
1.3).  Following the E2 domain is a transmembrane (TM) domain that includes the Aβ sequence.  
Finally, the cytoplasmic C-terminal domain contains a YENPTY motif that is conserved across 
homologs (Haass et al., 1994) and the NPXY sequence necessary for internalization (Borg et al., 
1996).  
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Figure 1.3.  The domain structure of the members of the APP family.  The domain and subdomain 
structures of APP770, APP695, APLP1 and APLP2 are shown.  The extracellular region contains the 
E1 and E2 domains connected by an acidic (Ac) region and the Kunitz protease inhibitor (KPI) 
domain, which is subject to splicing.  Within the E1 domain are Zinc (ZnBD) and Copper (CuBD) 
binding domains and the Heparin-binding (HBD)/Growth Factor-like (GFLD) domains.  The E2 
domain is subdivided into a second Heparin-binding domain (HBD2) and a random coil (RC) 
region.  Following the E2 domain is a transmembrane (TM) domain that contains the Aβ sequence 
and finally, the C-terminal domain with the highly conserved YENPTY sequence motif.     
 
 1.2.3. Proteolysis  
 APP can be enzymatically metabolized in either the amyloidogenic or non-amyloidogenic 
pathways (Figure 1.4), resulting in a number of proteolytic products.  Under normal conditions, the 
non-amyloidogenic pathway accounts for the processing of ~90% of all cellular APP, while the 
remaining ~10% of cellular APP is processed in the amyloidogenic pathway (Pop et al., 2012).  
Three distinct proteases have been identified as key players in the proteolytic processing of APP: α-
secretase, β-secretase and γ-secretase.   
 The non-amyloidogenic pathway is initiated by the activity of α-secretase.  α-secretase 
belongs to the A Disintegrin and Metalloproteinase (ADAM) family and three enzymes have been 
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identified to have α-secretase activity:  ADAM9, ADAM10 and ADAM17 (Agostinho et al., 2015).  
Of the enzymes identified in this family, ADAM10 is thought to be a central player in the processing 
of APP (Nunan and Small, 2000).    α-secretase cleaves APP within the Aβ region between Lys612 
and Leu613 (APP695 numbering) (Esch et al., 1990), precluding generation of the Aβ peptide.  As a 
result, the secreted APPα (sAPPα) ectodomain is liberated into the extracellular space (Kojro and 
Fahrenholz, 2005).  The remaining 83 amino acid C-terminal fragment (CTF) α is then subsequently 
cleavage by γ-secretase, yielding the p3 fragment and the APP intracellular domain (AICD) (Haass et 
al., 1993, Haass and Selkoe, 1993).   
       β-secretase (also known as β-site APP cleaving enzyme, or BACE) activity initiates the 
amyloidogenic pathway.    BACE first cleaves APP between Met596 and Asp597 (APP695 numbering).  
This results in the shedding of the secreted APPβ (sAPPβ) ectodomain into the extracellular space 
and retention of the 99 amino acid CTFβ.  BACE can also cleave APP between Tyr606 and Glu607, 
liberating a longer sAPPβ and retaining an 89 amino acid CTFβ (Vassar et al., 1999).  Next, CTFβ is 
cleaved by γ-secretase, yielding Aβ and AICD (Haass and Selkoe, 1993).  Due to its promiscuous 
proteolytic activity, several species of Aβ peptide (ranging from 37 to 49 residues long) can result 
from the cleavage of CTFβ by γ-secretase (LaFerla et al., 2007).  Of these species, the most 
abundant are Aβ40 (~90-80%) and Aβ42 (~5-10%) (Murphy and LeVine, 2010).   
 γ-secretase is an intramembrane cleaving aspartyl protease made up of a multi-subunit 
complex consisting of four proteins: anterior pharynx-defective-1 (APH-1),  nicastrin,  presenilin-1  
(PS1) or presenilin-2 (PS2) and presenilin enhancer-2 (PEN-2) (Kimberly et al., 2003).  Each 
individual component of the complex carries out a unique function.  Nicastrin serves as a substrate 
receptor by recognizing and binding to specific residues on the substrate N-termius (Shah et al., 
2005).  APH-1 is a scaffolding protein that stabilizes the γ-secretase complex as it assembles and 
assists in its trafficking (Dries and Yu, 2008).  Presenilin is the catalytic component of the complex 
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and is structured as a multipass, nine-membrane domain protein (Wakabayashi and De Strooper, 
2008). In order to acquire activation, presenilin must first be cleaved to generate stable C- and N-
terminal fragments (Thinakaran et al., 1996).  Finally, PEN-2 is thought to assist in the maturation of 
the γ-secretase complex by facilitating the cleavage of presenilin to its active form and allowing for 
the trafficking of γ-secretase from the ER to the Golgi (Dries and Yu, 2008)           
   
Figure 1.4.  APP proteolysis.  APP can be cleaved via two distinct pathways:  the non-amyloidogenic 
pathway (left) or the amyloidogenic pathway (right).  Under normal conditions, the majority of APP 
is first cleaved by α-secretase within the Aβ domain to produce secreted APP α (sAPPα) and C-
terminal fragment α (CTFα).  CTFα is further cleaved by γ-secretase, producing the extracellular p3 
fragment and the APP intracellular domain (AICD).  In the amyloidogenic pathway, APP is first 
cleaved by β-secretase to produce secreted APP β (sAPPβ) and membrane bound C-terminal 
fragment β (CTFβ).  Cleavage of CTFβ by γ-secretase yields the Aβ peptide and the intracellular 
CTF peptide and the intracellular AICD.  Insoluble Aβ is deposited and aggregates to form amyloid 
plaques in the brain; a hallmark lesion in Alzheimer’s disease. 
 
 1.2.4. Intracellular Trafficking  
  1.2.4.1. Biosynthesis and Trafficking through the Secretory Pathway 
  Full-length APP (FL-APP) is synthesized in the endoplasmic reticulum (ER) where it is 
subjected to N-glycosylation to form immature APP (imAPP).  The imAPP is then transported 
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through the Golgi/trans-Golgi network (TGN) where it undergoes O-glycosylation to form mature 
APP (mAPP) (Figure 1.5).  Subsequently, secretory vesicles shuttle the mAPP from the TGN to the 
plasma membrane (Xu et al., 1997).  Only a small proportion (~10%) of cellular APP is found at the 
cell surface (Haass et al., 2012) whereas the majority of APP localizes to the Golgi and TGN (Haass 
et al., 2012).  The presence of the YENPTY endocytic sorting motif on the carboxyl terminus of 
APP (residues 682-687 of the APP695 isoform) allows APP to be quickly reinternalized via clatherin-
coated pits once it reaches the cell surface (Lai et al., 1995, Marquez-Sterling et al., 1997).  Following 
its endocytosis, APP is sorted into early endosomes where a fraction of APP is then recycled back to 
the cell surface and another fraction is targeted to undergo degradation in the lysosomes (Koo and 
Squazzo, 1994, Koo et al., 1996).           
 
Figure 1.5.  APP maturation.  APP is subjected to N-glycosylation at the ER to form imAPP 
followed by O-glycosylation at the Golgi/TGN to form mAPP.  mAPP is transported to the cell 
surface where it is either cleaved by α-secretase or endocytosed and cleaved by β-secretase.  
 
  1.2.4.2. Endocytic APP Sorting and Aβ Production   
 The intracellular trafficking of APP and its relevant secretases is crucial in determining the 
proteolytic pathway by which APP is processed.   While γ-secretase activity can complement either 
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pathway, the sub-cellular co-localization of APP with α- or β-secretase directly determines which of 
the two mutually exclusive proteolytic pathways APP will commit to.  The predominant proteolytic 
pathway for APP is the non-amyloidogenic pathway.  Upon synthesis in the ER, APP is transported 
to the TGN and subsequently delivered to the cell surface where constitutively active α-secretase is 
enriched (Capell et al., 2002).  APP is primarily processed via the non-amyloidogenic pathway at the 
cell surface, however α-secretase can also reside in the TGN where it is regulated by protein kinase 
C (PKC) and competes with the activity of BACE (Skovronsky et al., 2000).  As mentioned 
previously, a very small percentage of total cellular APP is found at the plasma membrane due to 
rapid removal of cell surface APP.  Due to the constitutive proteolysis of APP by α-secretase at the 
plasma membrane and endocytosis of the remaining FL-APP, the half-life of cell surface APP is 
estimated to be less than 10 minutes (Koo et al., 1996).  However, once APP is cleaved by α-
secretase, the half-life of the CTFα is much longer, lending itself to further processing by γ-secretase 
(Oltersdorf et al., 1990).  Furthermore, inhibition of cholesterol biosynthesis has resulted in 
enhanced α-secretase activity, suggesting that its α-cleavage takes place outside of the lipid rafts 
(Kojro et al., 2010). 
 BACE is a type I transmembrane aspartic protease that is synthesized as a pro-enzyme and, 
upon cleavage of its pro-domain, is trafficked to the cell surface via the secretory pathway where it is 
internalized into early endosomal compartments and recycled (Venugopal et al., 2008).  Though 
BACE reaches the cell surface due to intracellular trafficking, it is rapidly endocytosed and very little 
BACE mediated cleavage takes place at the plasma membrane (Chow et al., 2010). At steady state, β-
secretase is localized to the TGN and endosomal/lysosomal compartments and its activity is 
thought to be tightly associated with the cholesterol rich lipid rafts in the membrane (Tun et al., 
2002).  BACE activity is maximal under the acidic pH 3.3-4.4, suggesting that cleavage of APP 
occurs in acidic endosomal or Golgi subcellular compartments (Koo and Squazzo, 1994, Haass et 
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al., 1995).  Additionally, upon mutation of the C-terminal YENPTY endocytic reinternalization 
motif, APP is retained at the cell surface and Aβ generation subsequently decreased (Perez et al., 
1999).  This suggests that endocytosis of APP is essential for amyloidogenic processing and Aβ 
production. 
  1.2.5. Biological Function 
 While the contribution of APP and its toxic metabolite, Aβ, have been widely studied in 
Alzheimer’s disease research, the physiological function of APP is still poorly understood.  The 
possible functions of APP have been primarily studied using in vitro assays as in vivo experiments are 
complicated by two major obstacles:  In and of itself, APP consists of multiple functional domains 
and once cleaved, generates multiple intracellular and extracellular fragments that differentially 
mediate various functions.  Additionally, APP belongs to a gene family that also encodes APP-like 
proteins 1 and 2.  Because the proteins in this gene family are highly conserved, the redundant 
functions of each protein may compensate for the loss of another.  To date, a number of studies 
have attempted to define the normal function of APP, along with its many metabolites.         
  1.2.5.1. In Vivo Function of APP 
 The sequence homology between the APP family of proteins suggest that they may have 
evolutionary conserved, overlapping functions.  A number of studies have examined mice lacking 
individual or all combinations of APP family members to assess the phenotypic changes associated 
with APP family of proteins.  Not surprisingly, these genetic knockout studies have revealed 
redundancies amongst APP, APLP1 and APLP2.   
 Single deletion of each gene (i.e. APP-/-, APLP1-/- or APLP2-/-) produce both viable and 
fertile mice with minor phenotypic changes.  Single APP-KO display altered circadian activity and 
deficits in exploratory activity, grip strength, spatial learning and long-term potentiation (LTP) 
(Muller et al., 1994, Zheng et al., 1995, Ring et al., 2007).  Additionally, APP-KO mice have reduced 
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body and brain weight (Zheng et al., 1995, Magara et al., 1999), increased levels of copper (White et 
al., 1999) and cholesterol (Grimm et al., 2005) in the brain, and exhibit hypersensitivity to kainite-
induced seizure (Steinbach et al., 1998).  Single APLP1-KO and APLP2-KO mice exhibit less of an 
obvious phenotype; APLP1-KO mice have decreased in weight (Heber et al., 2000) and APLP2-KO 
mice exhibit elevated copper levels in the cerebral cortex (White et al., 1999).   
 In contrast to the minor deficits in single KO mice, some double knockouts have more 
remarkable outcomes.  Perinatal lethality was observed in both APLP2-/-/APP-/- and APLP2-/-
/APLP1-/- mice whereas APLP2-/- are viable (von Koch et al., 1997).  On the contrary, APLP1-/-
/APP-/- display a similar phenotype to single knockouts with viable and fertile offspring and 
decrease in body weight (Heber et al., 2000).  It seems that APLP2 has a necessary function for 
compatibility with life and it is quite possible that it compensates in function for the loss of APP or 
APLP1.  Consistent with this idea, mice with deficiency of all three APP genes (APP-/-/APLP1-/-
/APLP2-/-) die shortly after birth.  The majority of these mice exhibit cranial abnormalities, focal 
dysplasia and a partial loss of cortical Cajal-Retzius cells (Herms et al., 2004).  These findings 
conclude that the APP family of proteins play an essential role in normal brain development. 
  1.2.5.2. The APP Ectodomain 
 The APP ectodomain can be subdivided into two major subdomains: E1 and E2.  As 
previously described, the E1 domain can further be subdivided into a HBD/GFLD and a metal 
binding domain (copper and zinc).  Following the E1 domain is the KPI domain, which is subjected 
to alternative splicing and is only present in APP770, APP751, and APLP2, and an acidic region.  The 
E2 domain has a second HBD and a random coil region.  A number of studies have addressed the 
function of this region of APP; either as a functional domain or as a functional metabolite (sAPPα 
or sAPPβ).      
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   1.2.5.2.1. Cell Surface Receptor 
 In its original description, the sequence and structure of APP predicted functionality of the 
protein as a cell surface receptor (Kang et al., 1987).  The ectodomain of APP contains 
GFBD/HBDs that enable it to bind a number of proteins, however there has been no clear 
evidence that these ligands are responsible for initiating APP-mediated signaling  (Reinhard et al., 
2005, Coburger et al., 2014).  A number of studies have identified potential ligand interactions with 
the E1 and/or E2 domains in the N-terminus of APP (discussed in detail below), including Aβ 
peptide.  Fibrillar Aβ was shown to bind to cell surface holo-APP in cortical neurons, resulting in 
downstream neurotoxicity (Lorenzo et al., 2000).  The extracellular domain of APP has also been 
shown to directly interact with F-spondin, a secreted signaling molecule that is implicated in 
neuronal development and repair.  This interaction resulted in the inhibition of β-secretase cleavage 
of APP (Ho and Sudhof, 2004).  Likewise, N-terminal APP has been shown to interact with the 
Nogo receptor which, when bound to Nogo protein, inhibits axonal outgrowth and neuritic 
sprouting (Fournier et al., 2002).  The interaction between Nogo receptor and APP has been shown 
to result in decreased cell surface APP and increased Aβ deposition (Park et al., 2006, Zhou et al., 
2011).  Further supporting the hypothesis that APP might function as a cell surface receptor is the 
finding that APP family members can undergo cis-dimerization through the E1 domain and the 
GxxxG motif in the transmembrane domain (Kaden et al., 2008).  In mammalian cells, the 
transmembrane proteins that function as cell surface receptors exist in a monomeric form and, upon 
binding with a ligand, dimerize to elicit signal transduction (Schlessinger, 2002).  This consistency 
between APP and cell surface receptors have prompted many theories that APP could possibly 
function as a receptor and initiate signal transduction in an oligomerized state.  This physiological 
function however, has remained elusive.      
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   1.2.5.2.2. Cell Adhesion 
 Numerous studies have demonstrated the adhesion properties for all members of the APP 
family due to the binding properties of the E1 and E2 domains.  These domains have been shown 
to interact with extracellular matrix components and heparin sulfate proteoglycans, supporting a role 
in cell substratum adhesion promoting properties of APP (Kibbey et al., 1993, Beher et al., 1996, 
Clarris et al., 1997, Mok et al., 1997).  In vitro X-ray crystallography analysis has revealed that the E2 
domain of the APP family members can reversibly form antiparallel homo- and hetero- trans-
dimerization (Wang and Ha, 2004, Soba et al., 2005), which could promote cell to cell adhesion.  
Downstream of the E1 and E2 domains, the RHDS motif found in the extracellular region of APP, 
within the Aβ region, has been identified to promote cell adhesion and stimulate neurite outgrowth.  
A number of proteins are thought to bind to this motif to mediate these effects, such as integrin 
proteins (Storey et al., 1996, Yamazaki et al., 1997).     
   1.2.5.2.3. Trophic Functions 
 The trophic functions of APP on neurons and synapses have been well established and 
consistently documented, both as a holo-protein and as a secreted metabolite.  The trophic function 
of full length APP may, in part, be due to the adhesion properties previously described.  For 
example, the binding of substratum proteoglycans to the APP HBD in chick sympathetic and mouse 
primary neurons has been shown to mediate neurite outgrowth (Small et al., 1994).  Furthermore, 
downregulation of FL-APP in neuronal cells has been shown to result in inhibition of neurite 
outgrowth and impaired synaptic activity (Allinquant et al., 1995, Herard et al., 2006, Young-Pearse 
et al., 2008).   
 Most studies, however, have focused on the neurotrophic properties of the sAPPα 
metabolite.  Early studies first correlated low CSF sAPPα to AD patients compared to their healthy 
aged counterparts (Lannfelt et al., 1995), suggesting a neurotrophic role for the soluble fragment.  In 
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vivo studies have shown that intracerebroventricular injection of sAPPα results in enhanced learning 
and memory in both rats and mice (Meziane et al., 1998, Taylor et al., 2008).  A multitude of studies 
have established the neurotrophic effect of sAPPα in vitro.  sAPPα has been shown to enhance long 
term survival in rat primary cortical neurons and attenuate cell death in cultured neurons or neural 
cells exposed to assaults such as hypoglycemia, glutamate toxicity, Aβ and UV irradiation 
(Chasseigneaux and Allinquant, 2012).  Additionally, a number of studies have demonstrated that 
sAPPα can stimulate cellular growth in a number of cell types in vitro (Saitoh et al., 1989, Araki et al., 
1991, Milward et al., 1992, Hoffmann et al., 2000, Young-Pearse et al., 2008).  Tellingly, the lethal 
phenotype of double APP/APLP2 knockout mice and behavioral deficits observed in single APP 
knockout mice is rescued by knockin of sAPPα, further highlighting its trophic function (Ring et al., 
2007, Weyer et al., 2011).       
 From a signaling perspective, recent studies have demonstrated that sAPPα is able to 
antagonize the induction of the GSK-3β pro-apoptotic signaling pathway (Jimenez et al., 2011, 
Milosch et al., 2014).  Jimenez et al. suggested that sAPPα-dependent neuroprotection may be 
facilitated by the insulin growth factor-1 receptor (IGF1-R) and/or the insulin receptor (IR).  In this 
signaling cascade, sAPPα signals through IGF1-R or IR to induce the phosphoinositide 3 kinase 
(PI3K)/Akt pathway, resulting in the phosphorylation and subsequent inhibition of GSK-3β kinase 
activity (Jimenez et al., 2011).  Similarly, Milosch et al. showed that sAPPα-mediated Akt activation 
abolished GSK-3β activity, however the presence of holo-APP was necessary for this signaling 
cascade, not IGF1-R or IR.  Furthermore, the APP C-terminal YENPTY motif (discussed in 
Section 1.2.5.2) was necessary for sAPPα to elicit its effect (Milosch et al., 2014).  This group 
suggested that sAPPα may signal either directly or indirectly through membrane tethered APP and 
that APP might serve as a receptor to trigger the G-protein-dependent activation of the PI3K/Akt 
pathway (Milosch et al., 2014).  
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   1.2.5.2.4. Axon Pruning and Degeneration 
 Unlike the sAPPα fragment, the sAPPβ that results from BACE cleavage has no 
neurotrophic function.  Instead, sAPPβ is thought to play a role in axonal pruning.  A study by 
Nikolaev et al. found that growth factor deprivation results in the BACE cleavage of APP to liberate 
sAPPβ.  sAPPβ then undergoes further proteolysis to generate a ~35kDa N-terminal APP fragment 
that acts as a ligand for Death Receptor 6 (DR6) and subsequently leads to the activation of caspases 
6 and 3, resulting in axonal and cell body degeneration, respectively (Nikolaev et al., 2009).  This 
pathway was linked to both normal developmental axonal pruning and neurodegeneration in AD.   
  1.2.5.3. The APP Intracellular Domain  
 The protein members of the APP gene gamily share a high degree of sequence homology in 
their intracellular domain, suggesting that this region participates in regulating APP function.   
   1.2.5.3.1. Phosphorylation and Protein-Protein Interaction 
 The APP C-terminal domain contains at least eight putative serine/threonine 
phosphorylation sites that are thought to modulate APP trafficking and signal transduction (Muller 
et al., 2008, Tamayev et al., 2009, Schettini et al., 2010).  Residue Thr668 (APP695 numbering), located 
within the 667VTPEER672 C-terminal motif of APP, is a highly conserved site and its phosphorylation 
has emerged as a crucial modification that may dictate APP function.  APP Thr668 has been shown to 
be directly phosphorylated by cdk1, cdk5, JNK-3, and GSK-3 (Iijima et al., 2000, da Cruz e Silva and 
da Cruz e Silva, 2003, Kimberly et al., 2003). This phosphorylation event implies a possible 
pathogenic function as Phospho-Thr668 APP levels are increased in AD patients compared to those 
of aged normal individuals (Lee et al., 2003).  Phosphorylation of APP at Thr668 induces a 
conformational change of the intracellular domain that lends itself to BACE proteolysis and Aβ 
production (Lee et al., 2003).  This conformational change also affects the binding affinity of the C-
terminus of APP to its cytosolic partners (Slomnicki and Lesniak, 2008, Tamayev et al., 2009, 
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Schettini et al., 2010).  For example, phosphorylation of AICD at Thr668 has been shown to be 
essential for its binding with the adaptor protein Fe65 (Chang et al., 2006).  Furthermore, our lab has 
found that phosphorylation of APP at Thr668 may play a role in cell cycle regulation (discussed in 
Chapter 2).   
 The second phosphorylation site that is highly conserved within the APP family is located at 
residue Tyr682 within the C-terminal 682YENPTY687 motif.  Phosphorylation of APP at this residue is 
mediated by non-receptor tyrosine kinases Abl and Src, as well as nerve growth factor tyrosine 
kinase receptor A (TrkA) (Russo et al., 2005).  Phosphorylation of this site promotes the docking of 
adaptor proteins that contain phosphotyrosine binding domains (PTB) or Src homology 2 (SH2) 
domains such as Grb2, ShcA, Mint-1/X11z, Fe65 and JNK interacting protein (JIP) (Ando et al., 
2001, Ramelot and Nicholson, 2001, Kimberly et al., 2003, Russo et al., 2005) and could be 
functionally coupled to intracellular signaling cascades.  Interestingly, phosphorylation of APP at 
Tyr682 is increased in the brain of AD patients, suggesting a pathological link to the disease (Russo et 
al., 2001).     
   1.2.5.3.2. Gene Transactivation  
 The possible cell surface receptor function of APP (discussed previously) has been 
strengthened by its structural similarity to the receptor, Notch.  When Notch interacts with its 
associated ligands, it results in proteolysis that is common to that of APP.  Many of the same 
secretases that cleave APP also cleave Notch, resulting in the release of a Notch intracellular domain 
(NICD) that is necessary for its signaling (Selkoe and Kopan, 2003).  Likewise, the intracellular 
domain of APP has been shown to translocate into the nucleus and function as a transcriptional 
regulator (Cupers et al., 2001, Gao and Pimplikar, 2001, Kimberly et al., 2003).  The AICD peptide 
has a short half-life and undergoes rapid degradation, however interaction with Fe65 stabilizes 
AICD and protects it from proteasomal degredation (Slomnicki and Lesniak, 2008, Tamayev et al., 
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2009).  Consequently, AICD-Fe65 undergoes nuclear translocation (Nakaya and Suzuki, 2006).  
Once in the nucleus, AICD-Fe65 interacts with Tip60, a histone acetyl transferase (HAT), and the 
complex is thought to mediate transcription of GSK-3β, APP, Tip60, neprilysin and others (Baek et 
al., 2002, Kim et al., 2003, von Rotz et al., 2004, Pardossi-Piquard et al., 2005).  
   1.2.5.3.3. Apoptosis 
 Overexpression of the β-secretase cleaved APP C-terminal fragment (CTFβ) exhibits 
cytotoxicity in a number of neuronal cell lines (Yankner et al., 1989).  These in vitro studies were 
further supported by an in vivo model utilizing transplanted PC12 cells overexpressing CTFβ (the last 
104 amino acids) in mouse brain (Neve et al., 1992, Fukuchi et al., 1994). At 2 and 5 months post 
transplantation, the mouse brain exhibited hippocampal shrinkage, astrogliosis enhanced 
immunoreactivity to Aβ, suggesting neurotoxic properties (Fukuchi et al., 1994). In addition to 
gliosis and neurodegeneration in the hippocampus and neocortex, intracerebroventricular injection 
of recombinant CTFβ (the last 105 amino acids) into mouse brain has also resulted in behavioral 
impairments, including deficits in working memory (Song et al., 1998).  Over the years, multiple lines 
of transgenic mice expressing CTFβ (the last 100 amino acids in the C-terminus) have been created 
and the expression of this c-terminal fragment appears to elicit changes in the brain that are 
congruent with AD pathology.  Some mice exhibit Aβ deposition in the brain with concomitant 
occurrence of dystrophic neurites and degeneration in the hippocampus (Kammesheidt et al., 1992, 
Neve et al., 1992).  Behavioral deficits and impaired long term potentiation (LTP) have also been 
associated with these transgenic mice (Nalbantoglu et al., 1997, Berger-Sweeney et al., 1999).  
Conversely, others have reported either absent or much milder phenotypes associated with 
transgenic CTFβ mice (Sato et al., 1997, Rutten et al., 2003).       
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 1.2.6. Aβ and its Role in Alzheimer’s Disease 
 Aβ can adopt a number of conformations including soluble monomers and oligomers that 
go on to form insoluble protofibrils and fibrils.  Though literature typically addressed Aβ40 and Aβ42 
peptides, a number of N-terminally and C-terminally truncated Aβ species exist.  Regarding the two 
most common species, Aβ42 is thought to be more toxic than Aβ40.   The Aβ42 species is more 
hydrophobic than Aβ40, lending itself to a higher propensity of self-aggregation into fibrils (Jarrett et 
al., 1993).  Furthermore, this Aβ42 is the predominant species found in amyloid plaques of the AD 
brain (Younkin, 1998) and the majority of familial AD cases exhibit an increase in ratio of cerebral 
Aβ42 to Aβ40 (Suzuki et al., 1994).        
1.2.6.1. Soluble Aβ oligomers 
Initially, Alzheimer’s research focused on the toxicity of insoluble Aβ fibrils due to their 
contribution to neuritic plaques.  In primary rat hippocampal neurons, Aβ fibrils elicited increased 
frequency of action potentials and membrane depolarization which resulted in neuronal death 
(Lorenzo and Yankner, 1996).  Intracranial injection of Aβ fibrils in the dorsal dentate gyrus of rats 
also resulted in impaired synaptic transmission cognitive deficits and neuronal death in vivo (Stephan 
et al., 2001).  Despite these findings, insoluble Aβ aggregates and plaque load in human brain 
correlate poorly with both adjacent neuronal death, synaptic loss and ultimately, AD symptoms 
(Terry et al., 1991, Davis et al., 1999, De Meyer et al., 2010).  Instead, recent studies have identified a 
robust correlation between levels of soluble Aβ oligomers, neuronal toxicity and cognitive deficits.  
Aβ oligomers extracted from human AD brain were applied to mouse hippocampal slices and 
resulted in LTP inhibition, enhanced long-term depression (LTD) and a reduction in dendritic spine 
density (Walsh et al., 2002, Townsend et al., 2006, Shankar et al., 2008).  These findings were further 
supported by impaired memory and cognitive function observed in rodents who received 
27 
 
intracerebroventricular injection of Aβ oligomers (Cleary et al., 2005, Lesne et al., 2006, Shankar et 
al., 2008).   
How soluble Aβ oligomers form and the mechanisms by which they exert toxicity, however, 
remains unclear.  It has been proposed that various conformations of Aβ oligomers and how they 
result in neuronal death and synaptic impairment could result from different intracellular and 
extracellular pathways (Glabe, 2008).    
1.2.6.2. Extracellular Mechanisms for Aβ Toxicity 
Aβ has high affinity for the lipid rafts found in the plasma membrane (Fantini and Yahi, 
2010).  These microdomains are enriched with GM1 ganglioside which is especially abundant in 
neuronal membranes and Aβ monomers have been shown to interact directly with GM1 in the AD 
brain (Yanagisawa, 2007).  Moreover, a study carried out by Yamamototo et al. demonstrated that 
Aβ undergoes structural changes in the presence of GM1 ganglioside, inducing the oligomerization 
of Aβ via a pathway distinct from that of fibril formation (Yamamoto et al., 2007).  Others have 
reported that Aβ can interact with other proteins such as the small heat shock protein αB-crystallin 
and the apolipoprotein clusterin that maintain Aβ in its toxic, non-fibrillar form (Oda et al., 1995, 
Stege et al., 1999).  
Soluble oligomeric Aβ has been shown to bind to the pan neurotrophin receptor (p75NTR) 
with high affinity, resulting in receptor activation and signaling to induce neuronal apoptosis (Yaar et 
al., 1997, Yaar et al., 2002).  The binding of Aβ to p75NTR is thought to trigger cell death via the 
downstream signaling of JNK and nuclear factor kappa B (NFκB) (Kuner et al., 1998).  Conversely, 
there has been conflicting evidence that p75NTR exerts a protective role against Aβ oligomers 
(Zhang et al., 2003, Costantini et al., 2005).  Sporadic AD is consistently associated with 
dysregulation of both neurotrophins and their receptors.  A number of studies suggest that in the 
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late onset AD brain, neurotrophic signaling involving nerve growth factor (NGF) and tropomyosin 
receptor kinase (Trk) receptors are downregulated while neurodegenerative signaling involving 
ligands like soluble oligomeric A and proNGF with the p75NTR are increased (Coulson, 2006).   
Another potential receptor-mediated mechanism that results in Aβ toxicity involves the 
binding of Aβ-derived diffusible ligands (ADDLs) to N-methyl-D-aspartate (NMDA)-type glutamate 
receptor (NMDAR).  This interaction has been shown to result in perturbation of calcium 
homeostasis, resulting in oxidative stress and synaptic dysfunction (De Felice et al., 2007, Shankar et 
al., 2007).  In the AD brain vasculature, receptor for advanced glycation end products (RAGE) has 
been shown to be upregulated (Yan et al., 1996).  Aβ has been shown to interact with RAGE 
receptors, which mediated the uptake of Aβ from the peripheral circulation into the brain (Chaney et 
al., 2005).   
Epidemiological studies indicate a strong correlation to peripheral insulin resistance and risk 
of AD (de la Monte et al., 2006).  Aβ oligomers have been shown to induce loss of plasma 
membrane insulin receptors in primary neuronal cultures, triggering oxidative stress, synaptic spine 
loss and altered IR signaling (Zhao et al., 2008).  Furthermore, insulin can competitively bind to 
insulin receptors, inhibiting Aβ oligomer binding and neurotoxicity (De Felice et al., 2009).  There is 
also evidence that soluble Aβ can directly affect the Wnt/β-catenin pathway.  Aβ oligomers can bind 
the Fizzled receptor, inhibiting Wnt binding and subsequent signaling (Magdesian et al., 2008).  This 
ultimately resulted in the activation of GSK-3β and phosphorylation of tau, suggesting a role for 
toxicity of Aβ by altering Wnt/β-catenin signaling.       
1.2.6.3. Intracellular Mechanisms for Aβ Toxicity 
As previously described, the Aβ peptide is intracellularly generated from the proteolysis of its 
precursor, APP.  Secreted Aβ can also be re-internalized by a number of receptors such as low-
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density lipoprotein receptor-related protein 1 (LRP1), NMDAR and AMPA receptor, and  α7 
nicotinic cholinergic receptor (α7nChR) (Lai and McLaurin, 2010).  It seems logical then that 
intracellular Aβ elicits a toxic effect, and in fact, intraneuronal accumulation of Aβ has been 
observed in the brains of AD patients (Gouras et al., 2000, Gyure et al., 2001, Wegiel et al., 2007, 
Aoki et al., 2008).   To date, a number of mechanisms by which intracellular Aβ mediates toxicity 
have been proposed.   
In the brains of transgenic APP mutant mice and human AD patients, Aβ accumulation 
occurs in the multivesicular bodies (MVBs) (Takahashi et al., 2002, Langui et al., 2004).  This MVB 
accumulation of Aβ was also shown to inhibit the ubiquitin-proteosome system (UPS) (Longva et 
al., 2002).  Furthermore, other studies demonstrate that the inhibition of the UPS results in elevated 
Aβ levels both in vivo and in vitro (Oh et al., 2005, Tseng et al., 2008).  Similarly, Aβ induced 
proteasomal impairment also results in other pathogenic consequences such as the intracellular 
buildup of tau (Oddo et al., 2006, Tseng et al., 2008).   
Intraneuronal Aβ has also been shown to play a role in synaptic dysfunction and 
subsequently, cognitive deficits.  In 3xTg-AD mice, the accumulation of intraneuronal Aβ coincides 
with cognitive impairment at four months of age while other pathological markers are absent (i.e. 
extracellular amyloid plaques and phosphorylated tau) (Billings et al., 2005).  Sequestration of 
intraneuronal Aβ with immunotherapy resulted in the restored cognitive abilities (Billings et al., 
2005).  Reflecting this finding, other studies have shown that intracellular Aβ results in significant 
LTP deficits (Gong et al., 2006, Oddo et al., 2006).   
Finally, many in vitro and in vivo studies suggest that Aβ oligomers exert their toxicity by 
promoting tau pathology.  In vitro studies have demonstrated that Aβ can induce activation of a 
number of kinases that pathogenically phosphorylate tau in cell types ranging from primary neurons 
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to neuronal cell lines (Lambert et al., 1994, De Felice et al., 2008, Ma et al., 2009, Zempel et al., 
2010, Zeng et al., 2010, Jin et al., 2011, Mairet-Coello et al., 2013).   Previously, an in vivo study 
showed that intrahippocampal injection of antibodies raised against Aβ clears not only intracellular 
and extracellular Aβ deposits, but also results in clearance of tau pathology in 3xTg-AD mice (Oddo 
et al., 2004).  In a later study, the same group demonstrated that injection of antibodies specific to 
oligomeric Aβ resulted in the same effect (Oddo et al., 2006).  This finding was supported by the 
fact that Aβ does not confer toxicity when applied to hippocampal neurons derived from tau 
knockout mice (Rapoport et al., 2002).   
1.3. Etiopathogenesis of Alzheimer’s Disease 
 1.3.1. Genetic Basis  
 Conventionally, Alzheimer’s disease can be subdivided into two groups:  familial (also 
known as early onset) and sporadic (also known as late onset).  Genetically, familial Alzheimer’s 
disease (FAD) is transmitted in a Mendelian fashion with autosomal dominant inheritance.   
Sporadic Alzheimer’s disease (SAD), however, seems to be more influenced by such factors such as 
age, lifestyle and environment.    
  1.3.1.1. Familial Alzheimer’s Disease 
 Familial AD is relatively rare and represents only 1-5% of all AD cases (Association, 2016).  
At diagnosis, patients are typically in their fifties or sixties, though in some cases onset can occur in 
the patient’s early thirties (Acosta-Baena et al., 2011).  A number of rare, yet highly penetrant disease 
causing mutations in APP (chromosome 21), PS1 (chromosome 14) and PS2 (chromosome 1) genes 
have been identified.  To date, 52 APP mutations have been mutations have been identified in FAD 
patients (Cacace et al., 2016), some of which are listed in Table 1.1.  More recently, an Icelandic 
mutation (A673T) near the β-secretase cleavage site on APP was identified to be protective against 
FAD by reducing Aβ secretion by approximately 40% (Jonsson et al., 2012).  Furthermore, 215 PS1 
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and 31 PS2 mutations have also been identified (Cacace et al., 2016).  The vast majority of these 
mutations are concentrated proximal to the β-secretase (amino acid 671) or γ-secretase (amino acid 
717) cleavage sites in APP that confer either enhanced generation of Aβ peptide (Cai et al., 1993) or 
an increased Aβ42 to Aβ40 ratio (Suzuki et al., 1994).  Patients with Down’s syndrome (DS), which 
arises from trisomy of chromosome 21, have an extra copy of the APP gene and exhibit 
neuropathology similar to AD by 40 years of age  (Mann, 1989).  Interestingly, brains from these 
patients exhibit neuritic plaques containing Aβ42 prior to the formation of neurofibrillary tangles 
(Hyman, 1992, Hyman et al., 1995).  These findings, coupled with the fact that there are no known 
tau mutations associated with AD, have driven the proposed amyloid cascade hypothesis which 
speculates that the toxic Aβ peptide plays a central role in the initiation Alzheimer’s disease and the 
hyperphosphorylation of tau (Glenner and Wong, 1984a).             
Table 1.1.  Amyloid precursor protein mutations.  The listed mutations have been identified in familial 
AD.  These mutations occur in proximity to β- and γ- secretase cleavage sites on APP (at amino 
acids 671 and 717, respectively).  This table has been adapted from (Meraz-Rios et al., 2014). 
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  1.3.1.2. Sporadic Alzheimer’s Disease 
 The majority of AD cases (>95%) are considered sporadic and are not associated with 
known mutations that yield an AD phenotype (Association, 2016).  Only the epsilon allele in the 
apolipoprotein E (APOE) gene has been reliably associated with an increase in risk for developing 
AD.  Three variants of APOE exist (E2, E3 and E4) which are encoded by ε2, ε3 and ε4 alleles 
(Barber, 2012).  On a protein level, these alleles confer distinct biochemical properties.  Individuals 
that carry the APOE2 allele have a decreased risk of developing sporadic AD (Corder et al., 1994).  
However, those who carry the APOE4 allele are at greater risk for developing sporadic AD.  There 
is a gene-dosage effect in APOE4 carriers:  individuals carrying one copy are at three times more at 
risk for AD, while homozygous individuals have a fifteen-fold increase in risk (Singh et al., 2006).  
APOE4 has a high correlation with increased Aβ deposition both in the human and mouse brain 
(Holtzman et al., 1999, Tiraboschi et al., 2004), however the exact mechanism by which it increases 
risk for AD is not clear.   
 It is thought that ApoE4 modulates plaque pathology by reducing the clearance of Aβ from 
the brain, thus enhancing its deposition into plaques(Strittmatter et al., 1993, Bales et al., 1999, 
Holtzman et al., 2000, Shibata et al., 2000, Holtzman, 2001).  Initial evidence that linked ApoE to 
AD pathology was immunoreactivity of ApoE in amyloid plaque and neurofibrillary tangle lesions 
(Namba et al., 1991). It has since been demonstrated that ApoE complexes with Aβ peptide.  
ApoE2 and E3 have been shown to bind Aβ more efficiently than E4 (LaDu et al., 1994, Aleshkov 
et al., 1997, Yang et al., 1997), and these complexes both influence the seeding of fibrillar Aβ and 
transport of soluble Aβ. AD transgenic mice lacking ApoE exhibit decreased amyloid plaque 
deposition and elevated levels of soluble Aβ in the CSF (Bales et al., 1999, DeMattos, 2004).  Thus, 
ApoE4 seems to affect accumulation, deposition and clearance of Aβ.    
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 1.3.2. Molecular Basis  
  1.3.2.1. Neuroinflammation  
 Neuroinflammation is a common feature in nearly all neurodegenerative diseases, including 
Alzheimer’s disease.  While it is a well-established hallmark to the disease, it is unclear whether this 
feature is causative or subsequent to AD pathogenesis.   
   1.3.2.1.1. Cellular Inflammatory Mediators 
 Immunohistochemical analyses reveal an inflammatory status of post-mortem human AD 
brains with the presence of active glia in proximity to Aβ deposits (Haga et al., 1989, Itagaki et al., 
1989, Akiyama et al., 1999, Heneka and O'Banion, 2007).  Likewise, this immune response is also 
observed around amyloid plaques in the brains of transgenic AD mice that express APP carrying the 
Swedish mutation (Stalder et al., 1999, Wegiel et al., 2001, Gordon et al., 2002, Sasaki et al., 2002, 
Wegiel et al., 2003).  The brain’s resident microglia and astrocytes are the main cellular mediators 
that become activated in response to injury.  Astrocytes are the most abundant type of glial cells in 
the central nervous system (CNS) and the pathology associated with AD triggers what is called 
“reactive astrogliosis” (DeWitt et al., 1998).  This activation is defined by an increase in number, size 
and mobility of astrocytes, which is thought to be important for Aβ clearance and degradation 
(Meraz-Rios et al., 2013).  Microglia comprises a marginal portion of the glial cell population in the 
brain and when activated, undergoes distinct morphological changes and migrates to the 
compromised area.  There, they produce reactive oxygen species (ROS), cytokines, chemokines, 
growth factors and complement factors that are released to the surrounding tissue (Lawson et al., 
1992, Walker et al., 1995, Lue et al., 2001, Kettenmann et al., 2011).   
 Several in vitro studies implicate the highly, insoluble form of Aβ in inducing microglial 
activation and inflammatory protein expression (Del Bo et al., 1995, Giulian et al., 1995, Klegeris et 
al., 1997, Combs et al., 2000, Combs et al., 2001, Sondag et al., 2009, Dhawan et al., 2012).  This 
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effect has also been observed with in vivo imaging of microglial migration to amyloid deposits within 
transgenic AD mouse brain (Bolmont et al., 2008, Meyer-Luehmann et al., 2008).  In fact, treatment 
of transgenic AD mice with the recombinant β-sheet breaker peptide iAβ5, with the sequence Leu-
Pro-Phe-Phe-Asp, has been shown to not only reduce plaque load, but also lessen inflammation-
induced cerebral damage (Permanne et al., 2002).  Aβ has also been shown to induce cytokine 
production in various ways.  The NFκB pathway leads to cytokine production and this signaling 
pathway can be induced by the Aβ peptide (Combs et al., 2001).  Aβ is able to bind to receptors 
expressed on the microglial membrane and induce the MAPK signaling cascade which subsequently 
leads to expression of inflammatory genes and production of chemokines and cytokines (Ho et al., 
2005).  A working hypothesis for these findings is that the dense and irreversible nature of the 
amyloid plaque leads to stimulation of glial cells and chronic inflammation in the brain.  The release 
of proinflammatory mediators in response to the fibrillar Aβ- along with Aβ itself- results in a 
neurotoxic effect for healthy, adjacent neurons in the brain microenvironment (Halliday et al., 2000).  
Additionally, these inflammatory mediators are thought to facilitate enhanced amyloidogenic 
processing of APP, producing more Aβ, which then feeds into the vicious cycle (Del Bo et al., 1995, 
Ringheim et al., 1998, Misonou et al., 2000).  Conversely, others believe inflammation precedes 
fibrillar plaque pathology.  For example, a study carried out in macaque monkeys found that glial 
activation is an event that occurs before deposition of fibrillar Aβ in the aging brain (Martin et al., 
1994).  Several studies have also linked polymorphisms in pro-inflammatory cytokine genes, in 
particular Interleukin-1 (IL-1), to AD (Du et al., 2000, Griffin et al., 2000, Grimaldi et al., 2000, 
Nicoll et al., 2000, Hedley et al., 2002, Rainero et al., 2004).  Another example is that from a study in 
Down syndrome patients who typically develop AD-like pathology by middle age as they carry an 
extra copy of the APP gene.  This study showed that the brains of fetal and neonate Down 
syndrome patients (considered to be pre-amyloid plaque bearing) exhibit gliosis and show 
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upregulation of cytokines, further supporting the notion that inflammation and plaque development 
occur sequentially (Griffin et al., 1989). 
   1.3.2.1.2. Molecular Mediators  
 Activated microglia and astrocytes surrounding amyloid plaques secrete cytokines and 
chemokines that contribute to the inflammatory process.  A number of cytokines and chemokines 
are found to be upregulated in AD brains compared to the non-demented controls (Griffin and 
Mrak, 2002, Cacquevel et al., 2004, Mrak and Griffin, 2005a, Finch and Morgan, 2007). 
 Chemokines are a family of small proteins that recruit monocytes, macrophages, 
lymphocytes, neutrophils, basophils, eosinophils and dendritic cells to compromised tissues (Luster, 
1998).  The Aβ peptide can promote the generation of chemokines such as IL-8, monocyte 
chemoattractant protein 1 (MCP-1), macrophage inflammatory protein (MIP) -1α and -1β (Fiala et 
al., 1998) from human monocytes (Lue et al., 2001).  Additionally, MIP-1β has been detected within 
activated astrocytes and around amyloid plaques (Xia et al., 1998).  Cytokines are soluble proteins 
that are secreted by glia in the AD brain in response to Aβ aggregates (Meda et al., 1999).  Analysis 
of both AD human and transgenic AD mouse tissues and cerebral spinal fluid (CSF) show a marked 
increase in the levels of IL-1β, IL-1α, IL-6, IL-10, IL-12, granulocyte macrophage-colony stimulating 
factor (GM-CSF), tumor necrosis factor α (TNF-α), and transforming growth factor β (TGF-β) 
(Blum-Degen et al., 1995, Tarkowski et al., 2002, Meager, 2004, Meager et al., 2005, Mrak and 
Griffin, 2005b, Patel et al., 2005, Swardfager et al., 2010, Jiang et al., 2011).   
 In the brain, TNF-α is predominantly produced by activated microglia in response to injury; 
however it has also been shown to be produced by neurons (Breder et al., 1993).  The role of TNF-α 
in AD is unclear as it has both beneficial and detrimental effects.  Under non-pathological 
conditions, TNF-α levels are low in the brain (Rubio-Perez and Morillas-Ruiz, 2012) but in AD its 
levels are elevated in serum, CSF, cortex and glial cells (Fillit et al., 1991, Tarkowski et al., 1999, Lue 
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et al., 2001).  The role of TNF-α is dichotomous in nature:  it is able to stimulate NFB, which in 
turn induces transcription of proinflammatory genes and stimulation of survival proteins such as 
anti-apoptotic Bcl, manganese superoxide dismutase and calbindin (Wajant et al., 2003, Kamata et 
al., 2005).  It has been demonstrated in vitro that TNF-α is able to induce expression of APP and Aβ 
in glial cells (Lahiri et al., 2003).  Its harmful effects also include its stimulation of microglia to 
release glutamate, resulting in excitotoxicity (Takeuchi et al., 2006).  TNF-α has been implicated in 
increased expression of both β- and γ-secretase.  Furthermore, inhibition of TNF-α has been shown 
to mitigate disease progression in transgenic AD mice (McAlpine et al., 2009, Tweedie et al., 2012).  
On the contrary, chronic TNF-α suppression can hinder the microglial response in early stages of 
Aβ deposition, leading to accelerated aggregation (Montgomery et al., 2011).  It is possible that the 
effect that TNF-α exerts is dependent on both its levels and duration of brain exposure. 
 IL-1 is an immunomodulatory cytokine and a key player in initiation of the immune 
response.  IL-1 is found to be elevated immediately after brain injury (Woodroofe et al., 1991, 
Winter et al., 2002) and this effect is also seen in response to amyloid plaques, as concentrations of 
Il-1 are increased in the AD brain (Griffin et al., 1995, Prehn et al., 1996, Griffin et al., 1998).  
Interestingly, IL-1 has been found to not only induce the synthesis of APP, but also mediate its 
pathogenic processing (Goldgaber et al., 1989, Griffin et al., 1995).  This implies a role for IL-1 in 
neurodegeneration, which is further highlighted by the finding that IL-1 promoted synthesis of the 
beta subunit of S100 protein (S100β) in astrocytes, which promotes dystrophic neurite (Griffin et al., 
1989, Griffin et al., 1995, Li et al., 1998).  Inhibition of IL-1β activity has also been shown to 
promote neurogenesis via the Wnt/β-catenin signaling cascade by inhibiting GSK-3β activity and 
subsequent tau phosphorylation (Kitazawa et al., 2011).  The role of IL-1β in neurodegeneration, 
however, is not straightforward.  One study showed a protective effect of IL-1β when overexpressed 
in the astrocytes of transgenic AD mice; Shaftel et al. showed that sustained activation of IL-1β 
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results in a significant decrease in the hippocampal amyloid plaque load in these mouse brains 
(Shaftel et al., 2007). 
 Similar to IL-1, the cytokine IL-6 is found to be increased in AD patient tissue and it also 
induces the expression of APP (Altstiel and Sperber, 1991, Hull et al., 1996, Ringheim et al., 1998).  
Conversely, IL-6 levels increase after treatment of cultured glial cells with the carboxy terminal 
fragment of APP (the last 105 amino acids) (Chong, 1997).  While some have found that IL-6 
enhances Aβ-induced neurodegeneration in primary rat neuronal cultures (Qiu and Gruol, 2003), 
others have found that overexpression of IL-6 in transgenic AD mouse brain results in increased 
gliosis and phagocytosis, attenuating Aβ deposition (Chakrabarty et al., 2010).  The contradictory 
nature of these findings can be bridged by the idea that neuroinflammation is a complex and fine 
balanced response, capable of being both beneficial and deleterious to the brain. 
 Another inflammatory marker, alpha-1-antichymotrypsin (ACT) is an acute phase 
inflammatory protein and serine protease inhibitor found to be elevated in the CSF, serum and brain 
of AD patients (Abraham et al., 1988, Licastro et al., 1995, Licastro et al., 1998).  In the normal 
brain, ACT is localized to astrocytes and in the AD brain it is overexpressed in the astrocytes 
surrounding amyloid plaques (Abraham et al., 1988, Pasternack et al., 1989, Abraham et al., 1990).  It 
has been implicated in the pathophysiology of AD as transgenic AD mice carrying the human ACT 
gene exhibit accelerated amyloid plaque pathology development (Mucke et al., 2000, Nilsson et al., 
2001) and cognitive decline.  IL-1β has been shown to increase the expression of ACT in human 
astrocytes, with a subsequent increase in synthesis of APP (Das and Potter, 1995, Nilsson et al., 
2001).  ACT has been shown to enhance both amyloid and tau-associated pathologies. It has been 
shown to bind the toxic Aβ peptide and accelerate its fibrilization (Fraser et al., 1993, Eriksson et al., 
1995, Ma et al., 1996, Abraham et al., 2000).  Studies from our lab have shown that treatment of 
primary mouse neurons with purified ACT protein results in tau phosphorylation and apoptosis, 
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implying a role for ACT in neurofibrillary tangle formation and neuronal loss associated with AD 
(Padmanabhan et al., 2006).  Furthermore, we determined that transgenic mice expressing human 
tau and human ACT show enhanced tau phosphorylation upon IL-1β injection, which is mediated 
by JNK signaling, indicating ACT and IL-1β work in collaboration to enhance tau pathology 
development (Tyagi et al., 2013). 
 Another inflammatory mediator whose expression has been shown to be regulated by the 
cytokines IL-1β and TNF-α is Cyclooxygenase-2 (COX-2), which is responsible for the production 
of prostaglandin.  Its function in inflammation is to induce vasodilation, thus mediating the 
transport of immune cells to injured tissue (Williams, 1978).  Interestingly, neurons are the main cell 
types that show increased expression of COX-2 in the AD brain (Oka and Takashima, 1997, 
Pasinetti and Aisen, 1998, Yermakova et al., 1999, Hoozemans et al., 2001), suggesting its role in the 
inflammatory response.  COX-2 has been shown to not only correlate with AD pathology load 
(neurofibrillary tangles and neuritic plaques), but also with cognitive impairment (Ho et al., 2001).              
 1.3.2.2. Cell Cycle Deregulation  
Mature primary neurons are thought to be quiescent and terminally differentiated.  
Surprisingly, vulnerable neurons in the human AD brain exhibit activation of signaling cascade, 
expression of cell cycle regulatory proteins and transcriptional activation, suggesting an abnormal 
emergence from post-mitotic state.   
   
  1.3.2.2.1. An Overview of Cell Cycle Regulation  
In the eukaryotic cell, the cell cycle can be divided into four discrete phases: G1 (gap 1), S 
(synthesis), G2 (gap 2) and M (mitotic) phase (Figure 1.6.) (Cooper, 2000).  Most differentiated cells 
have withdrawn from cell cycle and reside in G0 phase.  Upon mitogenic stimulation, quiescent cells 
may re-enter cell cycle and, once the cell has left G1 phase, it must fully commit to progressing 
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through the cell cycle.  In order for a successful progression through the cell cycle, the cell must pass 
tightly regulated checkpoints.  This regulation is primarily controlled by the periodic and highly 
ordered activation of cyclin-dependent kinases (cdks) binding to specific cyclins and their 
inactivation following disassociation (Hochegger et al., 2008).  As shown in Figure 1.6, when the cell 
leaves G0, cyclin D is synthesized and it interacts with cdk4 or cdk6, forming an active complex that 
then phosphorylates retinoblastoma (Rb) protein.  Phosphorylation of Rb results of the liberation of 
the Rb-bound transcription factor, E2 promoter binding factor 1 (E2F1).  Upon its release, E2F1 
activity is restored and it induces the synthesis of necessary proteins required for DNA replication 
(Liu et al., 1998).  Transition from G1 to S is regulated by cyclin E and cdk2 association which 
further phosphorylates Rb.  Once Rb is phosphorylated, there is an irrevocable commitment of the 
cell to continue into S phase (Pardee, 1989).  Once the cell enters S phase, cyclin E is rapidly 
degraded and cdk2 can then complex with cyclin A.  The cdk2/cyclin A complex drives synthesis of 
DNA (Pagano et al., 1992).  S phase to G2 progression requires the coupling of cdk1 and cyclin A 
and G2 transitions to M phase is regulated by the formation of the cdk1/cyclin B complex 
(Gopinathan et al., 2011).     
 
Figure 1.6. Cell cycle progression. A schematic of the cell cycle and its regulation (Frade and Ovejero-
Benito, 2015). 
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 1.3.2.2.2. Cell Cycle Dysregulation and Mitotic Catastrophe in Neurons 
Recent studies have explored the possibility of cell cycle re-entry in susceptible neurons of 
the human AD brain.  These neurons exhibit features that are similar to that of a cell that is in 
preparation for cell division with the reappearance of a number of cell cycle regulatory proteins 
including cyclins D, E and B as well as cdks 4, 2 and 1 (Vincent et al., 1997, Busser et al., 1998, 
Raina et al., 1999, Raina et al., 2000).  The expression of these cell cycle markers suggests that the 
neurons in AD have emerged from the G0 phase and are no longer quiescent.  In rare cases 
binucleation in the hippocampal neurons of AD patients have been observed, indicating cell cycle 
progression followed by defective cytokinesis (Zhu et al., 2008).   In fact, the treatment of 
differentiated cortical neurons with oligomeric Aβ can promote expression of cell cycle markers 
necessary for G1/S transition and, once entered into S phase, neurons begin to duplicate their 
DNA, subsequently leading to apoptosis (Copani et al., 1999).  These findings implicate cell cycle 
deregulation and subsequent mitotic catastrophe as possible underlying mechanisms in neuronal loss 
associated with AD.                   
1.3.2.3. Interplay Between Inflammation and Cell Cycle Deregulation in 
Alzheimer’s Disease 
 Pathogenic stimuli such as inflammation and oxidative stress have been shown to induce cell 
cycle events in the compromised brain (Arendt et al., 1996, McShea et al., 1997, Vincent et al., 1997, 
Bonda et al., 2010).  In fact, there is increasing evidence for DNA synthesis and ectopic expression 
of cell cycle proteins such as cyclin E, cyclin B, cdc2 and cdk4 in the vulnerable neuronal 
populations in AD (Arendt et al., 1996, McShea et al., 1997, Hoozemans et al., 2002, Harris, 2007, 
Bhaskar et al., 2014) and the aberrant cell cycle events seem to coincide with microglial activation 
(Varvel et al., 2009).  Supporting this, one study has shown that the media from microglia treated 
with Aβ can induce abnormal neuronal cell cycle entry and subsequently, death (Wu et al., 2000).  
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Studies by another group showed that these cell cycle events closely correlated with secretion of 
TNF-α (Engelhart et al., 2004).  Further, preincubation of Aβ-treated microglia with TNF-α 
antibody significantly reduced BrdU incorporation in neurons treated with conditioned media, 
implaying that TNF-α secreted by the microglia is responsible for the observed cell cycle events in 
primary neurons (Engelhart et al., 2004).  Another study used an in vivo adoptive transfer model, 
where purified microglia from transgenic AD mice were injected into wild type mice that were either 
injected with IgG or anti-TNF-α antibody.  Mice injected with anti-TNF-α antibody showed 
significant decrease in neuronal cyclin D1 levels (Bhaskar et al., 2014).  This was highlighted by the 
fact that AD transgenic mice crossed with TNF-α null mice show basal levels of cyclin D1 in 
neurons (Bhaskar et al., 2014).  Finally, this group looked at the role of JNK as it was found to be 
elevated in the transgenic AD mice.  Using the previously described in vitro system, they discovered 
that treatment of neurons with SP600125, a specific JNK inhibitor, decreased BrdU incorporation 
upon treatment with condioned media, suggesting the TNF-α induces cell cycle events through JNK 
signaling (Bhaskar et al., 2014).  These studies indicate that it is likely that inflammation induced glial 
activation could lead to the aberrant expression of cell cycle proteins and subsequent neuronal death 
in the AD brain. 
 Expression of inflammation-associated genes is associated with cell cycle dysregulation.  
COX-2 has been implicated in cell cycle deregulation as its enhanced expression correlated with 
promotion of cancer growth and its inhibition attenuates this growth (Harris, 2007).  Studies have 
also drawn parallels between cell cycle changes and COX-2 expression in the neurons of the AD 
brain.  In addition to its elevated levels in the AD brain, COX-2 is found to be co-localized with 
cyclin D1, cyclin E and phosphorylated retinoblastoma (Rb) protein in the pyramidal neurons, which 
may be indicative of aberrant cell cycle activation in neurons (Hoozemans et al., 2002, Hoozemans 
et al., 2004).  COX-2 homozygous transgenic mice show a marked decrease in the mRNA of the cdk 
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inhibitor p18INK4 and exhibit accelerated glutamate-induced apoptotic damage which could be 
attenuated by administration of the cdk inhibitor, flavopiridol (Mirjany et al., 2002).  This study also 
showed that wild type primary hippocampal neurons treated with the COX-2 inhibitor nimesulide 
diminishes glutamate-mediated apoptotic damage and inhibits subsequent phosphorylation of Rb 
(Mirjany et al., 2002). 
 In prospective case-cohort epidemiological studies, elevated serum levels of specific acute 
phase proteins have shown a positive correlation with development of AD (Schmidt et al., 2002, 
Yaffe et al., 2003, Engelhart et al., 2004, Dik et al., 2005).  Other studies have shown the beneficial 
effects of chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) in slowing, or even 
preventing AD (McGeer et al., 1996, Stewart et al., 1997, in t' Veld et al., 2001, Vlad et al., 2008) and 
post mortem analysis of brain tissue from AD patients on NSAIDs has also revealed a consistent 
reduction in inflammation (Mackenzie, 2001).  In vivo studies using transgenic AD mice show that 
long-term administration of the NSAID Ibuprofen both decreases neuroinflammation and improves 
cognition (Varvel et al., 2009).  An early treatment regimen with Ibuprofen given to transgenic AD 
mice improved spatial learning and hippocampal-dependent memory function (Kukar et al., 2007).  
Early Ibuprofen administration also resulted in reduced amyloid plaque load, glial activation and 
expression of inflammatory mediators in the transgenic AD mouse brain (Lim et al., 2000, Lim et al., 
2001, Kukar et al., 2007).  Epidemiologists have been interested in studying patients with 
rheumatoid arthritis and osteoarthritis as these individuals exposed to NSAIDs for long periods of 
time show an inverse relationship between AD and treated arthritis (Zandi and Breitner, 2001). 
 It is debated how NSAIDs might exert these effects.  Some studies find that NSAIDs act as 
modulators of γ-secretase by interacting with APP itself and shifting the pathogenic cleavage site to 
yield a shorter Aβ fragment (Weggen et al., 2001, Avramovich et al., 2002, Eriksen et al., 2003, 
Kukar et al., 2008).  Others have suggested that NSAIDs are capable of lowering β-secretase levels 
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(Sastre et al., 2006).  Finally, an in vitro study by Hirohata et al. found that NSAIDs have a direct 
inhibitory effect on formation of Aβ fibrils (Hirohata et al., 2005).  These observations however, 
have not held up in clinical trials.  Individuals with clinical AD symptoms that were treated with 
NSAIDs showed no beneficial effects (Aisen, 2002, van Gool et al., 2003, Group et al., 2008).  It is 
possible that the inverse relationship between rheumatoid arthritis and AD could be due to the 
intrinsic factors underlying the autoimmune disorder.  Injection of transgenic AD mice with 
granulocyte macrophage-colony stimulating factor (GM-CSF), an inflammatory cytokine involved in 
leukocyte stimulation in rheumatoid arthritis, has been shown to reduce amyloid plaque burden, 
rescue cognitive deficits and increase hippocampal synaptic area (Boyd et al., 2010). 
 Many studies, however, maintain that there is a direct link in NSAID usage and reduced AD 
risk.  A recent study modeled inflammation in AD through the activation of microglia by injecting 
lipopolysaccharide (LPS) into young AD mice, which were then aged.  Tellingly, the administration 
of NSAIDs to young mice prevented AD pathology (Varvel et al., 2009).  As a culmination of the 
relationship between inflammation and cell cycle dysregulation in Alzheimer’s disease, this study also 
indicated that early treatment leads to blockade of microglial activation and neuronal cell cycle 
events (Varvel et al., 2009).  Late NSAID treatment in aged mice, while halting new neuronal cell 
cycle events, could not reverse existing ones (Varvel et al., 2009).  This study underscores the close 
relationship between neuroinflammation and cell cycle in compromised neurons of the AD brain 
and suggests that early therapeutic intervention may lead to the best outcome.   
 It is unclear whether the downstream effects of cell cycle dysregulation triggers an 
inflammatory response or if neuroinflammation precedes these cell cycle events.  As shown in 
Figure 1.7, it is likely that there is interplay between these complex biological events and timing is 
important in targeting these events for prevention of neurodegeneration associated with AD.      
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Figure 1.7.  Schematic of the inflammation and cell cycle-dependent signaling in AD.  Amyloidogenic 
processing of APP leads to the production of the neurotoxic Aβ peptide.  Reduced clearance and Aβ 
aggregation leads to glial activation and subsequent production of pro-inflammatory cytokines and 
chemokines, which can enhance expression of cell cycle regulatory proteins in the AD brain.  In 
particular, TNF-α and COX-2 have been shown to correlate with expression of cell cycle markers.  
TNF-α is thought to initiate cell cycle events through the activation of the JNK pathway.  Chronic 
exposure of neurons to inflammatory mediators thus lead to accelerated neuritic plaque and 
neurofibrillary tangle formation in AD brain.  Inhibition of inflammation could potentially prevent 
aberrant cell cycle signaling and neurodegeneration associated with AD. 
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CHAPTER 2:  MITOSIS-SPECIFIC PHOSPHORYLATION OF AMYLOID 
PRECURSOR PROTEIN AT THREONINE 668 LEADS TO ITS ALTERED 
PROCESSING AND ASSOCIATION WITH THE CENTROSOMES1 
 
2.1. Introduction 
 As previously discussed, AD brains show neuroinflammation and neuronal loss, which is 
associated with aberrant expression of cell cycle regulatory proteins (Arendt et al., 1996, Vincent et 
al., 1996, McShea et al., 1997, Nagy et al., 1997, Vincent et al., 1997). The cause or the function of 
the increased levels of cell cycle regulatory proteins in post-mitotic neurons is not clearly 
understood. Studies by different groups suggest that fully differentiated neurons in adult brains 
emerge from quiescence and attempt to re-enter the cell cycle under pathological conditions 
(Freeman et al., 1994, Lee et al., 1994, Herrup and Busser, 1995, Kranenburg et al., 1996, Busser et 
al., 1998, Arendt, 2000, Herrup and Arendt, 2002, Hoozemans et al., 2002, Malik et al., 2008). This 
apparent upregulation of cell cycle regulatory proteins in neurons, along with the findings that the 
inhibitors of cell cycle activation protect neurons from undergoing apoptosis, led to the hypothesis 
that inappropriate attempts by neurons to re-enter the cell cycle may lead to neurodegeneration and 
apoptosis (Feddersen et al., 1995, Vincent et al., 1996, Padmanabhan et al., 1999, Giovanni et al., 
2000, Konishi and Bonni, 2003, Verdaguer et al., 2003, Kruman et al., 2004, Padmanabhan et al., 
                                                          
1 The information in this chapter has been legally reproduced under the Creative Commons Attribution (CC-BY) license 
and are utilized with the permission of the publisher. See Appendices B and C.  Judge M, Hornbeck L, Potter H, 
Padmanabhan J (2011) Mitosis-specific phosphorylation of amyloid precursor protein at threonine 668 leads to its 
altered processing and association with centrosomes. Molecular neurodegeneration 6:80. 
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2007).  In addition to neuronal loss, it is possible that dysregulation of the cell cycle may lead to cell 
cycle-dependent modifications in APP and tau, the two major proteins associated with AD, favoring 
plaque and tangle formation and neurodegeneration in the AD brains. 
Mutations in APP and PS1 are associated with increased generation of Aβ and increased 
pathology development in AD (Scheuner et al., 1996). In addition to the accumulation of Aβ into 
amyloid, studies in neurons have shown that Aβ peptides can induce cell cycle activation and 
neuronal apoptosis (Copani et al., 2002).  Expression of a mutant form of APP or PS1, as well as 
treatment with Aβ, have been shown to induce chromosome mis-segregation and aneuploidy in cells 
(Geller and Potter, 1999, Boeras et al., 2008), which indicates aberrant cell cycle activation under 
these conditions. Studies conducted in two different AD mouse models have shown an upregulation 
of cell cycle regulatory proteins in glial cells (Gartner et al., 2003) and neurons (Yang et al., 2006). 
Thus, cell cycle deregulation may influence both neuronal and glial functions, and a keen analysis of 
the cell cycle-dependent changes in these cells may reveal the significance of the upregulated 
expression of cell cycle markers in AD brains. Mice generally do not show much neuronal loss, but 
it is possible that the upregulation of cell cycle regulatory proteins may mediate synaptic loss and 
neurodegeneration by inducing modifications in tau and APP. Here we analyzed the specific effects 
of cell cycle activation on APP modifications. 
APP is phosphorylated by multiple kinases, which affects its proteolytic processing, 
trafficking, and protein-protein interaction (Suzuki et al., 1994, Arendt, 2003, Muresan and Muresan, 
2004, Chang et al., 2006, Muresan and Muresan, 2007, Suzuki and Nakaya, 2008). We tested the 
hypothesis that cell cycle activation can affect APP modifications and plaque development, using in 
vitro cultured cells and transgenic mice. The studies presented here show that transgenic mice 
expressing mutant APP (APPV717F) and PS1 (PS1M146L) show an increase in the levels of cell cycle 
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regulatory proteins which is associated with induction of APP phosphorylation at Thr668 and 
formation of Aβ and phosphorylated C-terminal fragment of APP. Experiments conducted in H4 
neuroglioma cells overexpressing APP confirmed that this phosphorylation is mitosis-specific and 
can be inhibited by G1/S transition inhibitors, which prevent Aβ generation. A role for G1/S 
specific inhibition was further determined by inhibition of P-APP formation by siRNA to cdk-2. 
This observation, along with our finding that P-APP co-localizes with MPM2 at centrosomes in 
mitotic cells suggests that mitotic mechanisms may influence AD pathology by not only affecting 
APP phosphorylation and Aβ generation, but also by enabling it to have a role in spindle assembly 
and cell cycle regulation. Thus, APP may act as a cell cycle inducer under mitotic conditions and 
might play a feed forward role in pathology development in AD. 
2.2. Materials and Methods 
 2.2.1. Materials 
 The tissue culture reagents, electrophoresis supplies, and Alexa fluorphores were purchased 
from Gibco/Invitrogen, Carlsband, CA. Poly-D-Lysine (PDL), α-tubulin antibody and Hoechst 
were from Sigma, St. Louis, MO. Anti-Aβ/APP antibody (6E10 raised against Aβ1-16) was from 
Signet, C-terminal APP antibody was from Chemicon/Millipore, Thr668 P-APP, MPM-2, and P-
cdc2 antibodies were from Cell Signaling, and cyclin D1, cyclin E, and E2F1 antibodies were from 
Santa Cruz Biotechnology. The reagents for brightfield staining were purchased from Vector 
Laboratories. Enhanced chemiluminescence (ECL) reagent was from Pierce Biotechnology Inc., 
Rockford, IL. H4 neuroglioma cells overexpressing WT-APP (H4-APP) was a kind gift from Dr. 
Todd Golde (Mayo clinic, Jacksonville, Florida). 
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 2.2.2. Transgenic Mice 
 Heterozygous PDGF-hAPP (V717F) mice (Swiss-Webster × C57BL/6) were crossed with 
PDGF-hPS1 (M146L) heterozygotes (Swiss-Webster × C57BL/6) to generate mice with an APP+/-, 
PS1+/- genotype. All offspring were screened by PCR to verify the expression of APP and PS1 gene 
(Games et al., 1995, Duff et al., 1996). The APP mutant mice develop many of the pathological 
hallmarks of AD, including neuritic plaques (appear at around 10-12 months of age), and cognitive 
deficits in an age-dependent manner, and the expression of mutant PS1 in these mice accelerates the 
pathology development significantly (plaques are visible as early as 4-6 months of age). In the 
current study we used these transgenic and age-matched non-transgenic (Ntg) mice. Mice were 
anesthetized using Nembutal (10 mg/kg body weight) and perfused with saline solution. The brains 
were dissected out and half of each brain was immersion fixed with 4% para-formaldehyde and the 
other half was used for protein extraction. For protein extraction, brains were homogenized in 
Hepes lysis buffer (50 mM HEPES pH 7.4, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 5 mM 
MgCl2, 1 mM EGTA, 20 mM NaF, 2 mM Na3VO4, and protease inhibitors (Roche)). Samples were 
centrifuged at 14,000 rpm for 30 min and equal amounts of proteins were used for western blot 
analysis. The brains were processed as described before for immunohistochemical analysis 
(Padmanabhan et al., 2006). Brain sections were made using a freezing stage sliding microtome and 
stored at 4°C in phosphate buffered saline (PBS) containing sodium azide (0.02%) for 
immunohistochemical analysis. 
 2.2.3. Immunostaining 
 This was done following the established protocols (Padmanabhan et al., 2006, 
Padmanabhan, 2009). Briefly, H4-15X cells cultured in 8-chamber tissue culture slides coated with 
PDL were treated with or without different inhibitors of the cell cycle for 18hr; roscovitine (20μM) 
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as G1/S inhibitor, aphidicolin (5μg/ml) as S-phase inhibitor, nocodazole or vinblastine (100ng/ml 
or 10μM respectively) or taxol (placitaxel, 100ng/ml) as mitotic inhibitor. At the end of the 
treatment, cells were fixed with 4% para-formaldehyde and staining was performed using the 
appropriate antibodies. Staining was analyzed under a Zeiss microscope using the AxioVision Rel 4.8 
software. Centrosome specific staining of P-APP in H4-APP cells was confirmed by confocal 
microscopy under an Olympus imaging system using Fluoview FV1000 ver.1.7 software. 
 For immunostaining analysis of the brain sections, sections were mounted onto superfrost 
slides, and non-specific binding was blocked by incubating with 10% normal goat serum 
(NGS)/TBST for 2hrs at room temperature. Sections were then incubated with appropriate 
dilutions of the primary antibody (APP (6E10), Thr668-P-APP, cyclin D1, cyclin E, E2F1, and P-
cdc2 antibodies) in 1% BSA/TBST overnight at 4°C in a humidified chamber. After thorough 
washing, the sections were incubated with biotinylated mouse or rabbit secondary antibodies for 1hr 
at room temperature and developed following the manufacturer's protocol with the DAB kit from 
Vector laboratories. The staining was visualized using a Nikon E1000 microscope using Image-Pro 
Plus software. In the case of fluorescent labeling, after primary antibody incubation as outlined 
above, sections were incubated with Alexa 488 or 594 fluorophores for 2hrs at room temperature 
protected from light. Sections were washed and nuclei were counter stained using Hoechst 33342 
and washed again before mounting using aqueous Gel/Mount. Sections were stained with secondary 
antibody alone to determine non-specific binding of antibodies to the tissue (data not shown). The 
results were analyzed under a Zeiss microscope using the AxioVision Rel 4.8 software. The signal 
intensity of the images was determined by Image J, image processing and analysis program 
(Padmanabhan et al., 2007). Adjacent sections from at least 3 independent mice expressing different 
transgenes were stained using the antibody of interest. Prior to measurement, the images were 
converted to 8-bit grayscale and the threshold of all the images from each set of experiments was 
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adjusted to the same level. This keeps the sample-to-sample variation minimal. The intensity 
obtained with Hoechst staining was used as a normalizing control for each section. 
 2.2.4. Immunoprecipitation and Western Blot Analysis 
 H4-15X cells were cultured in OPTI-MEM containing 10% FBS and 50μg/ml hygromycin 
in 100 mm culture dishes overnight and serum starved for 48 to 72 hr. Serum stimulation of the cells 
was done in the presence or absence of different pharmacological inhibitors for the indicated time 
periods. Cell culture supernatants and cell lysates (made in Hepes lysis buffer) were 
immunoprecipitated using 6E10 antibody and analyzed using the same antibody to detect secreted 
and cellular levels of Aβ. In the case of brain extracts, equal amounts of protein were boiled with 
Tricine sample buffer and PAGE and western-immunoblot analysis was performed using 
appropriate antibodies. For quantification, western blot images on the X-ray film were scanned and 
densitometric analysis was performed using the Image J, image processing and analysis tool after 
selecting and plotting the bands of interest. 
 2.2.5. siRNA Transfection of H4-APP Cells 
 We obtained Silencer validated siRNA to cdk2 (locus ID: 1017) from (Ambion, Inc. Applied 
Biosystems), siRNA to cdk5 from Santa Cruz Biotechnology and siRNA to GSK-3αβ from 
Invitrogen. The siRNA was used at the indicated concentrations and transfected using 
oligofectamine (Invitrogen) using OPTI-MEM without serum. 6hrs after transfection the media was 
replenished with an equal volume of OPTI-MEM containing 2X serum and cultured for 24 to 48hrs. 
At the end of the time period cells were harvested in sample buffer and analyzed by western blot for 
downregulation of the kinases using the corresponding kinase antibody and phosphorylation of APP 
by Thr668 P-APP antibody. 
 Statistical analysis was performed using Student's t-Test. 
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2.3. Results 
 2.3.1. Upregulation of Cell Cycle Regulatory Proteins in AD Transgenic Mice 
 Atypical expression of cell cycle regulatory proteins has been shown primarily in neurons of 
AD brains. Studies in different mouse models of AD showed upregulation of cell cycle regulatory 
proteins with some variation in the observations; while one study showed upregulation of cyclins 
D1, B and E in astrocytes with cdk4 nuclear translocation (Gartner et al., 2003), another study 
showed upregulation of PCNA and cyclin A in neurons (Yang et al., 2006). Because there is 
variation in cell cycle protein expression in different AD transgenic mice, we tested the transgenic 
mice that we used in our studies for changes in the reported cell cycle regulatory proteins. The 
brains from 12 month old mice expressing mutant human APP (V717F), mutant PS1 (M136L), a 
combination of these two transgenes, and age matched non-transgenic (Ntg) controls were analyzed 
by quantitative immunohistochemistry using specific antibodies to cyclin D1, cyclin E, E2F1, P-
cdc2, and cdc2. Significant increases in cyclin D1, cyclin E, P-cdc2, and E2F1 were observed in the 
PS/APP double transgenic mice (Figure 2.1, A and B). Mice expressing APP alone showed a smaller 
increase in the level of these cell cycle regulatory proteins compared to the double transgenic mice 
(Figure 2.1, A, d compared to A, e), possibly due to the differences in the transgene expression and 
the fact that PS/APP mice develop pathology at an earlier age compared to APP expressing mice. 
E2F1 and cyclin E stained cells surrounding the plaques (Figure 2.1, A, inset b, d, and e) appeared to 
have glial-like morphology, whereas P-cdc2 appeared to stain both neuronal and glial-like cells 
(Figure 2.1, A, g: black arrow head - neuron & white arrow head - glia). We did not observe any 
change in the level of staining with a non-phospho-cdc2 antibody. Figure 2.1, B shows the 
quantitative analysis of cyclin D1 and E levels in APP and PS/APP mice compared to Ntg mice. 
Co-immunostaining analysis of brains from 10 month old PS/APP mice with cyclin D1 or cyclin E 
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and 6E10 antibodies showed increased levels of these cell cycle regulatory proteins in neurons in the 
brains (Figure 2.2, A and B). Studies from other groups have shown that Aβ can induce 
neurodegeneration through activation of cell cycle dependent mechanisms (Giovanni et al., 1999, 
Varvel et al., 2008). Further studies are necessary to determine whether the increased expression of 
cell cycle regulatory proteins in neurons is brought about by increased levels of Aβ in the AD 
transgenic brains. It is possible that the cell cycle activation and Aβ generation are regulated in a feed 
forward manner, with cell cycle activation inducing Aβ production and Aβ in turn inducing cell cycle 
deregulation. 
 
Figure 2.1. Increased expression of cell cycle regulatory proteins in AD transgenic mice. A) Cyclin E, E2F1 and 
P-cdc2 levels are upregulated in transgenic mice expressing APP and PS/APP: Brain sections from 
Ntg normal mice (a, c, f) were compared to those from transgenic mice expressing APP (d, g) and 
PS/APP (b, e, h) using cyclin E (upper panel), E2F1 (middle panel) or P-cdc2 (lower panel) 
antibodies. Images (a-e, 5×and f-h 20×) were taken using a Nikon E1000 microscope and analyzed 
using Image-Pro Plus software. The P-cdc2 and images in the inset show magnified images (20×) of 
the plaques to visualize the cells. We found that the cells surrounding the plaques were positive for 
cyclin E, E2F1,and P-cdc2, and it appears that both neurons (black arrow head) and glia (white 
arrow head) were positive for P-cdc2. ‘Secondary antibodies only’ control did not show any specific 
staining of the sections (data not shown). B) Quantitative analysis of cyclin D1 and E expression in 
APP and PS/APP transgenic mice brains: Brain sections from Ntg and mice expressing APP and 
PS/APP were stained using a monoclonal cyclin D1 or a polyclonal cyclin E antibody and nuclei 
visualized using Hoechst. The signal intensity was measured using Image J, image processing and 
analysis program. The signal strength was compared to that with Hoechst nuclear staining from each 
section to avoid mouse-to-mouse variation. The means of results from six independent mice are 
shown with standard error bars and P values. While APP mice showed a significantly higher level of 
only cyclin E compared to cyclin D1, PS/APP mice showed higher levels of both cyclin D1 and E 
levels compared to Ntg. 
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Figure 2.2. AD transgenic mice show increased expression of cyclin D and cyclin E in neurons.  Brain sections 
from 10 month old Ntg and PS/APP mice were co-stained using A) monoclonal 6E10 and 
polyclonal cyclin D1 or B) 6E10 and polyclonal cyclin E antibodies. Staining was visualized using 
Alexa fluor 488 (APP and Ab, green) and Alexa fluor 594 (red) and analyzed under a Zeiss 
microscope using AxioVision Rel 4.8. The images were taken at 20× magnification. The composite 
image shows staining with Hoechst, cyclin, and 6E10 antibodies. The area indicated by arrows is 
enlarged and shown on the right to clearly see the positive staining in neurons. 
 
 2.3.2. Phosphorylation of APP at Thr668 in Mice Expressing AD Transgenes 
 APP is a transmembrane protein and is phosphorylated by several kinases including the cell 
cycle-dependent kinase cdc2 (Suzuki et al., 1994). Phosphorylation of APP seems to enhance its 
proteolytic processing and altered localization (Arendt, 2003, Chang et al., 2006). In order to 
determine the phosphorylation levels of APP in cells associated with AD pathology, we performed 
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immunohistochemical and western blot analysis of brain samples from mice expressing PS1 or APP 
alone or together and compared the results to that from age-matched Ntg mice. Co-staining with the 
Aβ antibody (6E10) and Thr668 specific P-APP antibody (P-Thr668-APP) showed that significantly 
higher levels of P-APP and Aβ (6E10 positive) associate with the plaques in AD mice (Figure 2.3). 
The Aβ staining (6E10) was localized mostly to the plaque cores with some diffuse staining around 
the plaques whereas P-APP was distributed towards the periphery of the plaques. 
 
Figure 2.3.  APP overexpressing mice show increased levels of Thr668 P-APP.  Brain sections from Ntg, APP, 
and PS/APP mice were immunostained using monoclonal 6E10 antibody and polyclonal Thr668 
specific P-APP antibody. A) Representative sections from Ntg (top row), APP (middle row), and 
PS/APP (bottom row) mice stained with a 6E10 antibody (left column), Thr668 P-APP antibody 
(middle column) and composite image (right column) with Hoechst showing nuclear staining. 
Magnification: 40×. B) Quantification of the intensity of 6E10 and P-APP staining in Ntg, APP, 
PS/APP and PS mouse brains. Both APP and PS/APP mice showed significantly higher levels of 
APP and Thr668 P-APP with more intensity in mice expressing both PS and APP transgenes 
compared to APP alone. The Ntg and PS expressing mice showed low levels of APP and P-APP. 
 
 The staining pattern observed with Thr668 P-APP antibody around the plaques suggested that 
P-APP is accumulating in dystrophic neurites. In order to confirm this, we performed co-staining of 
the sections with antibodies specific for P-APP and phosphorylated neurofilament H protein (NF-
H, SMI34) (Figure 2.4). SMI34 stains neurofilament proteins when phosphorylated, and it has been 
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shown to stain NFTs and dystrophic neurites (Stoltzner et al., 2000). We found co-localization of 
SMI34 and P-APP in the areas surrounding the plaques in APP and PS/APP mice (Figure 2.4, rows 
3 and 4), suggesting the association of Thr668 P-APP with degenerating neurites. Ntg mice and PS1 
mice did not show any specific staining with either Thr668 P-APP or SMI34 antibodies (Figure 2.4, 
rows 1 and 2). 
 
Figure 2.4.  Thr668 P-APP antibody co-localizes with phospho-neurofilament NFH antibodies in the plaques. 
Brain sections from Ntg, PS, APP and PS/APP mice were analyzed with Thr668 P-APP and 
monoclonal P-NFH (SMI34) antibodies and visualized using Alexafluor 594 and 488, respectively.  
Nuclei were visualized using Hoechst stain.  Magnification: 40X. 
 
 2.3.3. APP Phosphorylation and Processing in AD Transgenic Mice 
 Western blot analysis of brain extracts from transgenic mice using the human specific 6E10 
(raised against amino acids 1-16 of Aβ) antibody confirmed over expression of APP in both APP 
and PS/APP transgenic mice (Figure 2.5., A). As 6E10 is more specific for human APP, for 
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detection of mouse APP the blots were reprobed with C-APP antibody, which showed the total 
expression level of APP in vivo in the non-transgenic and transgenic mice (Figure 2.5, C). The 
transgenic mice expressing APP and PS/APP showed very high levels of C-terminal APP fragments 
(Figure 2.5, A and C). 6E10 antibody detected Aβ in both APP and PS/APP mice (Figure 2.5, A). 
The level of Aβ showed variation between mice probably due to the altered levels of transgene 
expression.  
 
Figure 2.5. Increased levels of APP phosphorylation and processing in transgenic mice expressing APP and 
PS/APP. Equal amounts of proteins from Ntg, APP, PS1, and PS/APP brain extracts were analyzed 
using 6E10, C-APP, 22C11, and P-Thr668 APP antibodies. A) Shows western blot analysis using 
monoclonal 6E10 antibody (detect APP, Aβ, and any Aβcontaining fragments of APP), B) shows 
reprobe of the same blot using actin antibody (indicated by arrow) without stripping to show equal 
amounts of protein loading, C) western blot using a polyclonal C-terminal APP antibody (detects full 
length and C-terminal fragments of APP), and D) represents the western blot using Thr668 P-APP 
antibody. Mice expressing APP and PS/APP showed very high levels of full length and C-terminal 
APP fragments. Aβ levels showed mouse-to-mouse variation probably due to varied expression of 
the transgenes. Levels of P-APP were significantly higher in both APP and PS/APP transgenic mice 
and the antibody detected the phosphorylated C-terminal fragment of APP as well. Blots were 
analyzed using supersignal ECL solution from Pierce. The histograms represent quantitative analysis 
of P-APP compared to the corresponding counterpart of total APP detected using C-terminal APP 
antibody: E) percent of full length P-APP, F) percent of P-C-APP (phosphorylated C-terminal 
fragment), and G) percent of total P-APP compared to total APP. 
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 Examination of blots using Thr668 P-APP antibody showed that both full length and C-
terminal fragment of APP show significantly higher levels of Thr668 phosphorylation compared to 
that detected in non-transgenic and PS1 mice (Figure 2.5, D). This finding, along with the finding 
that in primary rat neurons the C-terminal fragment generated by BACE cleavage shows more 
phosphorylation at Thr668 than does α-secretase cleaved C-APP (Arendt, 2003), suggests that the 
amyloidogenic cleavage of APP is enhanced upon phosphorylation at Thr668. The Thr668 P-APP 
antibody detects APP only when phosphorylated at Thr668 (Muresan and Muresan, 2004) and has 
been shown to react with human, mouse, and rat P-APP (Cell Signaling Technologies). On the 
western blot, it detected the intracellular levels of P-APP in the mouse (Ntg and PS), but the levels 
in APP expressing mice were significantly higher. The histograms in Figure 2.5, E, F and G show 
the percent of P-APP (full length, C-terminal fragment, and total) compared to the total counterpart 
of APP detected by the C-terminal antibody, in the brain extracts. 
 2.3.4. Age-dependent Changes in Thr668 Specific Phosphorylation of APP in 
Transgenic Mice 
 The above results showed that APP phosphorylation and processing are enhanced in 
transgenic mice expressing APP. In order to determine whether the APP phosphorylation varies 
with age, we examined transgenic mice expressing APP and PS/APP at different ages. Brain extracts 
were prepared from mice at 1.5, 2, 3 and 6 months of age and western blotted using Thr668 P-APP 
and 6E10 Antibodies (Figure 2.6, A-G). As expected, it was found that the total levels of APP and 
C99 fragments (using 6E10 antibody) were significantly higher in the AD transgenic mice (APP and 
PS/APP) compared to the non-transgenic mice. Within the transgenic groups, we did not observe 
any age-dependent increase in the levels of full length APP or C-99 fragments (Figure 2.6, A and D). 
On the other hand, the transgenic mice showed an age-dependent increase in Aβ generation, with 
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the mice expressing PS/APP showing higher levels of Aβ than that expressing just APP (Figure 2.6, 
A and G). Expression levels of full length P-APP did not vary significantly with age whereas the 
levels of phosphorylated C-terminal fragments (P-C-APP) were increased in an age-dependent 
manner in the AD mice (Figure 2.6, B and E). Figure 2.6, F shows the levels of Aβ compared to full 
length APP in the transgenic mice, and Figure 2.6, G shows the levels of Aβ compared to the levels 
of P-C-APP. A reprobe of the APP blots using actin antibody showed equal amounts of proteins on 
the blot (Figure 2.6, C). It is known that pathology development in AD is age-dependent. The data 
presented here further demonstrates that APP phosphorylation and processing as well as Aβ 
generation are also age-dependent and these fragments may contribute to the enhanced pathology 
development in AD. 
 In order to determine the localization of P-APP in mice at different ages we examined the 
brains from 1.5 and 6 month old mice using Thr668 P-APP and 6E10 antibodies. 1.5 month old APP 
and PS/APP mice showed a general increase in overall staining and an association of P-APP with 
degenerating (beaded) neurites (Figure 2.7, A and B show enlarged images of beaded neurites in 
APP and PS/AP mice). 6E10 staining was mainly visible within the neuronal cell bodies of APP and 
PS/APP mice (Figure 2.7, A). At 6 months of age the APP mice showed accumulation of P-APP in 
some neurons without any plaque pathology (Figure 2.7, D and B show neurons that show 
accumulation of P-APP). Unlike APP mice, 6 month old PS/APP mice showed very strong 
localized accumulation of P-APP in plaque-like structures, which did not always relate with 6E10 
stained plaques (Figure 2.7, D and E show the enlarged image of the area indicated by arrows in 
PS/APP mice). 
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Figure 2.6. Age-dependent changes in Thr668 specific phosphorylation and Aβ generation in transgenic mice. Brain 
extracts from 1.5, 2, 3, and 6 month old Ntg mice and transgenic mice expressing APP and PS/APP 
were examined by western blot using Thr668 P-APP and 6E10 antibodies. Panel A) shows the levels 
of full length APP and fragments of APP such as C-99 and Aβ in the mice at different ages. The 
transgenic mice expressing APP and PS/APP showed very high levels of full length APP. Only the 
levels of Aβ were altered in an age-dependent manner. Panel B) shows staining of the blot with 
Thr668 P-APP antibody, which detects mouse and human APP phosphorylated at this site. The levels 
of full length P-APP were higher in the transgenic mice. Levels of phosphorylated C-terminal P-
APP fragments were induced in an age-dependent manner in the transgenic mice. Panel C) shows 
reprobe of the blot with actin antibody without stripping to show approximately equal amount of 
protein loading. D-F) shows the relative signal intensity of the various APP fragments from the 
western blot analysis. D) Represents signal intensity of full-length APP and C-99 fragments, E) that 
of full length P-APP and phosphorylated C-terminal fragments of P-APP (P-C-APP), F) represents 
the levels of APP and Aβ and G) shows signal intensity of P-C-APP and Aβ. 
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Figure 2.7.  Immunohistochemical analysis of brain sections from transgenic mice at different ages. In order to 
determine whether there is accumulation of P-APP in the brain mice at 1.5 and 6 months were 
analysed using 6E10 and P-APP antibodies. Brain sections from transgenic mice showed an increase 
in overall staining using the 6E10 and P-APP antibodies (A-D). Panel A) shows brain sections from 
1.5 month old mice where P-APP showed beaded staining of neurites occasionally in APP and 
PS/APP mice. 6E10 staining showed APP in the neuronal bodies in these sections. The enlarged P-
APP positive neurites are shown in panel B. Panel C shows examples of neurons in APP mice at 6 
months that show P-APP accumulation. Panel D) shows the P-APP and 6E10 staining in 6 month 
old Ntg, APP, and PS/APP mice. The accumulation of Aβ and P-APP are visible only in the 
PS/APP mice at 6 months. Panel E) shows the magnification of the area shown with the arrows 
from 6E10 and PAPP stained PS/APP sections. Images in panel A) were taken at 10× and in panel 
B) at 20 × magnifications. Images shown in Panel D were taken at 5× magnification. 
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 2.3.5. Cell Cycle-dependent Phosphorylation of APP 
 The phosphorylation of APP at Thr668 in transgenic mice correlated with the expression of 
cell cycle regulatory proteins in the brains. This result, together with the published findings (Suzuki 
et al., 1994), prompted us to determine whether the APP phosphorylation is due to cell cycle 
activation. Since it is difficult to verify this in vivo, we decided to examine APP phosphorylation in 
cells cultured in vitro. H4 neuroglioma cells overexpressing WT-APP (H4-APP) were cultured for 24 
hr and serum starved for 48 hr. At the end of the starvation period, cells were serum stimulated in 
the presence or absence of pharmacological inhibitors of cell cycle progression for different time 
periods, and cell extracts were immunoprecipitated using 6E10 antibody and analyzed using P-APP 
antibody. The treatment of the cells included roscovitine (20 μM for 12-14 hr) an inhibitor of cdk2, 
cdc2, and cdk5 (Meijer et al., 1997), olomoucine (50 μM for 12-14 hr) an inhibitor of cdk1 (cdc2), 
cdk2, and cdk5 (Glabe, 2008), aphidicolin an S-phase inhibitor (5 μg/ml for 12-14 hr), or the mitotic 
inhibitors nocodazole (100 ng/ml), vinblastine (10 μM), or taxol (100 ng/ml) for 16 to 18 hr. 
Analysis of the cells using a fluorescence activated cell sorter (FACS) showed that roscovitine and 
aphidicolin treated cells were mostly arrested in the G1 phase of the cell cycle (60-70%), while 
nocodazole arrested cells were mostly in the G2/M phase (Figure 2.8, E). Cell extracts after 
treatment were immunoprecipitated using 6E10 antibody and the blot was analyzed using P-APP 
antibody. We found that Thr668 specific phosphorylation on APP was induced in a time dependent 
manner upon serum stimulation, and maximum levels of phosphorylation occurred upon mitotic 
arrest using nocodazole or vinblastine (Figure 2.8, A and D). The total levels of APP (reprobe using 
6E10 antibody) also showed a similar profile, but the levels were not as significant as those we 
observed with P-APP (Figure 2.8, B). Reprobe of blots using actin antibody (without stripping) 
showed approximately equal amounts of proteins on the gel (Figure 2.8, C). Roscovitine treatment 
consistently resulted in a decrease in the levels of P-APP, and aphidicolin and olomoucine kept the 
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phosphorylation more or less at the basal levels (Figure 2.8, A and D). These data confirm that the 
Thr668 specific phosphorylation on APP occurs in a cell cycle-dependent manner and peaks during 
mitosis.  
 
Figure 2.8. Mitosis-specific phosphorylation of APP.  H4-15X cells were growth arrested by serum 
starvation for 48 hr and serum stimulated with and without roscovitine, olomoucine, or aphidicolin 
for 12 hr, and nocodazole, vinblastine, or taxol for 16 hr. Cell extracts were prepared and equal 
amounts of proteins were immunoprecipitated using 6E10 antibody and western blotted using P-
APP antibody (A). B) APP levels in total lysate analyzed using 6E10 antibody. Panel C shows 
reprobe of blot B (without stripping) with actin antibody showing equal amount of proteins on gel. 
The histogram in panel D shows the percent of P-APP in cells under the different treatment 
conditions. The data represent the mean of 3 independent experiments with standard deviation 
shown. Cells arrested in metaphase showed significantly higher levels of P-APP (P < 0.05). Panel E 
shows the FACS analysis data from cells treated with cell cycle inhibitors. Cells were treated with 
roscovitine or aphidicolin for 12 hr or nocodazole or taxol for 16 hr and fixed and stained using 
propidium iodide before analysis on a FACS machine. Mean percent of cells in different phases of 
the cell cycle from 3 independent experiments is shown. 
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 Cells treated for 16-18 hr with taxol, a microtubule stabilizing agent, largely accumulated in 
the G1 (~45-50%) and G2 (~40-45%) phases, which was similar to that observed with serum 
stimulation for 16 hr and showed slightly higher levels of P-APP compared to serum stimulated 
cells. The results from the time course with serum as well as treatment with roscovitine, olomoucine, 
and aphidicolin suggest that APP phosphorylation occurs very early during the cell cycle. Thus, it is 
possible that in the brains of transgenic mice APP phosphorylation arises from cells attempting to 
enter the cell cycle and inhibitors of G1/S checkpoint may inhibit this phenomenon. 
 2.3.6. si-cdk2 Inhibits Serum Stimulation-induced APP Phosphorylation in H4-APP 
Cells 
 We found that APP is phosphorylated at Thr668 in a cell cycle-dependent manner and that 
roscovitine, an inhibitor of cdks such as cdc2, cdk2, and cdk5, prevented both APP phosphorylation 
and Aβ generation while nocodazole, a mitotic inhibitor, induced these phenomena. Earlier studies 
had shown that both cdk5 and cdc2 could induce Thr668 specific phosphorylation of APP while 
nothing was known about cdk2. In order to determine whether cdk2 or cdk4 are involved in APP 
phosphorylation during mitosis, we transfected H4-APP cells with different concentrations of cdk2 
and cdk4 siRNA and analyzed for changes in APP after 16 to 18 hr. Western blot analysis of extracts 
using specific cdk antibodies confirmed the downregulation of the kinases in the transfected cells 
(Figure 2.9, A). Analysis of extracts from cdk2 downregulated cells showed that this is associated 
with a decrease in APP phosphorylation at Thr668 (Figure 2.9, A) whereas cdk4 inhibition was not 
(data not shown). A non-specific control siRNA did not have any effect on the kinases or APP 
phosphorylation, suggesting that the results we observed with si-cdk2 are specific to this cdk. In the 
G1 phase of the cell cycle, cdk2 associates with cyclin E and enables the transition of cells through 
the G1/S checkpoint. The result with si-cdk2 thus agrees with the results shown in Figure 2.8 in 
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which APP phosphorylation is induced upon serum stimulation and is inhibited by blocking the 
G1/S transition. 
 
Figure 2.9.  siRNA to cdk2, cdk5 and GSK-3αβ inhibits serum stimulation-induced APP phosphorylation at 
Thr668. H4-APP cells plated in serum-free OPTI-MEM were transfected with siRNA to cdk2 (Panel 
A), GSK-3ab (panel B) or cdk5 (Panel C) at the indicated concentrations using oligofectamine. After 
6 hr serum containing media was added to the cells and samples were collected after 24-48 hr. Cell 
lysates were western blotted using the corresponding kinase antibodies to confirm downregulation 
of the respective kinases. Phosphorylation status of APP was analyzed using P-Thr668 APP antibody, 
and actin was used as a loading control. Down regulation of each kinase was associated with 
inhibition of serum stimulation-induced phosphorylation on APP. The histograms below each blot 
show the quantification of the level of the respective kinase and P-APP compared to the levels 
present in siRNA control transfected cells. The data are representative of one of three independent 
experiments. 
 
 Since it is known that cdk5 as well as GSK-3β can induce tau hyperphosphorylation in AD 
brains, and since these kinases have also been shown to affect APP phosphorylation, we examined 
the effect of downregulation of these kinases on APP phosphorylation. Cells transfected with 
siRNA to GSK-3αβ (Figure 2.9, B) and siRNA to cdk5 (Figure 2.9, C) also showed downregulation 
of APP phosphorylation as expected and it correlated with the levels of down regulation of the 
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corresponding kinases. These data thus suggest that APP and tau are phosphorylated under similar 
conditions, and that inhibitors of these kinases should be tested for their ability to reduce 
development of pathology in AD. The G1/S inhibitor roscovitine has been shown to inhibit cdk5 
and therefore the effect we see with this inhibitor could be due to its effect on not only cdk2 but 
other responsive kinases as well. 
 2.3.7. Distribution of P-APP in Asynchronously Growing Cells 
 Our results from H4-APP cells using the pharmacological inhibitors suggested that G1/S 
checkpoint inhibition prevents APP phosphorylation at Thr668. This prompted us to determine the 
expression and distribution of P-APP in cells at different phases of the cell cycle. First, we examined 
the localization of P-APP in asynchronously growing H4-APP cells. The cells were trypsinized and 
cultured for 24 hr and fixed and analyzed with monoclonal α-tubulin and polyclonal Thr668 P-APP 
antibodies. As expected, the asynchronously growing culture contained a non-homogeneous 
population of cells in different phases of cell cycle (Figure 2.10 A and B). P-APP showed a cell-cycle 
specific localization with more staining in cells that are in active division (prophase, metaphase, 
anaphase) and very little or no staining in early interphase cells (Figure 2.10, A-C). The cells that 
were in metaphase showed prominent localization of P-APP to the centrosomes (microtubule 
organizing centers; MTOCs) suggesting a role for phosphorylated APP in cell cycle activation 
and/or spindle assembly. We confirmed the localization of P-APP to centrosomes in metaphase 
cells using confocal microscopy (Figure 2.11). Cellular distribution of P-APP was also examined in 
cells treated with the pharmacological inhibitors roscovitine, aphidicolin, nocodazole, or taxol. While 
cells treated with roscovitine and aphidicolin showed very few cells in active division and hence little 
P-APP staining, the majority of the nocodazole treated cells were in the mitotic phase and exhibited 
significantly higher levels of P-APP (data not shown). 
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Figure 2.10.  Analysis of P-APP distribution in asynchronously growing H4-15X cells show cell cycle-dependent 
localization of P-APP. Panels A and B show asynchronously growing H4-15X cells fixed and 
immunostained using Thr668 P-APP polyclonal and a-tubulin monoclonal antibodies and visualized 
using Alexa 594 (red) and 488 (green) fluorophores respectively. Staining was analyzed using the 
AxioVision Rel 4.8 software for Zeiss microscope. Nuclei were visualized using Hoechst staining. 
Cells in mitotic phase showed P-APP localized to the centrosomes, nucleus and cytoplasm with 
maximum immunoreactivity in mitotic cells and minimum/none in interphase cells. Cells in 
telophase showed PAPP staining in the midbody which was absent in cells undergoing cytokinesis. 
The absence of staining in the interphase cells suggests that APP phosphorylation at Thr668 occurs 
only when cells are undergoing division. Panel C shows a cell cycle schematic with representative 
cells from different stages of the cell cycle (selected from an asynchronously growing culture) 
illustrating the phosphorylation event occurring once the cells enter prophase and tapering off as it 
exits the cell cycle (cytokinesis). Magnification: 63×.  
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Figure 2.11. Centrosome association of Thr668 P-APP in mitotic cells. Asynchronously growing H4-APP 
cells were fixed and immunostained using Thr668 P-APP polyclonal and a-tubulin monoclonal 
antibodies and visualized using Alexa 594 (red) and 488 (green) fluorophores, respectively. Nuclei 
were visualized using Hoechst staining. Staining was analyzed using the FV10-ASW 1.7 software for 
Olympus confocal microscope. Cells in metaphase and anaphase showed very clear P-APP 
localization at the centrosomes. Staining was very weak or absent in the interphase cells. 
Magnification: 63×. 
 
 2.3.8. Evidence for Mitotic Phosphorylation and Centrosome Localization of P-APP 
 In order to confirm that the phosphorylation of APP at Thr668 is mitosis-specific, we co-
stained cells with antibodies that are specific for mitotic phosphoepitopes. The best-characterized 
antibodies for this purpose are the metaphase protein monoclonal-2 (MPM2). MPM2 antibodies 
detect phosphoproteins that are present in mitotic cells and have been shown to associate with the 
kinetochore, centrosome, midbody and fibers of the mitotic spindle (Vandre et al., 1991). Our 
analysis of asynchronously growing untreated cells showed that, in metaphase, P-APP co-localized 
with MPM2 at the centrosomes (Figure 2.12, top row). In cells arrested with nocodazole, although 
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P-APP levels were significantly elevated (Figure 2.12, bottom row), due to the microtubule 
destabilizing function of nocodazole we did not observe any metaphase cells with classic spindles 
and spindle poles. The high levels of P-APP in these cells correlated well with the western blot data 
and confirm that APP is heavily phosphorylated under mitotic conditions. These results suggest that 
the phosphorylation of APP may play a role in cell cycle dependent processes including centrosome 
replication. 
 
Figure 2.12.  P-APP co-localization with MPM-2 at centrosomes in metaphase cells. Asynchronously growing 
(untreated, top row) and nocodazole arrested (bottom row) H4-15X cells were immunostained using 
the mitosis specific monoclonal antibody MPM2 and Thr668 P-APP polyclonal antibodies and 
staining was visualized using Alexa 488 and 594 fluorophores, respectively. The untreated cells show 
P-APP localization in centrosomes in the mitotic cells. In the cells arrested with nocodazole the 
microtubules were completely depolymerized and P-APP showed significantly higher levels of 
amorphous staining. The nuclei were visualized using Hoechst stain. Magnification: 63×. 
  
 Nocodazole is a powerful microtubule depolymerizing agent, therefore to determine if 
phosphorylation of APP at Thr668 is a modification specific to cell cycle activation and not an effect 
of the drug itself, we synchronized H4-15X cells by culturing in serum-free media for 48hrs.  After 
48hrs the cells were either maintained in serum-free media or stimulated with serum-supplemented 
media and treated with either early cell cycle inhibitors, roscovitine, aphidicolin, or RRD for 14hrs, 
or treated with mitotic inhibitors nocodazole or taxol for 18hrs (Figure 2.13).  Western blot analysis 
showed that cells not undergoing active cell division (serum starved) exhibited no visible P-APP. 
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However, synchronized serum stimulated cells treated with vehicle (Untr) had basal levels of 
phosphorylation, which is diminished in the presence of early cell cycle inhibitors (Figure 2.13).  
Phosphorylation of APP at Thr668 was elevated in serum stimulated cells treated with mitotic 
inhibitors, nocodazole and taxol, which was not observed in serum starved conditions, suggesting 
that this effect is indeed due to cell cycle activation.  Moreover, hyperphosphorylation of APP was 
observed in nocodazole treated cells (Figure 2.13) which, according to Figure 2.8, E, effectively 
accumulates cell in G2/M phase of cell cycle.    
 
Figure 2.13.  Phosphorylation of APP at Thr668 correlates with proliferative signaling. H4-15X cells were 
synchronized by 48 hrs of serum starvation and were then either maintained in serum free 
conditions (serum starved) or stimulated with serum supplemented media (serum stimulated) and 
treated with treated with various cell cycle inhibitors or with vehicle DMSO (Untr).  Cell cycle 
inhibitors used include Roscovitine (20μM ), or Aphidicolin (5 μg/ml) for 14 hrs and Nocodazole 
(100ng/ml) or Taxol (100ng/ml) for 18 hrs. Samples were analyzed by Western blot and membranes 
were probed with P-Thr668 APP antibody and actin antibody for loading control.   
 
 Immunostaining analysis of synchronized H4-15X cells treated with DMSO, or the S-phase 
inhibitor aphidicolin, or mitotic inhibitor nocodazole agreed with the previous findings.  DMSO 
treated cells showed few cells undergoing active cell division and positive staining for P-APP.  H4-
15X cells arrested with nocodazole exhibited depolymerized microtubules (green) and significant 
staining for P-APP (red).  However, aphidicolin treated cells attenuated this phosphorylation with 
only weak staining for P-APP (Figure 2.14).   
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Figure 2.14.  P-Thr668 APP is maximal at G2/M and attenuated with G1/S inhibition.  H4-15X cells were 
synchronized by sersum starvation for 48 hrs and were then either maintained in serum free 
conditions (serum starved) or stimulated with serum supplemented media (serum stimulated) and 
treated with vehicle DMSO or aphidicolin (5 μg/ml) for 18 hrs or nocodazole (100ng/ml)for 18 hrs. 
Cells were immunostained using mouse monoclonal α-tubulin and Thr668 P-APP rabbit polyclonal 
antibodies and staining was visualized using Alexa 488 and 594 fluorophores, respectively. The 
untreated cells show increased levels of P-APP in mitotic cells. In the cells arrested with nocodazole 
the microtubules were completely depolymerized and P-APP showed significantly higher levels of 
staining. Treatment with aphidicolin attenuated staining for P-APP. The nuclei were visualized using 
Hoechst stain. Magnification: 63×. 
 
 2.3.9. Cell Cycle Activation Induces Altered Processing of APP and Aβ Generation 
 We next examined whether Aβ generation is altered in a cell cycle-dependent manner and 
whether it parallels the phosphorylation of APP. Cells were growth arrested by serum starvation for 
48 hr and serum stimulated in the presence or absence of pharmacological inhibitors of cell cycle 
progression for different time periods. The cell culture supernatants and cell extracts were then 
immunoprecipitated and western blotted using the Aβ-specific 6E10 antibody. The results showed 
that intracellular and secreted levels of Aβ increase in a time-dependent manner upon serum 
stimulation of growth arrested cells (Figure 2.15, A-D, C and D show the bottom region of the blot 
from longer exposure to detect Aβ in lysates), and followed a similar profile as in APP 
phosphorylation (Figure 2.8). The histograms in E and F show the percent levels of Aβ in 
supernatant and lysate in comparison to the total levels of full length APP in the respective samples.  
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Figure 2.15.  Aβ generation is altered in a cell cycle-dependent manner. H4-15X cells were synchronized by 
serum starvation and stimulated with serum containing media plus or minus olomoucine, 
roscovitine, aphidicolin, nocodazole, vinblastine, or taxol. Cell culture supernatants (A and C) and 
cell extracts (B and D) were immunoprecipitated and western blotted using 6E10 antibody. Control 
was performed similarly to the rest of the samples, except no primary antibody was used in 
immunoprecipitation assay. Cell culture supernatant showed a time dependent increase in Aβ 
generation upon serum stimulation (A and C). The extracts showed similar results which was visible 
only after longer exposure (D). Panels C and D represent longer exposure of the bottom part of the 
blots shown in A and B to show the Aβ levels in cell extracts. In both the cases roscovitine 
treatment was associated with a decrease in the level of secreted and cellular Aβ. Secreted APP was 
not altered in the supernatant although the level of APP and C-APP fragments are increased in the 
extracts prepared from nocodazole and vinblastine-arrested cells. Panel E and F show mean percent 
of Aβ (compared to secreted and full length APP) from 3 independent experiments under different 
treatment conditions. Data that showed significant changes are marked using a star (P < 0.05). 
 
 Finally, we sought to determine if altered processing of APP was, in fact, due to cell cycle 
activation or occurs under serum-starved conditions. H4-15X cells were synchronized by serum 
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starvation for 48 hrs.  Subsequently, cells were either maintained in serum-free media or stimulated 
with serum supplemented media in the presence or absence of pharmacological inhibitors of cell 
cycle progression for different time periods. Cell lysates were analyzed by Western blotting using 
6E10 antibody (detecting C-terminal fragments and FL-APP) and actin for normalization.  As 
shown in Figure 2.16, while C-terminal fragments were apparent in both serum starved and serum 
stimulated cells, it appears that there was enhanced generation of the C99 BACE cleaved APP C-
terminal fragment in serum stimulated cells (Figure 2.16), which suggests a concurrent and cell cycle-
dependent increase in Aβ under proliferative conditions.  Furthermore, treatment with early cell 
cycle inhibitors aphidicolin and roscovitine, lowered cellular levels of C99 implying that early 
inhibition of cell cycle would protect against increased A generation and associated 
neurodegeneration in the brain.   
 
Figure 2.16.  Cell cycle activation enhances BACE cleavage of APP to generate C99. H4-15X cells were 
synchronized by 48hrs of serum starvation.  Subsequently, cells were then either maintained in 
serum free conditions (serum starved) or stimulated with serum supplemented media (serum 
stimulated) and treated with treated with various cell cycle inhibitors or with vehicle DMSO (Untr).  
Cell cycle inhibitors include Aphidicolin (5 μg/ml), Roscovitine (20μM ) or RRD (10μM) for 14 hrs 
or Nocodazole (100ng/ml) or Taxol (100ng/ml) for 18 hrs. Samples were analyzed by Western 
blotting using 6E10 antibody (detecting FL-APP and CTFs) and actin antibody for loading control. 
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 In the case of cells arrested with pharmacological agents, the maximum levels of intracellular 
and secreted Aβ were present in mitosis-arrested cells (nocodazole, vinblastine, and taxol) with the 
lowest levels in the roscovitine treated (G1/S inhibited) cells. Treatment of neurons in vitro with Aβ 
peptide has been shown to induce cell cycle activation and neuronal apoptosis (Giovanni et al., 1999, 
Giovanni et al., 2000). Thus, these findings not only imply that APP is phosphorylated and 
processed in a cell cycle-dependent manner, but also suggest that the observed cell cycle activation 
in the brains of AD transgenic mice may induce APP phosphorylation, leading to enhanced levels of 
intracellular and extracellular Aβ that subsequently induce cell cycle activation and 
neurodegeneration. 
2.4. Discussion 
 Alzheimer's disease is characterized by the presence of neuritic plaques and neurofibrillary 
tangles in the affected areas of the brain. In addition, AD brains show considerable neuronal loss 
and neuroinflammation, the causal mechanisms of which are under active investigation. Studies 
from several laboratories have shown that AD brains exhibit aberrant upregulation of cell cycle 
regulatory proteins (Arendt et al., 1996, Vincent et al., 1996, McShea et al., 1997, Busser et al., 1998, 
Nagy and Esiri, 1998, McShea et al., 1999). It is suggested that the deregulated expression of cell 
cycle proteins in neurons may contribute to the pathology associated with Alzheimer's, possibly due 
to inappropriate induction of the cell cycle in post-mitotic neurons. A causal link can be established 
between cell cycle activation, neurodegeneration, and neuronal loss in vitro, but it has been difficult 
to illustrate how cell cycle activation can induce a slowly developing but ultimately catastrophic 
effect in human AD brain. In order to understand the mechanisms involved in cell cycle activation 
and AD pathogenesis, we used mice expressing APPV717F and PS1M146L mutant transgenes. The 
PS/APP mice develop plaques at approximately 6 months of age and the APP mice show plaques at 
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approximately 10-12 months of age. We found that, similar to human AD, brains from these mice 
also show increased expression of some of the cell cycle regulatory proteins. This was associated 
with increased phosphorylation of APP. 
 In vitro analysis of asynchronously growing H4-APP cells clearly showed that the 
phosphorylation of APP occurs mainly in the cells that are undergoing cell division. In the 
interphase, cells APP phosphorylation was negligible and was induced as soon as the cells entered 
prophase. The experiments with si-cdk2 and pharmacological inhibitors of the G1/S checkpoint 
further supports the conclusion that APP phosphorylation and processing occurs in a mitosis-
specific manner and reinforces the idea that inhibition of cell cycle activation at an early stage may 
prevent the APP modifications associated with the development of AD pathology. APP 
phosphorylation is not just mediated by cyclin-dependent kinases. Kinases such as GSK-3β, JNK, 
and cdk5 have also been shown to affect Thr668 specific phosphorylation of APP. Our studies also 
showed that this specific phosphorylation could be inhibited by downregulation of GSK-3β and 
cdk5. Both GSK-3 and cdk5 have been shown to play roles in the cell cycle and hence the possibility 
that these kinases are also behaving in a cell cycle-dependent manner needs to be established (Guo 
et al., 2005, Zhang et al., 2008). Nocodazole-induced mitotic arrest led to a significant increase in 
APP phosphorylation compared to that induced by serum stimulation alone. One of the reasons for 
this result could be that the number of metaphase cells obtained upon treatment with nocodazole 
(~80% by FACS analysis) is much higher than that obtained by serum stimulation or taxol treatment 
(~40%). The data shown in Figure 2.8 agrees with this interpretation; quantitative analysis of the 
levels of P-APP and APP showed that while serum stimulation shows ~30% APP phosphorylation 
(~40% cells in G2/M), nocodazole treatment shows ~80%, both of which correlate with the 
percent of cells in metaphase.  Treatment of cells with taxol, another mitotic inhibitor that brings 
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about cell cycle arrest through microtubule stabilization, showed only ~40% of cells in metaphase 
and a P-APP level of ~30%.  
 The results presented here strongly indicate that Thr668 specific phosphorylation on APP is 
intimately associated with cell cycle activation and that the maximum phosphorylation occurs in 
metaphase. This phosphorylation transition was associated with increased APP processing and Aβ 
generation (Figure 2.15). Thus the cells do not have to go through a full division to bring about the 
modifications in APP suggesting that an attempt by the cells in AD brain to re-enter cell cycle could 
lead to APP phosphorylation and proteolytic cleavage without the cells undergoing cell division. The 
findings that AD brains show binucleated neurons (Zhu et al., 2008), as well as aneuploidy and mis-
segregation of different chromosomes (Arendt, 2000, Mosch et al., 2007, Iourov et al., 2009, 
Zekanowski and Wojda, 2009) further strengthens the conclusion that neurons in AD brain attempt 
to undergo DNA replication and cell division. It is suggested that the cell cycle regulatory proteins 
may have a different role in neurons compared to that in cells undergoing active cell division; studies 
show that terminally differentiated neurons use the mechanisms involved in proliferation to 
maintain the synaptic plasticity (Arendt, 2003, Schmetsdorf et al., 2005, Arendt, 2009). It is possible 
that the complex architecture of mature plastic neurons makes it impossible for the cells to undergo 
division without undergoing damage. The report that centrosomes localize to the area where the 
neurites sprout from and the number of centrosomes determines the number of neurites (de Anda 
et al., 2005) suggest that cell cycle activation may cause asymmetric dynamics on the chromosomes 
leading to mis-segregation and formation of aneuploid cells in the AD brain. The localization of P-
APP (data presented here) and PS1 at the centrosomes (Ferreira et al., 1997) suggest that these 
molecules may play a role in spindle assembly and chromosome segregation, and hence the 
enhanced expression or mutations of these proteins may cause chromosome mis-segregation in cells. 
The data from our lab support this hypothesis, in which we showed that expression of APP, Aβ, or 
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PS1 lead to chromosome mis-segregation and aneuploidy (Boeras et al., 2008).  Aβ oligomers have 
been reported to induce neuronal cell cycle activation (Giovanni et al., 1999, Varvel et al., 2008), and 
this along with the data presented here, suggest that Aβ generated upon APP phosphorylation may 
have a feed forward role in cell cycle activation and enhanced neurodegeneration in AD brain. 
 Cell cycle activation not only induced the phosphorylation and proteolytic processing of 
APP, but also affected the localization of P-APP in cells; mitotic cells clearly showed centrosome 
specific localization of P-APP. It has been proposed that the phosphorylation of structural or 
transient components of centrosomes may affect cell cycle dependent processes such as centrosome 
duplication and microtubule nucleation (Vandre et al., 1991). Thus, in addition to enhanced 
proteolytic cleavage, APP phosphorylation may influence cell proliferation through its association 
with the cell cycle machinery. The co-localization of P-APP with MPM2, a metaphase protein 
marker, further reiterates APP's role as a growth-promoting molecule. Therefore, it is possible that 
high levels of P-APP may promote proliferation in dividing cells and centrosome duplication or 
chromosome mis-segregation and cell death in post-mitotic neurons. APP's function as a mitogenic 
molecule is evident from the fact that its upregulation is associated with cancers of different organs 
(Hansel et al., 2003, Casas et al., 2004); neurons being postmitotic are fully differentiated and 
undergo apoptosis rather than transformation upon cell cycle activation. It has been reported that 
APP and PS1 associate with other proteins at the centrosome and localize to centrosomes (Nizzari 
et al., 2007a, Nizzari et al., 2007b). An N-terminal APP antibody conjugated to an Alexa fluorophore 
was used to detect the localization of APP at the centrosomes. In our hand staining of the cells with 
the Aβ immunoreactive 6E10 antibody did not show any significant localization of non-phospho 
APP to the centrosomes. It is possible that either the antibody or the techniques we applied to 
detect the localization are not strong enough to detect non-phospho APP at the centrosomes. 
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 Our studies showed that APP and PS/APP mice show formation of Aβ and phosphorylated 
C-terminal fragments of APP at a very early age (1.5 month), and the generation of these fragments 
are increased in an age-dependent manner. Although this is the case, PS/APP mice showed clear 
accumulation of P-APP and Aβ in their brains by 6 months of age whereas APP mice showed only 
by 10-12 months. This result suggests that unless there is an accelerating factor present, the 
pathology in AD develops very slowly and if diagnosed early in life it can be prevented. The facts 
that deregulation in PS1 can induce chromosome miss-segregation and tumor generation (Xia et al., 
2001, Boeras et al., 2008), and both PS1 and APP associate with centrosomes, suggest that in 
addition to Aβ generation, expression of PS1 in APP transgenic mice may affect cell cycle 
deregulation and therefore APP phosphorylation. Whether or not these associates with early 
neurodegeneration and neuronal loss observed in AD brains needs to be determined. Even though 
the PS/APP mice we used show significantly higher levels of P-APP and accumulation of Aβ in to 
plaques, unlike in some of the other AD mouse models such as APPSL/PS1-KI and 5XFAD mice 
(Casas et al., 2004, Oakley et al., 2006, Ohno et al., 2007), we did not observe any significant 
neuronal loss. The reason for this is unclear. It is possible that the genetic background and the 
transgene expression levels play a role in plaque load and neuronal loss associated with different 
transgenic mouse models. The APP mice we used do not exhibit as aggressive an AD-like disease as 
the ones above, and probably inclusion of an additional APP mutation in the transgene may be 
required to obtain detectable levels of neuronal loss. 
2.5. Conclusions 
 In conclusion, cell cycle deregulation may influence the pathogenesis of AD through 
multiple pathways: 1) through phosphorylation and processing of APP to generate Aβ leading to 
plaque formation, 2) through Aβ and C-terminal fragment of APP inducing tau 
132 
 
hyperphosphorylation (Greenberg, 1994, Oster-Granite et al., 1996, Ferreira et al., 1997, Xu et al., 
2007), and 3) through both Aβ and P-APP affecting cell cycle deregulation and contributing to the 
unwarranted progression of cell cycle. From the data presented here it is apparent that an inhibition 
of aberrant activation of the cell cycle prior to G1/S checkpoint could potentially hinder the 
modifications in APP and therefore development of AD pathology. In this respect, G1/S inhibitors, 
which are known to protect neuronal apoptosis in vitro (Park et al., 1998, Padmanabhan et al., 1999, 
Padmanabhan et al., 2007), need to be explored in vivo for their efficacy in preventing APP 
phosphorylation and processing. Once the neurons start expressing higher levels of cell cycle 
proteins due to environmental stress, or inflammation, or high levels of Aβ, the modifications in the 
proteins associated with the development of pathology will take place, and the cells will succumb to 
degeneration. The data presented above and the previous support for the cell cycle hypothesis, 
which suggests that the neurons in AD brain enter the G1 phase of cell cycle (Arendt et al., 1996, 
Vincent et al., 1996, Woods et al., 2007), indicate that inhibitors of the early phases of cell cycle such 
as those associated with the G1/S checkpoint may prove to be beneficial in treating 
neurodegenerative diseases such as Alzheimer's. However, it must be noted that microtubules are 
essential for many neuronal functions, and thus any drugs designed to inhibit APP modifications or 
Aβ generation should be tested for their effect on microtubule dynamics both in vitro and in 
vivo before assuming that they will be risk-free therapies for AD. 
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CHAPTER 3:  SILAC-BASED PROTEOMIC ANALYSIS TO INVESTIGATE THE 
IMPACT OF AMYLOID PRECURSOR PROTEIN EXPRESSION IN 
NEURONAL-LIKE B103 CELLS1 
3.1. Introduction 
 In the previous chapter, we demonstrated that phosphorylation and cellular distribution of 
APP are affected in a cell cycle-dependent manner and this is associated with altered processing of 
APP. The discoveries demonstrating that cells expressing APP show enhanced growth rate and the 
observation that APP localizes to centrosomes under mitotic conditions led to the hypothesis that it 
may play a role in cell cycle progression. The exact role of APP in cell cycle activation and cell 
proliferation is not yet identified. Here, we sought to determine the mechanism(s) by which APP 
affects cellular functions using APP null B103 neuroblastoma cells. 
 Elegant studies by Schubert and colleagues have shown that B103 neuroblastoma cells do 
not express either APP or the APP like proteins APLP1 or APLP2 (Schubert and Behl, 1993). 
Therefore, these cells are appropriate for studying the cellular functions of APP. These investigators 
showed that expression of APP in B103 cells enhances cell adhesion, neurite outgrowth, and cell 
proliferation but the molecular mechanisms by which APP induces these cellular functions are not 
quite clear. It is possible that APP or a metabolite of APP can induce these either by itself or by 
affecting expression of genes associated with these functions. In order to determine whether APP 
                                                          
1 The information in this chapter has been legally reproduced under the Creative Commons Attribution (CC-BY) license 
and are utilized with the permission of the publisher. See Appendices B and C.   
Chaput D, Kirouac LH, Bell-Temin H, Stevens SM, Jr., Padmanabhan J (2012) SILAC-based proteomic analysis to 
investigate the impact of amyloid precursor protein expression in neuronal-like B103 cells. Electrophoresis 33:3728-
3737. 
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affects expression of proteins associated with cell adhesion or cell cycle progression or cell signaling 
processes in general, we performed an unbiased, global-scale analysis to assess APP-mediated 
protein expression changes in B103 cells. We used the stable isotope labeling by amino acids in cell 
culture (SILAC) approach for comparing the protein complement of B103 cells expressing the 695 
isoform of APP (referred to as B103-695) to B103 APP-null cells (referred to as B103) as shown in 
Figure 3.1. The advantage of this approach is that B103 cells can be grown in media containing 
normal or “light” versions of amino acids and B103-APP in media with “heavy” amino acids. The 
labeled (heavy) amino acids are added to media that are deficient in specific amino acids (in this case 
L-arginine and L-lysine) and the cells metabolically incorporate these amino acids during protein 
synthesis. This technique allows one to differentiate proteins from one cell system to the other and 
analyze both simultaneously using tandem mass spectrometry. This approach decreases experimental 
variability that occurs during sample processing and provides more consistent and reliable data for 
relative protein quantitation. Here we provide evidence for protein expression changes in B103 cells 
expressing APP-695 versus APP null cells and validate changes in selected proteins involved in cell 
signaling as well as cell morphology, assembly and organization. 
 
Figure 3.1. SILAC experimental workflow.  B103 and B103-695 cells are cultured in media containing 
heavy or light amino acids.   Equal protein from whole cell lysates were taken from each cell type 
and digested using the filter-aided sample preparation (FASP).  Strong cation-exchange (SCX) was 
used to reduce sample complexity and peptide fractions were analyzed by LC-MS/MS. 
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3.2. Materials and Methods 
 3.2.1. Cell Culture and SILAC Labeling 
 B103 and B103-695 rat neuroblastoma cells were initially cultured in DMEM/F12 (1:1) 
media supplemented with 10% FBS, 50U/ml penicillin and 50µg/ml streptomycin, at 37°C and 5% 
CO2 (Jin et al., 1994). Cells were grown in T75 cm
2 flasks to near confluence, and then split into 3 × 
T75 cm2 flasks for stable isotope labeling with heavy or light amino acids in cell culture (SILAC). 
B103 and B103-695 cells were labeled for quantitation using SILAC media supplemented with 10% 
dialyzed FBS, pen/strep, and either L-lysine and L-arginine for B103 or 13C6-L-Lysine 2HCl 
and 13C6-
15N4-Arginine HCl for B103-695 cells (Thermo Scientific). Cells were grown in SILAC 
media for 7 days, during which they were passaged once and media was changed every 48 hours, for 
a minimum of 5 doublings, corresponding to > 98% labeling efficiency. 
 Cells were collected using Trypsin-EDTA and washed 3 times with PBS to remove serum 
proteins. Cells were lysed in 250µl of 100mM Tris-HCl (pH 7.6) containing 4% SDS, 100 mM 
dithiothreitol (DTT), and Halt protease inhibitor cocktail (Pierce) at 95°C for 5 minutes. Lysed 
samples were briefly sonicated. Protein concentrations were determined using the Pierce 660nm 
protein assay with the ionic detergent compatibility reagent (Pierce). These experiments were done 
in triplicate. 
 3.2.2. Sample Preparation 
 Whole cell lysates were digested using the filter-aided sample preparation (FASP) kit (Protein 
Discovery), as developed by Wisniewski and Mann (Wisniewski et al., 2009). Four digestions of 
approximately 100µg of protein were performed for each biological replicate, which were then 
pooled for a total of 400µg per biological replicate. Thirty microliters of protein sample and 8 M 
145 
 
urea were mixed and added to the 30kDa FASP spin filter for buffer exchange. Samples were 
alkylated according to manufacturer’s instructions with iodoacetamide (IAA) for 30 minutes in the 
dark. Following alkylation, samples underwent further buffer exchange with 3 × 100 µl additions of 
50 mM ammonium bicarbonate, followed by centrifugation at 14,000 × g for 10 minutes. Samples 
were incubated with trypsin at 1:100 (w:w, trypsin:protein) for proteolytic digestion of proteins and 
incubated overnight at 37°C. Peptides were collected by centrifugation with the addition of 2 × 40 µl 
50 mM ammonium bicarbonate and 40 µl NaCl. Peptides were desalted using Supelco Discovery 
DSC-18 solid-phase extraction columns in combination with a Supelco vacuum manifold. Samples 
were dried using a vacuum concentrator (Thermo) and resuspended in 20 µl of 0.1% formic acid in 
H2O. 
 Peptides were fractionated on a Dionex U3000 HPLC system with a 150 cm × 1.0 mm i.d. 
strong cation-exchange (SCX) column (PolyLC Inc.) packed with 5 µm 300 Å polySULFOETHYL 
A-SCX material. Two minute fractions were collected using a 30 minute gradient, where ammonium 
formate increased from 15–200 mM in 25% acetonitrile (ACN) at a flow rate of 250 µl/min. Ten 
peptide-containing fractions were selected for LC-MS/MS analysis from each biological replicate 
(n=3 total). Peptides were again dried in a vacuum concentrator and resuspended in 10µl of 0.1% 
formic acid in H2O. 
 3.2.3. LC-MS/MS 
 SCX peptide fractions were separated on a 10 cm × 75 µm i.d. reversed-phase column (New 
Objective) packed with 5 µm 300 Å C18 material (ProteoPep II). Tandem mass spectrometric 
analysis was carried out using a hybrid linear ion trap-Orbitrap instrument (LTQ Orbitrap XL, 
Thermo). A 90 minute gradient was used, where 0.1% formic acid in ACN increased from 2 to 40%, 
increasing to 80% at 95 minutes through 100 minutes. Orbitrap full MS scans were collected at a 
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mass resolving power of 60,000, with positive polarity in profile mode, and a scan range of m/z 
350–1500. The top 5 most abundant ions were selected for further fragmentation in the ion trap. 
Global settings include dynamic exclusion of 90 seconds, with an exclusion list size of 500, and a 
repeat count of 2. 
 3.2.4. Database Searching and Pathway Analysis 
 Raw files were processed in MaxQuant version 1.2.0.13, a quantitative proteomics software 
package for the analysis of large, high resolution MS data sets (Cox and Mann, 2008). The raw files 
were processed and searched against the current UniprotKB database containing Rattus 
norvegicus protein sequences as well as a second MaxQuant database of known contaminants. The 
search parameters included a constant modification of cysteine by carbamidomethylation and 
variable modification of methionine oxidation. Additional parameters include multiplicity set to 2, 
with a heavy set of lysine-6 and arginine-10. The search tolerance was set to 8 ppm and the fragment 
ion mass tolerance was set to 0.5 Da with a false discovery rate (FDR) of < 1%. 
 Statistical analysis was carried out using Perseus software, which assesses the statistical 
significance of protein expression based on the approach developed by Benjamini and Hochberg. A 
threshold q-value of 0.05 for the Benjamini-Hochberg false discovery rate was used. Functional and 
pathway analysis of identified proteins was carried out using Ingenuity Pathway Analysis (IPA, 
Ingenuity Systems). 
 3.2.5. Western Blotting 
 Proteins were selected for Western blot validation of protein expression changes based on 
significance as well as function. Twenty micrograms of B103 and B103-695 cell lysate were separated 
on a 15% Tris/Glycine SDS-PAGE gel, run at 90V for 90 minutes. Proteins were semi-wet 
transferred to a nitrocellulose membrane (Whatman) at 30V for 90 minutes. The membrane was 
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subsequently blocked in 5% non-fat milk-TBS for 1 hour at room temperature, and washed using 
PBS containing Tween 20 (PBST). Primary antibodies specific for Ras (Abcam, mouse monoclonal, 
1:1000), P-ERK and ERK44/42 (Cell Signaling, rabbit polyclonal, 1:1000), and actin (Sigma, mouse 
monoclonal, 1:7000) were diluted in 3%BSA/TBS/0.02% sodium azide and incubated overnight at 
4°C. Membranes were then incubated with corresponding anti-rabbit (Pierce) and anti-mouse 
(Pierce) secondary antibodies for 90 minutes at room temperature and washed thoroughly. The blots 
were developed using the Super Signal chemiluminescence reagents (Pierce). 
 3.2.6. Immunostaining Analysis 
 B103 and B103-695 cells were plated onto poly-lysine coated 8 chamber slides and cultured 
overnight in DMEM/F12 (1:1) medium with serum and Pen-Strep. After 24 hrs of culturing, cells 
were washed with PBS and fixed with 4% para-formaldehyde for 10 minutes at room temperature. 
At the end of the fixation, cells were washed and incubated in 1% BSA in TBS containing 0.1 % 
Triton X-100 (BSA/TBST) to block any non-specific binding. After 1 hr incubation at room 
temperature, γ-synuclein (Millipore, rabbit monoclonal,1:500) and actin (Sigma, mouse monoclonal, 
1:500) antibodies diluted in BSA/TBST was added to the cells and incubated overnight at 4°C by 
gentle rocking. The slides were washed with PBS thoroughly and incubated with Alexa Fluor 488 
anti-mouse and Alexa Fluor 594 anti-rabbit secondary antibodies (Invitrogen/Gibco) for 1–2 hr at 
room temperature in the dark. At the end of the incubation cells were washed again and incubated 
with 1 µg/ml Hoechst 33258, diluted in PBS, for 10 minutes at room temperature protected from 
light. After further washes, the slides were mounted using Fluoro-gel mounting media (Electron 
Microscopy Sciences) and analyzed under a Zeiss Fluorescent microscope using AxioVision Rel 4.8 
software program. 
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3.3. Results 
 3.3.1. B103 and B103-695 Proteome Comparison 
 A total of 2979 protein groups were identified among 3 biological replicates, excluding 
contaminants and false positive (reverse sequence) identifications. Biological replicates A, B, and C 
identified 2549, 2335, and 2542 protein groups, respectively. Over 1900 protein groups were shared 
by all 3 biological replicates. Replicates A and B shared 2053, replicates A and C shared 2228, and 
replicates B and C shared 2080 protein groups. The overlap of protein identifications between 
biological replicates is demonstrated by the Venn diagram (Figure 3.2).   
 
Figure 3.2. Venn diagram of differential protein expression between B103 and B103-695 cells.  Represents the 
number of unique protein groups identified in biological replicate A, B and C, and the overlap of 
proteins identified between the biological replicates.   
 
 Perseus was used to identify proteins with statistically significant changes in expression 
across multiple biological replicates. Two significance tests were employed, Significance A and 
Significance B, where the A significance gives no weight to signal intensity and B significance is 
weighted by signal intensity. Significance A test identified 79 significant proteins, while 83 significant 
proteins were identified using Significance B, for a combined total of 100 non-redundant proteins 
that were differentially expressed in B103-695 cells (selected proteins listed in Table 3.1). Of the 100 
differentially expressed proteins, 8 proteins were downregulated and 92 proteins were upregulated. 
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Table 3.1. Selected proteins with significant hits identified using Perseus.  Selected differentially expressed 
proteins implicated in neurodegenerative disease that were identified in B103-695 cells using SILAC-
based quantitative proteomic analysis.   
 
   
 3.3.2. Functional Enrichment 
 Several proteins that are important in cellular and molecular functions including cellular 
assembly and organization, cell cycle, cell morphology, lipid metabolism, protein folding, and post 
translational modifications were identified as having differential expression upon proteome 
comparison in B103 and B103-695 cells using IPA (Figure 3.3). Lipids and lipid carriers have been 
shown to play a role in AD pathology development. People with high cholesterol levels are at high 
risk of developing AD and studies in mouse models of AD have shown that drugs that lower 
cholesterol levels can reduce the levels of Aβ and therefore plaque pathology (Hutter-Paier et al., 
2004). Studies in AD patients have shown that people carrying the apolipoproteins E4 allele are 
more prone to get the disease than those carrying apolipoprotein E2 or E3 allele. ApoE is the major 
apolipoprotein in the brain and is the protein component of the lipids such as very low density 
lipoprotein (VLDL). Although this led to the hypothesis that ApoE4 is a genetic risk factor for AD 
it does not mean that all the ApoE4 carriers do get the disease. The exact mechanism by which 
ApoE4 affects pathology development in AD is not clear. It has been shown that ApoE4 promotes 
the aggregation of Aβ and therefore accelerates plaque pathology and cognitive deficit. Lipids seem 
to play a role in not only the aggregation of Aβ but also its generation. Studies have shown that 
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APP, beta-secretase and γ-secretase co-localize in the lipid rich raft domains leading to enhanced 
amyloidogenic processing of APP whereas α-secretase-mediated cleavage occurs at membrane 
domains outside of the lipid rafts. Regarding proteins associated with lipid metabolism, our analysis 
showed that the sterol O-acetyl transferase 1 (SOAT1) and Acyl CoA: cholesterol acyl transferase 2 
(ACAT2) are induced by ~2.5 to 3 fold in B103-695 cells. Studies by others have shown that an 
increase in SOAT1 is associated with an increase in APP processing to generate Aβ, and a 
downregulation of SOAT1 using siRNA descreased generation of Aβ, suggesting a role for this 
enzyme in pathology development in AD. Similarly, studies have shown that ACAT2 can more 
efficiently esterify cholesterol than ACAT1, which is more efficient in esterification of sitosterol 
(Temel et al., 2003). This again suggests that the cholesterol modifying enzymes are induced by APP 
expression in B103 cells implying a role for APP in altered lipid metabolism. Many of the proteins 
identified are also involved in regulating physiological system development and function processes 
such as connective tissue, cardiovascular system, and nervous system development and function, as 
well as embryonic tissue development (Figure 3.3). 
 
Figure 3.3.  Ingenuity pathway analysis of APP-mediated differential protein expresion in B103 cells.  B103 cells 
expressing APP show over-represented catagories associated with (a) molecular and cellular 
function, (b) physiological system development and function, (c) canconical pathways and, (d) cell 
localization. 
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 IPA also identified significant canonical pathways associated with a number of identified 
proteins that were differentially expressed including CDK5 signaling, cell cycle G2/M DNA damage 
checkpoint regulation, actin cytoskeleton signaling, protein kinase A signaling and ERK5 signaling as 
shown in the selected canonical pathways in Figure 3.3. CDK5 signaling is involved in cell 
differentiation and morphology regulation and has been implicated in neuron degeneration (Nikolic 
et al., 1996). CDK5 signaling is important for proper brain development and dysregulation in CDK5 
leads to defects in cell migration, plasticity, and other neurological defects (Tsai et al., 1993, 
Iwatsubo et al., 1994, Rakic et al., 2006, Su and Tsai, 2011). Additionally, actin cytoskeleton and 
protein kinase A signaling were also over-represented from the SILAC dataset. Actin cytoskeleton 
signaling is associated with cell motility, axon guidance, cellular assembly, organization, function, and 
maintenance whereas protein kinase A is a serine/threonine kinase that functions as a second 
messenger regulating a variety of diverse functions including growth, development, and memory. 
Interestingly, the G2/M DNA damage checkpoint was identified as a potential altered pathway from 
the SILAC dataset as well and provides additional evidence of the involvement of cell cycle-
dependent mechanisms upon APP expression in this cell model system. The G2/M DNA damage 
checkpoint is the second checkpoint within the cell cycle and is important for maintaining genomic 
stability as it prevents damaged DNA from entering M-phase. 
 3.3.3. Pathway Analysis Reveals APP-mediated Alterations in Cell Morphology and 
Ras Signaling 
 The top protein interaction network identified using IPA is primarily involved in cell 
morphology, assembly, and organization, as well as nervous system development and function which 
is shown in Figure 3.4.   
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Figure 3.4. Top-scoring pathway from Ingenuity Pathway Analysis.  The IPA identified top scoring 
pathways associated with cellular assembly and organization based on differentially expressed 
proteins identified from B103 cells expressing APP-695.  The network diagram uses different shapes 
to represent protein functions: enzymes (diamond), kinases (inverted triangle), transporters 
(trapezoid), and other (circles).  Single lines represent protein-protein interactions; solid or dashed 
lines represent direct or indirect interactions, respectively.  Proteins that regulate another protein are 
indicated by arrows.   
 
 Proteins of particular interest include γ-synuclein and Ras, which are both found to be 
upregulated in B103-695 cells.  Western blots were performed to validate the increased expressio n 
of γ-synuclein and Ras in B103-695 cells. While Ras showed a significant increase by western blot 
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analysis (Figure 3.5, b), we were unable to detect the γ-synuclein with this technique. We believe that 
this is due to the limited antibody reactivity on western blots as immunostaining analysis using the 
anti-γ-synuclein antibody showed a significant increase in this protein in B103-695 cells compared to 
B103 (Figure 3.5, a). Co-staining of the cells with an actin antibody showed altered actin staining in 
B103-695, providing some additional support to the functional enrichment analysis results in which 
actin cytoskeleton signaling and subsequent cytoskeletal organization could potentially be altered 
through APP expression.  
 Gamma synuclein, a member of the synuclein family, was the most significantly up-regulated 
protein, showing a 59.6 fold increase. Increased expression of γ-synuclein mRNA has been observed 
in the brains of Alzheimer’s disease patients, supporting its potential contribution in AD pathology 
(Ji et al., 1997). γ-synuclein has also been shown to bind microtubule and promote tubulin 
polymerization and cell adhesion (Zhang et al., 2011). Studies in cancer cells have shown that it 
enhances cell migration and protects against mitotic inhibitor-mediated apoptosis. It was initially 
identified as a breast cancer specific gene 1 (BCSG1) and was associated with breast tumor 
progression (Ji et al., 1997, Jia et al., 1999). γ–synuclein has been shown to interact with the 
checkpoint protein BubR1 to bring about the defects in mitosis (Gupta et al., 2003, Inaba et al., 
2005).  
 Ras, a small GTPase, is involved in signal transduction regulating cell growth, differentiation, 
and survival. Increased Ras expression has been implicated in AD brains but the functional 
significance of this in AD pathology development is not known (Luth et al., 2000). Interestingly, 
nerve growth factor receptor (NGFR) protein in the plasma membrane, which is upregulated in our 
dataset as a result of APP expression in B103 cells, has been shown to increase activation of Ras 
protein(s) in the cytoplasm (Tinhofer et al., 1996). Ras activation consequently results in increased 
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MAP-kinase activity. It is possible that a Ras-mediated cell signaling cascade may play a role in the 
aberrant cell cycle activation and neurodegeneration associated with pathology development in AD. 
 
Figure 3.5. APP induces γ-synuclein and ras expression in B103 cells and activation of ERK. (a)  
Immunostaining: B103 and B103-695 cells were co-immunostained using γ-synuclein (rabbit 
polyclonal) and actin (mouse monoclonal) primary antibodies and Alexa Fluor 594 anti-rabbit and 
Alexa Fluor 488 anti-mouse secondary antibodies. Hoechst was used to visualize nuclei. The 
expression of γ-synuclein was significantly higher in B103-695 than that in B103 cells and it seems to 
localize to the nucleus and cytoplasm. Images were taken on a Zeiss fluorescent microscope fitted 
with an Axiocam MRm camera and analyzed using AxioVision Rel 4.8 software (magnification: 
63×). The bar graph shows the percent increase in γ-synuclein intensity measured using ImageJ, 
after converting the images to 8 bit gray. Intensity of γ-synuclein in three independent images taken 
from B103 and B103-695 cells were normalized to the intensity of Hoechst within the same sample 
for comparison. (b) Western blot validation: Equal amounts of proteins from B103 and B103-695 
cell extracts done in quadruplicate were separated on a 15% Tris-glycine gel and probed with Ras, 
and P-ERK antibodies. Ras and P-ERK were significantly increased in B103-695 cells compared to 
B103 cells (bar graphs labeled Ras and P-ERK). Re-probe of the Ras blot with actin antibody shows 
equal amount of proteins on gel and re-probe of P-ERK blot with ERK antibody shows no change 
in expression of ERK upon expression of APP (bar graph labeled ERK).    
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 MAPK functions downstream from Ras in signal transduction pathway and responds to 
extracellular signals by inducing different cellular functions such as proliferation, mitosis, 
differentiation and apoptosis. Ras activation of the MAPK signaling pathway has been well 
established. Although the Ras – MAPK signaling pathway has a well-known role in cancer, there is 
increasing evidence for its involvement in neurodegenerative disease as well (Ferrer et al., 2001). The 
Ras – MAPK signaling pathway has been found to be induced during very early stages of AD, prior 
to the formation of plaques and tangles (Gartner et al., 1995, Gartner et al., 1999). MAP-kinase is 
also involved in the regulation of γ-synuclein mRNA expression (Li et al., 2010). Analysis of the 
active phosphorylated form of mitogen activated protein kinase P44/42 MAPK (ERK1/2) showed 
that it is significantly induced in B103-695 cells while the non-phospho ERK levels were unaffected 
by APP expression (Figure 3.5, b). Given potential crosstalk between PKA and MAPK signaling, we 
also investigated the impact of siRNA-mediated knockdown and chemical inhibition of PKA and 
found no effect on ERK phosphorylation status (Figure 3.6). These findings suggest that APP 
expression specifically affects activation of ERK and do not have any effect on the expression of the 
protein.  
 Down-regulated proteins in this pathway (Table 3.1) include PD2 and LIM domain 1 
(PDLIM1) protein, a transcription regulator that has been shown to be responsive to hypoxia and 
also oxidative stress (Basu et al., 2012). Differential PDLIM1 mRNA expression in human vastus 
lateralis muscle has been associated with Huntington's disease, making PDLIM1 a potential 
biomarker (Strand et al., 2005). SYNCRIP is a member of the heterogeneous nuclear 
ribonuceloprotein (hnRNP) family, and was recently identified in a microarray study as a gene 
potentially involved in AD (Guttula et al., 2012). Our SILAC study provides additional evidence for 
these potential markers of AD at the protein level. 
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Figure 3.6.  PKA knockdown in B103 and B103-695 cells do not affect ERK activation.  B103 and B103-695 
cells plated in serum free Advanced DMEM/F-12 media were transfected with incremental concentrations of 
siRNA to PKA, ranging from 25nM 10 150nM.  After 6 hrs, serum containing media was added to the cells 
and samples were were collected after 24-48 hrs.  Cell lysates were western blotted using antibodies against 
PKA and P-ERK.  Actin was used as a loading control. While PKA was knocked down, we saw no significant 
change in activated ERK.   
 
3.4. Discussion 
 Bioinformatic analysis of the 100 statistically significant proteins identified numerous 
proteins with roles in a variety of neurological diseases. We have listed differentially expressed 
proteins from our SILAC analysis that have been implicated in neurodegenerative disease in Table 
3.1, reporting only those proteins with ratios having less than 30% relative standard deviation values. 
For example, hypoxanthine phosphoribosyltransferase 1 (HPRT1) was increased 10 fold and nerve 
growth factor receptor was increased 3.5 fold, and both of these proteins have been associated with 
neurodegeneration (Terrisse et al., 1998). Nerve growth factor receptor as well as γ-synuclein also 
have emerging roles in AD (Navarro et al., 2003).  There are two different types of nerve growth 
factor receptors; the low affinity nerve growth factor receptor, also known as p75NTR, which binds all 
neurotrophins and the Trk family of tyrosine kinase receptors which bind specific neurotrophins. 
Both of these receptors have been associated with neurodegeneration and implicated in AD 
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pathology as these receptors bind Aβ, and are upregulated in AD (Yaar et al., 2002, Podlesniy et al., 
2006). 
 B103 cells expressing APP showed a decrease in Reticulon 4 (RTN4), an endoplasmic 
reticulum associated protein that is involved in neuroendocrine secretion. RTN4 has been shown to 
inhibit neurite outgrowth, and consequently has also been named neurite outgrowth inhibitor or 
Nogo. Increased expression of RTN4 has been shown to decrease Aβ peptide production by 
reducing BACE1 activity (Dasgupta et al., 2004). Park and colleagues found that RTN4 and its 
receptor RTN4R demonstrate altered subcellular localization in AD. In normal brain RTN4 shows 
reduced cellular and enhanced neuropil localization whereas in AD brain it shows enhanced cellular 
localization. Similarly, while RTN4R is mainly localized to cell soma in normal brain it showed 
reduced cellular localization with more diffused staining in the neuropil and plaques in AD brain. 
RTN4R was also found to physically interact with APP and Aβ, limiting Aβ accumulation (Park et 
al., 2006). Another protein that showed downregulation in the B103-695 cells is the eukaryotic 
translation initiation factor 4A2 (eIF4A2), which showed a 7.98 fold decrease and is also associated 
with the ER. A decrease in expression of the proteins associated with ER may indicate that 
expression of APP leads to an induction of ER stress. ER responds to stress by activating various 
signaling pathways including the unfolded protein response (UPR), which leads to attenuation of 
protein translation. Studies have shown that APP induces ER stress-mediated apoptosis in cells and 
further studies are necessary to confirm that APP expression in B103 cells lead to an induction in 
ER stress-associated signaling pathways (Takahashi et al., 2009). In AD, ER stress has been shown 
to induce inflammation, which leads to enhanced pathology development in AD. eIF4A2 has been 
suggested as one of 2 suitable reference genes for RT-qPCR studies in human AD post mortem 
brain samples, as its mRNA is stably expressed (Penna et al., 2011). 
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 Analyses of AD brains have shown aberrant expression of cell cycle regulatory proteins in 
neurons. The roles of the cell cycle regulators in neurons as well as the mechanisms that lead to the 
induced expression of these proteins are not known. It is possible that either APP or a metabolite of 
APP may enhance expression of proteins such as γ-synuclein and Ras, thus affecting cell 
proliferation in transformed cells and degeneration in terminally differentiated cells. γ-synuclein has 
already been shown to bind and alter microtubule dynamics. Our co-immunostaining analysis with 
actin and γ-synuclein antibodies show altered localization of actin in the cells expressing APP. This 
is a significant finding and suggests that APP-mediated induction in γ-synuclein may lead to 
alterations in cytoskeletal and microtubule-associated proteins, which in turn affects neuronal 
signaling and synaptic function in AD. Since γ-synuclein affects the mitotic checkpoint, it is possible 
that the neuronal expression of this protein may not only alter the neuronal cytoskeleton but also 
affect the differentiation state of neurons. Neurons are terminally differentiated cells and do not 
have an active cell cycle machinery and therefore may respond to cell cycle activation by undergoing 
apoptosis instead of transformation. In addition to a role in AD, studies from different groups have 
shown that cancers of different organs show increased levels of APP or a metabolite of APP. Thus, 
a careful analysis of APP function may enhance our knowledge on the role of APP in bringing about 
pathologies associated with not only AD but also cancers of different organs. 
3.5. Conclusions 
 This study represents the first comprehensive proteomic analysis of B103 and B103-695 rat 
neuronal-like cells, including relative quantitation of protein expression using SILAC-based 
proteomics. Several proteins were identified as being significantly upregulated or downregulated in 
B103-695 cells, many with potential implications in AD pathology. The comprehensive dataset 
provides insight into proteins that may be affected by APP-695 expression and provides a 
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foundation for future mechanistic studies. The proteins identified are associated with a number of 
diverse processes including cellular assembly and organization, cell cycle, lipid metabolism, protein 
folding, post translational modifications, as well as physiological system development and function. 
These findings suggest that several different processes are influenced by APP expression, which may 
contribute to synaptic dysfunction, amyloid plaque formation, and AD pathology. 
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CHAPTER 4:  POTENTIAL ROLE OF PCTAIRE-2, PCTAIRE-3 AND P-HISTONE H4 
IN AMYLOID PRECURSOR PROTEIN-DEPENDENT ALZHEIMER PATHOLOGY1 
 
4.1. Introduction 
The actual role of full length APP protein in cells is difficult to determine as APP gets 
proteolytically cleaved to generate both N- and C- terminal fragments with various cellular 
functions.  In the previous chapter, we showed that APP promotes expression of proliferation-
associated proteins, supporting the notion that APP has a cell cycle regulatory function.  This study 
was carried out with B103 rat neuroblastoma cells that are null for or expressing the APP-695 
(B103-695) isoform, using SILAC-based mass spectrometry. Our findings indicate that altered 
expression of APP induces signaling cascades that may be involved in cell cycle-mediated neuronal 
degeneration observed in AD. Since cell cycle deregulation and protein phosphorylation are 
fundamental to AD neurodegeneration, in the current study we analyzed global changes in protein 
phosphorylation upon APP expression using mass spectrometry-based phosphoproteomics. Mass 
spectrometry was used for identification of phosphopeptides from complex mixtures, including site 
localization and relative quantification. Phosphoproteomics involves enrichment of 
phosphopeptides to increase identification and sequence information, which is useful for 
bioinformatic analysis of affected pathways. Phosphoproteomics can identify potential changes in 
                                                          
1 The information in this chapter has been legally reproduced under the Creative Commons Attribution (CC-BY) license 
and are utilized with the permission of the publisher. See Appendices B and C.   
Chaput D, Kirouac L, Stevens SM, Jr., Padmanabhan J (2016) Potential role of PCTAIRE-2, PCTAIRE-3 and P-Histone 
H4 in amyloid precursor protein-dependent Alzheimer pathology. Oncotarget 7:8481-8497. 
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kinase activity by analysis of overrepresented phosphorylated consensus motifs (Schwartz and Gygi, 
2005). Several phosphopeptide enrichment techniques are described, including antibody 
immunoaffinity enrichment, immobilized metal-affinity chromatography (IMAC) using Fe3+ metal 
ions (Andersson and Porath, 1986, Li and Dass, 1999, Stensballe et al., 2001), and metal oxide 
affinity chromatography (MOAC) using TiO2 (Pinkse et al., 2004, Larsen et al., 2005). Currently, 
there are few phosphoproteomic studies related to AD. Here, we used a titanium-based 
nanopolymer phosphopeptide enrichment in combination with strong cation exchange. 
Phosphoproteomic analysis identified over 2000 phosphopeptides in SILAC-labeled B103 and 
B103-695 cells. Targeted validation of selected signaling markers in PS/APP mice, Aβ-treated 
primary neurons and human AD and MCI patient brain tissue provided insights into novel 
biomarkers associated with AD pathology. 
4.2. Materials and Methods 
 4.2.1. Materials 
 B103 and B103-695 rat neuroblastoma cells were obtained from Dr. David Schubert (Salk 
Institute, La Jolla, CA). Tissue culture reagents, Hoechst 33258, and Alexa Fluor 488 and 594 dyes 
were purchased from Life Technologies (Carlsbad, CA). Amino acids for SILAC labeling were 
purchased from Cambridge Isotopes (Tewksbury, MA). Protein assay 660 reagent, ionic detergent 
compatibility reagent (IDCR), Halt Protease Cocktail Inhibitor, and chemiluminescence reagents 
were purchased from Pierce (Rockford, IL). Poly-L-Lysine (PLL) and antibodies against α-tubulin 
and β-actin were purchased from Sigma-Aldrich (St. Louis, MO). Anti-APP antibody (6E10) was 
from Covance (Princeton, NJ). Anti-Tau1 antibody and FASP 30kDa regenerated cellulose filters 
were purchased from Millipore (Billerica, MA). Antibodies against PCTAIRE-2 and PCTAIRE-3 
were purchased from Santa Cruz (Dallas, TX), anti-GAPDH and anti-histone H4 antibodies were 
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purchased from Cell Signaling (Danbers, MA), and anti-phosphoSer47-histone H4 antibody was 
purchased from Abcam (Cambridge, MA). Recombinant Aβ (1-42) peptide was purchased from 
American Peptide Company (Sunnyvale, CA). Sprague Dawley E16 time-pregnant rats were 
obtained from Harlan Laboratories (Indianapolis, IN). Anti-PHF-1 (phospho-tau Ser396/Ser404) 
antibody was kindly provided by Dr. Peter Davies (Albert Einstein College of Medicine, Manhasset, 
NY). Trypsin/Lys-C was purchased from Promega (Madison, WI) and PolyMAC 
phosphoenrichment kits were from Expedeon (San Diego, CA). C18 SPE desalting columns were 
purchased from Thermo Fisher (Waltham, MA) and strong cation exchange columns were from 
PolyLC Inc (Columbia, MD). 
 4.2.2. Cell Culture and SILAC Labeling 
 B103 and B103-695 cells were grown in SILAC DMEM:F12 SILAC media supplemented 
with 10% dialyzed FBS, Pen-Strep-Glutamine, and either unlabeled L-arginine and L-lysine for B103 
or heavy labelled 13C6-L-lysine 2HCl and 
13C6-
15N4-arginine HCl for B103-695 cells. Cells were grown 
for 5 doublings to achieve >99% incorporation of labeled amino acids before being collected. 
 4.2.3. Sample Preparation and Phosphopeptide Enrichment 
 Cells were lysed in 100mM Tris-HCl (pH 7.6), 4% SDS, 100mM DTT and Halt Protease 
Cocktail Inhibitor and incubated at 95˚C for 5 minutes, followed by sonication at 20% amplitude. 
Protein was quantified using the Pierce 660 assay supplemented with ionic-detergent compatibility 
reagent. Experiments were performed in triplicate. A total of 1.2mg B103 and 1.2mg B103-695 
lysate were combined and processed by filter-aided sample preparation (FASP) (Wisniewski et al., 
2009), followed by digestion with Trypsin/Lys-C at 1:50 (w:w; protease:protein) overnight at 37˚C. 
Peptides were desalted using C18 SPE columns with a Supelco vacuum manifold and dried before 
resuspension in mobile phase A prior to fractionation. Peptides were fractionated on a Dionex 
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U3000 HPLC system with a 200 x 4.6mm i.d. strong cation-exchange (SCX) column packed with 
5µm 200Å polySULFOETHYL A-SCX material. One minute fractions were collected using a 45 
minute gradient (15-200mM ammonium formate, pH 3-6.5, 25% acetonitrile) at a flow rate of 
1ml/minute. 
 Peptide fractions were enriched for phosphopeptides using PolyMAC, a nanopolymer 
titanium-based enrichment, as described by the manufacturer. Following PolyMAC enrichment the 
samples were dried and resuspended in 0.25% formic acid for LC-MS/MS analysis. 
 4.2.4. LC-MS/MS 
 Peptides were analyzed on a Q-Exactive Plus (Thermo Fisher Scientific) following with a 
75µm x 50cm C18 reversed-phase(RP)-UPLC column (Dionex) using a 90 minute gradient on an 
EASY-nLC 1000 system (Thermo Fisher Scientific). Full MS survey scans used a resolving power of 
60,000, selecting the top ten most abundant ions for MS/MS fragmentation and analysis. 
 4.2.5. Database Searching and Consensus Motif Analysis 
 Raw data files were processed in MaxQuant (version 1.5.0.30, http://www.maxquant.org) 
and searched against the UniprotKBRattus norvegicus protein sequence database. The search 
parameters included a constant modification of cysteine by carbamidomethylation and variable 
modifications of methionine oxidation and phosphorylation of serine, threonine, and tyrosine. 
Statistical analysis was carried out using Perseus software (version 
1.5.0.31, http://141.61.102.17/perseus_doku). Statistically significant changes in phosphopeptide 
abundance were determined using Significance A, an outlier test with a threshold p-value of 0.05. 
Only phosphopeptides identified in at least 2 biological replicates with a minimum ratio count of 2 
were used for statistical analyses. Phosphopeptide ratios were normalized against total protein ratios 
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from our previous SILAC-based proteomic analysis of B103 and B103-695 cells. Both non-
normalized and normalized median phosphopeptide ratios were analyzed to account for potential 
changes in phosphorylation of proteins that were not identified in our initial proteomic analysis. 
Consensus motif analysis was performed using Scaffold PTM (version 2.1.3) to determine 
overrepresented kinase motifs surrounding phosphorylation sites, using the method developed by 
Gygi and Schwartz (Schwartz and Gygi, 2005), as well as potential enzyme recognition sites. 
 4.2.6. Transgenic Mouse Tissue 
 Heterozygous PDGF-hAPP (V717F) mice (Swiss-Webster x C57BL/6) were crossed with 
PDGF-hPS1 (M146L) heterozygotes (Swiss-Webster x C57BL/6) to generate APP+/-/PS1+/-
 genotyped mice. In this study we used these transgenic mice with age-matched non-transgenic (Ntg) 
mice to serve as control. Mice were anesthetized at 9 months with pentobarbital (10mg/kg body 
weight) and perfused with a saline solution. Brains were dissected out and half of each brain was 
fixed with 4% paraformaldehyde and the other half was used for protein extraction using RIPA lysis 
buffer. Brains were processed prior to immunohistochemical analysis as previously described 
(Padmanabhan et al., 2006). Brain sections were prepared using a freezing stage microtome and then 
stored at 4°C in phosphate buffered saline (PBS) containing 0.02% sodium azide. 
 4.2.7. Oligomeric Aβ42 Preparation 
1mg of monomeric Aβ42 was dissolved in 1ml trifluoroacetic acid and lyophilized in 100μg aliquots. 
Lyophilized Aβ42 was solubilized in sterile DMSO to a concentration of 5mM and then diluted to 
100μM in DMEM media and left a 4°C overnight. 
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 4.2.8. B103 Culture and Treatment 
 B103 and B103-695 cells were cultured in Advanced DMEM/F12 supplemented with 10% 
FBS and 1% Penicillin/Streptomycin at 37°C and 5% CO2 as previously described (Jin et al., 1994). 
Cells were plated on 8-chamber slides coated with PLL at a density of approximately 5x104 cells per 
well. After 24 hours, cells were treated with either 5μM Aβ42 or DMSO, which served as a vehicle 
control. 
 4.2.9. Primary Neuron Culture and Treatment 
 Primary neurons were cultured in Neurobasal Medium supplemented with 2X B-27, 1% 
Penicillin/Streptomycin and 2mM glutamine. Neurons were cultured in 8-chamber glass slides and 
100mm cell culture dishes coated with PLL. Briefly, E18 pregnant rats were euthanized by 
phentobarbital injection and feti excised and placed in isotonic solution. The meninges were then 
removed and cortices separated. Cortices were triturated into a single cell suspension in isotonic 
buffer and spun down at 1500 RPM for 5 mins at 4°C. The neuronal pellet was resuspended in 2ml 
Neurobasal media and filtered through a cell strainer. 8-chamber slides were plated with 
~5X104 neurons per well and 100mm dishes were plated with ~6X106 neurons. Neurons were fed 
every third day and grown for 5 days prior to treatment. Neurons grown on 100mm dishes were 
treated with either DMSO vehicle or 5μM Aβ42 and harvested after 24 hrs. Neurons grown on 8-
chamber were treated with wither DMSO vehicle or incremental concentrations of Aβ42 ranging 
from 1μM to 5μM and used for immunostaining analysis. 
 4.2.10. Nuclear Fractionation 
 B103 and B103-695 cells were grown in DMEM:F12 as described above, collected and 
pelleted by centrifugation at 500 x g for 15 minutes at 4˚C. Cells were resuspended in 1ml of 10mM 
Tris-HCl (pH 7.4), 1mM EDTA, 200mM sucrose, and Halt Protease Inhibitor Cocktail and 
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subjected to gentle dounce homogenization. Nuclei and cell debris were pelleted by centrifugation at 
900 x g for 10 minutes at 4˚C. The nuclei containing pellet was lysed in 100mM Tris-HCl (pH 7.6), 
4% SDS, 100mM DTT and Halt Protease Cocktail Inhibitor as described above. Protein was 
quantified using the Pierce 660 assay supplemented with ionic-detergent compatibility reagent before 
preparing 1μg/µl samples in Laemmli Buffer for western blot analysis. 
 4.2.11. Western Blotting 
 Proteins were selected for validation by western blot analysis based on significance as well as 
function. Proteins were separated on an AnyKD SDS-PAGE gel (BioRad) and transferred to a 
PVDF membrane using the Trans Turboblot system (BioRad). Membranes were blocked in 5% 
non-fat milk in TBS for 1 hour at room temperature. Primary antibodies specific for phospho-
Serine47-Histone H4 (rabbit polyclonal, 1:500), Histone H4 (mouse monoclonal, 1:1000), 
PCTAIRE-2 and PCTAIRE-3 (rabbit polyclonal, 1:1000), actin (mouse monoclonal, 1:7000) and 
GAPDH (rabbit monoclonal, 1:5000) were diluted in 5% BSA-TBS, containing 0.05% sodium azide 
and incubated overnight at 4˚C. Membranes were washed and then incubated with appropriate 
corresponding secondary antibodies, donkey anti-rabbit HRP-conjugated or goat anti-mouse HRP-
conjugated for 1.5 hours at room temperature. After further washes, all blots were developed with 
Pico Chemiluminescence reagents, with the exception of pS47-Histone H4 which was developed 
using Femto Chemiluminescence reagents, using an Amersham Imager 600RGB (GE Healthcare). 
 4.2.12. Immunostaining  
 For immunostaining analysis of mouse brain sections, sections were mounted onto 
superfrost slides and rehydrated with TBS for 5 minutes. For antigen retrieval, sections were 
incubated in 10mM citrate buffer, pH 6.0 for 10mins at 95°C and cooled to room temperature. After 
washing with PBS, sections were incubated with blocking buffer (10% normal goat serum (NGS) in 
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TBST with 0.02% sodium azide) for 2hrs at room temperature. Sections were then incubated with 
APP (6E10) primary antibody (mouse monoclonal 1:500) and either PCTAIRE-2 (1:50) or 
PCTAIRE-3 (1:50) primary antibody diluted in 1% BSA-TBST at 4°C in a humidified chamber 
overnight. Next, sections were washed and incubated for 2hrs at room temperature with goat anti-
mouse IgG Alexa Fluor 488 (1:1000) and goat anti-rabbit IgG Alexa Fluor 594 (1:4000) diluted in 
blocking buffer. After washing, slides were incubated with 1μg/ml Hoechst 33342 DNA dye in PBS 
for 3mins. After thorough washing, the slides were coverslipped with Fluoro-Gel mounting media 
and analyzed with a Zeiss Fluorescence Axio Imager using AxioVision Rel 4.8 software. 
 For immunostaining analysis of cultured cells, they (either B103, B103-695 or primary 
neurons) were fixed with 4% paraformaldehyde for 10mins at room temperature and washed with 
PBS. Following this, cells were blocked in blocking buffer for 1hr. B103 and B103-695 cells were 
then incubated overnight at 4°C with α-tubulin (mouse monoclonal, 1:1000) and either PCTAIRE-2 
(1:50) or PCTAIRE-3 (1:50) primary antibodies diluted in 1%BSA-TBST containing 0.02% sodium 
azide. Neurons were incubated with Tau 1 (mouse monoclonal, 1:500) and either PCTAIRE-2 (1:50) 
or PCTAIRE-3 (1:50) primary antibodies. After incubation, cells were washed and incubated in goat 
anti-mouse IgG Alexa Fluor 488 (1:1000) and goat anti-rabbit IgG Alexa Fluor 594 (1:4000) diluted 
in blocking buffer. After brief washing, cells were incubated for 3mins with 1μg/ml Hoechst 33342 
DNA dye. Cells were thoroughly washed and mounted using Fluoro-Gel before being visualized and 
analyzed as mentioned above. 
 4.2.13. Human Brain Tissue  
 Human brain tissue was obtained from Dr. David Cribbs at the University of California 
Irvine Alzheimer’s Disease Research Center. Brain samples were de-identified and categorized based 
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on post-mortem Braak stage and pre-mortem clinical MMSE score. Additional information on this 
brain material is detailed in Table 4.1.  
Table 4.1. Specifications on human brain tissue samples.  Details of the brain samples used in the study are 
provided in this table.  PMI indicates post mortem interval.  MMSE indicates clinical assessment 
using The Mini Mental State Examination.  NAD: Non-Alzheimer’s Disease (normal samples); MCI: 
Mild Cognitive Impairment; LAD: Late-stage Alzheimer’s disease. 
 
 Samples were categorized based on disease stage; Non-AD (NAD), Mild Cognitive Impaired 
(MCI) or late-AD (LAD). Tissue was homogenized in 100mM Tris-HCl (pH 7.6) containing 4% 
SDS, 100mM DTT and Halt protease inhibitor cocktail, heated at 100°C for 5mins, briefly sonicated 
and centrifuged for 15mins at 14,000 RPM. The soluble supernatant fraction was then separated 
from the insoluble pellet, protein concentrations were determined using Pierce 660 reagent and 
equal amounts of proteins were used for sample analysis by western blot.  
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4.3. Results 
 4.3.1. B103 and B103-695 Phosphoproteome Comparison Reveals Differential 
Phosphorylation of Proteins in APP Expressing Cells 
 A total of 2478 phosphopeptides were identified among 3 biological replicates in B103 and 
B103-695 cells; 1082 were quantified in a minimum of 2 biological replicates with a minimum ratio 
count of 2. Of the 1082 phosphorylation sites confidently identified and quantified, 712 
corresponded to proteins previously quantified by SILAC in our global scale proteomic analysis of 
B103 and B103-695 cells (Chaput et al., 2012). When possible, phosphosite ratios were normalized 
against corresponding protein ratios previously determined in the B103 and B103-695 proteomic 
analysis. Perseus was used to identify significant changes in phosphopeptide expression across 
biological replicates using Significance A, a statistical outlier test, with a p-value threshold of 0.05. 
Significant changes were identified in 92 phosphosites corresponding to 71 different proteins when 
using non-normalized ratios, and 50 phosphosites corresponding to 46 proteins when using 
normalized ratios. Selected differentially phosphorylated sites, both normalized and non-normalized, 
are listed in Table 4.2. Bioinformatic analysis of statistically significant phosphosites was performed 
using Ingenuity Pathway Analysis which identified several proteins associated with neurological 
disease and psychological disorders as well as molecular and cellular functions including cell 
morphology, cellular assembly and organization, function and maintenance, and growth and 
proliferation. 
 Our phosphoproteomic analysis identified a number of differentially phosphorylated 
proteins that have been previously associated with AD, including A-kinase anchor protein 12 
(AKAP12), heat shock protein beta 1 (HspB1) and myristoylated alanine-rich C-kinase substrate 
(MARCKS). AKAP 12 exhibited significantly increased phosphorylation at Ser507 (2.46-fold) in 
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B103-695 cells after normalization against total protein expression. AKAP12 is a scaffolding protein 
that serves as a negative regulator of G1 to S cell cycle progression (Frankfort and Gelman, 1995). 
Increased phosphorylation of AKAP12 at Ser290 was also observed in an early phosphoproteomic 
study of human AD brain (Xia et al., 2008), however, the functional relevance of this residue is not 
known. B103-695 cells also showed increased phosphorylation of HspB1, a molecular chaperone 
involved in regulating cell proliferation and cytoskeletal reorganization at Ser15 (3.16-fold) and Ser86 
(4.49-fold) (Huot et al., 1997, Rane et al., 2003, Gibert et al., 2011).  
Table 4.2. Selected proteins that showed significant change in phosphorylation in B103-695 cells compared to B103 
cells.  Phosphoproteins and the amino acid position are provided in this table. Normalized and non-
normalized phosphosite ratios were analyzed using Significance A with a Benjamini-Hochberg q-
value cutoff of 0.05, protein ratios with q-values ≤ 0.05 in two out of three biological replicates were 
considered significant. 
  
 
 A recent quantitative phosphoproteomic study of frontal cortex from human AD brains also 
identified increased phosphorylation of HspB1 at these sites (Dammer et al., 2015). MARCKS 
showed significant decrease in phosphorylation at several sites in B103-695 cells, however these 
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phosphopeptide ratios were unable to be normalized against total protein levels. A previous study 
showed that human AD cortical neurons exhibited an overall decrease in MARCKS 
phosphorylation, however they also reported an increase in phosphorylation of this protein in 
microglia from AD brains (Kimura et al., 2000).  Taken together, we have identified a number of 
differentially phosphorylated proteins that have previously been reported to show altered 
phosphorylation in AD, which provides confidence in our cell model for APP-related studies as well 
as the quality of our phosphoproteomic dataset. 
 4.3.2. Consensus Motif Analysis of Identified Phosphorylation Sites 
 Mass spectrometry provides site localization of phosphorylated peptides as well as 
surrounding sequence information, which enables consensus motif analysis. Most kinases 
phosphorylate residues within a specific consensus motif; determining overrepresented consensus 
motifs can be an indication of changes in kinase activity. Consensus motif analysis identified several 
phosphopeptides that were phosphorylated within the growth associated Histone H1 kinase 
substrate motif in B103-695 cells but not in B103 cells, suggesting increased activity of this kinase in 
APP-695 expressing cells Figure 4.1.  Growth-associated Histone H1 kinase has been shown to be 
involved in regulating mitotic entry (Langan et al., 1989), suggesting altered cell cycle regulation in 
B103-695 cells. 
 
Figure 4.1. Growth-associated Histone H1 kinase substrate motif.  The Histone H1 substrate motif is 
represented in APP-695 expressing B103-695 cells, but not APP-null B103 cells. 
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 The normalized ratio of phosphoSer47-Histone H4 showed a statistically significant 1.89-
fold increase in B103-695 cells compared to B103 cells and was selected for further validation. 
Histone H4 is involved in chromatin structure and function and modification of Histone H4 
influences both dynamic and long-term gene expression. Histone H4 is phosphorylated at Ser47 by 
p21-protein-activated kinase 2 (Pak2) (Kang et al., 2011). Pak2 is activated upon phosphorylation at 
Ser141 (Jung and Traugh, 2005). We observed a slight increase in phosphorylation of Pak2 at Ser141 
(1.15-fold increase after normalization to total Pak2) in B103-695 cells by phosphoproteomics (data 
not shown). The extracted ion chromatogram (XIC) for the SILAC heavy and light labeled Ser47 
phosphorylated Histone H4 peptide identified by LC-MS/MS analysis, as well as their base peak 
chromatograms, are shown in Figure 4.2 (a) and (b). The area under the curve for each XIC is 
representative of peptide abundance, which is significantly greater in the heavy labeled peptides from 
B103-695 cells. The annotated MS/MS spectra showing the amino acid sequence determined by LC-
MS/MS of the Ser47 phosphorylated Histone H4 peptide is shown in Figure 4.2 (c). Increased 
phosphorylation of Ser47-Histone H4 in B103-695 cells was validated by western blot analysis of 
nuclear fractions from B103 and B103-695 samples (Figure 4.3, a).  
 4.3.3. APP Expressing Cells Show Increased Phosphorylation of Histone H4 at Ser47 
 Since we observed significant changes in Histone H4 phosphorylation in APP expressing 
cells, we evaluated if similar changes occur in Aβ treated neurons and human AD brain samples. 
Primary cortical neurons were treated with 5µM oligomeric Aβ42 for 24 hours, and analyzed using 
the phospho-specific Histone H4 antibody, which showed a significant increase in phosphorylation 
of Histone H4 at Ser47 while total Histone H4 levels were unaltered (Figure 4.3, b). Next we tested 
if similar changes in Histone H4 phosphorylation occur in the MCI or AD brain samples. Western 
blot analysis with Aβ-directed 6E10 and PHF-1 (Ser396/Ser404) P-tau antibodies were performed 
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to validate that the MCI and LAD brain samples indeed show increased levels of Aβ and/or 
hyperphosphorylation of tau compared to the NAD samples (Figure 4.3, c; specifications of the 
samples are provided in Table 4.1). Reprobe of the blots with the Ser47-specific P-Histone H4 
antibodies showed an increase in P-Histone H4 levels in MCI, with significant increase in LAD, 
compared to the NAD samples (Figure 4.3, d). Total levels of H4 appeared to be unaltered between 
the various brain samples. These data imply that phosphorylation of Histone H4 at Ser47 is a 
disease-specific modification and this might have implications in advancement of pathology 
development in AD. 
 
 
Figure 4.2.  Mass spectrometry identified increased phosphorylation of Histone H4 at Ser47 in B103-695 cells. 
(a) Extracted ion chromatogram for “light” (top) and “heavy” (bottom) Histone H4 peptide 
RpSGLIYEETR. (b) Base peak chromatogram showing isotope clusters for both “light” and 
“heavy” peptides with monoisotopic masses labelled.  (c) Annotated MS/MS spectra of Histone H4 
peptide showing phosphorylation detected at Ser47. 
178 
 
 
Figure 4.3. APP expressing cells, Aβ-treated neurons and AD samples show increased phosphorylation of Histone 
H4 at Serine 47. (a) B103-695 cells show increased phosphorylation of Ser47 Histone H4:  Nuclear 
fractions isolated from B103 and B103-695 cells were analyzed using P-Histone H4 Ser47 (top 
panel) antibodies.  Blot was reprobed with total Histone H4 antibody for normalization (bottom 
panel).  The bar graph shows ratio of P-Histone H4 to total Histone H4.  (b) Neurons treated with 
Aβ show increased phosphorylation of Histone H4 at Ser 47: Primary cortical neurons were treated 
with 5μM Aβ for 24hr and samples were analyzed by western blot using Ser 47 P-Histone H4 
antibody (top panel).  Blots were reprobed with total Histone H4 antibody for normalization 
(bottom panel).  The bar graph shows ratio of P-Histone H4 to total Histone H4.  (c) Human MCI 
and LAD samples show increased levels of P-Histone H4 compared to non-AD: Equal amounts of 
proteins from human brain samples (shown in Table 4.1) were analyzed using PHF-1 (top panel) 
and 6E10 (middle panel) antibodies.  Antibodies show increased levels of P-tau (top panel) and Aβ 
(middle panel) in LAD samples compared to MCI and non-AD.  Actin antibody was used for 
normalization (bottom panel).  (d) P-Histone H4 Ser47 is significantly increased in LAD brain 
samples:  Blots from the human samples were reprobed with P-Histone H4 (top panel) and total 
Histone H4 (bottom panel) antibodies, which showed a tendency towards increase in Ser47 P-
Histone H4 in MCI and significant increase in LAD; bar graph shows ratio of P-Histone H4 to total 
Histone H4. *p value <0.05. 
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 4.3.4. Increased Expression of PCTAIRE-2 and PCTAIRE-3 in APP-expressing Cells 
 Phosphopreoteome analysis showed that PCTAIRE-2 (CDK17) and PCTAIRE-3 (CDK18), 
members of the cyclin-dependent kinase family, are differentially phosphorylated in B103-695 cells 
compared with B103 cells (Table 4.2). PCTAIRE-2 and PCTAIRE-3 were not identified in our 
initial proteomic analysis of B103 and B103-695 cells (Chaput et al., 2012), but their non-normalized 
phosphosite ratios showed significant increases in phosphorylation. PCTAIRE-2 showed increased 
phosphorylation at Ser146 (1.86-fold) and Ser180 (2.27-fold). PCTAIRE-3 showed increased 
phosphorylation at Ser66 (3.5-fold) and Ser109 (3.85-fold). Western blot analysis revealed that 
expression of both PCTAIRE-2 and PCTAIRE-3 were significantly increased in B103-695 cells 
compared to B103 cells (Figure 4.4, a). 
 4.3.5. Aβ Treated Neurons Show Altered Cellular Distribution and Enhanced 
Expression of PCTAIRE-2 and PCTAIRE-3 
 To determine if Aβ affects expression or cellular distribution of the PCTAIRE proteins we 
next analyzed primary neurons treated with or without Aβ. Cortical neurons were treated with 
oligomeric Aβ42 for 24 hours and analyzed by western blot and immunostaining. Western blot 
analysis revealed a significant increase in levels of both PCTAIRE-2 and PCTAIRE-3 following 
treatment with 5µM Aβ for 24 hours (Figure 4.4, b). Immunostaining of these neurons treated with 
1µM, 2.5µM, and 5µM oligomeric Aβ42 showed dose-dependent alteration of PCTAIRE-2 and 
PCATIRE-3 expression and cellular distribution. Control neurons treated with DMSO exhibited 
basal, cytoplasmic staining of PCTAIRE-2 whereas those treated with even the lowest concentration 
of Aβ showed enhanced PCTAIRE-2 staining that accumulates both in the nuclear and perinuclear 
areas (Figure 4.4, c). PCTAIRE-3 staining in the neurons showed reduced levels compared to that of 
PCTAIRE-2, agreeing with our western blot analysis. In control DMSO treated neurons, 
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PCTAIRE-3 exhibited basal, punctate nuclear staining (Figure 4.4, d, top row). Upon Aβ treatment, 
expression of PCTAIRE-3 was increased, as indicated by enhanced staining, which appeared to 
localize to not only nuclear regions, but also to the cell body in a fibrillar pattern (Figure 4.4, d). 
 
Figure 4.4. APP expression and Aβ treatment increase the levels of PCTAIRE-2 and PCTAIRE-3 in cells. 
Western blot analysis shows that PCTAIRE-2 and PCTAIRE-3 are significantly increased in (a) 
B103-694 cells compared to B103 cells and (b) primary neurons treated with Aβ compared to 
vehicle treated controls.  The bar graphs to the right of the blots show data normalized to GAPDH 
levels in B103 and B103-695 cells and actin in primary neurons. *p<0.05.  (c) and (d) Primary 
neurons were treated with or without 1, 2.5 and 5μM Aβ for 24hrs and co-immunostaining analysis 
was performed using (c) PCTAIRE-2 or (d) PCTAIRE-3 and Tau1 antibodies.  Hoechst was used to 
visualize the nuclei.  Neurons treated with Aβ show increased nuclear and perinuclear staining.   
 
 4.3.6. Aβ-mediated Induction in PCTAIRE-2 and PCTAIRE-3 is Dependent on APP 
Expression 
 Aβ-mediated cell toxicity has been shown to depend on APP expression on the cellular 
membrane (Lorenzo et al., 2000). To examine both the independent and concerted roles of Aβ and 
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APP in inducing expression of PCTAIRE-2 and 3, we treated B103 and B103-695 cells with 5μM 
oligomeric Aβ42 for 24 hours and analyzed for changes in expression and localization of 
PCTAIREs. DMSO (vehicle) treated B103 cells appeared to have focused, perinuclear staining with 
PCTAIRE-2, and Aβ treatment did not appear to affect the staining in the perinuclear area (Figure 
4.5, a, top 2 rows). B103-695 cells treated with vehicle showed staining for PCTAIRE-2 spread 
throughout the cell and, upon Aβ treatment, appeared to show increased staining in the nucleus 
(Figure 4.5, a, bottom 2 rows). Similar to PCTAIRE-2, PCTAIRE-3 also showed slight alterations in 
staining in B103 cells exposed to Aβ, with the vehicle-treated control cells showing condensed 
perinuclear staining, which became more compact and intense after Aβ treatment (Figure 4.5, b, top 
2 rows). In B103-695 cells, vehicle treated cells showed perinuclear PCTAIRE-3 staining with light 
punctate staining in the nucleus (Figure 4.5, b, bottom 2 rows). This staining became significantly 
enhanced upon Aβ treatment, with PCTAIRE3 showing increased staining in the nucleus and in the 
perinuclear area (Figure 4.5, b). These data suggest that APP and Aβ play an equal and important 
role in expression of PCTAIRE-2 and PCTAIRE-3 and under pathogenic conditions the increased 
levels of Aβ act together with APP to exacerbate its cytotoxic effects on cells. 
 
Figure 4.5. Aβ affects PCTAIRE-2 and PCTAIRE-3 cellular distribution in an APP-dependent manner.  
B103 and B103-695 cells were treated with 5μM Aβ for 24hrs and immunostaining analysis was 
performed using (a) PCTAIRE-2 or (b) PCTAIRE-3 and α-tubulin antibodies.  Hoechst was used to 
visualize the nuclei.  We observed an increase in nuclear staining in B103-695 cells following Aβ 
treatment, while APP-null B103 cells did not show any significant change in staining.   
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 4.3.7. Brains from AD Transgenic Mice and AD Human Show Increased Expression 
of PCTAIRE-2 and PCTAIRE-3 
 Our results show that expression of both PCTAIRE-2 and 3 are significantly increased in 
B103-695 cells compared to APP-null B103 cells and primary neurons treated with oligomeric Aβ. 
These data suggest that either APP or its pathogenic Aβ metabolite is able to induce the expression 
of these cdks. To test if these changes occur in vivo we analyzed brain samples from AD transgenic 
mice as well as those from non-AD, MCI and late AD human subjects (the specifications of the 
human samples are provided in Table 4.1). The brains from 9 month old PS/APP double transgenic 
AD mice were examined by western blot and immunostaining analyses using both PCTAIRE-2 and 
PCTAIRE-3 antibodies. PS/APP transgenic mice demonstrate accelerated plaque pathology and 
increased accumulation of Aβ42 in the cerebral cortex and hippocampus at 6 months age (Holcomb 
et al., 1998). PS/APP transgenic mice showed a significant increase in PCTAIRE-2 expression 
compared with non-transgenic mice, while PCTAIRE-3 expression was only slightly increased 
(Figure 4.6, a and b). Immunostaining analysis for PCTAIRE-2 and PCTAIRE-3 also revealed 
increased expression in PS/APP mice compared to their non-transgenic (non-Tg) littermates (Figure 
4.6, c and d) and showed strong localization of PCTAIRE-2 staining to the dense core of the 
amyloid plaques, as detected by co-staining with 6E10 antibody (Figure 4.6, c). 
 Similar to the results from western blot analysis, PCTAIRE-3 staining was weaker in 
PS/APP mice as compared to PCTAIRE-2, and it showed punctate staining within the amyloid 
plaques in these brain sections (Figure 4.6, d). As a control, sections stained without primary 
antibody but with secondary antibody, exhibited no non-specific signal (data not shown).  Signifying 
the results from the cell lines, neurons and mouse models of AD, analysis of human brain samples 
from MCI and AD patients showed that PCTAIRE-2 and PCTAIRE-3 levels are significantly 
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increased in AD individuals (Figure 4.6, e and f). PCTAIRE-2 expression was also significantly 
increased in MCI brain, suggesting that this particular cdk might play a relevant role in disease 
advancement.  
 
Figure 4.6. PCTAIRE-2 and PCTAIRE-3 levels in AD transgenic mice and human AD brains.  Brain 
extracts from Ntg (non-transgenic) and PS/APP mice were analyzed using (a) PCTAIRE-2 
and (c) PCTAIRE-3 antibodies. PCTAIRE-2 showed a significant increase in the PS/APP mice. 
GAPDH was used to normalize the blots and ratios are shown in the bar graphs. Co-
immunostaining analysis of brain sections from the mice using 6E10 (recognizing full-length APP 
and Aβ) and PCTAIRE antibodies reveals increased localization of (b) PCTAIRE-2 
and (d) PCTAIRE-3 to amyloid plaques in PS/APP transgenic mice. (e) Analysis of brain lysates 
from human NAD, MCI and LAD samples show increased levels of PCTAIRE-2 in MCI and LAD 
and PCTAIRE-3 in LAD. Actin was used for normalization and the intensity ratios are shown in the 
bar graph (f). *p value < 0.05. 
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4.4. Discussion 
 The results presented here show identification of novel downstream targets of APP and/or 
Aβ that might play a role in APP-dependent neurodegeneration in AD. The results from this study 
are summarized in a schematic shown in Figure 4.7. A comprehensive phosphoproteomic analysis of 
B103 and B103-695 cells resulted in the identification of both changes in phosphorylation and 
expression of proteins in response to APP expression. Selected, significant differentially 
phosphorylated proteins listed in Table 4.2 shows that several of these proteins are associated with 
cell division cycle. For example, AKAP12 has been shown to physically bind cyclin D1 in the 
cytoplasm and inhibit its nuclear translocation, which is necessary for its function in cell cycle 
progression (Lin et al., 2000, Lin and Gelman, 2002). AKAP12 is phosphorylated at Ser507/515 by 
protein kinase C (PKC) and this modification has been shown to disrupt the cyclin binding motifs 
present on AKAP12 (Lin et al., 2000). Our finding that Ser507 phosphorylation on AKAP12 is 
enhanced upon APP expression implies that APP mediates inactivation of AKAP12, thereby 
allowing nuclear translocation of cyclin D1 and G1 progression. 
 Phosphoproteome analysis of B103-695 cells also revealed increased phosphorylation of heat 
shock protein beta 1 (HspB1) at Ser15 (3.16-fold) and Ser86 (4.49-fold). The HpsB1 protein is a 
molecular chaperone that belongs to a family of survival proteins that modulate cell proliferation 
and cytoskeletal reorganization (Huot et al., 1997, Rane et al., 2003, Gibert et al., 2011). The 
phosphorylation status of HspB1 is thought to dictate both its structure and function (Gusev et al., 
2002, Kostenko and Moens, 2009) and has been shown to occur in response to activation of a 
number of kinases (Kostenko and Moens, 2009). An in vitro study using dorsal root ganglion sensory 
neuron model has shown that phosphorylation of HspB1 can induce cytoskeletal reorganization and 
neurite outgrowth (Williams and Mearow, 2011). In another study, stress stimuli were shown to 
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promote phosphorylation of HspB1 at Ser15 and Ser86 and influence its subcellular localization in 
hippocampal rat neurons, increasing its recruitment to dendrites and synaptic sites (Schmidt et al., 
2012). APP is known to induce neurite outgrowth in B103 cells (Schubert and Behl, 1993) and it is 
possible that this is partly mediated through enhanced phosphorylation of HspB1. APP expression 
was not always associated with enhanced phosphorylation on proteins. For example, B103-695 cells 
showed a significant reduction in the phosphorylation of myristoylated alanine-rich C-kinase 
substrate (MARCKS) at multiple sites. MARCKS is phosphorylated by kinases such as PKC and 
CaM-Kinases and has been shown to elicit cell type specific phosphorylation changes in the AD 
brains, where neurons showed a decrease and microglia showed an increase in phosphorylation 
(Kimura et al., 2000). The mechanism behind the reduced phosphorylation of MARCKS observed 
in B103-APP cells is unclear at this point. 
 Phosphorylation of Histone H4 at Ser47, which was significantly increased in B103-695 cells 
compared to B103 cells is novel, has not previously been reported in AD, and this was confirmed by 
western blot analysis. Histone H4 Ser47 phosphorylation has been shown to regulate nucleosome 
assembly, promoting assembly of H3.3-H4 by the histone chaperone HIRA, while inhibiting CAF-1 
mediated assembly of H3.1-H4 (Kang et al., 2011). While Histone variant H3.3 differs from H3.1 by 
only 5 amino acids, the functions of H3.3 are unique and cannot be substituted by H3.1 (Couldrey et 
al., 1999, Sakai et al., 2009, Szenker et al., 2011). H3.3 is localized to gene bodies of actively 
transcribed genes, and this positively correlates with gene expression (Ahmad and Henikoff, 2002, 
Mito et al., 2005). Ser47 on Histone H4 is phosphorylated by Pak2, a member of the p21-activated 
serine/threonine kinase family (Kang et al., 2011). Additionally, phosphatases PP1α, PP1β, and 
Wip1 also regulate P-Ser47-Histone H4 levels (Zhang et al., 2013) through activation of Pak2; 
depletion of PP1α and PP1β result in increased Pak2 phosphorylation at Ser141 (Jung and Traugh, 
2005, Zhang et al., 2013). Pak2 phosphorylation at Ser141 was identified in our phosphoproteomic 
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dataset but it was not significantly increased in B103-695 cells, suggesting that additional 
mechanisms are involved in the observed increase in P-Ser47 Histone H4. LAD human brain 
samples showed a significant increase in phosphorylation of Histone H4 at Ser47, whereas NAD 
showed no specific phosphorylation and MCI showed slightly enhanced phosphorylation. 
Furthermore, increased phosphorylation was also observed in Aβ-mediated signaling is treated 
primary neurons, which provides strong evidence that APP and/or Aβ are involved promotion of 
Histone H4-Ser47 phosphorylation. While the significance of this in AD progression has not been 
determined, this data suggests that APP and its metabolites may influence Histone H4-associated 
gene function, which may have consequences in AD. 
 PCTAIRE-2 and PCTAIRE-3 were also differentially phosphorylated in B103-695 cells 
compared to APP-null B103 cells, and this was confirmed by western blot analysis. Phosphorylation 
of PCTAIRE-2 at Ser146 and Ser180 has been identified in previous phosphoproteomic studies of 
human tissue (Wissing et al., 2007, Daub et al., 2008, Dephoure et al., 2008). Phosphorylation of 
PCTAIRE-3 at Ser66 has been shown previously in rats (Hoffert et al., 2006). Additionally, 
phosphorylation of PCTAIRE-3 at Ser12, Ser66, and Ser109 has been shown in HEK293T human 
cells (Matsuda et al., 2014). We did not confirm the changes in levels of phosphorylation at these 
residues due to lack of phospho-specific antibodies, only total protein expression was examined. 
 PCTAIRE-2 expression was significantly increased in PS/APP transgenic mice, while 
PCTAIRE-3 showed only slight increase. Immunostaining analysis of the Tg-AD mouse brain slices 
showed that both PCTAIRE-2 and 3 were localized to the dense, amyloid plaques suggesting a 
possible role for these kinases in Aβ-dependent pathology development. This is supported by the 
results from the primary neurons treated with oligomeric Aβ42, which showed an increase in 
expression of these two proteins, upon both immunostaining and western blot analyses. 
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Furthermore, the finding that the changes in PCTAIRE expression and localization were more 
prominent in Aβ-treated APP expressing B103 cells imply that APP might act as a receptor for Aβ 
mediated signaling and deregulation of these less characterized cdk family members. The findings 
that MCI brains show increased expression of both PCTAIRE-2 and PCTAIRE-3 and LAD brains 
show an increase in both PCTAIRE-2 and PCTIARE-3 may imply that PCTAIRE-2 may act early 
in the development of the disease and persists through the progression while PCTAIRE-3 is 
associated with the late stage pathological changes in AD. 
 
Figure 4.7. Potential APP or Aβ-mediated mechanism in neurodegeneration.  The figure shows a schematic 
of the mechanism by which APP or Aβ may be inducing neuropathology development in AD. The 
arrows and font in red are proposed mechanisms, while arrows in black are mechanisms previously 
established in literature.  The results described here imply that APP or Aβ (in an APP-dependent 
manner) induces phosphorylation and/or expression of proteins that play a role in cell cycle 
(PCTAIREs) or transcriptional (P-Histone H4) dysregulation in neurons, by an unknown 
mechanism. This could potentially lead to additional phosphorylation on tau or possibly APP, 
contributing to neurofibrillary tangle formation and plaque pathology development, or promote 
expression of genes that play a role in AD pathology development. Interfering with these signaling 
cascades might prevent APP-dependent activation and promotion of neurodegeneration by these 
downstream targets of APP. 
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PCTAIRE kinases are categorized by a serine to cysteine mutation in the PSTAIRE cyclin 
binding consensus motif of the cell cycle associated well known CDKs (Okuda et al., 1992). 
PCTAIRE-2 and PCTAIRE-3 are Cdc-2-related serine/threonine kinases; however their functions 
remain to be discovered. Whether PCTAIREs are involved in cell cycle regulation or are regulated 
by the cell cycle is yet to be determined. A study by Meek and colleagues (2004) identified 
PCTAIRE-2 and PCTAIRE-3 as 14-3-3 binding partners, and furthermore PCTAIRE-2 interacted 
with 14-3-3 in a cell cycle-regulated manner (Meek et al., 2004). Other studies, however, indicate that 
PCTAIREs may function independently of the cell cycle (Meyerson et al., 1992, Whitfield et al., 
2002).  PCTAIRE-2 is expressed in terminally differentiated neurons and has been found to 
phosphorylate Ser and Thr residues of Histone H1 (Hirose et al., 1997). PCTAIRE-3 is expressed in 
the brain and testis. A study by Herskovits and Davies (2006) found increased levels of PCTAIRE-3 
in the temporal cortex of AD brains compared with control brains, where it co-localized with paired 
helical filaments (PHFs). Furthermore, they showed that PCTAIRE-3 is indirectly involved in 
promoting phosphorylation of tau at residues T231 and S235, early modifications in AD 
pathogenesis (Herskovits and Davies, 2006). A separate study recently found that PCTAIRE-3 can 
be activated through association with Cyclin A and/or phosphorylation by Protein Kinase A (PKA) 
(Matsuda et al., 2014). PKA increased phosphorylation of PCTAIRE-3 at Ser12, Ser66, and Ser109, 
though only phosphorylation of Ser12 appeared to increase kinase activity; the function of 
PCTAIRE-3 phosphorylation at S109 and S66 by PKA is still unknown (Matsuda et al., 2014). 
Interestingly, PKA was also found by Herskovits and Davies (2006) in the same PHF fractions that 
PCTAIRE-3 was present. Bioinformatic analysis of our previous proteomic study of B103 and 
B103-695 cells have shown increased PKA signaling in B103-695 cells (Chaput et al., 2012) and the 
increased phosphorylation of PCTAIRE-3 at S109 and S66 in B103-695 cells in this 
phosphoproteomic dataset, imply a role for PKA in the observed phosphorylations on PCTAIRE. 
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4.5. Conclusions 
While further investigation is required to determine the functional role of the specific 
phosphorylations or expression changes in proteins described here to AD neurodegeneration and 
pathology development, the comprehensive phosphoproteomic dataset, together with the validation 
studies, provide insights into pathways that may be affected by APP expression, thereby providing a 
foundation for future mechanistic studies. Based on the results from A-β treated neurons, AD 
transgenic mice, and brain samples from AD and MCI patients, we hypothesize that the increased 
expression or posttranslational modifications of these identified proteins may play a relevant role in 
AD pathogenesis and timely inference with these modifications could prevent further progression of 
AD. 
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CHAPTER 5: ACTIVATION OF RAS-ERK SIGNALING AND GSK3 BY AMYLOID 
PRECURSOR PROTEIN AND AMYLOID BETA FACILITATES 
NEURODEGENERATION IN ALZHEIMER’S DISEASE  
 
5.1. Introduction 
While extracellular neuritic plaques and intracellular neurofibrillary tangles constitute the 
major pathologies in AD (Braak & Braak 1991, Braak & Braak 1995, Glenner & Wong 1984, Gold 
et al 2000, Masters et al 1985), the molecular mechanisms that induce these pathogenic 
transformations are unclear.  The contribution of A to AD pathology is understood and yet little is 
known about the physiological function of the APP holoprotein or its role in AD pathogenesis. APP 
phosphorylation at Threonine 668 (Thr668) in the cytoplasmic domain has been shown to enhance 
proteolysis by -secretase (Chang et al 2006, Lee et al 2003).  Kinases such as GSK3, JNK, cdk5, 
cdk4 and cdc2 phosphorylate this site on APP (Aplin et al 1996, Iijima et al 2000, Judge et al 2011, 
Muresan & Muresan 2005, Standen et al 2001, Suzuki et al 1994) and studies in AD brains have 
shown that compromised neurons exhibit activation of these kinases as well as aberrant expression 
of cyclins B, D and E (Busser et al 1998, Nagy et al 1997, Raina et al 1999, Vincent et al 1997).  
Brains from AD patients also show increased levels of Thr668 phosphorylation (Lee et al 2003) on 
APP but whether this phosphorylation is due to aberrant cell cycle activation is unclear.   
In Chapter 2, we demonstrated that transgenic mice expressing APP or APP and PS1 show 
ectopic expression of P-cdc2, cyclin D and cyclin E together with enhanced phosphorylation of 
APP at Thr668 (Judge et al 2011). Using APP expressing human neuroglioma cells we showed that 
197 
 
this phosphorylation occurs in a mitosis-specific manner, predominantly at the G2/M phase of the 
cell cycle, and leads to APP centrosomal association implying a role for APP in cell cycle regulation 
(Judge et al 2011). In Chapter 3, we utilized Stable Isotope Labeling by Amino Acids in Cell Culture 
(SILAC) to show that APP induces expression of proteins involved in cellular assembly, 
organization and morphology and cell cycle (Chaput et al 2012). Cells expressing APP showed 
enhanced Ras expression and activation of extracellular signal regulated kinases (ERK1/2) (Chaput 
et al 2012). These findings prompted us to hypothesize that APP or a metabolite of APP promotes 
Ras-mitogen-activated protein kinase (MAPK) signaling and enhanced proliferation in cells. 
 Primary cortical rat neurons treated with A42 have shown aberrant expression of cell cycle 
markers, DNA replication and mitotic catastrophe (Copani et al 1999, Giovanni et al 1999).  Based 
on our findings that APP induces Ras-MAPK signaling and that mitosis-specific phosphorylation of 
APP at Thr668 leads to centrosome-association of APP, we hypothesize that APP or its metabolites 
play a fundamental role in promotion of cell cycle deregulation observed in AD. Utilizing APP 
specific siRNAs, here we present evidence for APP-mediated activation of Ras-MAPK signaling 
cascade and GSK-3 activation in B103 neuroblastoma cells expressing APP, which are recapitulated 
upon treatment of neurons with A42. In addition to enhanced Ras-ERK signaling and GSK3 
activation, neurons showed enhanced phosphorylation of APP and tau upon A treatment. Since 
phosphorylation of APP can lead to enhanced BACE-mediated proteolysis and A generation, it 
implies that A may promote a positive feedback mechanism by which A induces APP-dependent 
neurodegeneration.  Our studies in human AD brain samples enabled us to validate these findings, 
demonstrating the importance of interfering with aberrant APP or A-dependent signaling for 
prevention of cell cycle deregulation and neurodegeneration in AD. 
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5.2. Materials and Methods 
5.2.1. Reagents and Antibodies 
Tissue culture reagents, Hoechst 33258, Alexa Fluor 488 and 594 dyes were purchased from Life 
Technologies, Carlsbad, CA.  Electrophoresis supplies were from Bio-Rad laboratories, Hercules, 
CA.  HRP-conjugated Goat Anti-Mouse IgG and Goat Anti-Rabbit IgG secondary antibodies were 
purchased from Southern Biotech, Birmingham, AL and SuperSignal West Pico Chemiluminescent 
Substrate was obtained from Thermo Fisher Scientific, Waltham, MA.  Poly-L-Lysine (PLL) and 
antibodies to anti-α tubulin, and anti- actin were purchased from Sigma-Aldrich, St. Louis, MO.  
Anti-A antibody (6E10 raised against A1-16) was from Covance, Princeton, NJ and anti-Tau1 
antibody was purchased from EMD Millipore, Billerica, MA.  APP siRNA, Control siRNA-A, 
siRNA Transfection Reagent, and antibodies to anti-Cyclin D1, anti-Na+/K+-ATPase and anti-SOS2 
were from Santa Cruz Biotechnology, Dallas, TX.  Anti-Phospho-APP (P-Thr668), anti-Phospho-
p44/p42 MAPK (Thr202/Tyr204) (P-ERK1/2), anti-p44/42 MAPK (Erk1/2), anti-Phospho-GSK-
3α/ (Ser 21/9), and anti-GSK-3α/ antibodies were from Cell Signaling Technology, Danvers, 
MA.  Anti-Ras and anti-MAP2 antibodies were purchased from Abcam, Cambridge, MA and anti-
Phospho-Thr231 tau antibody was purchased from Bioscience International, Camarillo, CA.   Anti-
PHF-1 (Phopho-tau Ser 396/Ser404) antibody was kindly provided by Dr. Peter Davies (Albert 
Einstein College of Medicine, Manhasset, NY). Recombinant A (1-42) peptide was purchased from 
American Peptide Company, Sunnyvale, CA.  Sprague Dawley E16 timed-pregnant rats were 
obtained from Harlan Laboratories, Indianapolis, IN.            
5.2.2. Cell Culture 
B103 and B103-695 rat neuroblastoma cells were obtained from Dr. David Schubert (Salk 
Institute, La Jolla, CA).  B103 and B103-695 rat neuroblastoma cells were cultured in Dulbecco’s 
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Modified Eagle Medium/Ham’s F-12 (Advanced DMEM/F-12) supplemented with 10% Fetal 
Bovine Serum (FBS) and 1% Penicillin/Streptomycin at 37˚C and 5% CO2 (Jin et al 1994). 
 5.2.3. Primary Neuron Culture 
Neurobasal Medium was supplemented with 2X B-27, 1% Penicillin/Streptomycin and 
2mM glutamine.  8-chamber glass slides, 6-well plates and 100mm cell culture dishes were coated 
with 200μg/mL PLL for 30 minutes and rinsed with sterile water.  Timed pregnant Sprague Dawley 
rats were obtained from Harlan and E18 embryos were collected after euthanatization by 
pentobarbital injection.  Fetal brains were collected and placed in isotonic solution, meninges 
removed and cortices excised.  Single cell suspension was prepared by triturating cortices with fire 
polished glass pipettes in 2mL of isotonic buffer.  The neuronal suspension was then spun down at 
1500 RPM for 5 minutes at 4˚C and isotonic buffer aspirated.  The neuronal pellet was then 
resuspended in 2mL Neurobasal media by pipetting with fire polished glass pipettes.  Resuspended 
cells were then filtered through a cell strainer.  8-chamber slides were plated with approximately 
5x104 neurons per well.  6 well plates were plated with approximately 1x106 neurons per well.  
100mm dishes were plated with approximately 6x106 neurons.  Neurons were replenished with 50% 
fresh medium every third day and grown for at least 5 days prior to treatment.   
5.2.4. Oligomeric A Preparation and Treatment 
1mg of monomeric A42 was dissolved in 1mL trifluoroacetic acid (TFA) and divided into 
100μL aliquots.  Aliquots containing approximately 100μg of A were then lyophilized.  The 
lyophilized A was solubilized in sterile DMSO to obtain a concentration of 5mM.  This solution 
was then diluted to 100μM in DMEM medium and left at 4˚C overnight to produce oligomeric 
Aβ42 peptide.  Primary rat cortical neurons were treated with 2.5μM or 5μM oligomeric A42 for 24 
hours.  DMSO treatment served as a vehicle control. For low concentration A treatment neurons 
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were incubated with 10-100 nM A for 24 to 144 hours, lysates were prepared and analyzed by 
western blot.   
5.2.5. Human Brain Samples 
The brain tissues used for this project was provided by the University of California, Irvine 
Alzheimer’s Disease Research Center (UCI-ADRC) and the Institute of Memory Impairments and 
Neurological Disorders.  Brain samples were categorized based on clinical MMSE score and post-
mortem Braak stage. Additional information on this brain material is detailed in Table 5.1.  Brain 
samples from 4 males and 10 females were categorized as NAD, MCI or LAD.  Tissue was 
homogenized with 100mM Tris-HCL (pH 7.6) containing 4%SDS, 100mM DTT and Halt protease 
inhibitor cocktail (Pierce).  Homogenates were briefly sonicated then centrifuged for 15 minutes at 
14,000 RPM.  The soluble supernatant fraction was separated from the insoluble pellet.     
Table 5.1. Demographic and cognitive state of human brain tissue samples. MMSE indicates clinical 
assessment using the Mini Mental State Examination. F, Female; M, Male; PMI, post-mortem 
interval; NAD, non-AD (control); MCI, Mild Cognitive Impaired; LAD, Late Alzheimer’s disease. 
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5.2.6. siRNA Transfection of B103-695 Cells 
For APP knockdown studies, B103-695 cells were grown to 60% confluence in 6 well plates 
with Penicillin/Streptomycin free Advanced DMEM/F-12.  Cells were then transfected with 30nM, 
40nM, 60nM, 90nM and 120nM of APP siRNA or with 120nM scrambled siRNA-A.  7 hours after 
transfection, media was replenished with an equal volume of Advanced DMEM/F-12 containing 2X 
serum and cultured for 48 hours before harvesting.    
5.2.7. MEK Inhibitor Treatment 
B103 and B103-695 cells were treated with or without 10M U0126 in the presence or 
absence of 2.5M A for 24 hours and analyzed by Western blot with P-ERK, Ras and cyclin D.  
Primary rat cortical neurons were treated with or without 10M U0126 in the presence or absence 
of 2.5M A for 24 hours and analyzed by immunostaining, as described below, for cellular levels 
and distribution of Ras, P-ERK and P-APP using the corresponding antibodies. MAP2 antibody was 
used as neuronal marker. 
5.2.8. Immunostaining Analysis 
Primary neurons were fixed with 4% paraformaldehyde for 10 minutes at room temperature, 
rinsed three times with 1X PBS and incubated for 1 hour in 1X TBS with 10% Normal Goat Serum 
(NGS) and 0.2% Triton X-100 Blocking Buffer.  Neurons were then incubated overnight at 4˚C 
with P-Thr668 APP (1:1000), cyclin D1 (1:250), P-ERK (1:500), or Ras (1:500) rabbit primary 
antibody and MAP2 (1:1000) mouse primary antibody, diluted in 1X TBS with 1% Bovine Serum 
Albumin (BSA) containing 0.1% Triton X-100.  After incubation, cells were washed with 1X PBS 
four times, 5 minutes each.  Cells were then incubated for 2 hours at room temperature with goat 
anti-mouse IgG Alexa Fluor 488 (1:1000) and goat anti-rabbit IgG Alexa Fluor 594 (1:4000) diluted 
in blocking buffer.  After two washes, cells were then incubated with 1μg/mL Hoechst 33342 DNA 
dye diluted in 1X PBS for 3 minutes.  After several washes, the slides were coverslipped with 
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Fluoro-Gel mounting media and analyzed with a Zeiss Fluorescence Axio Imager using AxioVision 
Rel 4.8 software. 
5.2.9. Western Blot Analysis 
Cells were harvested in their media and pelleted at 1500 RPM for 5 minutes at 4˚C.  Media 
was discarded with the exception of neuronal media, which was diluted with a final concentration of 
1X Laemmli’s sample buffer (to validate Aβ42 levels and oligomerization).  The pellet was 
resuspended in 1X PBS and washed 3 times with subsequent centrifugation.  Cell pellets were then 
lysed with 1X RIPA lysis buffer containing protease and phosphatase inhibitors (1mM PMSF, 1mM 
NaF, 1mM sodium orthovanadate) and complete miniprotease inhibitor (Roche Diagnostics).  Cell 
lysates were placed on ice for 30 minutes, further lysed by sonication and then pelleted by 
centrifugation at 14,000 RPM for 15 minutes.  Pellet was separated from supernatant and protein 
measured using Pierce 660nm Protein Assay Reagent (Thermo Fisher Scientific).  Equal amounts of 
protein were diluted and resuspended in a final concentration of 1X Laemmli’s sample buffer.  
Samples were boiled for 5 minutes, separated on 12% Tris-Glycine gels and electrotransferred to 
nitrocellulose membranes (GE Healthcare). Membranes were incubated in 5% non-fat dairy milk in 
1X TBS for 1 hour at room temperature to inhibit non-specific binding.  Blots were then incubated 
with primary antibody overnight at 4˚C, followed by four 5 minute washes in 1X PBS with 0.05% 
Tween-20 (PBST).  Blots were then incubated with appropriate secondary antibody conjugated to 
horseradish peroxidase.  Immunoreactivity was detected using SuperSignal West Pico 
Chemiluminescent Substrate and captured on autoradiography film (MidSci) or imaged using an 
Amersham 600 Chemiluminescence Imager.  Results were quantified using ImageJ.   
5.2.10. Statistical Analysis 
Statistical analysis was performed using Student’s Paired t-Test or One-way analysis of 
variance (ANOVA, for experiments involving human samples). 
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5.3. Results 
 5.3.1. APP Expression Enhances Proliferative Signaling and GSK-3 Activation 
Our previous studies described in Chapter 3 suggest that APP induces Ras activation.  To 
confirm our findings, we utilized an RNAi approach to downregulate APP expression in B103-695 
cells and examined if APP knockdown affects Ras-ERK signaling.  B103-695 cells were transfected 
with incremental concentrations (30nM to 120nM) of siRNA targeting APP mRNA or with a non-
targeting, scrambled control siRNA-A (120nM).  At APP siRNA concentrations of 90nM and 
higher, the B103-695 cells showed significant decrease in expression of APP protein compared to 
control cells (Figure 5.1, A and B).  At siRNA concentrations that showed significant APP 
downregulation in B103-695 cells, a significant decrease in SOS2 (Figure 5.1, C and D), Grb2 
(Figure 5.1, E and F), Ras (Figure 5.1, G and H) and CyclinD1 (Figure 5.1, K and L) were also 
observed.  ERK activation, as indicated by phosphorylation, showed a significant decrease even at 
the lowest APP siRNA concentrations tested (Figure 5.1, I and J). Total levels of ERK were not 
affected by APP knockdown (Figure 5.1, I) and actin was used as a loading control (Figure 5.1, O). 
These findings confirm that APP is indeed an upstream modulator of the proliferation-associated 
Ras-MAPK signaling cascade.  In vitro studies have identified that the Lys-Ser-Pro motifs in tau are 
substrates for ERK1/2 phosphorylation (Drewes et al 1992, Goedert et al 1992), and it is therefore 
possible that APP plays a role in regulation of this pathway and the subsequent pathogenic 
phosphorylation of tau.  Another kinase involved in tau phosphorylation is GSK-3.  GSK-3α and  
significantly contribute to tau hyperphosphorylation at both primed and unprimed phosphorylation 
sites (Cho & Johnson 2003, Hanger et al 1992, Lovestone et al 1994).  Interestingly, APP 
intracellular domain (AICD) has been shown to affect GSK-3 expression and activity (Zhou et al 
2012), therefore, we next examined if APP knockdown affects GSK-3 activity or expression.  We 
found that phosphorylation at Ser9 and Ser21 on GSK3β and GSK3, respectively, were 
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significantly increased upon APP downregulation while total GSK-3 levels remained unchanged 
(Figure 5.1, M and N). These phosphorylations are known to inhibit GSK3 activity of the respective 
kinases, and the observed increase in phosphorylation upon APP downregulation indicates that APP 
or a metabolite of APP is capable of regulating GSK-3 activity.  
 
5.3.2. Brains from Human AD Brain Samples Show Increased Ras Expression, GSK3 
Activation and APP and Tau Phosphorylation 
Next, we sought to determine if the APP-dependent changes in expression of proliferation-
associated proteins that we observed in B103-695 cells would translate to protein expression in the 
human AD brains.  Protein extracts from the post-mortem neocortex of NAD, MCI and LAD 
patients were examined by Western blot analysis.  Disease state was confirmed by probing with 
6E10 antibody, detecting full-length APP and Aβ, and PHF-1 antibody, detecting 
hyperphosphorylation at Ser396/404.  While expression levels of full-length APP showed no 
significant difference between disease states, Aβ generation was significantly higher in the LAD 
individuals compared to MCI and control (Figure 5.2, A and E); it is possible that enhanced 
proteolysis and generation of A prevents APP from accumulating in the brain.  Similar to A, 
PHF-1 also showed significant increase in LAD brain, with the samples showing higher molecular 
weight and lower molecular weight bands showing PHF-1 signal (Figure 5.2 B and E). Total level of 
tau seems to be unaltered between the control (NAD), MCI and LAD brain samples (Figure 5.2, C 
and E).  GAPDH served as loading control (Figure 5.2, D).  The adaptor protein Grb2 was 
significantly elevated in LAD individuals (Figure 5.2, F and L). In MCI and LAD individuals, Ras 
expression was significantly elevated compared to NAD samples (Figure 5.2, G and L).  Levels of 
phosphorylated ERK1/2 (P-ERK) normalized to total ERK showed a trend towards increase but 
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showed inconsistencies within disease states and did not reach significance when compared to NAD 
(Figure 5.2, H, I and L).  
Increased expression of Ras is indicative of enhanced cell cycle deregulation and proliferative 
signaling in the brains of MCI and AD patients. A growing body of evidence indicates that the 
human AD brain exhibits cell cycle dysregulation and show aberrant expression of cell cycle 
regulatory proteins (Busser et al 1998, Nagy et al 1997, Raina et al 1999, Vincent et al 1997). 
Additionally, AD brains show increased APP phosphorylation at Thr668, which is known to be 
phosphorylated by kinases such as GSK-3, cdk5, ERK, JNK and Cdc2 (Aplin et al 1996, Iijima et al 
2000, Judge et al 2011, Muresan & Muresan 2005, Standen et al 2001, Suzuki et al 1994).  
Our lab previously demonstrated that brains from transgenic mouse models of AD 
recapitulate these findings, with altered expression of P-cdc-2, cyclin D1, and cyclin E (Judge et al 
2011).  Furthermore, we found that expression of cell cycle regulatory proteins in transgenic AD 
mouse brain correlated with enhanced phosphorylation of APP at Thr668 (Judge et al 2011). Upon 
analysis of the blots with the Thr668 specific APP antibody we found that samples from LAD 
patients show enhanced phosphorylation (Figure 5.2, O and Q). Additionally, inhibitory 
phosphorylation on GSK-3 was decreased in LAD samples indicative of activation of the kinase 
(Figure 5.2, M and Q). Total GSK seem to be unaltered between samples (Figure 5.2, N). GSK-3 is a 
tau kinase and its activation has been associated with phosphorylation at PHF-1 sites as well as 
phosphorylation of the Thr231 priming site on tau (Cho & Johnson 2003, Cho & Johnson 2004, 
Goedert et al 1994).  Analysis of the blots with P-Thr231 tau antibody showed that levels of 
phosphorylation at this tau epitope were significantly higher in LAD compared to NAD controls 
(Figure 3, J and L).  MCI also showed a trend towards increased P-Thr231 levels, though 
significance could not be established. The proliferative signaling and activation of GSK3 appear to 
correlate with Aβ levels in the human brain, suggesting that Aβ could elicit its toxic effects by 
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modulating GSK3 activity and the Ras-MAPK signaling axis, contributing to the enhanced APP and 
tau phosphorylation and neuritic plaque and neurofibrillary tangle pathology development in AD.           
 
Figure 5.1.  Knockdown of APP in B103-695 cells results in decreased Ras-MAPK signaling and GSK-3 
activity. B103-695 cells were transfected with increasing concentrations of APP siRNA ranging from 
30nM to 120nM or with 120nM scrambled siRNA-A. At 48 hours after transfection, cell extracts 
were prepared and analyzed by Western blot.  The membrane was initially probed with A) antibody 
to 6E10 to visualize knockdown efficiency.  The membrane was then sequentially probed with C) 
SOS2, E) Grb2, G) Ras, I) P-ERK and total ERK, K) CycD1 and M) P-GSK3αβ and total GSK3αβ 
antibodies.  Finally, the membrane was probed with antibody to Actin (O), which served as loading 
control.  The histograms represent the quantitative analysis of protein levels normalized to Actin; B) 
full length APP, D) SOS2, F) Grb2, H) Ras and L) CycD1, respectively.  Histograms representing 
the quantitative analysis of P-ERK and P-GSK3 normalized to corresponding total ERK or GSK3 
proteins were also shown (J and N for P-ERK and P-GSK3, respectively). Statistical analysis was 
performed using Student’s t-Test.  The data represent the mean ±SEM from seven independent 
experiments (n=7); *p<0.05. 
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Figure 5.2. Human brain samples from MCI and LAD show increased expression of Ras, 
activation of GSK-3 and phosphorylation of APP and tau.  Brain lysates from MCI, LAD and 
NAD control subjects were analyzed by Western blot using the indicated antibodies.  To confirm 
disease state, membranes were probed with A) 6E10 antibody to detect both FL-APP and Aβ, B) 
PHF-1 antibody to detect phosphorylated tau and C) Tau 1 antibody to detect total tau.  D) 
Finally, blots were probed with antibody to GAPDH, which served as a loading control.  E) The 
bar graphs represent the quantitative analysis of protein levels normalized to GAPDH.  
Additional sets of membranes were probed with F) Grb2, G) Ras, H) P-ERK and after stripping 
with I) non-phospho ERK antibody to detect total ERK expression and J) P-Thr231 tau.  The 
membrane was then probed with K) GAPDH antibody, which served as loading control.  The bar 
graph L) represents the qualitative analysis of the normalized proteins.  Analyses were also done 
using antibodies to M) P-GSK3αβ, N) total GSK3αβ and O) P-Thr668. Membranes were 
reprobed GAPDH antibody (P), which served as loading control.  Q) The bar graph represents 
the quantitative analysis of protein levels normalized to the corresponding total protein GSK3 or 
to GAPDH.  Statistical analysis was performed using One-way analysis of variance. The data 
represent the mean ±SEM; Non-AD (NAD) n=4, Mild Cognitive Impaired (MCI) n=5 and Late 
AD (LAD) n=5; *p<0.05. 
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5.3.3. Oligomeric Aβ42 Treatment Induces Proliferative Signaling in Primary 
Neurons 
Since Aβ appears to correlate with Ras expression in Alzheimer’s disease brains we 
examined if Aβ induces Ras-ERK signaling in neurons.  Towards this we treated primary rat 
cortical neurons with oligomeric Aβ42 at 2.5 or 5μM and DMSO was used as a vehicle control.  
Our Aβ preparation consisted of small oligomers (Figure 5.3, A and B) and the concentrations 
chosen have previously been shown to induce neuronal death within 24 hours (Kayed et al 2003, 
Nicholson & Ferreira 2009, Reifert et al 2011).  After treatment for 24 hours, whole cell lysates 
were prepared from control and Aβ treated neurons and were analyzed by Western blot.  Results 
showed that Ras levels were significantly increased with 5μM A treatment (Figure 5.3, C and 
D), while P-ERK levels were significantly increased at both 2.5 and 5M concentrations 
(Figures 5.3, E and F).  Total levels of ERK were unchanged (Figure 5.3, G).  These data suggest 
that Aβ is able to induce the Ras-MAPK signaling pathway in neurons.   
The Ras-MAPK signaling pathway is known to stimulate activator protein (AP-1)-
dependent transcription of cyclin D1 (Balmanno & Cook 1999), so next  we sought to determine 
if cyclin D1 expression was also induced upon Aβ treatment.  Similar to Ras and P-ERK, our 
results show that at 2.5 and 5μM Aβ concentrations expression, of cyclin D1 was increased and 
at 5M the increase was significant (Figure 5.3, H and I). The protein load between samples was 
normalized by reprobing with actin antibody (Figure 5.3, J).  
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Figure 5.3. Oligomeric Aβ42 treatment induces proliferative signaling in primary rat cortical 
neurons.  Primary rat cortical neurons were cultured from E18 timed pregnant rats for at least 5 
days and treated with 2.5 or 5µM oligomeric Aβ42 for 24 hours.  DMSO treatment served as 
vehicle control. Western blot analysis using 6E10 antibody (A) shows presence of small Aβ 
oligomers in the neuronal culture supernatant.  Neuronal extracts were prepared and analyzed by 
Western blot using C) Ras, E) P-ERK, G) total ERK and H) cyclin D1 antibodies.  Finally, 
membranes were probed with Actin antibody (J) for protein loading on the membranes.  The 
histograms represent the quantitative analysis of B) oligomeric Aβ, D) Ras protein expression 
normalized to Actin, F) P-ERK levels normalized to total ERK expression and I) cyclin D1 
expression normalized to Actin.  Statistical analysis was performed using Student’s t-Test.  The 
data represent the mean ±SEM from three independent experiments (n=3); *p<0.05.          
 
The MAPK pathway becomes activated in response to a number of stimuli that mediate a 
signaling cascade from the cell surface to the nucleus, therefore the subcellular distributions of 
Ras and P-ERK are important in determining protein activity.  To determine if cellular 
distribution of Ras and ERK are altered in neurons, cells were treated with oligomeric Aβ42 and 
immunostaining analysis was performed.  Neurons were probed with antibody against the 
neuronal marker MAP-2, together with antibodies to Ras, P-ERK or cyclin D1.  Our results show 
that upon Aβ treatment, Ras levels and membrane association are increased (Figure 5.4, A and 
B).  This increase correlated with the increase we observed upon Western blot analysis (Figure 
5.4, C) and the immunostaining confirms that Ras associates with membrane upon A treatment.  
Next we examined P-ERK cellular distribution in the Aβ-treated neurons (Figure 5.4, C).  
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Neurons treated with DMSO showed weak cytosolic and nuclear staining for P-ERK.  At 2.5μM 
Aβ, both cytosolic and nuclear staining for P-ERK are increased and at 5μM Aβ, P-ERK staining 
was mainly observed in the nuclear compartment (Figure 5.4, C and D), indicative of its 
activation.  Additionally, we analyzed changes in cellular distribution of cyclin D1, which also 
showed an increase in staining and nuclear translocation upon treatment with Aβ (Figure 5.4, E 
and F).  Like Ras and P-ERK, changes in subcellular distribution of cyclin D1 affects its 
functional status; nuclear translocation of cyclin D1 is associated with cell cycle activation and 
G1/S progression (Baldin et al 1993) and the fact that A induces nuclear translocation of cyclin 
D1 indicates A-dependent cell cycle deregulation in neurons.  Taken together, these data 
suggest that oligomeric Aβ42 is able to stimulate the Ras-MAPK signaling cascade and aberrant 
cell cycle activation possibly contributing to the mitotic catastrophe and neurodegeneration 
associated with AD.    
5.3.4. Oligomeric Aβ42 Induces GSK-3 Activation as well as Phosphorylation of APP 
and Tau in Neurons 
To determine if Aβ is able to induce GSK-3 activation or APP and tau 
hyperphosphorylation we treated the primary rat cortical neurons with oligomeric Aβ42 for 24 hours 
at 2.5μM or 5μM, with DMSO treatment serving as control.  Our results show that upon 5μM Aβ 
treatment, phosphorylation of GSK-3αβ is significantly decreased, which is indicative of GSK-3 
kinase activation, and total levels were not affected (Figure 5.5, A-C).  We then examined levels of 
phosphorylated APP and tau, both substrates for GSK-3, and found that with 2.5μM and 5μM Aβ 
there was significant increase in P-Thr668 APP and PHF-1 compared to DMSO treated neurons 
(Figures 5.5, D-G). Protein loading on the blot was examined by reprobing the blot with actin 
antibody (Figure 5.5, H).   
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Figure 5.4.  Analysis of cellular distribution of Ras and P-ERK in neurons treated with oligomeric Aβ42. 
Primary rat cortical neurons from E18 embryos were cultured for at least 5 days and treated with 2.5 
or 5µM oligomeric Aβ42 for 24 hours.  DMSO treatment served as vehicle control.  Neurons were 
immunostained with neuron-specific MAP2 mouse monoclonal antibody and A) Ras, C) P-ERK or 
E) Cyclin D1 rabbit polyclonal antibodies. Arrow points to the magnified image of the cell to show 
nuclear staining of P-ERK or cyclin D1. Immunostaining was visualized with Alexa 594 (red) and 
Alexa 488 (green) flurophores, respectively.  Hoechst staining was used to visualize nuclei (blue).  
The staining was analyzed with AxioVision Rel 4.8 software for Zeiss microscope.  The 
corresponding histograms represent the qualitative analyses of the corrected total cell fluorescence 
for B) Ras, D) P-ERK and F) Cyclin D1.  Statistical analysis was performed using Student’s t-Test 
and the data is representative of three independent experiments (n=3).  Magnification: 63X.   
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Figure 5.5. Oligomeric Aβ42 treatment induces GSK-3 activation and pathogenic phosphorylation of both APP 
and tau in primary rat cortical neurons.  Primary rat cortical neurons were treated with 2.5 or 5µM 
oligomeric Aβ42 for 24 hours and neuronal lysates were analyzed by Western blot using A) P-
GSK3αβ and B) total GSKαβ antibodies.  C) The histogram represents the quantitative analysis of 
P-GSK3αβ levels normalized to total GSK3αβ expression.  Membranes were then probed with D) 
P-Thr668 APP and F) phospho-tau PHF-1 antibodies.  Finally, the membranes were re-probed with 
H) Actin antibody, which served as loading control.  The histograms represent the quantitative 
analysis of E) P-Thr668 APP levels normalized to Actin and G) PHF-1 levels normalized to Actin.  
Statistical analysis was performed using Student’s t-Test and the data represent the mean ±SEM 
from three independent experiments (n=3); *p<0.05.  I) Neurons were treated with indicated 
concentrations of A and immunostained with neuron-specific MAP2 mouse monoclonal antibody 
and P-Thr668-APP rabbit polyclonal antibody.  Immunostaining was visualized with Alexa 594 (red) 
and Alexa 488 (green) flurophores, respectively.  Hoechst staining was used to visualize nuclei (blue).  
The staining was analyzed with AxioVision Rel 4.8 software for Zeiss microscope. The 
corresponding histogram (J) represents the qualitative analysis of the corrected total cell fluorescence 
for P-APP.  Statistical analysis was performed using Student’s t-Test and the data is representative of 
three independent experiments (n=3).  Magnification: 63X. 
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In vitro and in vivo studies have demonstrated that Aβ peptides can induce tau 
phosphorylation and subsequently lead to microtubule destabilization, impaired axonal transport and 
neuronal death (Busciglio et al 1995, Geula et al 1998, Gotz et al 2001, Le et al 1997, Muresan & 
Muresan 2009, Takashima et al 1998).  While a number of studies have implicated Aβ in inducing 
tau hyperphosphorylation, Aβ has never been shown to induce phosphorylation of APP at Thr668.  
To determine the cellular distribution of P-Thr668 APP we performed immunostaining analysis of 
neurons treated for 24 hours with 2.5μM or 5μM oligomeric Aβ42, using antibodies specific to the 
neuronal marker MAP-2 and P-Thr668 APP.  Upon analysis we observed enhanced staining by P-
Thr668 APP antibody in neurons treated with Aβ compared to DMSO treated control neurons 
(Figure 5.5, I and J).  Notably, in Aβ treated neurons P-Thr668 APP staining extended out into the 
neurites, where it appears to accumulate in a beaded pattern (Figure 5.5, I), indicative of neurite 
degeneration and impaired axonal transport.  Taken together, these data suggest that oligomeric 
Aβ42 induces GSK-3 activation, resulting in pathogenic phosphorylation of both APP and tau, 
ultimately leading to enhanced neuronal degeneration.     
 To determine if low concentrations of A bring about similar changes in neurons, as seen 
with micromolar concentrations of A, we treated them with 10, 25, 50 and 100nM A for 24, 48, 
72, 96 and 144 hours and analyzed for changes in Ras, SOS2, Grb2, P-APP, P-Gsk3, P-ERK, cyclin 
D1 and PHF-1 levels. Unlike the higher concentrations of A we were unable to determine any 
significant changes in the expression of these proteins at 24, 48, 72 or 96 hours with low A 
treatment. We observed a significant increase in SOS2, P-ERK, cyclin D1, Ras and Grb2 after 144 
hours of treatment with 100nM A (Figure 5.6, A). 50nM concentration showed an increase in P-
ERK, cyclin D1 and Grb2 after treatment for 144 hours, whereas PHF-1 and P-APP showed a trend 
towards an increase. Additionally, GSK3 did not show any activation at any of these time points 
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or concentrations, implying that sustained exposure to low concentrations of A may mainly 
enhance proliferative signaling in neurons. This agrees with other reported studies where low 
concentrations of A have been shown to promote neuronal cell cycle entry (Lopez-Toledano & 
Shelanski 2004, Majd et al 2008). 
 
Figure 5.6. Low concentration A treatment enhances proliferative signaling in neurons.  A) Neurons were 
treated with 100nM A for 144 hours and samples were analyzed for changes in expression of the 
indicated proteins by western blot. B) Quantification of data from 4 independent experiments.is 
shown. Statistical analysis was performed using Student’s t-Test.  The data represent the mean 
±SEM (n=4); *p<0.05. 
 
To determine if inhibition of ERK affects A-dependent alterations in P-ERK and P-APP, 
we treated primary rat cortical neurons with or without A, in the presence or absence of 10M 
U0126 for 24 hours, fixed and immunostained using P-APP or P-ERK together with MAP2 
antibody as neuronal marker. As shown in Figures 5.7 A&B, the inhibitor treatment visibly reduced 
A-mediated increase in P-APP and P-ERK in neurons. This may suggest that one of the 
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mechanisms by which A enhances APP phosphorylation is via increased activation of Ras-ERK 
signaling. 
 
Figure 5.7. MEK inhibitor U0126 interfered with APP and ERK phosphorylation in neurons.  A-B) Primary 
rat neurons were treated with or without 10M U0126 in the presence or absence of 2.5M A and 
analyzed using A) P-APP and MAP2, B) P-ERK and MAP2. Hoechst was used for visualization of 
nuclei. Data is representative of two independent experiments (n=2). Magnification 63X. 
5.3.5. APP Expression in B103 Cells is Necessary for A-mediated Activation of the 
Ras-MAPK Pathway and MEK Inhibition Attenuates This Activation   
 Previous studies that the toxicity that Aβ elicits is dependent on the presence of cellular APP 
(Shaked et al 2006, Sola Vigo et al 2009).  In order to determine if the A-dependent activation of 
the Ras-MAPK signaling axis is dependent on the presence of APP, we treated both B103 and 
B103-695 cells with or without 2.5μM oligomeric A for 24 hours.  Our data shows that APP must 
be present in the cell to exert a significant change in activation of ERK relative to total ERK 
expression (Figure 5.8, A and B), as well as an increase in expression of cyclin D1 (Figure 5.8, A and 
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D) and Ras (Figure 5.8, A and C).  Furthermore, in the presence of 10μM U0126, the Aβ-dependent 
Ras-MAPK signaling was attenuated (Figure 5.8, A-D).   
 
Figure 5.8. A-mediated Ras-MAPK signaling activation in B103 cells is dependent on APP expression. B103 
and B103-695 cells were treated with or without 2.5μM A, in the presence of absence of MEK 
inhibition U0126 for 24 hours.  A) Samples were analyzed for changes in P-ERK, ERK, cyclin D1, 
and Ras by western blot. Quantification of data for B) P-ERK, C) cyclin D1 and D) Ras are shown 
in respective histograms.  Data from 3 independent experiments.is shown. Statistical analysis was 
performed using Student’s t-Test.  The data represent the mean ±SEM (n=3); *p<0.05. 
   
5.4. Discussion 
Genetic evidence for hereditary AD demonstrates genomic duplication of the APP locus and 
mutations in APP, Presenilin 1 and Presenilin 2, contributing to altered metabolism of APP and 
enhanced Aβ formation (Hardy 1997).  Additionally, the ApoE4 allele associated with sporadic AD 
is linked to increased aggregation and reduced clearance of Aβ (DeMattos et al 2004, Kim et al 2009, 
Wildsmith et al 2013).  It is therefore widely agreed that APP, specifically its toxic Aβ metabolite, is a 
central player in AD.  Soluble, small Aβ oligomers are toxic to neurons (Klein et al 2001, Walsh & 
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Selkoe 2004), however, the mechanisms by which oligomeric Aβ leads to synaptic dysfunction and 
neurodegeneration are not fully understood.  We find that APP and oligomeric Aβ42 activates 
altered neuronal intracellular signaling, resulting in pathogenic phosphorylation of APP and tau, 
contributing to neurodegeneration. 
 Using SILAC-based proteomic analysis, we previously demonstrated enhanced Ras 
expression and ERK phosphorylation upon APP expression in B103 rat neuroblastoma cells, 
suggesting that APP is a modulator of the proliferation-associated Ras-MAPK signaling pathway 
(Chaput et al 2012). Others have demonstrated that Ras signaling regulates APP promoter activation 
and expression (Cosgaya et al 1996, Mora et al 2013).  Our findings that APP downregulation leads 
to reduced Ras expression with a concomitant reduction in ERK phosphorylation indicate that APP 
acts as an upstream positive regulator of Ras-dependent signal transduction pathways in neurons. 
While this signaling promotes proliferation and transformation in dividing cells, it would induce 
mitotic catastrophe and neurodegeneration in terminally differentiated neurons. Studies on 
postmortem human brains implicate the Ras-MAPK pathway as an early driver of AD pathology 
development (Arendt et al 1995, Gartner et al 1999, Gartner et al 1995).  Immunocytochemistry has 
revealed localization of Ras and P-ERK in neurons proximal to plaques and tangles in the AD 
brains, while Western blot analysis has shown increased expression of components of the MAPK 
signaling cascade in conjunction with increased Aβ levels and phosphorylated tau (Arendt et al 1995, 
Ferrer et al 2001, Gartner et al 1999, Gartner et al 1995, Hyman et al 1994, McShea et al 1999, 
Trojanowski et al 1993).   
Our results suggest that elevated Ras levels persist from early AD through advanced stages 
of tau tangle formation, when neurons are most metabolically compromised.  Studies in AD brains 
have shown MAPK activation in response to ATP decline, which contributes to increased tau 
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phosphorylation (Blanchard et al 1994).  Others have demonstrated that P-ERK immunoreactivity 
in the AD brain follows the path of neuronal degeneration, projecting from trans-entorhinal cortex 
and progressing with the pathology (Pei et al 2002).  Our analysis on NAD, MCI and LAD brain 
samples showed that P-ERK levels varied randomly between groups.  This inconsistency could be 
due to the labile phosphorylation status of ERK in frozen tissue or to possible variations in 
postmortem tissue collection and processing. Strikingly, increased expression of Ras appears to 
correlate with A generation and persists through late AD stages, implying a pathological link 
between Aβ and altered Ras-MAPK signaling. Additionally, we observed a significant increase in 
phosphorylated tau in LAD individuals, confirming the molecular link between Aβ, Ras-MAPK 
signaling and tau pathology development. Our data suggests that elevated Aβ levels in the brain lead 
to APP-dependent increase in expression of Ras, activation of ERK1/2 and phosphorylation of 
APP and tau, thus contribution to the proliferative signaling and neurodegeneration observed in 
AD. 
 While the results from brain tissue samples were informative, we were unable to draw a 
conclusion on the role of Aβ in induction of Ras expression or downstream signaling.  Aβ treatment 
can activate the MAPK signaling cascade in acute hippocampal slices as well as primary neurons 
(Dineley et al 2001, Ekinci et al 1999, Rapoport & Ferreira 2000).  ERK activation is a rapid, 
transient event with peak activation occurring within 2-5 minutes and returning to baseline after 15 
minutes (Barge et al 1998, Dabrowski et al 1997, Porras et al 1998) and activity exceeding one hour 
after exposure to a stimuli is indicative of sustained kinase activation (Dabrowski et al 1997).  Our 
studies on primary neurons treated with oligomeric Aβ for 24 hours showed a significant increase in 
expression of Ras and phosphorylation of ERK.  It appears that chronic neuronal Aβ exposure 
elicits sustained MAPK signaling.  These cells also showed enhanced nuclear translocation of P-
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ERK and Ras membrane localization.  Ras interaction with its GEF at the inner plasma membrane 
is important for the GDP-GTP exchange and activation (Iversen et al 2014). Similarly, P-ERK 
nuclear translocation is a key step in ERK activation and signaling (Jaaro et al 1997).  Enhanced Ras-
MAPK signaling axis activates AP-1 and induces expression of cyclin D1 (Balmanno & Cook 1999) 
and our studies show that Aβ not only induces Ras-MAPK signaling but also enhances expression 
and nuclear accumulation of cyclin D1 in neurons.  Since increased nuclear levels of cyclin D1 are 
associated with cell cycle activation and G1/S progression, we believe a similar mechanism is 
activated by Aβ in neurons.  However, the lack of functional cell cycle machinery hinders the 
neurons from undergoing successful division and instead they undergo mitotic catastrophe and 
neurodegeneration.       
 We find that Aβ induces neuronal tau hyperphosphorylation, which is consistent with 
others’ observations (Busciglio et al 1995, Geula et al 1998, Gotz et al 2001, Le et al 1997, 
Takashima et al 1998).  While it is likely that P-ERK is contributing to tau phosphorylation (Lu et al 
1993, Raghunandan & Ingram 1995, Reynolds et al 2000, Tanaka et al 1998), tau is a substrate for 
other kinases such as stress activated kinase (Reynolds et al 1997), cyclin-dependent kinases 
(Kobayashi et al 1993), and most notably GSK-3 (Utton et al 1997). APP is implicated in regulation 
of GSK-3 activity and in vitro studies have demonstrated that AICD interacts with GSK-3β and 
induces its activity (Zhou et al 2012).  Similarly, AICD transgenic mice show a dramatic increase in 
GSK-3 activity (Ryan & Pimplikar 2005).  We found that upon APP knockdown, phosphorylation 
of GSK-3 is increased, indicative of its reduced activity.  Upon analysis of GSK-3 expression in 
human brain samples, we observed a reduction in P-GSK3 levels in MCI and LAD individuals 
compared to non-demented controls, suggesting that abnormal GSK-3 activity is a pathogenic 
process in both early and late stage AD.  GSK-3 can phosphorylate tau at both primed and 
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unprimed residues (Cho & Johnson 2004).  Thr231 is an important priming residue on tau and is a 
primary phosphorylation site for GSK-3 (Lin et al 2007).  We found that P-Thr231 levels were 
significantly elevated in LAD individuals; samples from MCI showed an increase that was not 
significant.  PHF-1, however, was only detected in LAD brain samples, which corresponded with 
high levels of Aβ.  Additionally, the phosphorylation of APP at Thr668 was significantly increased in 
LAD compared to MCI or non-AD individuals, implying that activation of Ras-MAPK signaling 
axis or GSK3 might contribute to the observed induction in tau and APP phosphorylation.   
The role of A in promotion of these signaling events is confirmed by our findings in 
neurons.  Aβ not only enhanced Ras-ERK activation, but also GSK3 activation, cyclin D1 increase 
and nuclear translocation, as well as phosphorylation of tau (PHF-1) and APP (Thr668). P-APP 
appeared to spread through the neurites and form beaded structures, indicative of neurite 
degeneration (Delisle & Carpenter 1984, Dickson et al 1999, Mattila et al 1999, Takeuchi et al 2005).  
The finding that Aβ induces APP phosphorylation is novel, and it is likely that aberrant activation of 
the Ras-MAPK signaling axis and GSK3 are the underlying causes of A-dependent APP and tau 
phosphorylation, contributing to the impaired axonal transport and microtubule destabilization 
observed in Alzheimer’ s disease.     
5.5. Conclusions  
In conclusion our results suggest that concerted signaling by both APP and Aβ plays an 
important role in induction of mitotic catastrophe and neurodegeneration observed in AD.  Others 
have shown that Aβ toxicity is dependent on the presence of APP (Shaked et al 2006, Sola Vigo et al 
2009), and APP has been implicated as a possible receptor for Aβ (Lorenzo et al 2000). Aβ has been 
shown to bind to not only N-terminal APP, but also to the A sequence in the extracellular 
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juxtamembrane domain and exert its toxic effects (Kedikian et al 2010).   Additionally, the 
cytoplasmic tail of APP contains the YENPTY motif, which serves as a docking sight for proteins 
involved in intracellular signaling (Nizzari et al 2012, Nizzari et al 2007).  Upon phosphorylation of 
the tyrosine residue in this motif, it is thought that adaptor proteins Shc and Grb2 can bind and 
recruit components of the MAPK cascade (Nizzari et al 2012, Nizzari et al 2007). Based on our 
results, we hypothesize that Aβ and APP induce downstream signaling through activation of the 
Ras-MAPK axis and/or GSK-3 to promote pathological phosphorylation of both tau and APP 
(Schematic in Figure 9).  We have previously shown that Thr668-phosphorylated APP associates 
with the centrosomes, indicative of a regulatory role for APP in cell cycle, and undergoes enhanced 
proteolysis to generate more A. Taken together, APP appears to play a central role in promotion of 
neurodegeneration, through activation of RAS-ERK and GSK3, and an inhibition of the aberrant 
signaling by APP would impede mitotic catastrophe and neurodegeneration in AD. 
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Figure 5.9. Schematic showing intracellular signaling by APP and Aβ.  Sporadic AD and Familial AD are 
associated with increased APP production, increased Aβ production or decreased Aβ clearance.  We 
hypothesize (as indicated with red arrows) that enhanced APP expression and Aβ production leads 
to the binding of Aβ within the extracellular Aβ sequence on APP, which then elicits downstream 
signaling events including GSK3 activation and Ras-MAPK signaling.  We believe that APP may be 
phosphorylated on its C-terminal Tyr682 residue within the YENPTY motif where adaptor protein 
Grb2 binds and facilitates the activation of the MAPK pathway, followed by cell cycle deregulation.  
Activation of ERK and GSK3 lead to the pathogenic phosphorylation of both APP and tau.  
Phosphorylation of APP at Thr668 results in pathogenic processing of APP and subsequently, 
enhanced production of Aβ which feed back into the vicious cycle.  Hyperphosphorylation of tau 
and enhanced Aβ production lead to neurodegeneration, neuritic plaque and neurofibrillary tangle 
formation, ultimately leading to neuronal loss in AD. 
223 
 
5.6. References for Chapter 5 
Aplin AE, Gibb GM, Jacobsen JS, Gallo JM, Anderton BH. 1996. In vitro phosphorylation of the 
cytoplasmic domain of the amyloid precursor protein by glycogen synthase kinase-3beta. 
Journal of neurochemistry 67: 699-707 
Arendt T, Holzer M, Grossmann A, Zedlick D, Bruckner MK. 1995. Increased expression and 
subcellular translocation of the mitogen activated protein kinase kinase and mitogen-
activated protein kinase in Alzheimer's disease. Neuroscience 68: 5-18 
Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G. 1993. Cyclin D1 is a nuclear protein required 
for cell cycle progression in G1. Genes & development 7: 812-21 
Balmanno K, Cook SJ. 1999. Sustained MAP kinase activation is required for the expression of 
cyclin D1, p21Cip1 and a subset of AP-1 proteins in CCL39 cells. Oncogene 18: 3085-97 
Barge RM, Dorrestijn J, Falkenburg JH, Willemze R, Maassen JA. 1998. Unconventional rapid 
Erk1,2 activation is indispensable for proliferation of the growth factor-independent myeloid 
leukemic cell line KG1. Leukemia 12: 699-704 
Blanchard BJ, devi Raghunandan R, Roder HM, Ingram VM. 1994. Hyperphosphorylation of 
human TAU by brain kinase PK40erk beyond phosphorylation by cAMP-dependent PKA: 
relation to Alzheimer's disease. Biochemical and biophysical research communications 200: 187-94 
Braak H, Braak E. 1991. Neuropathological stageing of Alzheimer-related changes. Acta 
neuropathologica 82: 239-59 
Braak H, Braak E. 1995. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiology of 
aging 16: 271-8; discussion 78-84 
Busciglio J, Lorenzo A, Yeh J, Yankner BA. 1995. beta-amyloid fibrils induce tau phosphorylation 
and loss of microtubule binding. Neuron 14: 879-88 
224 
 
Busser J, Geldmacher DS, Herrup K. 1998. Ectopic cell cycle proteins predict the sites of neuronal 
cell death in Alzheimer's disease brain. The Journal of neuroscience : the official journal of the Society 
for Neuroscience 18: 2801-7 
Chang KA, Kim HS, Ha TY, Ha JW, Shin KY, et al. 2006. Phosphorylation of amyloid precursor 
protein (APP) at Thr668 regulates the nuclear translocation of the APP intracellular domain 
and induces neurodegeneration. Molecular and cellular biology 26: 4327-38 
Chaput D, Kirouac LH, Bell-Temin H, Stevens SM, Jr., Padmanabhan J. 2012. SILAC-based 
proteomic analysis to investigate the impact of amyloid precursor protein expression in 
neuronal-like B103 cells. Electrophoresis 33: 3728-37 
Cho JH, Johnson GV. 2003. Glycogen synthase kinase 3beta phosphorylates tau at both primed and 
unprimed sites. Differential impact on microtubule binding. The Journal of biological chemistry 
278: 187-93 
Cho JH, Johnson GV. 2004. Primed phosphorylation of tau at Thr231 by glycogen synthase kinase 
3beta (GSK3beta) plays a critical role in regulating tau's ability to bind and stabilize 
microtubules. Journal of neurochemistry 88: 349-58 
Copani A, Condorelli F, Caruso A, Vancheri C, Sala A, et al. 1999. Mitotic signaling by beta-amyloid 
causes neuronal death. FASEB journal : official publication of the Federation of American Societies for 
Experimental Biology 13: 2225-34 
Cosgaya JM, Latasa MJ, Pascual A. 1996. Nerve growth factor and ras regulate beta-amyloid 
precursor protein gene expression in PC12 cells. Journal of neurochemistry 67: 98-104 
Dabrowski A, Groblewski GE, Schafer C, Guan KL, Williams JA. 1997. Cholecystokinin and EGF 
activate a MAPK cascade by different mechanisms in rat pancreatic acinar cells. The American 
journal of physiology 273: C1472-9 
225 
 
Delisle MB, Carpenter S. 1984. Neurofibrillary axonal swellings and amyotrophic lateral sclerosis. 
Journal of the neurological sciences 63: 241-50 
DeMattos RB, Cirrito JR, Parsadanian M, May PC, O'Dell MA, et al. 2004. ApoE and clusterin 
cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates 
extracellular Abeta metabolism in vivo. Neuron 41: 193-202 
Dickson TC, King CE, McCormack GH, Vickers JC. 1999. Neurochemical diversity of dystrophic 
neurites in the early and late stages of Alzheimer's disease. Experimental neurology 156: 100-10 
Dineley KT, Westerman M, Bui D, Bell K, Ashe KH, Sweatt JD. 2001. Beta-amyloid activates the 
mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine 
receptors: In vitro and in vivo mechanisms related to Alzheimer's disease. The Journal of 
neuroscience : the official journal of the Society for Neuroscience 21: 4125-33 
Drewes G, Lichtenberg-Kraag B, Doring F, Mandelkow EM, Biernat J, et al. 1992. Mitogen 
activated protein (MAP) kinase transforms tau protein into an Alzheimer-like state. The 
EMBO journal 11: 2131-8 
Ekinci FJ, Malik KU, Shea TB. 1999. Activation of the L voltage-sensitive calcium channel by 
mitogen-activated protein (MAP) kinase following exposure of neuronal cells to beta-
amyloid. MAP kinase mediates beta-amyloid-induced neurodegeneration. The Journal of 
biological chemistry 274: 30322-7 
Ferrer I, Blanco R, Carmona M, Ribera R, Goutan E, et al. 2001. Phosphorylated map kinase 
(ERK1, ERK2) expression is associated with early tau deposition in neurones and glial cells, 
but not with increased nuclear DNA vulnerability and cell death, in Alzheimer disease, Pick's 
disease, progressive supranuclear palsy and corticobasal degeneration. Brain pathology 11: 144-
58 
226 
 
Gartner U, Holzer M, Arendt T. 1999. Elevated expression of p21ras is an early event in Alzheimer's 
disease and precedes neurofibrillary degeneration. Neuroscience 91: 1-5 
Gartner U, Holzer M, Heumann R, Arendt T. 1995. Induction of p21ras in Alzheimer pathology. 
Neuroreport 6: 1441-4 
Geula C, Wu CK, Saroff D, Lorenzo A, Yuan M, Yankner BA. 1998. Aging renders the brain 
vulnerable to amyloid beta-protein neurotoxicity. Nature medicine 4: 827-31 
Giovanni A, Wirtz-Brugger F, Keramaris E, Slack R, Park DS. 1999. Involvement of cell cycle 
elements, cyclin-dependent kinases, pRb, and E2F x DP, in B-amyloid-induced neuronal 
death. The Journal of biological chemistry 274: 19011-6 
Glenner GG, Wong CW. 1984. Alzheimer's disease and Down's syndrome: sharing of a unique 
cerebrovascular amyloid fibril protein. Biochemical and biophysical research communications 122: 
1131-5 
Goedert M, Cohen ES, Jakes R, Cohen P. 1992. p42 MAP kinase phosphorylation sites in 
microtubule-associated protein tau are dephosphorylated by protein phosphatase 2A1. 
Implications for Alzheimer's disease [corrected]. FEBS letters 312: 95-9 
Goedert M, Jakes R, Crowther RA, Cohen P, Vanmechelen E, et al. 1994. Epitope mapping of 
monoclonal antibodies to the paired helical filaments of Alzheimer's disease: identification of 
phosphorylation sites in tau protein. The Biochemical journal 301 ( Pt 3): 871-7 
Gold G, Bouras C, Kovari E, Canuto A, Glaria BG, et al. 2000. Clinical validity of Braak 
neuropathological staging in the oldest-old. Acta neuropathologica 99: 579-82; discussion 83-4 
Gotz J, Chen F, van Dorpe J, Nitsch RM. 2001. Formation of neurofibrillary tangles in P301l tau 
transgenic mice induced by Abeta 42 fibrils. Science 293: 1491-5 
227 
 
Hanger DP, Hughes K, Woodgett JR, Brion JP, Anderton BH. 1992. Glycogen synthase kinase-3 
induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament 
epitopes and neuronal localisation of the kinase. Neuroscience letters 147: 58-62 
Hardy J. 1997. Amyloid, the presenilins and Alzheimer's disease. Trends in neurosciences 20: 154-9 
Hyman BT, Elvhage TE, Reiter J. 1994. Extracellular signal regulated kinases. Localization of 
protein and mRNA in the human hippocampal formation in Alzheimer's disease. The 
American journal of pathology 144: 565-72 
Iijima K, Ando K, Takeda S, Satoh Y, Seki T, et al. 2000. Neuron-specific phosphorylation of 
Alzheimer's beta-amyloid precursor protein by cyclin-dependent kinase 5. Journal of 
neurochemistry 75: 1085-91 
Iversen L, Tu HL, Lin WC, Christensen SM, Abel SM, et al. 2014. Molecular kinetics. Ras activation 
by SOS: allosteric regulation by altered fluctuation dynamics. Science 345: 50-4 
Jaaro H, Rubinfeld H, Hanoch T, Seger R. 1997. Nuclear translocation of mitogen-activated protein 
kinase kinase (MEK1) in response to mitogenic stimulation. Proceedings of the National Academy 
of Sciences of the United States of America 94: 3742-7 
Jin LW, Ninomiya H, Roch JM, Schubert D, Masliah E, et al. 1994. Peptides containing the RERMS 
sequence of amyloid beta/A4 protein precursor bind cell surface and promote neurite 
extension. The Journal of neuroscience : the official journal of the Society for Neuroscience 14: 5461-70 
Judge M, Hornbeck L, Potter H, Padmanabhan J. 2011. Mitosis-specific phosphorylation of amyloid 
precursor protein at threonine 668 leads to its altered processing and association with 
centrosomes. Molecular neurodegeneration 6: 80 
Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, et al. 2003. Common structure of 
soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300: 486-9 
228 
 
Kedikian G, Heredia F, Salvador VR, Raimunda D, Isoardi N, et al. 2010. Secreted amyloid 
precursor protein and holo-APP bind amyloid beta through distinct domains eliciting 
different toxic responses on hippocampal neurons. Journal of neuroscience research 88: 1795-803 
Kim J, Basak JM, Holtzman DM. 2009. The role of apolipoprotein E in Alzheimer's disease. Neuron 
63: 287-303 
Klein WL, Krafft GA, Finch CE. 2001. Targeting small Abeta oligomers: the solution to an 
Alzheimer's disease conundrum? Trends in neurosciences 24: 219-24 
Kobayashi S, Ishiguro K, Omori A, Takamatsu M, Arioka M, et al. 1993. A cdc2-related kinase 
PSSALRE/cdk5 is homologous with the 30 kDa subunit of tau protein kinase II, a proline-
directed protein kinase associated with microtubule. FEBS letters 335: 171-5 
Le WD, Xie WJ, Kong R, Appel SH. 1997. Beta-amyloid-induced neurotoxicity of a hybrid septal 
cell line associated with increased tau phosphorylation and expression of beta-amyloid 
precursor protein. Journal of neurochemistry 69: 978-85 
Lee MS, Kao SC, Lemere CA, Xia W, Tseng HC, et al. 2003. APP processing is regulated by 
cytoplasmic phosphorylation. The Journal of cell biology 163: 83-95 
Lin YT, Cheng JT, Liang LC, Ko CY, Lo YK, Lu PJ. 2007. The binding and phosphorylation of 
Thr231 is critical for Tau's hyperphosphorylation and functional regulation by glycogen 
synthase kinase 3beta. Journal of neurochemistry 103: 802-13 
Lopez-Toledano MA, Shelanski ML. 2004. Neurogenic effect of beta-amyloid peptide in the 
development of neural stem cells. The Journal of neuroscience : the official journal of the Society for 
Neuroscience 24: 5439-44 
Lorenzo A, Yuan M, Zhang Z, Paganetti PA, Sturchler-Pierrat C, et al. 2000. Amyloid beta interacts 
with the amyloid precursor protein: a potential toxic mechanism in Alzheimer's disease. 
Nature neuroscience 3: 460-4 
229 
 
Lovestone S, Reynolds CH, Latimer D, Davis DR, Anderton BH, et al. 1994. Alzheimer's disease-
like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 
in transfected mammalian cells. Current biology : CB 4: 1077-86 
Lu Q, Soria JP, Wood JG. 1993. p44mpk MAP kinase induces Alzheimer type alterations in tau 
function and in primary hippocampal neurons. Journal of neuroscience research 35: 439-44 
Majd S, Zarifkar A, Rastegar K, Takhshid MA. 2008. Different fibrillar Abeta 1-42 concentrations 
induce adult hippocampal neurons to reenter various phases of the cell cycle. Brain Res 1218: 
224-9 
Masters CL, Multhaup G, Simms G, Pottgiesser J, Martins RN, Beyreuther K. 1985. Neuronal origin 
of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein 
as the amyloid of plaque cores and blood vessels. The EMBO journal 4: 2757-63 
Mattila PM, Rinne JO, Helenius H, Roytta M. 1999. Neuritic degeneration in the hippocampus and 
amygdala in Parkinson's disease in relation to Alzheimer pathology. Acta neuropathologica 98: 
157-64 
McShea A, Zelasko DA, Gerst JL, Smith MA. 1999. Signal transduction abnormalities in Alzheimer's 
disease: evidence of a pathogenic stimuli. Brain research 815: 237-42 
Mora N, Santa Barbara Ruiz P, Ferreira N, Serras F. 2013. Ras signal triggers beta-amyloid precursor 
protein (APP) expression. Small GTPases 4: 171-3 
Muresan V, Muresan Z. 2009. Is abnormal axonal transport a cause, a contributing factor or a 
consequence of the neuronal pathology in Alzheimer's disease? Future neurology 4: 761-73 
Muresan Z, Muresan V. 2005. Coordinated transport of phosphorylated amyloid-beta precursor 
protein and c-Jun NH2-terminal kinase-interacting protein-1. The Journal of cell biology 171: 
615-25 
230 
 
Nagy Z, Esiri MM, Smith AD. 1997. Expression of cell division markers in the hippocampus in 
Alzheimer's disease and other neurodegenerative conditions. Acta neuropathologica 93: 294-300 
Nicholson AM, Ferreira A. 2009. Increased membrane cholesterol might render mature 
hippocampal neurons more susceptible to beta-amyloid-induced calpain activation and tau 
toxicity. The Journal of neuroscience : the official journal of the Society for Neuroscience 29: 4640-51 
Nizzari M, Thellung S, Corsaro A, Villa V, Pagano A, et al. 2012. Neurodegeneration in Alzheimer 
disease: role of amyloid precursor protein and presenilin 1 intracellular signaling. Journal of 
toxicology 2012: 187297 
Nizzari M, Venezia V, Repetto E, Caorsi V, Magrassi R, et al. 2007. Amyloid precursor protein and 
Presenilin1 interact with the adaptor GRB2 and modulate ERK 1,2 signaling. The Journal of 
biological chemistry 282: 13833-44 
Pei JJ, Braak H, An WL, Winblad B, Cowburn RF, et al. 2002. Up-regulation of mitogen-activated 
protein kinases ERK1/2 and MEK1/2 is associated with the progression of neurofibrillary 
degeneration in Alzheimer's disease. Brain research. Molecular brain research 109: 45-55 
Porras A, Alvarez AM, Valladares A, Benito M. 1998. p42/p44 mitogen-activated protein kinases 
activation is required for the insulin-like growth factor-I/insulin induced proliferation, but 
inhibits differentiation, in rat fetal brown adipocytes. Molecular endocrinology 12: 825-34 
Raghunandan R, Ingram VM. 1995. Hyperphosphorylation of the cytoskeletal protein Tau by the 
MAP-kinase PK40erk2: regulation by prior phosphorylation with cAMP-dependent protein 
kinase A. Biochemical and biophysical research communications 215: 1056-66 
Raina AK, Monteiro MJ, McShea A, Smith MA. 1999. The role of cell cycle-mediated events in 
Alzheimer's disease. International journal of experimental pathology 80: 71-6 
Rapoport M, Ferreira A. 2000. PD98059 prevents neurite degeneration induced by fibrillar beta-
amyloid in mature hippocampal neurons. Journal of neurochemistry 74: 125-33 
231 
 
Reifert J, Hartung-Cranston D, Feinstein SC. 2011. Amyloid beta-mediated cell death of cultured 
hippocampal neurons reveals extensive Tau fragmentation without increased full-length tau 
phosphorylation. The Journal of biological chemistry 286: 20797-811 
Reynolds CH, Betts JC, Blackstock WP, Nebreda AR, Anderton BH. 2000. Phosphorylation sites on 
tau identified by nanoelectrospray mass spectrometry: differences in vitro between the 
mitogen-activated protein kinases ERK2, c-Jun N-terminal kinase and P38, and glycogen 
synthase kinase-3beta. Journal of neurochemistry 74: 1587-95 
Reynolds CH, Utton MA, Gibb GM, Yates A, Anderton BH. 1997. Stress-activated protein 
kinase/c-jun N-terminal kinase phosphorylates tau protein. Journal of neurochemistry 68: 1736-
44 
Ryan KA, Pimplikar SW. 2005. Activation of GSK-3 and phosphorylation of CRMP2 in transgenic 
mice expressing APP intracellular domain. The Journal of cell biology 171: 327-35 
Shaked GM, Kummer MP, Lu DC, Galvan V, Bredesen DE, Koo EH. 2006. Abeta induces cell 
death by direct interaction with its cognate extracellular domain on APP (APP 597-624). 
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20: 
1254-6 
Sola Vigo F, Kedikian G, Heredia L, Heredia F, Anel AD, et al. 2009. Amyloid-beta precursor 
protein mediates neuronal toxicity of amyloid beta through Go protein activation. 
Neurobiology of aging 30: 1379-92 
Standen CL, Brownlees J, Grierson AJ, Kesavapany S, Lau KF, et al. 2001. Phosphorylation of 
thr(668) in the cytoplasmic domain of the Alzheimer's disease amyloid precursor protein by 
stress-activated protein kinase 1b (Jun N-terminal kinase-3). Journal of neurochemistry 76: 316-
20 
232 
 
Suzuki T, Oishi M, Marshak DR, Czernik AJ, Nairn AC, Greengard P. 1994. Cell cycle-dependent 
regulation of the phosphorylation and metabolism of the Alzheimer amyloid precursor 
protein. The EMBO journal 13: 1114-22 
Takashima A, Honda T, Yasutake K, Michel G, Murayama O, et al. 1998. Activation of tau protein 
kinase I/glycogen synthase kinase-3beta by amyloid beta peptide (25-35) enhances 
phosphorylation of tau in hippocampal neurons. Neuroscience research 31: 317-23 
Takeuchi H, Mizuno T, Zhang G, Wang J, Kawanokuchi J, et al. 2005. Neuritic beading induced by 
activated microglia is an early feature of neuronal dysfunction toward neuronal death by 
inhibition of mitochondrial respiration and axonal transport. The Journal of biological chemistry 
280: 10444-54 
Tanaka T, Zhong J, Iqbal K, Trenkner E, Grundke-Iqbal I. 1998. The regulation of phosphorylation 
of tau in SY5Y neuroblastoma cells: the role of protein phosphatases. FEBS letters 426: 248-
54 
Trojanowski JQ, Mawal-Dewan M, Schmidt ML, Martin J, Lee VM. 1993. Localization of the 
mitogen activated protein kinase ERK2 in Alzheimer's disease neurofibrillary tangles and 
senile plaque neurites. Brain research 618: 333-7 
Utton MA, Vandecandelaere A, Wagner U, Reynolds CH, Gibb GM, et al. 1997. Phosphorylation of 
tau by glycogen synthase kinase 3beta affects the ability of tau to promote microtubule self-
assembly. The Biochemical journal 323 ( Pt 3): 741-7 
Vincent I, Jicha G, Rosado M, Dickson DW. 1997. Aberrant expression of mitotic cdc2/cyclin B1 
kinase in degenerating neurons of Alzheimer's disease brain. The Journal of neuroscience : the 
official journal of the Society for Neuroscience 17: 3588-98 
Walsh DM, Selkoe DJ. 2004. Oligomers on the brain: the emerging role of soluble protein 
aggregates in neurodegeneration. Protein and peptide letters 11: 213-28 
233 
 
Wildsmith KR, Holley M, Savage JC, Skerrett R, Landreth GE. 2013. Evidence for impaired amyloid 
beta clearance in Alzheimer's disease. Alzheimer's research & therapy 5: 33 
Zhou F, Gong K, Song B, Ma T, van Laar T, et al. 2012. The APP intracellular domain (AICD) 
inhibits Wnt signalling and promotes neurite outgrowth. Biochimica et biophysica acta 1823: 
1233-41 
 
 
 234 
 
 
 
 
CHAPTER 6: DISCUSSION 
 
6.1. Summary 
 The Alzheimer’s disease (AD) brain is defined by two distinct lesions: neuritic 
plaques and neurofibrillary tangles. Neuritic plaques are formed extracellularly from the 
accumulation of the A peptide while neurofibrillary tangles form intracellularly from the 
hyperphosphorylation and aggregation of tau.   A accumulation in both sporadic and 
familial AD brains has been shown to precede tau pathology, highlighting altered A 
production, polymerization and impairedclearance as central to AD pathogenesis.  The 
mechanisms by which A exerts its toxic effects, however, remain unclear.    
 In Chapter 2, we demonstrated that expression of cell cycle regulatory proteins 
correlated with levels of phosphorylation of APP at Thr668 in the brains of transgenic AD 
mice. P-APP co-localizes with phosphoneurofilament staining adjacent to plaques, 
suggesting that conditions that promote A generation and accumulation are conducive to 
pathogenic phosphorylation of APP and neurite degeneration.  We also showed that APP is 
phosphorylated in a mitosis-specific manner and this modification resulted in its enhanced 
amyloidogenic processing.  Furthermore, while inhibition of G1/S transition resulted in 
decreased phosphorylation of APP and proteolysis, cell cycle arrest in M-phase resulted in 
increased APP phosphorylation and pathogenic processing.  Furthermore, our findings 
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indicated that Thr668-phosphorylated APP associates with the centrosomes, indicative of a 
regulatory role for APP in cell cycle. 
 The contribution of A to AD pathology is understood, however very little is known 
about the physiological function of APP.  In Chapter 3, we sought to further explore the 
function of APP.  Using stable isotope labeling by amino acids in cell culture (SILAC) and 
tandem mass spectrometry (MS/MS), we compared the differential expression of proteins in 
APP null, rat neuronal-like B103 cells to APP-695 isoform expressing B103-695 cells.  We 
were able to several unique protein groups expressed by these cells.  Of these, a total of 102 
nonredundant proteins were identified to have significant expression changes. Some of the 
top biological functions associated with the differentially expressed proteins identified 
included cellular assembly, organization and morphology, cell cycle, lipid metabolism, 
protein folding, and post-translational modifications. Notably, cells expressing APP showed 
enhanced Ras expression and activation of extracellular signal regulated kinases (ERK1/2).  
These findings indicate that APP expression induces signaling cascades that may be involved 
in cell cycle-mediated neuronal degeneration observed in AD. 
 Our findings that APP promotes expression of proliferation-associated proteins in 
Chapter 3 agreed with our hypothesis that APP has a cell cycle regulatory function as 
suggested Chapter 2. Since cell cycle deregulation and protein phosphorylation are 
fundamental to AD neurodegeneration, in Chapter 4 we analyzed global changes in protein 
phosphorylation upon APP expression using mass spectrometry-based phosphoproteomics. 
We observed that phosphorylation of PCTAIRE-2 (CDK17), PCTAIRE-3 (CDK18), and 
Histone H4 are significantly elevated in B103-695 cells; western blot analysis confirmed 
overexpression of PCTAIREs and increased phosphorylation of Histone H4. More 
importantly, analysis of primary neurons treated with Aβ, as well as brain samples from MCI 
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(mild cognitive impaired) and AD patients recapitulated these results, showing increased 
levels of PCTAIREs and P-Histone H4.  We also demonstrated that cellular APP was 
required for Aβ-mediated expression and altered distribution of PCTAIRE-2 and -3 in B103 
cells.  These novel findings identified a hitherto uncharacterized mechanism by which APP 
and/or Aβ may promote AD neurodegeneration. 
 Finally, the data presented in Chapter 5 demonstrated that APP expression and 
neuronal exposure to oligomeric Aβ42 indeed enhance Ras/ERK signaling cascade and 
glycogen synthase kinase3 (GSK3) activation. We found that knockdown of APP in B103-
695 cells inhibited Ras-ERK signaling and GSK3 activation, indicating that APP acts 
upstream of these signal transduction events. Analysis of human brain samples showed 
increased expression of Ras, activation of GSK3 and phosphorylation of APP and tau, 
which correlated with A levels in the AD brains. Furthermore, treatment of primary rat 
neurons with A recapitulated these events and showed enhanced Ras-ERK signaling, 
GSK3 activation, upregulation of cyclin D1, and phosphorylation of APP and tau. 
Moreover, Aβ could elicit the same effect in B103-695, but not in APP-null B103 cells, 
suggesting that APP is necessary for downstream signaling.  The finding that A induces 
Thr668 phosphorylation on APP, which enhances BACE cleavage of APP and Aβ 
generation (as shown in Chapter 2), denotes a vicious feed-forward mechanism by which 
APP and Aβ act concertedly to promote cell cycle deregulation and neurodegeneration in 
AD. 
6.2. Conclusions 
Based on our findings, we conclude that altered APP expression and Aβ production 
elicits downstream proliferative signaling, which in terminally differentiated neurons would 
cause mitotic catastrophe and neuronal death.  Altered activity of kinases, specifically ERK 
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and GSK-3, downstream of APP and Aβ result in the pathogenic phosphorylation of both 
APP and tau.  Phosphorylation of APP at Thr668 results in pathogenic processing of APP 
and subsequently, enhanced production of Aβ that feeds back into the vicious cycle.  
Hyperphosphorylation of tau and enhanced Aβ production lead to neurodegeneration, 
neuritic plaque and neurofibrillary tangle formation, ultimately leading to neuronal loss in 
AD.  As such, inhibition of the aberrant signaling by APP and Aβ would impede the mitotic 
catastrophe and neurodegeneration observed in AD.  
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Abstract
Alzheimer’s disease (AD) pathology is associated with neuroinflammation and 
the ectopic expression of cell cycle proteins, indicating that these two events may 
be involved in its pathogenesis.  The cause and consequences of these events are 
still elusive. Inflammatory signaling has been shown to induce expression of the 
Alzheimer’s associated amyloid precursor protein (APP), whose phosphorylation and 
pathogenic processing are regulated in a cell cycle specific manner. The amyloid 
beta (Aβ) generated upon secreatse-mediated processing of APP deposits in the 
brain parenchyma, extracellularly, to form amyloid plaques, which coincides with glial 
activation and chronic neuroinflammation.  As reviewed in this article, interplay of the 
inflammatory response and cell cycle dysfunction could be underlying pathogenic 
processes in the neurodegeneration observed in AD.  Both events are linked to neuronal 
abnormalities and pathological hallmarks of AD, including Tau phosphorylation and 
Aβ generation and deposition.  Epidemiological studies have linked the use of non-
steroidal anti-inflammatory drugs with a decrease in risk for developing AD, however 
its use in clinical trials on AD patients has largely been ineffective.  It seems that an 
early therapeutic intervention that could target neuroinflammation and mitotic changes 
in compromised neurons could potentially have a great impact on the progression of 
AD.     
ABBREVIATIONS
AD:Alzheimer’s disease; Aβ: Amyloid-beta; APP: Amyloid 
Precursor Protein; PS-1:  Presenilin-1; PS-2: Presenelin-2; CNS: 
Central Nervous System; ROS: Reactive Oxygen Species; NFκB: 
Nuclear Factor Kappa B; IL-1: Interleukin-1; MCP-1:  Monocyte 
Chemoattractant Protein 1; MIP: Macrophage Inflammatory 
Protein; CSF: Cerebral Spinal Fluid; GM-CSF: Granulocyte 
Macrophage-Colony Stimulating Factor; TNF-α: Tumor Necrosis 
Factor Alpha; TGFβ: Transforming Growth Factor α; S100β: Beta 
Subunit of S100; ACT: Alpha-1-Antichymotrypsin; JNK: c-Jun 
N-Terminal Kinase; COX-2: Cyclooxygenase-2; NSAIDs:  Non-
Steroidal Anti-Inflammatory Drugs; LPS: Lipopolysaccharides 
INTRODUCTION
Alzheimer’s disease (AD) is the most common form of senile 
dementia and is ranked 6th in leading causes of death in the 
United States.  In its initial stages, the disease presents itself 
with memory loss which later progresses to impaired executive 
function and ultimately, death.  Pathology development precedes 
cognitive decline and is thought to begin in the entorhinal cortex, 
gradually spreading to other areas of the brain and leading to 
widespread synaptic loss, metabolic dysfunction and atrophy 
[1].  The classic lesions of the AD brain are extracellular neuritic 
plaques and intracellular neurofibrillary tangles [2-4].  Neuritic 
plaques are formed by the deposition of the insoluble amyloid-
beta (Aβ) peptide, a product formed by the sequential cleavage 
of the amyloid precursor protein (APP) by β- and γ-secretase. 
Neurofibrillary tangle pathology follows plaque development 
and is formed byhyperphosphorylation of the microtubule-
associated protein, Tau.  AD can be divided into two subgroups 
based on genetic association and age at onset:  familial and 
sporadic. Familial AD occurs in early age and represents only 
5-10% of all AD cases.  This form of early-onset AD is largely 
genetic and is associated with mutations in Presenilin-1 (PS1), 
Presenilin-2 (PS2) and APP genes.  Late-onset AD, thought to 
be sporadic, accounts for ~90-95% of all AD cases and while its 
etiology is unclear, its onset occurs with advanced age.
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CELLULAR INFLAMMATORY MEDIATORS IN 
ALZHEIMER’S DISEASE
Neuroinflammation is a common feature in nearly all 
neurodegenerative diseases, including Alzheimer’s disease. 
While it is a wellestablished hallmark to the disease, it is 
unclear whether this feature is causative or subsequent to 
AD pathogenesis.  Immunohistochemical analyses reveal an 
inflammatory status of post-mortem human AD brains with 
the presence of activated glia in proximity to Aβ deposits [5-8]. 
Likewise, this immune response is also observed around amyloid 
plaques in the brains of transgenic AD mice that express human 
APP carrying the Swedish mutation [9-13].  
The brain’s resident microglia and astrocytes are the main 
cellular mediators that become activated in response to injury. 
Astrocytes are the most abundant type of glial cells in the 
central nervous system (CNS), and the pathology associated 
with AD triggers what is called “reactive astrogliosis” [14].  This 
activation is defined by an increase in number, size and mobility 
of astrocytes, which is thought to be important for Aβ clearance 
and degradation [15].  Microglia comprises a marginal portion 
of the glial cell population in the brain and when activated, 
undergoes distinct morphological changes and migration to the 
compromised area.  There, they produce a number of reactive 
oxygen species (ROS), cytokines, chemokines, growth factors and 
complement factors that are released to the surrounding tissue 
[16-19].   
Several in vitro studies implicate the highly insoluble, fibrillar 
form of Aβ in inducing microglial activation and inflammatory 
protein expression [20-26].  This effect has also been observed 
with in vivo imaging of microglial migration to amyloid deposits 
within transgenic AD mouse brain [27, 28].  In fact, treatment 
of transgenic AD mice with the recombinant 5 amino acid long 
β-sheet breaker peptide iAβ5, has been shown to not only reduce 
plaque load, but also lessen inflammation-induced cerebral 
damage [29].  Aβ has also been shown to induce cytokine 
production in various ways.  The nuclear factor kappa B (NFκB) 
pathway leads to cytokine production and this signaling pathway 
can be induced by the Aβ peptide [21].  Aβ is able to bind to 
receptors expressed on the microglial membrane and induce 
the MAPK pathway which subsequently leads to expression of 
inflammatory genes and production of chemokines and cytokines 
[30].  A working hypothesis for these findings is that the dense 
and irreversible nature of the amyloid plaque leads to stimulation 
of glial cells and chronic inflammation in the brain.  The release 
of proinflammatory mediators in response to the fibrillar Aβ- 
along with soluble Aβ itself- results in a neurotoxic effect for 
healthy, adjacent neurons [31]. Additionally, these inflammatory 
mediators are thought to facilitate enhanced amyloidogenic 
processing of APP, producing more Aβ, which then feeds into the 
vicious cycle [22,32,33].  Conversely, others believe inflammation 
precedes fibrillar plaque pathology.  For example, a study carried 
out in macaque monkeys found that glial activation is an event 
that occurs before deposition of fibrillar Aβ in the aging brain 
[34].  Several studies have also linked polymorphisms in pro-
inflammatory cytokine genes, in particular Interleukin-1 (IL-1), 
to AD (35-40).  Another example is that from a study in Down 
syndrome patients, who typically develop AD by middle age as 
they carry an extra copy of the APP gene; this study showed 
that the brains of fetal and neonate Down syndrome patients 
(considered to be pre-amyloid plaque bearing) exhibit gliosis, 
and showupregulation of cytokines, further supporting the notion 
that inflammation and plaque development occur sequentially 
[41].
MOLECULAR MEDIATORS OF INFLAMMATION IN 
ALZHEIMER’S DISEASE
Activated microglia and astrocytes surrounding amyloid 
plaques secrete cytokines and chemokines that contribute to the 
inflammatory process.  A number of cytokines and chemokines 
are found to be upregulated in AD brains compared to their non-
demented controls [42-45]. 
Chemokines are a family of small proteins that recruit 
monocytes, macrophages, lymphocytes, neutrophils, basophils, 
eosinophils and dendridic cells to compromised tissues [46].  The 
Aβ peptide can promote the generation of chemokines such as 
IL-8, monocyte chemoattractant protein 1 (MCP-1), macrophage 
inflammatory protein (MIP)- 1α and -1β [47] from human 
monocytes [17].    Additionally, MIP-1β has been detected within 
activated astrocytes around amyloid plaques [48].  Cytokines 
are soluble proteins that are secreted by glia in the AD brain in 
response to Aβ aggregates [49].  Analysis of both AD human and 
transgenic mouse brain tissues and cerebral spinal fluid (CSF) 
show a marked increase in the levels of IL-1β, IL-1α, IL-6, IL-10, 
IL-12, granulocyte macrophage-colony stimulating factor (GM-
CSF), tumor necrosis factor α (TNF-α) and transforming growth 
factor β (TGF-β) [50-57].  
In the brain, TNF-α is predominantly produced by activated 
microglia in response to injury; however it has also been shown 
to be produced by neurons [58].  The role of TNF-α in AD is 
unclear as it has both beneficial and detrimental effects.  Under 
non-pathological conditions, TNF-α levels are low in the brain 
[59] but in AD its levels are elevated in serum, CSF, cortex and 
glial cells [17,60,61].  The role of TNF-α is dichotomous in nature: 
it is able to stimulate NF-κB which in turn induces transcription 
of proinflammatory proteins and stimulation of survival proteins 
such as anti-apoptotic Bcl, manganese superoxide dismutase and 
calbindin [62,63].  It has been demonstrated in vitro that TNF-α 
is able to induce expression of APP and Aβ in glial cells [64].  Its 
harmful effects also include its stimulation of microglia to release 
glutamate, resulting in excitotoxicity [65].  TNF-α has been 
implicated in increased expression of both β- and γ-secretases. 
Furthermore, inhibition of TNF-α has been shown to mitigate 
disease progression in transgenic AD mice [66,67].  On the 
contrary, chronic TNF-α suppression can hinder the microglial 
response in early stages of Aβ deposition, leading to accelerated 
aggregation [68].   It is possible that the action that TNF-α exerts 
is dependent on both its levels and duration of tissue exposure 
in the brain.    
IL-1 is an immunomodulatory cytokine, which is a key player 
in initiation of the immune response.  IL-1 is found to be elevated 
immediately after brain injury [69,70] and this effect is also seen 
in response to amyloid plaques, as concentrations of IL-1 are 
increased in the AD brain [71-73].  Interestingly, IL-1 has been 
found to not only induce the synthesis of APP, but also mediate 
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Figure 1 (A) The pathological cascade in Alzheimer’s disease.  Oligomeric A in AD induces activation of glia and release of inflammatory mediators. 
The expression of cell cycle protein in compromised neuronal populations coincides with this neuroinflammatory response.  Aberrant cell cycle 
activation in the AD brain has been shown to result in pathological modifications in the AD-associated proteins, APP and Tau.  Hyperphosphorylation 
of APP results in increased production of the pathogenic Aβ peptide and its subsequent deposition in the brain.  Soluble Aβ has been shown to 
further induce tau hyperphosphorylation, neurofibrillary tangle formation, neurodegeneration and cell death.  
(B) Schematic of the inflammation and cell cycle-dependent signaling in Alzheimer’s disease: Amyloidogenic processing of APP leads to the 
production of the neurotoxic Aβ peptide. Reduced clearance and Aβ aggregation leads to glial activation and subsequent production of pro-
inflammatory cytokines and chemokines, which can enhance expression of cell cycle regulatory proteins in the AD brain.  In particular, TNF-α and 
COX-2 have been shown to correlate with expression of cell cycle markers.  TNF-α is thought to initiate cell cycle events through the activation of the 
JNK pathway.  Chronic exposure of neurons to inflammatory mediators thus lead to accelerated neuritic plaque and neurofibrillary tangle formation 
in AD brain. Inhibition of inflammation could potentially prevent aberrant cell cycle signaling and neurodegeneration associated with AD.    
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its pathogenic processing [71,74].  This implicates a role for IL-1 
in neurodegeneration, which is further highlighted by the finding 
that IL-1 promotes synthesis of the beta subunit of S100 protein 
(S100β) in astrocytes, which promotes dystrophic neurite growth 
[41,71,75].  Inhibition of IL-1β activity has also been shown to 
promote neurogenesis via the Wnt/β-catenin signaling cascade by 
inhibiting GSK-3β activity and subsequent Tau phosphorylation 
[76].  The role of IL-1β in neurodegeneration, however, is not 
straightforward.  One study shows a protective effect of IL-1β 
when overexpressed in the astrocytes of transgenic AD mice; 
Shaftel et al. showed that sustained activation of IL-1β results in 
a significant decrease in the hippocampal amyloid plaque load in 
these mouse brains [77].
Similar to IL-1, the cytokine IL-6 is found to be increased in AD 
patient tissue and it also induces the expression of APP [32,78,79]. 
Conversely, IL-6 levels increase after treatment of cultured glial 
cells with the carboxy terminal fragment of APP (the last 105 
amino acids) [80].  While some have found that IL-6 enhances 
Aβ-induced neurodegeneration in primary rat neuronal cultures 
[81], others have found that overexpression of IL-6 in transgenic 
AD mouse brain results in increased gliosis and phagocytosis, 
attenuating Aβ deposition [82].  The contradictory nature of 
these findings can be bridged by the idea that neuroinflammation 
is a complex and fine balanced response, capable of being both 
beneficial and deleterious to the brain.
Alpha-1-antichymotrypsin (ACT) is an acute phase 
inflammatory protein and serine protease inhibitor found to be 
elevated in the CSF, serum and brain of AD patients [83-85].  In 
the normal brain, ACT is localized to astrocytes and in the AD 
brain it is overexpressed in the astrocytes surrounding amyloid 
plaques [83,86,87].  It has been implicated in the pathophysiology 
of AD as transgenic AD mice carrying the human ACT gene 
exhibit accelerated amyloid plaque pathology development 
[88,89] and cognitive decline. ACT has also been shown to 
exert pathological effects in vitro [90]. IL-1β has been shown 
to increase the expression of ACT in human astrocytes, with a 
subsequent increase in synthesis of APP [88, 91].  ACT has been 
shown to enhance both amyloid and Tau-associated pathologies. 
It has been shown to bind the toxic Aβ peptide and accelerate 
its fibrilization [92-95].  Studies from our lab have shown that 
treatment of primary mouse neurons with purified ACT protein 
results in Tau phosphorylation and apoptosis, implying a role 
for ACT in neurofibrillary tangle formation and neuronal loss 
associated with AD [96].  Furthermore, we determined that 
transgenic mice expressing human tau and human ACT show 
enhanced Tau phosphorylation upon IL-1β injection, which is 
mediated by c-Jun N-terminal Kinase (JNK) signaling, indicating 
ACT and IL-1β work in collaboration to enhance tau pathology 
development  [97].
Another inflammatory mediator whose expression has 
been shown to be regulated by the cytokines IL-1β and TNF-α 
is Cyclooxygenase-2 (COX-2), which is responsible for the 
production of prostaglandin.  Its function in inflammation is to 
induce vasodilation, thus mediating the transport of immune 
cells to injured tissue [98].  Interestingly, neurons are the main 
cell typesthat show increased expression of COX-2 in the AD 
brain [99-102], suggesting its role in the inflammatory response. 
COX-2 has been shown to not only correlate with AD pathology 
load (neurofibrillary tangles and neuritic plaques), but also with 
cognitive impairment [103].
NEUROINFLAMMATION AND CELL CYCLE 
DYSEREGULATION IN ALZHEIMER’S DISEASE
Recent studies have explored aberrant cell cycle events in 
compromised neurons in the AD brain.  While mature neurons 
are terminally differentiated and post-mitotic, neurons in the 
human AD brain show expression of a number of cell cycle 
regulatory proteins including Cyclins B, D1, D2, D3 and E [104-
106].  In addition to the aberrant expression of these cell cycle 
markers, binucleation has been observed in the hippocampal 
neurons of AD patients, indicating cell cycle progression followed 
by defective cytokinesis [107].  Our lab has also observed ectopic 
expression of Cyclins D1, E and P-cdc2 (CDK1) in transgenic AD 
mice expressing mutant variants of APP alone or together with 
Presenilin 1 (PS1) [108].  We found that APP is phosphorylated 
at Thr668 in a mitosis-specific manner, leading to its association 
with centrosomes and pathogenic processing to generate 
enhanced Aβ peptide and C99 fragment [108].  Furthermore, 
the treatment of differentiated cortical neurons with oligomeric 
Aβ42 fragment has been shown to induce expression of cell cycle 
markers necessary for G1/S transition and, once entered into S 
phase, neurons begin to duplicate their DNA, which subsequently 
leads to apoptosis [109].  These findings implicate cell cycle 
deregulation as a possible underlying factor in neuronal loss 
associated with AD.
Pathogenic stimuli such as inflammation and oxidative stress 
have been shown to induce cell cycle events in the compromised 
brain [106,110-112].  In fact, there is increasing evidence for 
DNA synthesis and ectopic expression of cell cycle proteins such 
as cyclin E, cyclin B, cdc2 and CDK4 in the vulnerable neuronal 
populations in AD [110,111,115-117] and the aberrant cell 
cycle events seem to coincide with microglial activation [113]. 
Supporting this, one study has shown that the media from 
microglia treated with Aβ can induce abnormal neuronal cell 
cycle and subsequently, death [114].  Studies by another group 
showed that these cell cycle events closely correlated with 
secretion of TNF-α [121].Further, preincubation of Aβ-treated 
microglia with TNF-α antibody significantly reduced BrdU 
incorporation in neurons treated with the conditioned media, 
implying that TNF-α secreted by the microglia is responsible for 
the observed cell cycle events in neurons [121].Another study 
used an in vivo adoptive transfer model, where purified microglia 
from transgenic AD mice were injected into wild type mice that 
were either inoculated with IgG or anti-TNF-α antibody.  Mice 
inoculated with anti-TNF-α antibody showed significant decrease 
in neuronal cyclin D1 levels [115].  This was highlighted by the fact 
that AD transgenic mice crossed with TNF-α null mice show basal 
levels of cyclin D1 in neurons [115].  Finally, the group looked at 
the role of JNK as it was found to be elevated in the transgenic 
AD mice.  Using the previously described in vitro system, they 
discovered that treatment of neurons with SP600125, a specific 
JNK inhibitor, decreased BrdU incorporation upon treatment 
with conditioned media, suggesting that TNF-αinduces cell cycle 
events through JNK signaling[115].  These studies indicate that 
it is likely that inflammation induced glial activation could lead 
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to the aberrant expression of cell cycle proteins and subsequent 
neuronal death in the AD brain.                
Expression of inflammation-associated genes is associated 
with cell cycle dysregulation.  COX-2 has been implicated in 
cell cycle deregulation as its enhanced expression correlates 
with promotion of cancer growth andits inhibition declines the 
growth [116]. Studies have also drawn parallels between cell 
cycle changes and COX-2 expression in the neurons of AD brain. 
In addition to its elevated levels in the AD brain, COX2 is found 
to be co-localized with cyclin D1, cyclin E and phosphorylated 
retinoblastoma (Rb) protein in the pyramidal neurons, which may 
be indicativeof aberrant cell cycle activation in neurons[117,118]. 
COX-2 homozygous transgenic mice show a marked decrease in 
the mRNA of the cdk inhibitor p18INK4 and exhibit accelerated 
glutamate-induced apoptotic damage, which could be attenuated 
by administration of the cdk inhibitor, flavopiridol [119]. 
This study also showed that wild type primary hippocampal 
neurons treated with the COX-2 inhibitor nimesulide diminishes 
glutamate-mediated apoptotic damage and inhibits subsequent 
phosphorylation of Rb [119].    
TARGETING INFLAMMATION FOR TREATMENT 
OF ALZHEIMER’S DISEASE
In prospective case-cohort epidemiological studies, elevated 
serum levels of specific acute phase proteins have shown a positive 
correlation with development of AD [120-123].  Other studies 
have shown the beneficial effects of chronic use of non-steroidal 
anti-inflammatory drugs (NSAIDs) in slowing, or even preventing 
AD [124-127], and post mortem analysis of brain tissue from AD 
patients on NSAIDs has also revealed a consistent reduction in 
inflammation [128].  In vivo studies using transgenic AD mice 
show that long-term administration of the NSAID Ibuprofen both 
decrease neuroinflammation and improve cognition [113].  An 
early treatment regimen with Ibuprofen given to transgenic AD 
mice improved spatial learning and hippocampal-dependent 
memory function [129].  Early Ibuprofen administration also 
resulted in reduced amyloid plaque load, glial activation and 
expression of inflammatory mediators in the transgenic AD 
mouse brain [129-131].  Epidemiologists have been interested 
in studying patients with rheumatoid arthritis and osteoarthritis 
as these individuals exposed to NSAIDs for long periods of time 
show an inverse relationship between AD and treated arthritis 
[132].     
It is debated how NSAIDs might exert these effects.  Some 
studies find that NSAIDs act as modulators of γ-secrestase by 
interacting with APP itself and shifting the pathogenic cleavage 
site to yield a shorter Aβ fragment [133-136].  Others have 
suggested that NSAIDs are capable of lowering β-secretase 
levels [137].  Finally, an in vitro study by Hirohata et al. found 
that NSAIDs have a direct inhibitory effect on formation of Aβ 
fibrils [138]. These observations however, have not held up in 
clinical trials.  Individuals with clinical AD symptoms that were 
treated with NSAIDs showed no beneficial effects [139-141].  It 
is possible that the inverse relationship between rheumatoid 
arthritis and AD could be due to the intrinsic factors underlying 
the autoimmune disorder.  Injection of transgenic AD mice with 
granulocyte macrophage-colony stimulating factor (GM-CSF), 
an inflammatory cytokine involved in leukocyte stimulation in 
rheumatoid arthritis, has been shown to reduce amyloid plaque 
burden, improve cognitive deficits and increase hippocampal 
synaptic area [142].  
Many studies, however, maintain that there is a direct link 
in NSAID usage and reduced AD risk.  A recent study modeled 
inflammation in AD through the activation of microglia by 
injecting lipopolysaccharide (LPS) into young AD mice, which 
were then aged.  Tellingly, the administration of NSAIDs to 
young mice prevented AD pathology [113].  As a culmination 
of the reviewed relationship between inflammation, cell cycle 
dysregulation and Alzheimer’s disease, this study also indicated 
that early treatment leads to blockade of microglial activation 
and neuronal cell cycle events [113].  Late NSAID treatment in 
aged mice, while halting new neuronal cell cycle events, could 
not reverse existing ones [113].  This study underscores the 
close relationship between neuroinflammation and cell cycle in 
compromised neurons of the AD brain and suggests that early 
therapeutic intervention may lead to the best outcome. 
CONCLUSION
In Alzheimer’s disease, pathologically vulnerable neurons 
undergo ectopic cell cycle events that are thought to result in 
neuronal apoptosis.Expression of cell cycle markers in these 
susceptible neuronal populations could be an improper attempt 
of regeneration of an injured nerve cell, unable to properly 
proceed through mitosis.  Interestingly, ectopic cell cycle protein 
expression has been found to be induced by neuroinflammatory 
mediators.  In addition to the histopathological hallmarks of 
AD, namelyneuritic plaques and neurofibrillary tangles, AD 
brains also show neuroinflammation and neuronal loss.  Gliosis 
and inflammatory mediators coexist with amyloid plaques and 
neurofibrillary tangles.  It appears that neuroinflammation, 
while initially beneficial in protecting neurons from injury, can 
induce neurodegenerationupon chronic exposure.  Furthermore, 
there is strong evidence for collaboration between expression 
of cell cycle regulators and inflammatory mediators within 
these pathologies.  Epidemiological studies indicate that long-
term use of NSAIDs positively correlate with a decreased risk 
in developing AD, however clinical trials using NSAIDs to treat 
patients with AD have been unsuccessful.  Current research 
shows that preventative NSAID treatment could prove to be a 
beneficial strategy for treating AD.  Studies in transgenic AD mice 
show that early NSAID treatment inhibits chronic inflammation 
within the brain and halts mitotic events in compromised 
neurons. It is unclear whether the downstream effects of cell 
cycle dysregulation triggers an inflammatory response or if 
neuroinflammation precedes these cell cycle events.  In any 
case, it is likely that there is interplay between these complex 
biological events and timing is important in targeting these 
events for prevention of neurodegeneration associated with AD.
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Abstract
Background: Atypical expression of cell cycle regulatory proteins has been implicated in Alzheimer’s disease (AD),
but the molecular mechanisms by which they induce neurodegeneration are not well understood. We examined
transgenic mice expressing human amyloid precursor protein (APP) and presenilin 1 (PS1) for changes in cell cycle
regulatory proteins to determine whether there is a correlation between cell cycle activation and pathology
development in AD.
Results: Our studies in the AD transgenic mice show significantly higher levels of cyclin E, cyclin D1, E2F1, and P-
cdc2 in the cells in the vicinity of the plaques where maximum levels of Threonine 668 (Thr668)-phosphorylated
APP accumulation was observed. This suggests that the cell cycle regulatory proteins might be influencing plaque
pathology by affecting APP phosphorylation. Using neuroglioma cells overexpressing APP we demonstrate that
phosphorylation of APP at Thr668 is mitosis-specific. Cells undergoing mitosis show altered cellular distribution and
localization of P-APP at the centrosomes. Also, Thr668 phosphorylation in mitosis correlates with increased
processing of APP to generate Ab and the C-terminal fragment of APP, which is prevented by pharmacological
inhibitors of the G1/S transition.
Conclusions: The data presented here suggests that cell cycle-dependent phosphorylation of APP may affect its
normal cellular function. For example, association of P-APP with the centrosome may affect spindle assembly and
cell cycle progression, further contributing to the development of pathology in AD. The experiments with G1/S
inhibitors suggest that cell cycle inhibition may impede the development of Alzheimer’s pathology by suppressing
modification of bAPP, and thus may represent a novel approach to AD treatment. Finally, the cell cycle regulated
phosphorylation and processing of APP into Ab and the C-terminal fragment suggest that these proteins may have
a normal function during mitosis.
Keywords: Amyloid precursor protein, cell cycle, mitosis, kinases, APP phosphorylation, amyloid processing
Background
The major pathological characteristics of Alzheimer’s
disease are the presence of neuritic plaques and neurofi-
brillary tangles (NFT) in the affected areas of the brain
[1-3]. In addition, AD brains show neuroinflammation
and neuronal loss, which is associated with aberrant
expression of cell cycle regulatory proteins [4-8]. The
cause or the function of the increased levels of cell cycle
regulatory proteins in post-mitotic neurons is not clearly
understood. Studies by different groups suggest that
fully differentiated neurons in adult brains emerge from
quiescence and attempt to re-enter the cell cycle under
pathological conditions [4,8-23]. This apparent upregu-
lation of cell cycle regulatory proteins in neurons, along
with the findings that the inhibitors of cell cycle activa-
tion protect neurons from undergoing apoptosis, led to
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the hypothesis that inappropriate attempts by neurons
to re-enter the cell cycle may lead to neurodegeneration
and apoptosis [6,12,24-32]. In addition to neuronal loss,
it is possible that dysregulation of the cell cycle may
lead to cell cycle-dependent modifications in the amy-
loid precursor protein (APP) and tau, the two major
proteins associated with AD, favouring plaque and tan-
gle formation and neurodegeneration in the AD brains.
APP is a single transmembrane protein that is sequen-
tially cleaved by b and g- secretases to generate the Ab
peptide, which gets deposited extracellularly to form
plaques and vascular amyloid deposits [33]. Mutations
in APP and presenilin 1 (PS1) are associated with
increased generation of Ab and increased pathology
development in AD [34]. In addition to the accumula-
tion of Ab into amyloid, studies in neurons have shown
that Ab peptides can induce cell cycle activation and
neuronal apoptosis [35]. Expression of a mutant form of
APP or PS1, as well as treatment with Ab, have been
shown to induce chromosome mis-segregation and
aneuploidy in cells [36,37], which indicates aberrant cell
cycle activation under these conditions. Studies con-
ducted in two different AD mouse models have shown
an upregulation of cell cycle regulatory proteins in glial
cells [38] and neurons [39]. Thus, cell cycle deregulation
may influence both neuronal and glial functions, and a
keen analysis of the cell cycle-dependent changes in
these cells may reveal the significance of the upregulated
expression of cell cycle markers in AD brains. Mice gen-
erally do not show much neuronal loss, but it is possible
that the upregulation of cell cycle regulatory proteins
may mediate synaptic loss and neurodegeneration by
inducing modifications in tau and APP. Here we ana-
lyzed the specific effects of cell cycle activation on APP
modifications.
APP is phosphorylated by multiple kinases, which
affects its proteolytic processing, trafficking, and
protein-protein interaction [40-48]. We tested the
hypothesis that cell cycle activation can affect APP mod-
ifications and plaque development, using in vitro cul-
tured cells and transgenic mice. The studies presented
here show that transgenic mice expressing mutant APP
(APPV717F) and PS1 (PS1M146L) show an increase in the
levels of cell cycle regulatory proteins which is asso-
ciated with induction of APP phosphorylation at Thr668
and formation of Ab and phosphorylated C-terminal
fragment of APP. Experiments conducted in H4 neuro-
glioma cells overexpressing APP confirmed that this
phosphorylation is mitosis-specific and can be inhibited
by G1/S transition inhibitors, which prevent Ab genera-
tion. A role for G1/S specific inhibition was further
determined by inhibition of P-APP formation by siRNA
to cdk-2. This observation, along with our finding that
P-APP co-localizes with MPM2 at centrosomes in
mitotic cells suggests that mitotic mechanisms may
influence AD pathology by not only affecting APP phos-
phorylation and Ab generation, but also by enabling it
to have a role in spindle assembly and cell cycle regula-
tion. Thus, APP may act as a cell cycle inducer under
mitotic conditions and might play a feed forward role in
pathology development in AD.
Results
Upregulation of cell cycle regulatory proteins in AD
transgenic mice
Atypical expression of cell cycle regulatory proteins has
been shown primarily in neurons of AD brains. Studies
in different mouse models of AD showed upregulation
of cell cycle regulatory proteins with some variation in
the observations; while one study showed upregulation
of cyclins D1, B and E in astrocytes with cdk4 nuclear
translocation [38], another study showed upregulation of
PCNA and cyclin A in neurons [39]. Because there is
variation in cell cycle protein expression in different AD
transgenic mice, we tested the transgenic mice that we
used in our studies for changes in the reported cell
cycle regulatory proteins. The brains from 12 month old
mice expressing mutant human APP (V717F), mutant
PS1 (M136L), a combination of these two transgenes,
and age matched non-transgenic (Ntg) controls were
analyzed by quantitative immunohistochemistry using
specific antibodies to cyclin D1, cyclin E, E2F1, P-cdc2,
and cdc2. Significant increases in cyclin D1, cyclin E, P-
cdc2, and E2F1 were observed in the PS/APP double
transgenic mice (Figure 1A and 1B). Mice expressing
APP alone showed a smaller increase in the level of
these cell cycle regulatory proteins compared to the
double transgenic mice (Figure 1A, d compared to 1A,
e), possibly due to the differences in the transgene
expression and the fact that PS/APP mice develop
pathology at an earlier age compared to APP expressing
mice. E2F1 and cyclin E stained cells surrounding the
plaques (Figure 1A, inset b, d, and e) appeared to have
glial-like morphology, whereas P-cdc2 appeared to stain
both neuronal and glial-like cells (Figure 1A, g: black
arrow head - neuron & white arrow head - glia). We did
not observe any change in the level of staining with a
non-phospho-cdc2 antibody. Figure 1B shows the quan-
titative analysis of cyclin D1 and E levels in APP and
PS/APP mice compared to Ntg mice. Co-immunostain-
ing analysis of brains from 10 month old PS/APP mice
with cyclin D1 or cyclin E and 6E10 antibodies showed
increased levels of these cell cycle regulatory proteins in
neurons in the brains (Figure 2A and 2B). Studies from
other groups have shown that Ab can induce neurode-
generation through activation of cell cycle dependent
mechanisms [49,50]. Further studies are necessary to
determine whether the increased expression of cell cycle
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regulatory proteins in neurons is brought about by
increased levels of Ab in the AD transgenic brains. It is
possible that the cell cycle activation and Ab generation
are regulated in a feed forward manner, with cell cycle
activation inducing Ab production and Ab in turn indu-
cing cell cycle deregulation.
Phosphorylation of APP at Thr668 in mice expressing AD
transgenes
APP is a transmembrane protein and is phosphorylated
by several kinases including the cell cycle-dependent
kinase cdc2 [45]. Phosphorylation of APP seems to
enhance its proteolytic processing and altered localiza-
tion [42,43]. In order to determine the phosphorylation
levels of APP in cells associated with AD pathology, we
performed immunohistochemical and western blot ana-
lysis of brain samples from mice expressing PS1 or APP
alone or together and compared the results to that from
age-matched Ntg mice. Co-staining with the Ab anti-
body (6E10) and Thr668 specific P-APP antibody (P-
Thr668-APP) showed that significantly higher levels of
P-APP and Ab (6E10 positive) associate with the pla-
ques in AD mice (Figure 3). The Ab staining (6E10) was
localized mostly to the plaque cores with some diffuse
staining around the plaques whereas P-APP was distrib-
uted towards the periphery of the plaques.
The staining pattern observed with Thr668 P-APP
antibody around the plaques suggested that P-APP is
accumulating in dystrophic neurites. In order to confirm
this, we performed co-staining of the sections with anti-
bodies specific for P-APP and phosphorylated neurofila-
ment H protein (NF-H, SMI34) (Figure 4). SMI34 stains
neurofilament proteins when phosphorylated, and it has
been shown to stain NFTs and dystrophic neurites [51].
We found co-localization of SMI34 and P-APP in the
areas surrounding the plaques in APP and PS/APP mice
(Figure 4, rows 3 and 4), suggesting the association of
Thr668 P-APP with degenerating neurites. Ntg mice
and PS1 mice did not show any specific staining with
either Thr668 P-APP or SMI34 antibodies (Figure 4,
rows 1 and 2).
APP phosphorylation and processing in AD
transgenic mice
Western blot analysis of brain extracts from transgenic
mice using the human specific 6E10 (raised against
Figure 1 Increased expression of cell cycle regulatory proteins in AD transgenic mice: A) Cyclin E, E2F1 and P-cdc2 levels are upregulated
in transgenic mice expressing APP and PS/APP: Brain sections from Ntg normal mice (a, c, f) were compared to those from transgenic mice
expressing APP (d, g) and PS/APP (b, e, h) using cyclin E (upper panel), E2F1 (middle panel) or P-cdc2 (lower panel) antibodies. Images (a-e, 5×
and f-h 20×) were taken using a Nikon E1000 microscope and analyzed using Image-Pro Plus software. The P-cdc2 and images in the inset show
magnified images (20×) of the plaques to visualize the cells. We found that the cells surrounding the plaques were positive for cyclin E, E2F1,
and P-cdc2, and it appears that both neurons (black arrow head) and glia (white arrow head) were positive for P-cdc2. ‘Secondary antibodies
only’ control did not show any specific staining of the sections (data not shown). B) Quantitative analysis of cyclin D1 and E expression in APP
and PS/APP transgenic mice brains: Brain sections from Ntg and mice expressing APP and PS/APP were stained using a monoclonal cyclin D1 or
a polyclonal cyclin E antibody and nuclei visualized using Hoechst. The signal intensity was measured using Image J, image processing and
analysis program. The signal strength was compared to that with Hoechst nuclear staining from each section to avoid mouse-to-mouse
variation. The means of results from six independent mice are shown with standard error bars and P values. While APP mice showed a
significantly higher level of only cyclin E compared to cyclin D1, PS/APP mice showed higher levels of both cyclin D1 and E levels
compared to Ntg.
Judge et al. Molecular Neurodegeneration 2011, 6:80
http://www.molecularneurodegeneration.com/content/6/1/80
Page 3 of 20
amino acids 1-16 of Ab) antibody confirmed over
expression of APP in both APP and PS/APP transgenic
mice (Figure 5A). As 6E10 is more specific for human
APP, for detection of mouse APP the blots were
reprobed with C-APP antibody, which showed the total
expression level of APP in vivo in the non-transgenic
and transgenic mice (Figure 5C). The transgenic mice
expressing APP and PS/APP showed very high levels of
C-terminal APP fragments (Figure 5A and 5C). 6E10
antibody detected Ab in both APP and PS/APP mice
(Figure 5A). The level of Ab showed variation between
mice probably due to the altered levels of transgene
expression. Examination of blots using Thr668 P-APP
antibody showed that both full length and C-terminal
fragment of APP show significantly higher levels of
Thr668 phosphorylation compared to that detected in
non-transgenic and PS1 mice (Figure 5D). This finding,
along with the finding that in primary rat neurons the C-
terminal fragment generated by BACE cleavage shows
more phosphorylation at Thr668 than does a-secretase
cleaved C-APP [42], suggests that the amyloidogenic clea-
vage of APP is enhanced upon phosphorylation at
Thr668. The Thr668 P-APP antibody detects APP only
when phosphorylated at Thr668 [40] and has been shown
to react with human, mouse, and rat P-APP (Cell Signal-
ing Technologies). On the western blot, it detected the
intracellular levels of P-APP in the mouse (Ntg and PS),
but the levels in APP expressing mice were significantly
higher. The histograms in Figure 5E, F and 5G show the
percent of P-APP (full length, C-terminal fragment, and
total) compared to the total counterpart of APP detected
by the C-terminal antibody, in the brain extracts.
Figure 2 AD transgenic mice show increased expression of cyclin D and cyclin E in neurons: Brain sections from 10 month old Ntg and
PS/APP mice were co-stained using A) monoclonal 6E10 and polyclonal cyclin D1 or B) 6E10 and polyclonal cyclin E antibodies. Staining was
visualized using Alexa fluor 488 (APP and Ab, green) and Alexa fluor 594 (red) and analyzed under a Zeiss microscope using AxioVision Rel 4.8.
The images were taken at 20× magnification. The composite image shows staining with Hoechst, cyclin, and 6E10 antibodies. The area indicated
by arrows is enlarged and shown on the right to clearly see the positive staining in neurons.
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Age-dependent changes in Thr668 specific
phosphorylation of APP in transgenic mice
The above results showed that APP phosphorylation and
processing are enhanced in transgenic mice expressing
APP. In order to determine whether the APP phosphor-
ylation varies with age, we examined transgenic mice
expressing APP and PS/APP at different ages. Brain
extracts were prepared from mice at 1.5, 2, 3 and 6
months of age and western blotted using Thr668 P-APP
and 6E10 Antibodies (Figure 6A-G). As expected, it was
found that the total levels of APP and C99 fragments
(using 6E10 antibody) were significantly higher in the
AD transgenic mice (APP and PS/APP) compared to the
non-transgenic mice. Within the transgenic groups, we
did not observe any age-dependent increase in the levels
of full length APP or C-99 fragments (Figure 6A and
6D). On the other hand, the transgenic mice showed an
age-dependent increase in Ab generation, with the mice
expressing PS/APP showing higher levels of Ab than
that expressing just APP (Figure 6A and 6G). Expression
levels of full length P-APP did not vary significantly with
age whereas the levels of phosphorylated C-terminal
fragments (P-C-APP) were increased in an age-depen-
dent manner in the AD mice (Figure 6B and 6E). Figure
6F shows the levels of Ab compared to full length APP
in the transgenic mice, and Figure 6G shows the levels
of Ab compared to the levels of P-C-APP. A reprobe of
the APP blots using actin antibody showed equal
amounts of proteins on the blot (Figure 6C). It is known
that pathology development in AD is age-dependent.
The data presented here further demonstrates that APP
phosphorylation and processing as well as Ab generation
are also age-dependent and these fragments may contri-
bute to the enhanced pathology development in AD.
In order to determine the localization of P-APP in
mice at different ages we examined the brains from 1.5
and 6 month old mice using Thr668 P-APP and 6E10
antibodies. 1.5 month old APP and PS/APP mice
showed a general increase in overall staining and an
association of P-APP with degenerating (beaded) neur-
ites (Figure 7A, B shows enlarged images of beaded
neurites in APP and PS/AP mice). 6E10 staining was
mainly visible within the neuronal cell bodies of APP
and PS/APP mice (Figure 7A). At 6 months of age the
APP mice showed accumulation of P-APP in some neu-
rons without any plaque pathology (Figure 7D, B shows
neurons that show accumulation of P-APP). Unlike APP
mice, 6 month old PS/APP mice showed very strong
localized accumulation of P-APP in plaque-like struc-
tures, which did not always relate with 6E10 stained pla-
ques (Figure 7D, E shows the enlarged image of the area
indicated by arrows in PS/APP mice).
Cell cycle-dependent phosphorylation of APP
The phosphorylation of APP at Thr668 in transgenic
mice correlated with the expression of cell cycle
Figure 3 APP overexpressing mice show increased levels of Thr668 P-APP: Brain sections from Ntg, APP, and PS/APP mice were
immunostained using monoclonal 6E10 antibody and polyclonal Thr668 specific P-APP antibody. A: Representative sections from Ntg (top row),
APP (middle row), and PS/APP (bottom row) mice stained with a 6E10 antibody (left column), Thr668 P-APP antibody (middle column) and
composite image (right column) with Hoechst showing nuclear staining. Magnification: 40×. B: Quantification of the intensity of 6E10 and P-APP
staining in Ntg, APP, PS/APP and PS mouse brains. Both APP and PS/APP mice showed significantly higher levels of APP and Thr668 P-APP with
more intensity in mice expressing both PS and APP transgenes compared to APP alone. The Ntg and PS expressing mice showed low levels of
APP and P-APP.
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regulatory proteins in the brains. This result, together
with the published findings [45], prompted us to deter-
mine whether the APP phosphorylation is due to cell
cycle activation. Since it is difficult to verify this in vivo,
we decided to examine APP phosphorylation in cells
cultured in vitro. H4 neuroglioma cells overexpressing
WT-APP (H4-APP) were cultured for 24 hr and serum
starved for 48 hr. At the end of the starvation period,
cells were serum stimulated in the presence or absence
of pharmacological inhibitors of cell cycle progression
for different time periods, and cell extracts were immu-
noprecipitated using 6E10 antibody and analyzed using
P-APP antibody. The treatment of the cells included
roscovitine (20 μM for 12-14 hr) an inhibitor of cdk2,
cdc2, and cdk5 [52], olomoucine (50 μM for 12-14 hr)
an inhibitor of cdk1 (cdc2), cdk2, and cdk5 [53], aphidi-
colin an S-phase inhibitor (5 μg/ml for 12-14 hr), or the
mitotic inhibitors nocodazole (100 ng/ml), vinblastine
Figure 4 Thr668 P-APP antibody co-localizes with phospho-neurofilament NFH antibodies in the plaques: Brain sections from Ntg, PS,
APP, and PS/APP mice were analyzed with Thr668 P-APP and monoclonal P-NFH (SMI34) antibodies and visualized using Alexafluor 594 and 488
respectively. Nuclei were visualized using Hoechst stain. Magnification: 40×.
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(10 μM), or taxol (100 ng/ml) for 16 to 18 hr. Analysis
of the cells using a fluorescence activated cell sorter
(FACS) showed that roscovitine and aphidicolin treated
cells were mostly arrested in the G1 phase of the cell
cycle (60-70%), while nocodazole arrested cells were
mostly in the G2/M phase (Figure 8E). Cell extracts
after treatment were immunoprecipitated using 6E10
antibody and the blot was analysed using P-APP anti-
body. We found that Thr668 specific phosphorylation
on APP was induced in a time dependent manner upon
serum stimulation, and maximum levels of phosphoryla-
tion occurred upon mitotic arrest using nocodazole or
vinblastine (Figure 8A and 8D). The total levels of APP
(reprobe using 6E10 antibody) also showed a similar
profile, but the levels were not as significant as those we
observed with P-APP (Figure 8B). Reprobe of blots
using actin antibody (without stripping) showed
approximately equal amounts of proteins on the gel
(Figure 8C). Roscovitine treatment consistently resulted
in a decrease in the levels of P-APP, and aphidicolin
and olomoucine kept the phosphorylation more or less
at the basal levels (Figure 8A and 8D). These data con-
firm that the Thr668 specific phosphorylation on APP
occurs in a cell cycle-dependent manner and peaks dur-
ing mitosis. Cells treated for 16-18 hr with taxol, a
microtubule stabilizing agent, largely accumulated in the
G1 (~45-50%) and G2 (~40-45%) phases, which was
similar to that observed with serum stimulation for 16
hr and showed slightly higher levels of P-APP compared
to serum stimulated cells. The results from the time
course with serum as well as treatment with roscovitine,
olomoucine, and aphidicolin suggest that APP phos-
phorylation occurs very early during the cell cycle.
Thus, it is possible that in the brains of transgenic mice
APP phosphorylation arises from cells attempting to
enter the cell cycle and inhibitors of G1/S checkpoint
may inhibit this phenomenon.
si-cdk2 inhibits serum stimulation-induced APP
phosphorylation in H4-APP cells
We found that APP is phosphorylated at Thr668 in a
cell cycle-dependent manner and that roscovitine, an
inhibitor of cdks such as cdc2, cdk2, and cdk5, pre-
vented both APP phosphorylation and Ab generation
while nocodazole, a mitotic inhibitor, induced these
phenomena. Earlier studies had shown that both cdk5
and cdc2 could induce Thr668 specific phosphorylation
of APP while nothing was known about cdk2. In order
to determine whether cdk2 or cdk4 are involved in APP
phosphorylation during mitosis, we transfected H4-APP
cells with different concentrations of cdk2 and cdk4
siRNA and analyzed for changes in APP after 16 to 18
Figure 5 Increased levels of APP phosphorylation and processing in transgenic mice expressing APP and PS/APP: Equal amounts of
proteins from Ntg, APP, PS1, and PS/APP brain extracts were analyzed using 6E10, C-APP, 22C11, and P-Thr668 APP antibodies. A) Shows
western blot analysis using monoclonal 6E10 antibody (detect APP, Ab, and any Ab containing fragments of APP), B) shows reprobe of the same
blot using actin antibody (indicated by arrow) without stripping to show equal amounts of protein loading, C) western blot using a polyclonal
C-terminal APP antibody (detects full length and C-terminal fragments of APP), and D) represents the western blot using Thr668 P-APP antibody.
Mice expressing APP and PS/APP showed very high levels of full length and C-terminal APP fragments. Ab levels showed mouse-to-mouse
variation probably due to varied expression of the transgenes. Levels of P-APP were significantly higher in both APP and PS/APP transgenic mice
and the antibody detected the phosphorylated C-terminal fragment of APP as well. Blots were analyzed using supersignal ECL solution from
Pierce. The histograms represent quantitative analysis of P-APP compared to the corresponding counterpart of total APP detected using C-
terminal APP antibody: E) percent of full length P-APP, F) percent of P-C-APP (phosphorylated C-terminal fragment), and G) percent of total P-
APP compared to total APP.
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Figure 6 Age-dependent changes in Thr668 specific phosphorylation and Ab generation in transgenic mice: Brain extracts from 1.5, 2, 3,
and 6 month old Ntg mice and transgenic mice expressing APP and PS/APP were examined by western blot using Thr668 P-APP and 6E10
antibodies. Panel A shows the levels of full length APP and fragments of APP such as C-99 and Ab in the mice at different ages. The transgenic
mice expressing APP and PS/APP showed very high levels of full length APP. Only the levels of Ab were altered in an age-dependent manner.
Panel B shows staining of the blot with Thr668 P-APP antibody, which detects mouse and human APP phosphorylated at this site. The levels of
full length P-APP were higher in the transgenic mice. Levels of phosphorylated C-terminal P-APP fragments were induced in an age-dependent
manner in the transgenic mice. Panel C shows reprobe of the blot with actin antibody without stripping to show approximately equal amount
of protein loading. D-F shows the relative signal intensity of the various APP fragments from the western blot analysis. D) Represents signal
intensity of full-length APP and C-99 fragments, E) that of full length P-APP and phosphorylated C-terminal fragments of P-APP (P-C-APP), F)
represents the levels of APP and Ab and G) shows signal intensity of P-C-APP and Ab.
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Figure 7 Immunohistochemical analysis of brain sections from transgenic mice at different ages: In order to determine whether there is
accumulation of P-APP in the brain mice at 1.5 and 6 months were analysed using 6E10 and P-APP antibodies. Brain sections from transgenic
mice showed an increase in overall staining using the 6E10 and P-APP antibodies (A-D). Panel A shows brain sections from 1.5 month old mice
where P-APP showed beaded staining of neurites occasionally in APP and PS/APP mice. 6E10 staining showed APP in the neuronal bodies in
these sections. The enlarged P-APP positive neurites are shown in panel B. Panel C shows examples of neurons in APP mice at 6 months that
show P-APP accumulation. Panel D shows the P-APP and 6E10 staining in 6 month old Ntg, APP, and PS/APP mice. The accumulation of Ab and
P-APP are visible only in the PS/APP mice at 6 months. Panel E shows the magnification of the area shown with the arrows from 6E10 and P-
APP stained PS/APP sections. Images in panel A were taken at 10× and in panel B at 20 × magnifications. Images shown in Panel D were taken
at 5× magnification.
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hr. Western blot analysis of extracts using specific cdk
antibodies confirmed the downregulation of the kinases
in the transfected cells (Figure 9A). Analysis of extracts
from cdk2 downregulated cells showed that this is asso-
ciated with a decrease in APP phosphorylation at
Thr668 (Figure 9A) whereas cdk4 inhibition was not
(data not shown). A non-specific control siRNA did not
have any effect on the kinases or APP phosphorylation,
suggesting that the results we observed with si-cdk2 are
specific to this cdk. In the G1 phase of the cell cycle,
cdk2 associates with cyclin E and enables the transition
of cells through the G1/S checkpoint. The result with
si-cdk2 thus agrees with the results shown in Figure 8
in which APP phosphorylation is induced upon serum
stimulation and is inhibited by blocking the G1/S
transition.
Since it is known that cdk5 as well as GSK-3b can
induce tau hyperphosphorylation in AD brains, and since
these kinases have also been shown to affect APP phos-
phorylation, we examined the effect of downregulation of
these kinases on APP phosphorylation. Cells transfected
with siRNA to GSK-3ab (Figure 9B) and siRNA to cdk5
(Figure 9C) also showed downregulation of APP phos-
phorylation as expected and it correlated with the levels
of down regulation of the corresponding kinases. These
data thus suggest that APP and tau are phosphorylated
Figure 8 Mitosis-specific phosphorylation of APP: H4-15X cells were growth arrested by serum starvation for 48 hr and serum stimulated
with and without roscovitine, olomoucine, or aphidicolin for 12 hr, and nocodazole, vinblastine, or taxol for 16 hr. Cell extracts were prepared
and equal amounts of proteins were immunoprecipitated using 6E10 antibody and western blotted using P-APP antibody (A). B) APP levels in
total lysate analyzed using 6E10 antibody. Panel C shows reprobe of blot B (without stripping) with actin antibody showing equal amount of
proteins on gel. The histogram in panel D shows the percent of P-APP in cells under the different treatment conditions. The data represent the
mean of 3 independent experiments with standard deviation shown. Cells arrested in metaphase showed significantly higher levels of P-APP (P
< 0.05). Panel E shows the FACS analysis data from cells treated with cell cycle inhibitors. Cells were treated with roscovitine or aphidicolin for
12 hr or nocodazole or taxol for 16 hr and fixed and stained using propidium iodide before analysis on a FACS machine. Mean percent of cells
in different phases of the cell cycle from 3 independent experiments is shown.
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under similar conditions, and that inhibitors of these
kinases should be tested for their ability to reduce devel-
opment of pathology in AD. The G1/S inhibitor roscov-
itine has been shown to inhibit cdk5 and therefore the
effect we see with this inhibitor could be due to its effect
on not only cdk2 but other responsive kinases as well.
Distribution of P-APP in asynchronously growing cells
Our results from H4-APP cells using the pharmacological
inhibitors suggested that G1/S checkpoint inhibition pre-
vents APP phosphorylation at Thr668. This prompted us
to determine the expression and distribution of P-APP in
cells at different phases of the cell cycle. First, we exam-
ined the localization of P-APP in asynchronously growing
H4-APP cells. The cells were trypsinized and cultured for
24 hr and fixed and analyzed with monoclonal a-tubulin
and polyclonal Thr668 P-APP antibodies. As expected,
the asynchronously growing culture contained a non-
homogeneous population of cells in different phases of
cell cycle (Figure 10A and 10B). P-APP showed a cell-
cycle specific localization with more staining in cells that
are in active division (prophase, metaphase, anaphase)
and very little or no staining in early interphase cells (Fig-
ure 10A-10C). The cells that were in metaphase showed
prominent localization of P-APP to the centrosomes
(microtubule organizing centers; MTOCs) suggesting a
role for phosphorylated APP in cell cycle activation and/
or spindle assembly. We confirmed the localization of P-
APP to centrosomes in metaphase cells using confocal
microscopy (Figure 11). Cellular distribution of P-APP
was also examined in cells treated with the pharmacologi-
cal inhibitors roscovitine, aphidicolin, nocodazole, or
taxol. While cells treated with roscovitine and aphidicolin
showed very few cells in active division and hence little
P-APP staining, the majority of the nocodazole treated
cells were in the mitotic phase and exhibited significantly
higher levels of P-APP (data not shown).
Evidence for mitotic phosphorylation and centrosome
localization of P-APP
In order to confirm that the phosphorylation of APP at
Thr668 is mitosis-specific, we co-stained cells with
Figure 9 siRNA to cdk2, cdk5, and GSK-3ab inhibits serum stimulation-induced APP phosphorylation at Thr668: H4-APP cells plated in
serum-free OPTI-MEM were transfected with siRNA to cdk2 (Panel A), GSK-3ab (panel B) or cdk5 (Panel C) at the indicated concentrations using
oligofectamine. After 6 hr serum containing media was added to the cells and samples were collected after 24-48 hr. Cell lysates were western
blotted using the corresponding kinase antibodies to confirm downregulation of the respective kinases. Phosphorylation status of APP was
analyzed using P-Thr668 APP antibody, and actin was used as a loading control. Down regulation of each kinase was associated with inhibition
of serum stimulation-induced phosphorylation on APP. The histograms below each blot show the quantification of the level of the respective
kinase and P-APP compared to the levels present in siRNA control transfected cells. The data are representative of one of three independent
experiments.
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antibodies that are specific for mitotic phosphoepitopes.
The best-characterized antibodies for this purpose are
the metaphase protein monoclonal-2 (MPM2). MPM2
antibodies detect phosphoproteins that are present in
mitotic cells and have been shown to associate with the
kinetochore, centrosome, midbody and fibers of the
mitotic spindle [54]. Our analysis of asynchronously
growing untreated cells showed that, in metaphase, P-
APP co-localized with MPM2 at the centrosomes (Fig-
ure 12 top row). In cells arrested with nocodazole,
although P-APP levels were significantly elevated (Figure
12 bottom row), due to the microtubule destabilizing
function of nocodazole we did not observe any meta-
phase cells with classic spindles and spindle poles. The
high levels of P-APP in these cells correlated well with
the western blot data and confirm that APP is heavily
phosphorylated under mitotic conditions. These results
suggest that the phosphorylation of APP may play a role
in cell cycle dependent processes including centrosome
replication.
Figure 10 Analysis of P-APP distribution in asynchronously growing H4-15X cells show cell cycle-dependent localization of P-APP:
Panels A and B show asynchronously growing H4-15X cells fixed and immunostained using Thr668 P-APP polyclonal and a-tubulin monoclonal
antibodies and visualized using Alexa 594 (red) and 488 (green) fluorophores respectively. Staining was analyzed using the AxioVision Rel 4.8
software for Zeiss microscope. Nuclei were visualized using Hoechst staining. Cells in mitotic phase showed P-APP localized to the centrosomes,
nucleus and cytoplasm with maximum immunoreactivity in mitotic cells and minimum/none in interphase cells. Cells in telophase showed P-
APP staining in the midbody which was absent in cells undergoing cytokinesis. The absence of staining in the interphase cells suggests that APP
phosphorylation at Thr668 occurs only when cells are undergoing division. Panel C shows a cell cycle schematic with representative cells from
different stages of the cell cycle (selected from an asynchronously growing culture) illustrating the phosphorylation event occurring once the
cells enter prophase and tapering off as it exits the cell cycle (cytokinesis). Magnification: 63×.
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Cell cycle activation induces altered processing of APP
and Ab generation
We next examined whether Ab generation is altered in
a cell cycle-dependent manner and whether it parallels
the phosphorylation of APP. Cells were growth arrested
by serum starvation for 48 hr and serum stimulated in
the presence or absence of pharmacological inhibitors
of cell cycle progression for different time periods. The
cell culture supernatants and cell extracts were then
immunoprecipitated and western blotted using the Ab-
specific 6E10 antibody. The results showed that intra-
cellular and secreted levels of Ab increase in a time-
dependent manner upon serum stimulation of growth
arrested cells (Figure 13A-D, C and 13D show the bot-
tom region of the blot from longer exposure to detect
Ab in lysates), and followed a similar profile as in APP
phosphorylation (Figure 8). The histograms in E and F
show the percent levels of Ab in supernatant and lysate
in comparison to the total levels of full length APP in
the respective samples. In the case of cells arrested
with pharmacological agents, the maximum levels of
intracellular and secreted Ab were present in mitosis-
arrested cells (nocodazole, vinblastine, and taxol) with
the lowest levels in the roscovitine treated (G1/S inhib-
ited) cells. Treatment of neurons in vitro with Ab pep-
tide has been shown to induce cell cycle activation and
neuronal apoptosis [27,49]. Thus, these findings not
only imply that APP is phosphorylated and processed
in a cell cycle-dependent manner, but also suggest that
the observed cell cycle activation in the brains of AD
transgenic mice may induce APP phosphorylation,
leading to enhanced levels of intracellular and extracel-
lular Ab that subsequently induce cell cycle activation
and neurodegeneration.
Figure 11 Centrosome association of Thr668 P-APP in mitotic cells: Asynchronously growing H4-APP cells were fixed and immunostained
using Thr668 P-APP polyclonal and a-tubulin monoclonal antibodies and visualized using Alexa 594 (red) and 488 (green) fluorophores
respectively. Nuclei were visualized using Hoechst staining. Staining was analyzed using the FV10-ASW 1.7 software for Olympus confocal
microscope. Cells in metaphase and anaphase showed very clear P-APP localization at the centrosomes. Staining was very weak or absent in the
interphase cells. Magnification: 63×.
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Upon analysis of other proteolytic fragments of APP in
cultured cells, we found that, similar to our observations
in AD transgenic mice, phosphorylation was associated
with increased BACE cleavage of APP, as evident by the
C-terminal fragment detected by the 6E10 antibody. The
C-APP levels were lowest in roscovitine treated G1/S
checkpoint arrested cells. Recent studies using a C-term-
inal fragment of APP have shown that the administration
of this fragment induces apoptosis in cells of neuronal
origin [55]. Thus, our results support the suggestion that
inhibitors of G1/S transition may prevent neurodegenera-
tion by preventing unwarranted processing of APP to
generate neurotoxic Ab and C-APP.
Discussion
Alzheimer’s disease is characterized by the presence of
neuritic plaques and neurofibrillary tangles in the
affected areas of the brain. In addition, AD brains show
considerable neuronal loss and neuroinflammation, the
causal mechanisms of which are under active investiga-
tion. Studies from several laboratories have shown that
AD brains exhibit aberrant upregulation of cell cycle
regulatory proteins [4,6,7,14,22,56]. It is suggested that
the deregulated expression of cell cycle proteins in neu-
rons may contribute to the pathology associated with
Alzheimer’s, possibly due to inappropriate induction of
the cell cycle in post-mitotic neurons. A causal link can
be established between cell cycle activation, neurodegen-
eration, and neuronal loss in vitro, but it has been diffi-
cult to illustrate how cell cycle activation can induce a
slowly developing but ultimately catastrophic effect in
human AD brain. In order to understand the mechan-
isms involved in cell cycle activation and AD pathogen-
esis, we used mice expressing APPV717F and PS1M146L
mutant transgenes. The PS/APP mice develop plaques
at approximately 6 months of age and the APP mice
show plaques at approximately 10-12 months of age.
We found that, similar to human AD, brains from these
mice also show increased expression of some of the cell
cycle regulatory proteins. This was associated with
increased phosphorylation of APP.
In vitro analysis of asynchronously growing H4-APP
cells clearly showed that the phosphorylation of APP
occurs mainly in the cells that are undergoing cell divi-
sion. In the interphase, cells APP phosphorylation was
negligible and was induced as soon as the cells entered
prophase. The experiments with si-cdk2 and pharmaco-
logical inhibitors of the G1/S checkpoint further sup-
ports the conclusion that APP phosphorylation and
processing occurs in a mitosis-specific manner and rein-
forces the idea that inhibition of cell cycle activation at
an early stage may prevent the APP modifications asso-
ciated with the development of AD pathology. APP
phosphorylation is not just mediated by cyclin-depen-
dent kinases. Kinases such as GSK-3b, JNK, and cdk5
have also been shown to affect Thr668 specific phos-
phorylation of APP. Our studies also showed that this
specific phosphorylation could be inhibited by downre-
gulation of GSK-3b and cdk5. Both GSK-3 and cdk5
have been shown to play roles in the cell cycle and
hence the possibility that these kinases are also behaving
in a cell cycle-dependent manner needs to be estab-
lished [57,58]. Nocodazole-induced mitotic arrest led to
a significant increase in APP phosphorylation compared
to that induced by serum stimulation alone. One of the
reasons for this result could be that the number of
metaphase cells obtained upon treatment with nocoda-
zole (~80% by FACS analysis) is much higher than that
obtained by serum stimulation or taxol treatment
(~40%). The data shown in Figure 8 agrees with this
interpretation; quantitative analysis of the levels of P-
APP and APP showed that while serum stimulation
shows ~30% APP phosphorylation (~40% cells in G2/
M), nocodazole treatment shows ~80%, both of which
correlate with the percent of cells in metaphase. In
addition, nocodazole, being a powerful microtubule
depolymerizing agent, could affect other kinases or
phosphatases and induce APP phosphorylation indepen-
dent of its mitotic arrest-related effects. Treatment of
cells with taxol, another mitotic inhibitor that brings
about cell cycle arrest through microtubule stabilization,
showed only ~40% of cells in metaphase and a P-APP
level of ~30%.
The results presented here strongly indicate that
Thr668 specific phosphorylation on APP is intimately
Figure 12 P-APP co-localization with MPM-2 at centrosomes in
metaphase cells: Asynchronously growing (untreated, top row) and
nocodazole arrested (bottom row) H4-15X cells were
immunostained using the mitosis specific monoclonal antibody
MPM2 and Thr668 P-APP polyclonal antibodies and staining was
visualized using Alexa 488 and 594 fluorophores respectively. The
untreated cells show P-APP localization in centrosomes in the
mitotic cells. In the cells arrested with nocodazole the microtubules
were completely depolymerized and P-APP showed significantly
higher levels of amorphous staining. The nuclei were visualized
using Hoechst stain. Magnification: 63×.
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associated with cell cycle activation and that the maxi-
mum phosphorylation occurs in metaphase. This phos-
phorylation transition was associated with increased
APP processing and Ab generation (Figure 13). Thus
the cells do not have to go through a full division to
bring about the modifications in APP suggesting that an
attempt by the cells in AD brain to re-enter cell cycle
could lead to APP phosphorylation and proteolytic clea-
vage without the cells undergoing cell division. The
findings that AD brains show binucleated neurons [59],
as well as aneuploidy and mis-segregation of different
chromosomes [15,61-63] further strengthens the conclu-
sion that neurons in AD brain attempt to undergo DNA
replication and cell division. It is suggested that the cell
cycle regulatory proteins may have a different role in
neurons compared to that in cells undergoing active cell
division; studies show that terminally differentiated neu-
rons use the mechanisms involved in proliferation to
Figure 13 Ab generation is altered in a cell cycle-dependent manner: H4-15X cells were synchronized by serum starvation and stimulated
with serum containing media plus or minus olomoucine, roscovitine, aphidicolin, nocodazole, vinblastine, or taxol. Cell culture supernatants (A
and C) and cell extracts (B and D) were immunoprecipitated and western blotted using 6E10 antibody. Control was performed similarly to the
rest of the samples, except no primary antibody was used in immunoprecipitation assay. Cell culture supernatant showed a time dependent
increase in Ab generation upon serum stimulation (A and C). The extracts showed similar results which was visible only after longer exposure
(D). Panels C and D represent longer exposure of the bottom part of the blots shown in A and B to show the Ab levels in cell extracts. In both
the cases roscovitine treatment was associated with a decrease in the level of secreted and cellular Ab. Secreted APP was not altered in the
supernatant although the level of APP and C-APP fragments are increased in the extracts prepared from nocodazole and vinblastine-arrested
cells. Panel E and F show mean percent of Ab (compared to secreted and full length APP) from 3 independent experiments under different
treatment conditions. Data that showed significant changes are marked using a star (P < 0.05).
Judge et al. Molecular Neurodegeneration 2011, 6:80
http://www.molecularneurodegeneration.com/content/6/1/80
Page 15 of 20
maintain the synaptic plasticity [42,60,64]. It is possible
that the complex architecture of mature plastic neurons
makes it impossible for the cells to undergo division
without undergoing damage. The report that centro-
somes localize to the area where the neurites sprout
from and the number of centrosomes determines the
number of neurites [65] suggest that cell cycle activation
may cause asymmetric dynamics on the chromosomes
leading to mis-segregation and formation of aneuploid
cells in the AD brain. The localization of P-APP (data
presented here) and PS1 at the centrosomes [66] suggest
that these molecules may play a role in spindle assembly
and chromosome segregation, and hence the enhanced
expression or mutations of these proteins may cause
chromosome mis-segregation in cells. The data from
our lab support this hypothesis, in which we showed
that expression of APP, Ab, or PS1 lead to chromosome
mis-segregation and aneuploidy [36]. Ab oligomers have
been reported to induce neuronal cell cycle activation
[49,50], and this along with the data presented here,
suggest that Ab generated upon APP phosphorylation
may have a feed forward role in cell cycle activation and
enhanced neurodegeneration in AD brain.
Cell cycle activation not only induced the phosphory-
lation and proteolytic processing of APP, but also
affected the localization of P-APP in cells; mitotic cells
clearly showed centrosome specific localization of P-
APP. It has been proposed that the phosphorylation of
structural or transient components of centrosomes may
affect cell cycle dependent processes such as centrosome
duplication and microtubule nucleation [54]. Thus, in
addition to enhanced proteolytic cleavage, APP phos-
phorylation may influence cell proliferation through its
association with the cell cycle machinery. The co-locali-
zation of P-APP with MPM2, a metaphase protein mar-
ker, further reiterates APP’s role as a growth-promoting
molecule. Therefore, it is possible that high levels of P-
APP may promote proliferation in dividing cells and
centrosome duplication or chromosome mis-segregation
and cell death in post-mitotic neurons. APP’s function
as a mitogenic molecule is evident from the fact that its
upregulation is associated with cancers of different
organs [67,68]; neurons being postmitotic are fully dif-
ferentiated and undergo apoptosis rather than transfor-
mation upon cell cycle activation. It has been reported
that APP and PS1 associate with other proteins at the
centrosome and localize to centrosomes [69,70]. An N-
terminal APP antibody conjugated to an Alexa fluoro-
phore was used to detect the localization of APP at the
centrosomes. In our hand staining of the cells with the
Ab immunoreactive 6E10 antibody did not show any
significant localization of non-phospho APP to the cen-
trosomes. It is possible that either the antibody or the
techniques we applied to detect the localization are not
strong enough to detect non-phospho APP at the
centrosomes.
Our studies showed that APP and PS/APP mice show
formation of Ab and phosphorylated C-terminal frag-
ments of APP at a very early age (1.5 month), and the
generation of these fragments are increased in an age-
dependent manner. Although this is the case, PS/APP
mice showed clear accumulation of P-APP and Ab in
their brains by 6 months of age whereas APP mice
showed only by 10-12 months. This result suggests that
unless there is an accelerating factor present, the pathol-
ogy in AD develops very slowly and if diagnosed early in
life it can be prevented. The facts that deregulation in
PS1 can induce chromosome miss-segregation and
tumour generation [36,71], and both PS1 and APP
associate with centrosomes, suggest that in addition to
Ab generation, expression of PS1 in APP transgenic
mice may affect cell cycle deregulation and therefore
APP phosphorylation. Whether or not these associates
with early neurodegeneration and neuronal loss
observed in AD brains needs to be determined. Even
though the PS/APP mice we used show significantly
higher levels of P-APP and accumulation of Ab in to
plaques, unlike in some of the other AD mouse models
such as APPSL/PS1-KI and 5XFAD mice [68,72,73], we
did not observe any significant neuronal loss. The rea-
son for this is unclear. It is possible that the genetic
background and the transgene expression levels play a
role in plaque load and neuronal loss associated with
different transgenic mouse models. The APP mice we
used do not exhibit as aggressive an AD-like disease as
the ones above, and probably inclusion of an additional
APP mutation in the transgene may be required to
obtain detectable levels of neuronal loss.
Conclusions
In conclusion, cell cycle deregulation may influence the
pathogenesis of AD through multiple pathways: 1)
through phosphorylation and processing of APP to gen-
erate Ab leading to plaque formation, 2) through Ab
and C-terminal fragment of APP inducing tau hyper-
phosphorylation [66,74-76], and 3) through both Ab and
P-APP affecting cell cycle deregulation and contributing
to the unwarranted progression of cell cycle. From the
data presented here it is apparent that an inhibition of
aberrant activation of the cell cycle prior to G1/S check-
point could potentially hinder the modifications in APP
and therefore development of AD pathology. In this
respect, G1/S inhibitors, which are known to protect
neuronal apoptosis in vitro [26,31,32], need to be
explored in vivo for their efficacy in preventing APP
phosphorylation and processing. Once the neurons start
expressing higher levels of cell cycle proteins due to
environmental stress, or inflammation, or high levels of
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Ab, the modifications in the proteins associated with the
development of pathology will take place, and the cells
will succumb to degeneration. The data presented above
and the previous support for the cell cycle hypothesis,
which suggests that the neurons in AD brain enter the
G1 phase of cell cycle [6,7,77], indicate that inhibitors of
the early phases of cell cycle such as those associated
with the G1/S checkpoint may prove to be beneficial in
treating neurodegenerative diseases such as Alzheimer’s.
However, it must be noted that microtubules are essen-
tial for many neuronal functions, and thus any drugs
designed to inhibit APP modifications or Ab generation
should be tested for their effect on microtubule
dynamics both in vitro and in vivo before assuming that
they will be risk-free therapies for AD.
Methods
Ethics Statement
All studies involving animals were done in accord with
the rules and regulations set forth by the University of
South Florida’s Institutional Animal Care and Use Com-
mittee (IACUC). The care for the animals was provided
by the well-established animal care facility at University
of South Florida (USF), which is accredited by the
American Association of Laboratory Animal Care
(AALAC).
Materials
The tissue culture reagents, electrophoresis supplies, and
Alexa fluorphores were purchased from Gibco/Invitro-
gen, Carlsband, CA. Poly-D-Lysine (PDL), a-tubulin
antibody and Hoechst were from Sigma, St. Louis, MO.
Anti-Ab/APP antibody (6E10 raised against Ab1-16)
was from Signet, C-terminal APP antibody was from
Chemicon/Millipore, Thr668 P-APP, MPM-2, and P-
cdc2 antibodies were from Cell Signaling, and cyclin D1,
cyclin E, and E2F1 antibodies were from Santa Cruz
Biotechnology. The reagents for brightfield staining
were purchased from Vector Laboratories. Enhanced
chemiluminescence (ECL) reagent was from Pierce Bio-
technology Inc., Rockford, IL. H4 neuroglioma cells
overexpressing WT-APP (H4-APP) was a kind gift from
Dr. Todd Golde (Mayo clinic, Jacksonville, Florida).
Transgenic Mice
Heterozygous PDGF-hAPP (V717F) mice (Swiss-
Webster × C57BL/6) were crossed with PDGF-hPS1
(M146L) heterozygotes (Swiss-Webster × C57BL/6) to
generate mice with an APP+/-, PS1+/- genotype. All off-
spring were screened by PCR to verify the expression of
APP and PS1 gene [78,79]. The APP mutant mice
develop many of the pathological hallmarks of AD,
including neuritic plaques (appear at around 10-12
months of age), and cognitive deficits in an age-
dependent manner, and the expression of mutant PS1 in
these mice accelerates the pathology development signif-
icantly (plaques are visible as early as 4-6 months of
age) (Figure 7D). In the current study we used these
transgenic and age-matched non-transgenic (Ntg) mice.
Mice were anesthetized using Nembutal (10 mg/kg body
weight) and perfused with saline solution. The brains
were dissected out and half of each brain was immersion
fixed with 4% para-formaldehyde and the other half was
used for protein extraction. For protein extraction,
brains were homogenized in Hepes lysis buffer (50 mM
HEPES pH 7.4, 150 mM NaCl, 10% glycerol, 1% Triton
X-100, 5 mM MgCl2, 1 mM EGTA, 20 mM NaF, 2 mM
Na3VO4, and protease inhibitors (Roche)). Samples were
centrifuged at 14,000 rpm for 30 min and equal
amounts of proteins were used for western blot analysis.
The brains were processed as described before for
immunohistochemical analysis [80]. Brain sections were
made using a freezing stage sliding microtome and
stored at 4°C in phosphate buffered saline (PBS) con-
taining sodium azide (0.02%) for immunohistochemical
analysis.
Immunostaining
This was done following the established protocols
[80,81]. Briefly, H4-15X cells cultured in 8-chamber tis-
sue culture slides coated with PDL were treated with or
without different inhibitors of the cell cycle for 18 hr;
roscovitine (20 μM) as G1/S inhibitor, aphidicolin (5 μg/
ml) as S-phase inhibitor, nocodazole or vinblastine (100
ng/ml or 10 μM respectively) or taxol (placitaxel, 100
ng/ml) as mitotic inhibitor. At the end of the treatment,
cells were fixed with 4% para-formaldehyde and staining
was performed using the appropriate antibodies. Stain-
ing was analyzed under a Zeiss microscope using the
AxioVision Rel 4.8 software. Centrosome specific stain-
ing of P-APP in H4-APP cells was confirmed by confo-
cal microscopy under an Olympus imaging system using
Fluoview FV1000 ver.1.7 software.
For immunostaining analysis of the brain sections, sec-
tions were mounted onto superfrost slides, and non-spe-
cific binding was blocked by incubating with 10%
normal goat serum (NGS)/TBST for 2 hr at room tem-
perature. Sections were then incubated with appropriate
dilutions of the primary antibody (APP (6E10), Thr668-
P-APP, cyclin D1, cyclin E, E2F1, and P-cdc2 antibodies)
in 1% BSA/TBST overnight at 4°C in a humidified
chamber. After thorough washing, the sections were
incubated with biotinylated mouse or rabbit secondary
antibodies for 1 hr at room temperature and developed
following the manufacturer’s protocol with the DAB kit
from Vector laboratories. The staining was visualized
using a Nikon E1000 microscope using Image-Pro Plus
software. In the case of fluorescent labeling, after
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primary antibody incubation as outlined above, sections
were incubated with Alexa 488 or 594 fluorophores for
2 hr at room temperature protected from light. Sections
were washed and nuclei were counter stained using
Hoechst 33342 and washed again before mounting using
aqueous Gel/Mount. Sections were stained with second-
ary antibody alone to determine non-specific binding of
antibodies to the tissue (data not shown). The results
were analysed under a Zeiss microscope using the Axio-
Vision Rel 4.8 software. The signal intensity of the
images was determined by Image J, image processing
and analysis program [32]. Adjacent sections from at
least 3 independent mice expressing different transgenes
were stained using the antibody of interest. Prior to
measurement, the images were converted to 8-bit grays-
cale and the threshold of all the images from each set of
experiments was adjusted to the same level. This keeps
the sample-to-sample variation minimal. The intensity
obtained with Hoechst staining was used as a normaliz-
ing control for each section.
Immunoprecipitation and Western blot analysis
H4-15X cells were cultured in OPTI-MEM containing
10% FBS and 50 μg/ml hygromycin in 100 mm culture
dishes overnight and serum starved for 48 to 72 hr.
Serum stimulation of the cells was done in the presence
or absence of different pharmacological inhibitors for
the indicated time periods. Cell culture supernatants
and cell lysates (made in Hepes lysis buffer) were immu-
noprecipitated using 6E10 antibody and analyzed using
the same antibody to detect secreted and cellular levels
of Ab. In the case of brain extracts, equal amounts of
protein were boiled with Tricine sample buffer and
PAGE and western-immunoblot analysis was performed
using appropriate antibodies. For quantification, western
blot images on the X-ray film were scanned and densi-
tometric analysis was performed using the Image J,
image processing and analysis tool after selecting and
plotting the bands of interest.
siRNA transfection of H4-APP cells
We obtained Silencer validated siRNA to cdk2 (locus
ID: 1017) from (Ambion, Inc. Applied Biosystems),
siRNA to cdk5 from Santa Cruz Biotechnology and
siRNA to GSK-3ab from Invitrogen. The siRNA was
used at the indicated concentrations and transfected
using oligofectamine (Invitrogen) using OPTI-MEM
without serum. 6 hr after transfection the media was
replenished with an equal volume of OPTI-MEM con-
taining 2X serum and cultured for 24 to 48 hr. At the
end of the time period cells were harvested in sample
buffer and analyzed by western blot for downregulation
of the kinases using the corresponding kinase antibody
and phosphorylation of APP by Thr668 P-APP antibody.
Statistical analysis was performed using Student’s t-
Test.
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Abstract
Alzheimer’s disease (AD) is the most prevalent form of dementia in the elderly. Amyloid plaque
formation through aggregation of the amyloid beta peptide derived from amyloid precursor protein
(APP) is considered one of the hallmark processes leading to AD pathology; however, the precise
role of APP in plaque formation and AD pathogenesis is yet to be determined. Using stable
isotope labeling by amino acids in cell culture (SILAC) and mass spectrometry, protein expression
profiles of APP null, rat neuronal-like B103 cells were compared to B103-695 cells which express
the APP isoform, APP-695. A total of 2,979 unique protein groups were identified among 3
biological replicates and significant protein expression changes were identified in a total of 100
non-redundant proteins. Some of the top biological functions associated with the differentially
expressed proteins identified include cellular assembly, organization and morphology, cell cycle,
lipid metabolism, protein folding, and posttranslational modifications. We report several novel
biological pathways influenced by APP-695 expression in neuronal-like cells and provide
additional framework for investigating altered molecular mechanisms associated with APP
expression and processing and contribution to AD pathology.
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1. Introduction
Alzheimer’s disease is the most common form of dementia that affects elderly and is
associated with cognitive decline and loss of executive function. The two major pathological
characteristics of the disease are the presence of neuritic plaques and neurofibrillary tangles
(NFT) in the areas of the brain associated with learning and memory [1–3]. Neuritic plaques
are formed by extracellular accumulation of amyloid beta, a peptide derived from amyloid
precursor protein (APP). APP is a single transmembrane domain protein that is expressed at
high levels in brain. Studies in Alzheimer’s disease brains have shown that APP is cleaved
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by beta (BACE) and gamma secretases to generate amyloid beta (Aβ), a peptide fragment
that is 40–42 amino acids long (Aβ40 and Aβ42) [4–8]. In addition to beta and gamma
secretases, APP is also cleaved by alpha secretase; this secretase cleaves APP within the Aβ
domain and thus excludes the formation of Aβ from APP. The secretase-cleavages of APP
generate ectodomains and intracellular domains of APP in addition to Aβ (Fig. 1a). APP has
been reported to enhance neurite outgrowth, inhibit neurodegeneration and exert anti-
apoptotic activity. Of the different APP fragments, Aβ and AICD (APP intra cellular
domain) have been shown to enhance neurodegeneration while the secreted alpha-cleaved
ectodomain of APP (sAPPα) has been shown to have growth promoting activity.
A number of factors such as age, environment, and inflammatory proteins appear to affect
the onset of Alzheimer’s disease (AD). Several independent studies have shown that cell
cycle deregulation correlates with pathology development in AD. Analysis of brains from
AD patients and mice expressing AD transgenes have shown increased expression of cell
cycle regulatory proteins in neurons, which correlated with APP and tau phosphorylation
and pathology development [9–21]. We recently showed that phosphorylation and cellular
distribution of APP are affected in a cell cycle-dependent manner and this is associated with
altered processing of APP [10]. The discoveries demonstrating that cells expressing APP
show enhanced growth rate and the observation that APP localizes to centrosomes under
mitotic conditions led to the hypothesis that it may play a role in cell cycle progression. The
exact role of APP in cell cycle activation and cell proliferation is not yet identified. Here we
sought to determine the mechanism(s) by which APP affects cellular functions using APP
null B103 nerve cells.
Elegant studies by Schubert and colleagues have shown that B103 nerve cells do not express
either APP or the APP like proteins APLP1 or APLP2 [22]. Therefore, these cells are
appropriate for studying the cellular functions of APP. These investigators showed that
expression of APP in B103 cells enhances cell adhesion, neurite outgrowth, and cell
proliferation but the molecular mechanisms by which APP induces these cellular functions
are not quite clear. It is possible that APP or a metabolite of APP can induce these either by
itself or by affecting expression of genes associated with these functions. In order to
determine whether APP affects expression of proteins associated with cell adhesion or cell
cycle progression or cell signaling processes in general, we performed an unbiased, global-
scale analysis to assess APP-mediated protein expression changes in B103 cells. We used
the stable isotope labeling by amino acids in cell culture (SILAC) approach for comparing
the protein complement of B103 cells expressing the 695 isoform of APP (referred to as
B103-695) to B103 APP null cells (referred to as B103) as shown in Fig. 1b. The advantage
of this approach is that B103 cells can be grown in media containing normal or “light”
versions of amino acids and B103-APP in media with “heavy” amino acids. The labeled
(heavy) amino acids are added to media that are deficient in specific amino acids (in this
case L-arginine and L-lysine) and the cells metabolically incorporate these amino acids
during protein synthesis. This technique allows one to differentiate proteins from one cell
system to the other and analyze both simultaneously using tandem mass spectrometry. This
approach decreases experimental variability that occurs during sample processing and
provides more consistent and reliable data for relative protein quantitation. Here we provide
evidence for protein expression changes in B103 cells expressing APP-695 versus APP null
cells and validate changes in selected proteins involved in cell signaling as well as cell
morphology, assembly and organization.
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2. Materials and Methods
2.1 Cell Culture and SILAC Labeling
B103 and B103-695 rat neuroblastoma cells were initially cultured in DMEM/F12 (1:1)
media supplemented with 10% FBS, 50U/ml penicillin and 50µg/ml streptomycin, at 37°C
and 5% CO2 [23]. Cells were grown in T75 cm2 flasks to near confluence, and then split
into 3 × T75 cm2 flasks for stable isotope labeling with heavy or light amino acids in cell
culture (SILAC).
B103 and B103-695 cells were labeled for quantitation using SILAC media supplemented
with 10% dialyzed FBS, pen/strep, and either L-lysine and L-arginine for B103 or 13C6-L-
Lysine 2HCl and 13C6-15N4-Arginine HCl for B103-695 cells (Thermo Scientific). Cells
were grown in SILAC media for 7 days, during which they were passaged once and media
was changed every 48 hours, for a minimum of 5 doublings, corresponding to > 98%
labeling efficiency.
Cells were collected using Trypsin-EDTA and washed 3 times with PBS to remove serum
proteins. Cells were lysed in 250µl of 100mM Tris-HCl (pH 7.6) containing 4% SDS, 100
mM dithiothreitol (DTT), and Halt protease inhibitor cocktail (Pierce) at 95°C for 5 minutes.
Lysed samples were briefly sonicated. Protein concentrations were determined using the
Pierce 660nm protein assay with the ionic detergent compatibility reagent (Pierce). These
experiments were done in triplicate.
2.2 Sample Preparation
Whole cell lysates were digested using the filter-aided sample preparation (FASP) kit
(Protein Discovery), as developed by Wisniewski and Mann [24]. Four digestions of
approximately 100µg of protein were performed for each biological replicate, which were
then pooled for a total of 400µg per biological replicate. Thirty microliters of protein sample
and 8 M urea were mixed and added to the 30kDa FASP spin filter for buffer exchange.
Samples were alkylated according to manufacturer’s instructions with iodoacetamide (IAA)
for 30 minutes in the dark. Following alkylation, samples underwent further buffer exchange
with 3 × 100 µl additions of 50 mM ammonium bicarbonate, followed by centrifugation at
14,000 × g for 10 minutes. Samples were incubated with trypsin at 1:100 (w:w,
trypsin:protein) for proteolytic digestion of proteins and incubated overnight at 37°C.
Peptides were collected by centrifugation with the addition of 2 × 40 µl 50 mM ammonium
bicarbonate and 40 µl NaCl. Peptides were desalted using Supelco Discovery DSC-18 solid-
phase extraction columns in combination with a Supelco vacuum manifold. Samples were
dried using a vacuum concentrator (Thermo) and resuspended in 20 µl of 0.1% formic acid
in H2O.
Peptides were fractionated on a Dionex U3000 HPLC system with a 150 cm × 1.0 mm i.d.
strong cation-exchange (SCX) column (PolyLC Inc.) packed with 5 µm 300 Å
polySULFOETHYL A-SCX material. Two minute fractions were collected using a 30
minute gradient, where ammonium formate increased from 15–200 mM in 25% acetonitrile
(ACN) at a flow rate of 250 µl/min. Ten peptide-containing fractions were selected for LC-
MS/MS analysis from each biological replicate (n=3 total). Peptides were again dried in a
vacuum concentrator and resuspended in 10µl of 0.1% formic acid in H2O.
2.3 LC-MS/MS
SCX peptide fractions were separated on a 10 cm × 75 µm i.d. reversed-phase column (New
Objective) packed with 5 µm 300 Å C18 material (ProteoPep II). Tandem mass
spectrometric analysis was carried out using a hybrid linear ion trap-Orbitrap instrument
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(LTQ Orbitrap XL, Thermo). A 90 minute gradient was used, where 0.1% formic acid in
ACN increased from 2 to 40%, increasing to 80% at 95 minutes through 100 minutes.
Orbitrap full MS scans were collected at a mass resolving power of 60,000, with positive
polarity in profile mode, and a scan range of m/z 350–1500. The top 5 most abundant ions
were selected for further fragmentation in the ion trap. Global settings include dynamic
exclusion of 90 seconds, with an exclusion list size of 500, and a repeat count of 2.
2.4 Database Searching and Pathway Analysis
Raw files were processed in MaxQuant version 1.2.0.13, a quantitative proteomics software
package for the analysis of large, high resolution MS data sets [25]. The raw files were
processed and searched against the current UniprotKB database containing Rattus
norvegicus protein sequences as well as a second MaxQuant database of known
contaminants. The search parameters included a constant modification of cysteine by
carbamidomethylation and variable modification of methionine oxidation. Additional
parameters include multiplicity set to 2, with a heavy set of lysine-6 and arginine-10. The
search tolerance was set to 8 ppm and the fragment ion mass tolerance was set to 0.5 Da
with a false discovery rate (FDR) of < 1%.
Statistical analysis was carried out using Perseus software, which assesses the statistical
significance of protein expression based on the approach developed by Benjamini and
Hochberg [26]. A threshold q-value of 0.05 for the Benjamini-Hochberg false discovery rate
was used. Functional and pathway analysis of identified proteins was carried out using
Ingenuity Pathway Analysis (IPA, Ingenuity Systems).
2.5 Western Blotting
Proteins were selected for Western blot validation of protein expression changes based on
significance as well as function. Twenty micrograms of B103 and B103-695 cell lysate were
separated on a 15% Tris/Glycine SDS-PAGE gel, run at 90V for 90 minutes. Proteins were
semi-wet transferred to a nitrocellulose membrane (Whatman) at 30V for 90 minutes. The
membrane was subsequently blocked in 5% non-fat milk-TBS for 1 hour at room
temperature, and washed using PBS containing Tween 20 (PBST). Primary antibodies
specific for Ras (Abcam, mouse monoclonal, 1:1000), P-ERK and ERK44/42 (Cell
Signaling, rabbit polyclonal, 1:1000), and actin (Sigma, mouse monoclonal, 1:7000) were
diluted in 3%BSA/TBS/0.02% sodium azide and incubated overnight at 4°C. Membranes
were then incubated with corresponding anti-rabbit (Pierce) and anti-mouse (Pierce)
secondary antibodies for 90 minutes at room temperature and washed thoroughly. The blots
were developed using the Super Signal chemiluminescence reagents (Pierce).
2.6 Immunostaining analysis
B103 and B103-695 cells were plated onto poly-lysine coated 8 chamber slides and cultured
overnight in DMEM/F12 (1:1) medium with serum and Pen-Strep. After 24 hrs of culturing,
cells were washed with PBS and fixed with 4% para-formaldehyde for 10 minutes at room
temperature. At the end of the fixation, cells were washed and incubated in 1% BSA in TBS
containing 0.1 % Triton X-100 (BSA/TBST) to block any non-specific binding. After 1 hr
incubation at room temperature, γ-synuclein (Millipore, rabbit monoclonal,1:500) and actin
(Sigma, mouse monoclonal, 1:500) antibodies diluted in BSA/TBST was added to the cells
and incubated overnight at 4°C by gentle rocking. The slides were washed with PBS
thoroughly and incubated with Alexa Fluor 488 anti-mouse and Alexa Fluor 594 anti-rabbit
secondary antibodies (Invitrogen/Gibco) for 1–2 hr at room temperature in the dark. At the
end of the incubation cells were washed again and incubated with 1 µg/ml Hoechst 33258,
diluted in PBS, for 10 minutes at room temperature protected from light. After further
washes, the slides were mounted using Fluoro-gel mounting media (Electron Microscopy
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Sciences) and analyzed under a Zeiss Fluorescent microscope using AxioVision Rel 4.8
software program.
3. Results and Discussion
3.1 B103 and B103-695 proteome comparison
A total of 2979 protein groups were identified among 3 biological replicates, excluding
contaminants and false positive (reverse sequence) identifications (listed in Supplementary
Table 1). Biological replicates A, B, and C identified 2549, 2335, and 2542 protein groups,
respectively. Over 1900 protein groups were shared by all 3 biological replicates. Replicates
A and B shared 2053, replicates A and C shared 2228, and replicates B and C shared 2080
protein groups. The overlap of protein identifications between biological replicates is
demonstrated by the Venn diagram shown in Fig. 2.
Perseus was used to identify proteins with statistically significant changes in expression
across multiple biological replicates. Two significance tests were employed, Significance A
and Significance B, where the A significance gives no weight to signal intensity and B
significance is weighted by signal intensity. Significance A test identified 79 significant
proteins, while 83 significant proteins were identified using Significance B, for a combined
total of 100 non-redundant proteins that were differentially expressed in B103-695 cells
(listed in Supplementary Table 2). Of the 100 differentially expressed proteins, 8 proteins
were downregulated and 92 proteins were upregulated.
3.2 Functional enrichment
Several proteins that are important in cellular and molecular functions including cellular
assembly and organization, cell cycle, cell morphology, lipid metabolism, protein folding,
and post translational modifications were identified as having differential expression upon
proteome comparison in B103 and B103-695 cells using IPA (Fig. 3). Lipids and lipid
carriers have been shown to play a role in AD pathology development. People with high
cholesterol levels are at high risk of developing AD and studies in mouse models of AD
have shown that drugs that lower cholesterol levels can reduce the levels of A-beta and
therefore plaque pathology [27]. Studies in AD patients have shown that people carrying the
apolipoproteins E4 allele (ApoE4) are more prone to get the disease than those carrying
apolipoprotein E2 or E3 allele. ApoE is the major apolipoprotein in the brain and is the
protein component of the lipids such as very low density lipoprotein (VLDL). Although this
led to the hypothesis that ApoE4 is a genetic risk factor for AD it does not mean that all the
ApoE4 carriers do get the disease. The exact mechanism by which ApoE4 affects pathology
development in AD is not clear. It has been shown that ApoE4 promotes the aggregation of
amyloid β and therefore accelerates plaque pathology and cognitive deficit. Lipids seem to
play a role in not only the aggregation of amyloid β but also its generation. Studies have
shown that APP, beta-secretase (BACE) and γ-secretase co-localize in the lipid rich raft
domains leading to enhanced amyloidogenic processing of APP whereas α-secretase-
mediated cleavage occurs at membrane domains outside of the lipid rafts. Regarding
proteins associated with lipid metabolism, our analysis showed that the sterol O-acetyl
transferase 1 (SOAT1) and Acyl CoA: cholesterol acyl transferase 2 (ACAT2) are induced
by ~2.5 to 3 fold in B103-695 cells. Studies by others have shown that an increase in
SOAT1 is associated with an increase in APP processing to generate amyloid β, and a
downregulation of SOAT1 using siRNA descreased generation of amyloid β, suggesting a
role for this enzyme in pathology development in AD. Similarly, studies have shown that
ACAT2 can more efficiently esterify cholesterol than ACAT1, which is more efficient in
esterification of sitosterol [28]. This again suggests that the cholesterol modifying enzymes
are induced by APP expression in B103 cells implying a role for APP in altered lipid
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metabolism. Many of the proteins identified are also involved in regulating physiological
system development and function processes such as connective tissue, cardiovascular
system, and nervous system development and function, as well as embryonic tissue
development (Fig. 3).
IPA also identified significant canonical pathways associated with a number of identified
proteins that were differentially expressed including CDK5 signaling, cell cycle G2/M DNA
damage checkpoint regulation, actin cytoskeleton signaling, protein kinase A signaling and
ERK5 signaling as shown in the selected canonical pathways in Fig. 3. CDK5 signaling is
involved in cell differentiation and morphology regulation and has been implicated in
neuron degeneration [29]. CDK5 signaling is important for proper brain development and
dysregulation in CDK5 leads to defects in cell migration, plasticity, and other neurological
defects [5][30–32]. Additionally, actin cytoskeleton and protein kinase A signaling were
also over-represented from the SILAC dataset. Actin cytoskeleton signaling is associated
with cell motility, axon guidance, cellular assembly, organization, function, and
maintenance whereas protein kinase A is a serine/threonine kinase that functions as a second
messenger regulating a variety of diverse functions including growth, development, and
memory. Interestingly, the G2/M DNA damage checkpoint was identified as a potential
altered pathway from the SILAC dataset as well and provides additional evidence of the
involvement of cell cycle-dependent mechanisms upon APP expression in this cell model
system. The G2/M DNA damage checkpoint is the second checkpoint within the cell cycle
and is important for maintaining genomic stability as it prevents damaged DNA from
entering M-phase.
3.3 Pathway analysis reveals APP-mediated alterations in cell morphology and Ras
signaling
The top protein interaction network identified using IPA is primarily involved in cell
morphology, assembly, and organization, as well as nervous system development and
function which is shown in Fig. 4. Proteins of particular interest include γ-synuclein and
Ras, which are both found to be upregulated in B103-695 cells. Western blots were
performed to validate the increased expression of γ-synuclein and Ras in B103-695 cells.
While Ras showed a significant increase by western blot analysis (Fig 5b), we were unable
to detect the γ-synuclein with this technique. We believe that this is due to the limited
antibody reactivity on western blots as immunostaining analysis using the anti-γ-synuclein
antibody showed a significant increase in this protein in B103-695 cells compared to B103
(Fig. 5a). Co-staining of the cells with an actin antibody showed altered actin staining in
B103-695, providing some additional support to the functional enrichment analysis results in
which actin cytoskeleton signaling and subsequent cytoskeletal organization could
potentially be altered through APP expression.
Gamma synuclein, a member of the synuclein family, was the most significantly up-
regulated protein, showing a 59.6 fold increase. Increased expression of γ-synuclein mRNA
has been observed in the brains of Alzheimer’s disease patients, supporting its potential
contribution in AD pathology [33]. γ-synuclein has also been shown to bind microtubule
and promote tubulin polymerization and cell adhesion [34]. Studies in cancer cells have
shown that it enhances cell migration and protects against mitotic inhibitor-mediated
apoptosis. It was initially identified as a breast cancer specific gene (BCSG1) and was
associated with breast tumor progression [35, 36]. γ–synuclein has been shown to interact
with the checkpoint protein BubR1 to bring about the defects in mitosis [37, 38].
Ras, a small GTPase, is involved in signal transduction regulating cell growth,
differentiation, and survival. Increased Ras expression has been implicated in AD brains but
the functional significance of this in AD pathology development is not known [39].
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Interestingly, nerve growth factor receptor (NGFR) protein in the plasma membrane, which
is upregulated in our dataset as a result of APP expression in B103 cells, has been shown to
increase activation of Ras protein(s) in the cytoplasm [40]. Ras activation consequently
results in increased MAP-kinase activity. It is possible that a Ras-mediated cell signaling
cascade may play a role in the aberrant cell cycle activation and neurodegeneration
associated with pathology development in AD.
MAPK functions downstream from Ras in signal transduction pathway and responds to
extracellular signals by inducing different cellular functions such as proliferation, mitosis,
differentiation and apoptosis. Ras activation of the mitogen-activated protein kinase
(MAPK) signaling pathway has been well established. Although the Ras – MAPK signaling
pathway has a well-known role in cancer, there is increasing evidence for its involvement in
neurodegenerative disease as well [41]. The Ras – MAPK signaling pathway has been found
to be induced during very early stages of AD, prior to the formation of plaques and tangles
[42, 43]. MAP-kinase is also involved in the regulation of γ-synuclein mRNA expression
[44]. Analysis of the active phosphorylated form of mitogen activated protein kinase P44/42
MAPK (ERK1/2) showed that it is significantly induced in B103-695 cells while the non-
phospho ERK levels were unaffected by APP expression (Fig 5b). Given potential crosstalk
between PKA and MAPK signaling, we also investigated the impact of siRNA-mediated
knockdown and chemical inhibition of PKA and found no effect on ERK phosphorylation
status (data not shown). These findings suggest that APP expression specifically affects
activation of ERK and do not have any effect on the expression of the protein.
Down-regulated proteins in this pathway (Fig 4) include PD2 and LIM domain 1 (PDLIM1)
protein, a transcription regulator that has been shown to be responsive to hypoxia and also
oxidative stress [45]. Differential PDLIM1 mRNA expression in human vastus lateralis
muscle has been associated with Huntington's disease, making PDLIM1 a potential
biomarker [46]. SYNCRIP is a member of the heterogeneous nuclear ribonuceloprotein
(hnRNP) family, and was recently identified in a microarray study as a gene potentially
involved in AD [47]. Our SILAC study provides additional evidence for these potential
markers of AD at the protein level.
3.4 Implications in Alzheimer’s Disease
Bioinformatic analysis of the 100 statistically significant proteins identified numerous
proteins with roles in a variety of neurological diseases. We have listed differentially
expressed proteins from our SILAC analysis that have been implicated in neurodegenerative
disease in Table 1, reporting only those proteins with ratios having less than 30% relative
standard deviation values. For example, hypoxanthine phosphoribosyltransferase 1 (HPRT1)
was increased 10 fold and nerve growth factor receptor (NGFR) was increased 3.5 fold, and
both of these proteins have been associated with neurodegeneration [48]. Nerve growth
factor receptor as well as γ-synuclein also have emerging roles in AD [49]. There are two
different types of nerve growth factor receptors; the low affinity nerve growth factor
receptor, also known as p75NTR, which binds all neurotrophins and the Trk family of
tyrosine kinase receptors which bind specific neurotrophins. Both of these receptors have
been associated with neurodegeneration and implicated in AD pathology as these receptors
bind amyloid β, and are upregulated in AD [50, 51].
B103 cells expressing APP showed a decrease in Reticulon 4 (RTN4), an endoplasmic
reticulum (ER) associated protein that is involved in neuroendocrine secretion. RTN4 has
been shown to inhibit neurite outgrowth, and consequently has also been named neurite
outgrowth inhibitor or Nogo. Increased expression of RTN4 has been shown to decrease
amyloid-β peptide production by reducing β-amyloid converting enzyme 1 (BACE1)
activity [52]. Park and colleagues found that RTN4 and its receptor RTN4R demonstrate
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altered subcellular localization in AD. In normal brain RTN4 shows reduced cellular and
enhanced neuropil localization whereas in AD brain it shows enhanced cellular localization.
Similarly, while RTN4R is mainly localized to cell soma in normal brain it showed reduced
cellular localization with more diffused staining in the neuropil and plaques in AD brain.
RTN4R was also found to physically interact with APP and amyloid-β, limiting amyloid-β
accumulation [53]. Another protein that showed downregulation in the B103-695 cells is the
eukaryotic translation initiation factor 4A2 (eIF4A2), which showed a 7.98 fold decrease
and is also associated with the ER. A decrease in expression of the proteins associated with
ER may indicate that expression of APP leads to an induction of ER stress. ER responds to
stress by activating various signaling pathways including the unfolded protein response
(UPR), which leads to attenuation of protein translation. Studies have shown that APP
induces ER stress-mediated apoptosis in cells and further studies are necessary to confirm
that APP expression in B103 cells lead to an induction in ER stress-associated signaling
pathways [54]. In AD, ER stress has been shown to induce inflammation, which leads to
enhanced pathology development in AD. eIF4A2 has been suggested as one of 2 suitable
reference genes for RT-qPCR studies in human AD post mortem brain samples, as its
mRNA is stably expressed [55].
Analyses of AD brains have shown aberrant expression of cell cycle regulatory proteins in
neurons. The roles of the cell cycle regulators in neurons as well as the mechanisms that lead
to the induced expression of these proteins are not known. It is possible that either APP or a
metabolite of APP may enhance expression of proteins such as γ-synuclein and Ras, thus
affecting cell proliferation in transformed cells and degeneration in terminally differentiated
cells. γ-synuclein has already been shown to bind and alter microtubule dynamics. Our co-
immunostaining analysis with actin and γ-synuclein antibodies show altered localization of
actin in the cells expressing APP. This is a significant finding and suggests that APP-
mediated induction in γ-synuclein may lead to alterations in cytoskeletal and microtubule-
associated proteins, which in turn affects neuronal signaling and synaptic function in AD.
Since γ-synuclein affects the mitotic checkpoint, it is possible that the neuronal expression
of this protein may not only alter the neuronal cytoskeleton but also affect the differentiation
state of neurons. Neurons are terminally differentiated cells and do not have an active cell
cycle machinery and therefore may respond to cell cycle activation by undergoing apoptosis
instead of transformation. In addition to a role in AD, studies from different groups have
shown that cancers of different organs show increased levels of APP or a metabolite of APP.
Thus, a careful analysis of APP function may enhance our knowledge on the role of APP in
bringing about pathologies associated with not only AD but also cancers of different organs.
4. Concluding Remarks
This study represents the first comprehensive proteomic analysis of B103 and B103-695 rat
neuronal-like cells, including relative quantitation of protein expression using SILAC-based
proteomics. Several proteins were identified as being significantly upregulated or
downregulated in B103-695 cells, many with potential implications in AD pathology. The
comprehensive dataset provides insight into proteins that may be affected by APP-695
expression and provides a foundation for future mechanistic studies. The proteins identified
are associated with a number of diverse processes including cellular assembly and
organization, cell cycle, lipid metabolism, protein folding, post translational modifications,
as well as physiological system development and function. These findings suggest that
several different processes are influenced by APP expression, which may contribute to
synaptic dysfunction, amyloid plaque formation, and AD pathology.
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Figure 1.
a) Schematic of proteolytic processing of amyloid precursor protein (APP) by alpha,
gamma, and beta secretases. b) SILAC experimental workflow used for differential protein
expression profiling in B103 cells expressing APP-695.
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Figure 2.
Venn diagram representing the number of unique protein groups identified in biological
replicate A, B, and C, and the overlap of proteins identified between the biological
replicates.
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Figure 3.
Ingenuity Pathway Analysis of APP-mediated differential protein expression in B103 cells
showing over-represented categories associated with a) molecular and cellular function, (b)
physiological system development and function, (c) canonical pathways, and (d) cell
localization.
Chaput et al. Page 14
Electrophoresis. Author manuscript; available in PMC 2013 December 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 4.
Top-scoring pathway from Ingenuity Pathway Analysis associated with cellular assembly
and organization based on differentially expressed proteins identified from B103 cells
expressing APP-695. The network diagram uses different shapes to represent protein
functions: enzymes (diamond), kinases (inverted triangle), transporters (trapezoid), and
other (circles). Single lines represent protein-protein interactions; solid or dashed lines
represent direct or indirect interactions, respectively. Proteins that regulate another protein
are indicated by arrows.
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Figure 5.
(a) Immunostaining: B103 and B103-695 cells were co-immunostained using γ-synuclein
(rabbit polyclonal) and actin (mouse monoclonal) primary antibodies and Alexa Fluor 594
anti-rabbit and Alexa Fluor 488 anti-mouse secondary antibodies. Hoechst was used to
visualize the nuclei. The expression of γ-synuclein was significantly higher in B103-695
than that in B103 cells and it seems to localize to the nucleus and cytoplasm. Images were
taken on a Zeiss fluorescent microscope fitted with an Axiocam MRm camera and analyzed
using AxioVision Rel 4.8 software (magnification: 63×). The bar graph shows the percent
increase in γ-synuclein intensity measured using ImageJ, image analysis tool, after
converting the images to 8 bit gray. The intensity of γ-synuclein in three independent
images taken from B103 and B103-695 cells were normalized to the intensity of Hoechst
within the same sample for comparison. (b) Western blot validation: Equal amounts of
proteins from B103 and B103-695 cell extracts done in quadruplicate were separated on a 15
% Tris-glycine gel and probed with Ras, and P-ERK antibodies. Both Ras and P-ERK were
significantly increased in B103-695 cells compared to B103 cells (bar graphs labeled Ras
and P-ERK). Re-probe of the Ras blot with actin antibody shows equal amount of proteins
on gel and re-probe of P-ERK blot with ERK antibody shows no change in expression of
ERK upon expression of APP (bar graph labeled ERK).
Chaput et al. Page 16
Electrophoresis. Author manuscript; available in PMC 2013 December 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Chaput et al. Page 17
Ta
bl
e 
1
Se
le
ct
ed
 d
iff
er
en
tia
lly
 e
xp
re
ss
ed
 p
ro
te
in
s i
m
pl
ic
at
ed
 in
 n
eu
ro
de
ge
ne
ra
tiv
e 
di
se
as
e 
th
at
 w
er
e 
id
en
tif
ie
d 
in
 B
10
3–
69
5 
ce
lls
 u
sin
g 
SI
LA
C-
ba
se
d 
qu
an
tit
at
iv
e
pr
ot
eo
m
ic
 a
na
ly
sis
.
Fo
ld
C
ha
ng
e
St
an
da
rd
D
ev
ia
tio
n
ID
Sy
m
bo
l
En
tr
ez
 G
en
e N
am
e
Lo
ca
tio
n
59
.6
50
10
.1
7
F1
LQ
96
SN
CG
sy
nu
cl
ei
n,
 g
am
m
a 
(br
ea
st 
ca
nc
er-
sp
ec
ifi
c p
rot
ein
 1)
Cy
to
pl
as
m
11
.4
33
2.
78
Q8
11
A3
PL
O
D
2
pr
oc
ol
la
ge
n-
ly
sin
e,
 2
-o
xo
gl
ut
ar
at
e 
5-
di
ox
yg
en
as
e 2
Cy
to
pl
as
m
8.
36
3
0.
78
F1
LS
L3
IT
PR
3
in
os
ito
l 1
,4
,5
-tr
isp
ho
sp
ha
te
 re
ce
pt
or
, t
yp
e 3
Cy
to
pl
as
m
7.
95
3
0.
78
B
2B
9B
0
EP
H
B
2
EP
H
 re
ce
pt
or
 B
2
Pl
as
m
a 
M
em
br
an
e
4.
28
4
0.
65
D
3Z
Z6
3
FL
N
C
fil
am
in
 C
, g
am
m
a
Cy
to
pl
as
m
3.
81
9
0.
41
F1
M
A
96
N
CA
M
1
n
eu
ra
l c
el
l a
dh
es
io
n 
m
ol
ec
ul
e 
1
Pl
as
m
a 
M
em
br
an
e
3.
77
0
0.
85
P5
04
42
G
A
TM
gl
yc
in
e 
am
id
in
ot
ra
ns
fe
ra
se
 (L
-ar
gin
ine
:gl
yc
ine
 am
idi
no
tra
ns
fer
ase
)
Cy
to
pl
as
m
3.
63
8
0.
52
F1
LN
X
0
D
D
A
H
1
di
m
et
hy
la
rg
in
in
e 
di
m
et
hy
la
m
in
oh
yd
ro
la
se
 1
Cy
to
pl
as
m
3.
54
7
0.
21
Q5
HZ
V9
PP
P1
R7
pr
ot
ei
n 
ph
os
ph
at
as
e 
1,
 re
gu
la
to
ry
 su
bu
ni
t 7
N
uc
le
us
3.
51
9
0.
15
P0
71
74
N
G
FR
n
er
v
e 
gr
ow
th
 fa
ct
or
 re
ce
pt
or
Pl
as
m
a 
M
em
br
an
e
2.
97
0
0.
59
P7
06
36
LA
M
A
5
la
m
in
in
, a
lp
ha
 5
Ex
tra
ce
llu
la
r S
pa
ce
2.
87
2
0.
27
Q6
M
G6
0
D
D
A
H
2
di
m
et
hy
la
rg
in
in
e 
di
m
et
hy
la
m
in
oh
yd
ro
la
se
 2
u
n
kn
ow
n
2.
76
8
0.
17
F1
M
5W
8
A
FA
P1
L2
ac
tin
 fi
la
m
en
t a
ss
oc
ia
te
d 
pr
ot
ei
n 
1-
lik
e 
2
Cy
to
pl
as
m
2.
76
5
0.
08
P0
59
42
S1
00
A
4
S1
00
 c
al
ci
um
 b
in
di
ng
 p
ro
te
in
 A
4
Cy
to
pl
as
m
2.
65
7
0.
43
F1
LN
U
6
FA
D
S2
fa
tty
 a
ci
d 
de
sa
tu
ra
se
 2
Pl
as
m
a 
M
em
br
an
e
2.
65
3
0.
42
Q8
0W
E1
FM
R
1
fra
gi
le
 X
 m
en
ta
l r
et
ar
da
tio
n 
1
N
uc
le
us
2.
55
7
0.
17
F1
LY
K
7
CF
L2
co
fil
in
 2
 (m
us
cle
)
N
uc
le
us
2.
37
5
0.
40
F1
LZ
M
7
H
SD
L2
hy
dr
ox
ys
te
ro
id
 d
eh
yd
ro
ge
na
se
 li
ke
 2
Cy
to
pl
as
m
2.
31
7
0.
19
D
4A
4T
0
ST
U
B1
ST
IP
1 
ho
m
ol
og
y 
an
d 
U
-b
ox
 c
on
ta
in
in
g 
pr
ot
ei
n 
1,
 E
3 
ub
iq
ui
tin
 p
ro
te
in
 li
ga
se
Cy
to
pl
as
m
2.
30
9
0.
10
Q9
1Z
N1
CO
RO
1A
co
ro
n
in
, a
ct
in
 b
in
di
ng
 p
ro
te
in
, 1
A
Cy
to
pl
as
m
2.
29
8
0.
22
F1
LV
02
D
B
I
di
az
ep
am
 b
in
di
ng
 in
hi
bi
to
r (
GA
BA
 re
ce
pto
r m
od
ula
tor
, a
cy
l-C
oA
 bi
nd
ing
 pr
ote
in)
Cy
to
pl
as
m
2.
29
2
0.
18
F1
LN
D
7
FD
PS
fa
rn
es
yl
 d
ip
ho
sp
ha
te
 sy
nt
ha
se
Cy
to
pl
as
m
2.
20
6
0.
17
Q6
8G
41
EC
I1
en
o
yl
-C
oA
 d
el
ta
 is
om
er
as
e 
1
Cy
to
pl
as
m
2.
15
6
0.
38
Q4
G0
53
SA
M
D
9L
st
er
ile
 a
lp
ha
 m
ot
if 
do
m
ai
n 
co
nt
ai
ni
ng
 9
-li
ke
u
n
kn
ow
n
2.
14
4
0.
16
P4
06
15
D
K
C1
dy
sk
er
at
os
is 
co
ng
en
ita
 1
, d
ys
ke
rin
N
uc
le
us
Electrophoresis. Author manuscript; available in PMC 2013 December 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Chaput et al. Page 18
Fo
ld
C
ha
ng
e
St
an
da
rd
D
ev
ia
tio
n
ID
Sy
m
bo
l
En
tr
ez
 G
en
e N
am
e
Lo
ca
tio
n
2.
11
8
0.
08
P1
08
68
G
A
M
T
gu
an
id
in
oa
ce
ta
te
 N
-m
et
hy
ltr
an
sf
er
as
e
Cy
to
pl
as
m
2.
07
2
0.
06
Q6
30
81
PD
IA
6
pr
ot
ei
n 
di
su
lfi
de
 is
om
er
as
e 
fa
m
ily
 A
, m
em
be
r 6
Cy
to
pl
as
m
1.
88
0
0.
03
P1
32
33
CN
P
2'
,3
'-c
yc
lic
 n
uc
le
ot
id
e 
3' 
ph
os
ph
od
ie
ste
ra
se
Cy
to
pl
as
m
1.
86
5
0.
03
D
4A
BV
5
Ca
lm
1
ca
lm
od
ul
in
 1
N
uc
le
us
1.
85
3
0.
05
D
3Z
M
53
Y
w
ha
q
ty
ro
sin
e 
3-
m
on
oo
xy
ge
na
se
/tr
yp
to
ph
an
 5
-m
on
oo
xy
ge
na
se
 ac
tiv
at
io
n 
pr
ot
ei
n,
 th
et
a p
ol
yp
ep
tid
e
Cy
to
pl
as
m
1.
85
0
0.
21
D
4A
2V
9
G
PI
gl
uc
os
e−
6-
ph
os
ph
at
e i
so
m
er
as
e
Ex
tra
ce
llu
la
r S
pa
ce
1.
83
1
0.
28
P1
66
17
PG
K
1
ph
os
ph
og
ly
ce
ra
te
 k
in
as
e 
1
Cy
to
pl
as
m
1.
81
9
0.
13
P2
12
63
N
ES
n
es
tin
Cy
to
pl
as
m
1.
73
3
0.
13
P0
73
35
CK
B
cr
ea
tin
e 
ki
na
se
, b
ra
in
Cy
to
pl
as
m
1.
71
4
0.
10
O
35
24
4
PR
D
X
6
pe
ro
xi
re
do
xi
n 
6
Cy
to
pl
as
m
−
2.
01
5
0.
41
Q6
UR
K4
H
N
RN
PA
3
he
te
ro
ge
ne
ou
s n
uc
le
ar
 ri
bo
nu
cl
eo
pr
ot
ei
n 
A
3
N
uc
le
us
−
2.
14
3
0.
05
D
4A
8D
5
FL
N
B
fil
am
in
 B
, b
et
a
Cy
to
pl
as
m
−
2.
34
2
0.
03
F1
M
3G
6
H
SP
H
1
he
at
 sh
oc
k 
10
5k
D
a/
11
0k
D
a p
ro
te
in
 1
Cy
to
pl
as
m
−
2.
94
1
0.
06
Q5
U1
Z3
R
TN
4
re
tic
ul
on
 4
Cy
to
pl
as
m
−
3.
01
7
0.
10
Q7
TP
47
SY
N
CR
IP
sy
na
pt
ot
ag
m
in
 b
in
di
ng
, c
yt
op
la
sm
ic
 R
N
A
 in
te
ra
ct
in
g 
pr
ot
ei
n
N
uc
le
us
−
3.
61
5
0.
06
P5
29
44
PD
LI
M
1
PD
Z 
an
d 
LI
M
 d
om
ai
n 
1
Cy
to
pl
as
m
−
7.
97
7
0.
07
F1
LP
27
EI
F4
A
2
eu
ka
ry
ot
ic
 tr
an
sla
tio
n 
in
iti
at
io
n 
fa
ct
or
 4
A
2
Cy
to
pl
as
m
Electrophoresis. Author manuscript; available in PMC 2013 December 01.
Oncotarget8481www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 8
Potential role of PCTAIRE-2, PCTAIRE-3 and P-Histone H4 in 
amyloid precursor protein-dependent Alzheimer pathology
Dale Chaput1,*, Lisa Kirouac2,*, Stanley M. Stevens, Jr.1,** and Jaya Padmanabhan2,**
1 Department  of  Cell  Biology,  Microbiology,  and  Molecular  Biology,  University  of  South  Florida, Tampa, FL, USA
2 Department of Molecular Medicine, USF Health Byrd Alzheimer’s Institute, University of South Florida, Tampa, FL, USA
* Equal first author
** Equal last author
Correspondence to: Jaya Padmanabhan, email: jpadmana@health.usf.edu
Correspondence to: Stanley M. Stevens, Jr., email: smstevens@usf.edu
Keywords: Alzheimer’s disease, amyloid precursor protein, phosphoproteomics, A-beta, neurodegeneration, Gerotarget
Received: January 04, 2016 Accepted: January 30, 2016 Published: February 14, 2016
AbstrAct
Amyloid Precursor Protein (APP) is regulated in a mitosis-specific manner and 
plays a role in proliferative signaling in cells. Though APP-derived Aβ generation has a 
well-established role in neurodegeneration, the mechanistic role of APP in this process 
is not fully understood. Here, we performed an unbiased, comprehensive analysis of 
the phosphoproteome signature in APP-null neuroblastoma cells (B103) compared to 
those expressing APP-695 isoform (B103-695) to determine if APP expression affects 
protein phosphorylation. Stable isotope labeling by amino acids in cell culture (SILAC) 
followed by mass spectrometry-based phosphoproteomic analysis with PolyMAC 
identified a total of 2,478 phosphopeptides in the B103 and B103-695 cell culture 
model system. We observed that phosphorylation of PCTAIRE-2 (CDK17), PCTAIRE-3 
(CDK18), and Histone H4 are significantly elevated in B103-695 cells; western blot 
analysis confirmed overexpression of PCTAIREs and increased phosphorylation of 
Histone H4. More importantly, analysis of primary neurons treated with Aβ, as well 
as brain samples from MCI (mild cognitive impaired) and AD patients recapitulated 
these results, showing increased levels of PCTAIREs and P-Histone H4. These novel 
findings identify a hitherto uncharacterized mechanism by which APP and/or Aβ may 
promote AD neurodegeneration, and raises the possibility that their inhibition may 
protect against pathology development in AD.
IntroductIon
Alzheimer’s disease (AD) is the most prevalent form 
of dementia and causes deficits in memory and executive 
function. A central lesion in AD is the extracellular 
amyloid plaque, composed of aggregated Aβ peptide that 
accumulates in the brain before onset of disease symptoms 
[1]. Aβ is generated upon sequential cleavage of amyloid 
precursor protein (APP) by β-secretase and γ-secretase 
[2, 3]. When APP is cleaved by α-secretase within the Aβ 
domain, it liberates sAPPα and precludes the generation 
of Aβ [3]. Since APP expression leads to generation of not 
only full length APP but also APP fragments with various 
cellular functions, it is difficult to determine how the APP 
holoprotein and its metabolites differentially contribute to 
AD.
While genetic factors contributing to familial 
AD (FAD) are well described, little is known about the 
molecular processes leading to disease state in sporadic 
AD (SAD). In both subsets of AD, Aβ accumulation 
precedes formation of neurofibrillary tangles (NFTs), 
highlighting the role of Aβ in disease pathogenesis [4]. 
In early stages of AD, Aβ fibrils and oligomers induce 
microgliosis [5, 6] and this immune response can induce 
abnormal cell cycle events in compromised neurons of 
the AD brain [7-11]. Our earlier studies demonstrated that 
mouse models of AD, expressing APP alone or together 
with Presenilin 1 (PS1), show aberrant expression of 
cell cycle regulatory proteins with concomitant increase 
in phosphorylation of APP at Thr668 and association of 
P-APP with the centrosomes [12]. Phosphorylation of APP 
at this site is associated with altered APP trafficking and 
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enhanced proteolysis by β-secretase, [13-16].  Since Aβ 
is known to induce neuronal cell cycle entry [7, 17], this 
will further enhance APP phosphorylation and β-secretase-
mediated proteolysis to generate more Aβ, thereby feeding 
back to the vicious cycle of neurodegeneration.
Our published study, showing that APP promotes 
expression of proliferation-associated proteins, 
supports the notion that APP has a cell cycle regulatory 
function [18]. This study was carried out with B103 rat 
neuroblastoma cells that are null for or expressing the 
APP-695 (B103-695) isoform [19], using Stable Isotope 
Labeling by Amino Acids in Cell Culture (SILAC)-
based mass spectrometry. These findings indicate that 
APP expression induces signaling cascades that may be 
involved in cell cycle-mediated neuronal degeneration 
observed in AD. Since cell cycle deregulation and 
protein phosphorylation are fundamental to AD 
neurodegeneration, in the current study we analyzed 
global changes in protein phosphorylation upon 
APP expression using mass spectrometry-based 
phosphoproteomics. Mass spectrometry was used 
for identification of phosphopeptides from complex 
mixtures, including site localization and relative 
quantification. Phosphoproteomics involves enrichment 
of phosphopeptides to increase identification and 
sequence information, which is useful for bioinformatic 
analysis of affected pathways. Phosphoproteomics can 
identify potential changes in kinase activity by analysis 
of overrepresented phosphorylated consensus motifs 
[20]. Several phosphopeptide enrichment techniques 
are described, including antibody immunoaffinity 
enrichment, immobilized metal-affinity chromatography 
(IMAC) using Fe3+ metal ions [21-23], and metal oxide 
affinity chromatography (MOAC) using TiO2 [24, 25]. 
Currently, there are few phosphoproteomic studies related 
to AD. Here, we used a titanium-based nanopolymer 
phosphopeptide enrichment in combination with strong 
cation exchange (SCX). Phosphoproteomic analysis 
identified over 2000 phosphopeptides in SILAC-labeled 
B103 and B103-695 cells. Targeted validation of selected 
signaling markers in PS/APP mice, Aβ-treated primary 
neurons and human AD and MCI patient brain tissue 
provided insights into novel biomarkers associated with 
AD pathology.
results
b103 and b103-695 phosphoproteome comparison 
reveals differential phosphorylation of proteins in 
APP expressing cells
A total of 2478 phosphopeptides were identified 
among 3 biological replicates in B103 and B103-695 
cells; 1082 were quantified in a minimum of 2 biological 
replicates with a minimum ratio count of 2. Of the 1082 
phosphorylation sites confidently identified and quantified, 
712 of them corresponded to proteins previously quantified 
by SILAC in our global scale proteomic analysis of B103 
and B103-695 cells [18]. When possible, phosphosite 
ratios were normalized against corresponding protein 
ratios previously determined in the B103 and B103-695 
proteomic analysis. Perseus was used to identify significant 
changes in phosphopeptide expression across biological 
replicates using Significance A, a statistical outlier test, 
with a p-value threshold of 0.05. Significant changes 
were identified in 92 phosphosites corresponding to 71 
different proteins when using non-normalized ratios, and 
50 phosphosites corresponding to 46 proteins when using 
normalized ratios. Selected differentially phosphorylated 
sites, both normalized and non-normalized, are listed in 
Table 2. Bioinformatic analysis of statistically significant 
phosphosites was performed using Ingenuity Pathway 
Analysis (IPA) which identified several proteins associated 
with neurological disease and psychological disorders as 
well as molecular and cellular functions including cell 
morphology, cellular assembly and organization, function 
and maintenance, and growth and proliferation.
Our phosphoproteomic analysis identified a number 
of differentially phosphorylated proteins that have been 
previously associated with AD, including A-kinase 
anchor protein 12 (AKAP12), heat shock protein beta 1 
(HspB1) and myristoylated alanine-rich C-kinase substrate 
(MARCKS). AKAP 12 exhibited significantly increased 
phosphorylation at Ser507 (2.46-fold) in B103-695 cells 
after normalization against total protein expression. 
AKAP12 is a scaffolding protein that serves as a negative 
regulator of G1 to S cell cycle progression [26]. Increased 
phosphorylation of AKAP12 at Ser290 was also observed 
in an early phosphoproteomic study of human AD brain 
[27], however, the functional relevance of this residue 
is not known. B103-695 cells also showed increased 
phosphorylation of HspB1, a molecular chaperone 
involved in regulating cell proliferation and cytoskeletal 
reorganization at Ser15 (3.16-fold) and Ser86 (4.49-fold) 
[28-30]. A recent quantitative phosphoproteomic study 
of frontal cortex from human AD brains also identified 
increased phosphorylation of HspB1 at these sites [31]. 
MARCKS showed significant decrease in phosphorylation 
at several sites in B103-695 cells, however these 
phosphopeptide ratios were unable to be normalized 
against total protein levels. A previous study showed that 
human AD cortical neurons exhibited an overall decrease 
in MARCKS phosphorylation, however they also reported 
an increase in phosphorylation of this protein in microglia 
from AD brains [32]. Taken together, we have identified a 
number of differentially phosphorylated proteins that have 
previously been reported to show altered phosphorylation 
in AD, which provides confidence in our cell model 
for APP-related studies as well as the quality of our 
phosphoproteomic dataset.
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Figure 1: Growth-associated Histone H1 kinase substrate motif represented in APP-695 expressing b103-695 cells but 
not in APP-null b103 cells.
Table 1: Specifications on human brain tissue samples
case no. Age sex braak stage PMI MMse diagnosis
34 91 F 3 3.33 30 NAD
29 83 F 4 5.25 30 NAD
41 91 F 4 4.82 29 NAD
40 91 F 2 3.8 29 NAD
24 86 F 3 2.92 22 MCI
17 86 F 3 6.17 30 MCI
9 87 M 5 6.17 24 MCI
35 94 M 1 3.87 27 MCI
45 95 F 5 5.30 24 MCI
12 82 F 6 5.92 17 LAD
39 90 M 6 4.17 14 LAD
37 88 F 5 4.50 10 LAD
10 82 F 6 4.58 -5 LAD
40 96 F 6 4.50 20 LAD
Details of the brain samples used in the study are provided in this table. PMI indicates post mortem interval.  MMSE 
indicates clinical assessment using The Mini Mental State Examination. NAD: Non-Alzheimer’s Disease (normal samples); 
MCI: Mild Cognitive Impairment; LAD: Late-stage Alzheimer ’s disease.
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Consensus motif analysis of identified 
phosphorylation sites
Mass spectrometry provides site localization of 
phosphorylated peptides as well as surrounding sequence 
information, which enables consensus motif analysis. Most 
kinases phosphorylate residues within a specific consensus 
motif; determining overrepresented consensus motifs can 
be an indication of changes in kinase activity. Consensus 
motif analysis identified several phosphopeptides that 
were phosphorylated within the growth associated Histone 
H1 kinase substrate motif in B103-695 cells but not in 
B103 cells, suggesting increased activity of this kinase in 
APP-695 expressing cells (Figure 1). Growth-associated 
Histone H1 kinase has been shown to be involved in 
regulating mitotic entry [33], suggesting altered cell cycle 
regulation in B103-695 cells.
APP expressing cells show increased 
phosphorylation of Histone H4 at ser47
The normalized ratio of phosphoSer47-Histone 
H4 showed a statistically significant 1.89-fold increase 
in B103-695 cells compared to B103 cells and was 
selected for further validation. Histone H4 is involved 
in chromatin structure and function and modification of 
Histone H4 influences both dynamic and long-term gene 
expression. Histone H4 is phosphorylated at Ser47 by p21-
protein-activated kinase 2 (Pak2) [34]. Pak2 is activated 
upon phosphorylation at Ser141 [35]. We observed a 
slight increase in phosphorylation of Pak2 at Ser141 
(1.15-fold increase after normalization to total Pak2) in 
B103-695 cells by phosphoproteomics (data not shown). 
The extracted ion chromatogram (XIC) for the SILAC 
heavy and light labeled Ser47 phosphorylated Histone H4 
peptide identified by LC-MS/MS analysis, as well as their 
base peak chromatograms, are shown in Figure 2A and 
2B, respectively. The area under the curve for each XIC is 
representative of peptide abundance, which is significantly 
Figure 2: Mass spectrometry identified increased phosphorylation of Histone H4 at Ser47 in B103-695 cells. A. Extracted 
Ion Chromatogram for “Light” (top) and “Heavy” (bottom) Histone H4 peptide RpSGLIYEETR. b. Base peak chromatogram showing 
isotope clusters for both “Light” and “Heavy” peptides with monoisotopic masses labelled. c. Annotated MS/MS spectra of Histone H4 
peptide showing phosphorylation detected at Ser47.
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greater in the heavy labeled peptides from B103-695 
cells. The annotated MS/MS spectra showing the amino 
acid sequence determined by LC-MS/MS of the Ser47 
phosphorylated Histone H4 peptide is shown in Figure 2C. 
Increased phosphorylation of Ser47-Histone H4 in B103-
695 cells was validated by western blot analysis of nuclear 
fractions from B103 and B103-695 samples (Figure 3A).
Since we observed significant changes in Histone 
H4 phosphorylation in APP expressing cells, we evaluated 
if similar changes occur in Aβ treated neurons and human 
AD brain samples. Primary cortical neurons were treated 
with 5µM oligomeric Aβ42 for 24 hours, and analyzed 
using the phospho-specific Histone H4 antibody, which 
showed a significant increase in phosphorylation of 
Figure 3: APP expressing cells, Aβ-treated neurons and AD samples show increased phosphorylation of Histone H4 at 
serine 47. A. B103-695 cells show increased phosphorylation of Ser47 Histone H4: Nuclear fractions isolated from B103 and B103-695 
cells were analyzed using P-Histone H4 Ser47 (top panel) antibodies. Blot was reprobed with total Histone H4 antibody for normalization 
(bottom panel). The bar graph shows ratio of P-Histone H4 to total Histone H4. b. Neurons treated with Aβ show increased phosphorylation 
of Histone H4 at Ser 47: Primary cortical neurons were treated with 5µM Aβ for 24hr and samples were analyzed by western blot using 
Ser 47 P-Histone H4 antibody (top panel). Blots were reprobed with total Histone H4 antibody for normalization (bottom panel). The bar 
graph shows ratio of P-Histone H4 to total histone H4. c. Human MCI and AD samples show increased levels of P-Histone H4 compared 
to non-AD: Equal amounts of proteins from human brain samples (shown in Table 2) analyzed using PHF-1 (top panel) and 6E10 (middle 
panel) antibodies show increased levels of P-tau (top panel) and Aβ (middle panel) in LAD samples compared to MCI and non-AD. Actin 
antibody was used for normalization (bottom panel). d. P-Histone H4 Ser47 is significantly increased in LAD brain samples: Blots from 
the human samples were reprobed with P-Histone H4 (top panel) and total Histone H4 (bottom panel) antibodies, which showed a tendency 
towards increase in Ser47 P-Histone H4 in MCI and significant increase in LAD; bar graph shows ratio of P-Histone H4 to total Histone 
H4. *p value < 0.05.
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Figure 4: APP expression and Aβ treatment increase the levels of PCTAIRE-2 and PCTAIRE-3 in cells. Western blot 
analysis shows that PCTAIRE-2 and PCTAIRE-3 are significantly increased in A. B103-695 cells compared to B103 cells and b. primary 
neurons treated with Aβ compared to vehicle treated controls. The bar graphs to the right of the blots show data normalized to GAPDH 
levels in B103 and B103-695 cells and actin in primary neurons. *p value < 0.05. c. and d. Primary cortical neurons were treated with or 
without 1, 2.5 and 5 µM Aβ for 24 hr and co-immunostaining analysis was performed using (C) PCTAIRE-2 or (D) PCTAIRE-3 and Tau1 
antibodies. Hoechst was used to visualize the nuclei. Neurons treated with Aβ show increased nuclear and perinuclear staining.
Figure 5: Aβ affects PCTAIRE-2 and PCTAIRE-3 cellular distribution in an APP-dependent manner. B103 and B103-
695 cells were treated with 5µM Aβ for 24hr and immunostaining analysis was performed using A. PCTAIRE-2 or b. PCTAIRE-3 and 
α-tubulin antibodies. Hoechst was used to visualize the nuclei. We observed an increase in nuclear staining in B103-695 cells following Aβ 
treatment, while APP-null B103 cells did not show any significant change in staining. 
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Histone H4 at Ser47 while total Histone H4 levels were 
unaltered (Figure 3B). Next we tested if similar changes in 
Histone H4 phosphorylation occur in the MCI or AD brain 
samples. Western blot analysis with Aβ-directed 6E10 and 
PHF-1 (Ser396/Ser404) P-tau antibodies were performed 
to validate that the MCI and LAD brain samples indeed 
show increased levels of Aβ and/or hyperphosphorylation 
of tau compared to the NAD samples (Figure 3C; 
specifications of the samples are provided in Table 1). 
Reprobe of the blots with the Ser47-specific P-Histone H4 
antibodies showed an increase in P-Histone H4 levels in 
MCI, with significant increase in LAD, compared to the 
NAD samples (Figure 3D). Total levels of H4 appeared 
to be unaltered between the various brain samples. These 
data imply that phosphorylation of Histone H4 at Ser47 
is a disease-specific modification and this might have 
implications in advancement of pathology development 
in AD. 
Increased expression of PctAIre-2 and 
PctAIre-3 in APP-expressing cells
Phosphopreoteome analysis showed that 
PCTAIRE-2 (CDK17) and PCTAIRE-3 (CDK18), 
members of the cyclin-dependent kinase (Cdk) family, are 
Figure 6: PctAIre-2 and PctAIre-3 levels in Ad transgenic mice and human Ad brains. Brain extracts from Ntg 
(non-transgenic) and PS/APP mice were analyzed using A. PCTAIRE-2 and c. PCTAIRE-3 antibodies. PCTAIRE-2 showed a significant 
increase in the PS/APP mice. GAPDH was used to normalize the blots and ratios are shown in the bar graphs. Co-immunostaining analysis 
of brain sections from the mice using 6E10 (recognizing full-length APP and Aβ) and PCTAIRE antibodies reveals increased localization 
of b. PCTAIRE-2 and d. PCTAIRE-3 to amyloid plaques in PS/APP transgenic mice. e. Analysis of brain lysates from human NAD, MCI 
and LAD samples show increased levels of PCTAIRE-2 in MCI and LAD and PCTAIRE-3 in LAD. Actin was used for normalization and 
the intensity ratios are shown in the bar graph. *p value < 0.05. 
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differentially phosphorylated in B103-695 cells compared 
with B103 cells (Table 2). PCTAIRE-2 and PCTAIRE-3 
were not identified in our initial proteomic analysis of 
B103 and B103-695 cells [18], but their non-normalized 
phosphosite ratios showed significant increases in 
phosphorylation. PCTAIRE-2 showed increased 
phosphorylation at Ser146 (1.86-fold) and Ser180 (2.27-
fold). PCTAIRE-3 showed increased phosphorylation 
at Ser66 (3.5-fold) and Ser109 (3.85-fold). Western blot 
analysis revealed that expression of both PCTAIRE-2 and 
PCTAIRE-3 were significantly increased in B103-695 
cells compared to B103 cells (Figure 4A).
Aβ treated neurons show altered cellular 
distribution and enhanced expression of 
PctAIre-2 and PctAIre-3
To determine if Aβ affects expression or cellular 
distribution of the PCTAIRE proteins we next analyzed 
primary neurons treated with or without Aβ. Cortical 
neurons were treated with oligomeric Aβ42 for 24 hours 
and analyzed by western blot and immunostaining. Western 
blot analysis revealed a significant increase in levels of 
both PCTAIRE-2 and PCTAIRE-3 following treatment 
with 5µM Aβ for 24 hours (Figure 4B). Immunostaining 
Table 2: Selected proteins that showed significant change in phosphorylation in B103-695 compared to B103
Protein name Gene name Protein
Amino 
Acid Pos.
Median 
ratio Variance
Median 
Protein 
ratio
normalized 
Median
Heat shock 
protein beta-1 Hspb1 P42930 S 86 2.90 0.35 0.64 4.50
Heat shock 
protein beta-1 Hspb1 P42930 S 115 2.04 0.08 0.64 3.16
A-kinase 
anchor protein 
12
Akap12 Q5QD51 S 507 1.79 0.36 0.73 2.46
Cyclin-
dependent 
kinase 17
Cdk17 O35381 S 146 1.86 0.21 N/A N/A
Cyclin-
dependent 
kinase 17
Cdk17 O35381 S 180 2.27 0.92 N/A N/A
Cyclin-
dependent 
kinase 18
Cdk18 O35382 S 109 3.85 0.15 N/A N/A
Cyclin-
dependent 
kinase 18
Cdk18 O35382 S 66 3.5 0.099 N/A N/A
Histone H4 Hist1h4b P62804 S 47 2.24 0.018 1.18 1.90
Myristoylated 
alanine-rich 
C-kinase 
substrate
Marcks P30009 T 143 0.39 0.002 N/A N/A
Myristoylated 
alanine-rich 
C-kinase 
substrate
Marcks P30009 S 27 0.25 6.47E-4 N/A N/A
Myristoylated 
alanine-rich 
C-kinase 
substrate
Marcks P30009 S 138 0.26 2.17E-5 N/A N/A
Cell division 
cycle protein 
20
Cdc20 Q62623 T 106 2.15 0.004 0.96 2.25
Selected phosphoproteins of interest that showed significant change in phosphorylation in B103-695 cells compared to 
the APP-null B103 cells and the amino acid position (Pos.) are provided in this table. Normalized and non-normalized 
phosphosite ratios were analyzed using Significance A with a Benjamini-Hochberg q-value cutoff of 0.05, protein ratios 
with q-values ≤ 0.05 in two out of three biological replicates were considered significant.
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of these neurons treated with 1µM, 2.5µM, and 5µM 
oligomeric Aβ42 showed dose-dependent alteration of 
PCTAIRE-2 and PCATIRE-3 expression and cellular 
distribution. Control neurons treated with DMSO exhibited 
basal, cytoplasmic staining of PCTAIRE-2 whereas those 
treated with even the lowest concentration of Aβ showed 
enhanced PCTAIRE-2 staining that accumulates both in 
the nuclear and perinuclear areas (Figure 4C). PCTAIRE-3 
staining in the neurons showed reduced levels compared 
to that of PCTAIRE-2, agreeing with our western blot 
analysis. In control DMSO treated neurons, PCTAIRE-3 
exhibited basal, punctate nuclear staining (Figure 4D, 
top row). Upon Aβ treatment, expression of PCTAIRE-3 
was increased, as indicated by enhanced staining, which 
appeared to localize to not only nuclear regions, but also 
to the cell body in a fibrillar pattern (Figure 4D).
Aβ-mediated induction in PCTAIRE-2 and 
PctAIre-3 is dependent on APP expression
Aβ-mediated cell toxicity has been shown to depend 
on APP expression on the cellular membrane [36]. To 
examine both the independent and concerted roles of Aβ 
and APP in inducing expression of PCTAIRE-2 and 3, we 
treated B103 and B103-695 cells with 5μM oligomeric 
Aβ42 for 24 hours and analyzed for changes in expression 
and localization of PCTAIREs. DMSO (vehicle) treated 
B103 cells appeared to have focused, perinuclear staining 
with PCTAIRE-2, and Aβ treatment did not appear to 
affect the staining in the perinuclear area (Figure 5A, 
top 2 rows). B103-695 cells treated with vehicle showed 
staining for PCTAIRE-2 spread throughout the cell and, 
upon Aβ treatment, appeared to show increased staining 
in the nucleus (Figure 5A, bottom 2 rows). Similar to 
PCTAIRE-2, PCTAIRE-3 also showed slight alterations 
in staining in B103 cells exposed to Aβ, with the vehicle-
treated control cells showing condensed perinuclear 
staining, which became more compact and intense after 
Aβ treatment (Figure 5B, top 2 rows). In B103-695 cells, 
vehicle treated cells showed perinuclear PCTAIRE-3 
staining with light punctate staining in the nucleus (Figure 
5B, bottom 2 rows). This staining became significantly 
enhanced upon Aβ treatment, with PCTAIRE3 showing 
increased staining in the nucleus and in the perinuclear 
area (Figure 5B). These data suggest that APP and Aβ play 
an equal and important role in expression of PCTAIRE-2 
and PCTAIRE-3 and under pathogenic conditions the 
increased levels of Aβ act together with APP to exacerbate 
its cytotoxic effects on cells.
brains from Ad transgenic mice and Ad human 
show increased expression of PctAIre-2 and 
PctAIre-3
Our results show that expression of both 
PCTAIRE-2 and 3 are significantly increased in B103-
695 cells compared to APP-null B103 cells and primary 
neurons treated with oligomeric Aβ. These data suggest 
that either APP or its pathogenic Aβ metabolite is able 
to induce the expression of these cdks. To test if these 
changes occur in vivo we analyzed brain samples from 
AD transgenic mice as well as those from non-AD, MCI 
and late AD human subjects (the specifications of the 
human samples are provided in Table 1). The brains from 
9 month old PS/APP double transgenic AD mice were 
examined by western blot and immunostaining analyses 
using both PCTAIRE-2 and PCTAIRE-3 antibodies. PS/
APP transgenic mice demonstrate accelerated plaque 
pathology and increased accumulation of Aβ42 in the 
cerebral cortex and hippocampus at 6 months age [37]. 
PS/APP transgenic mice showed a significant increase in 
PCTAIRE-2 expression compared with non-transgenic 
mice, while PCTAIRE-3 expression was only slightly 
increased (Figure 6A and 6B). Immunostaining analysis 
for PCTAIRE-2 and PCTAIRE-3 also revealed increased 
expression in PS/APP mice compared to their non-
transgenic (non-Tg) littermates (Figure 6C and 6D) and 
showed strong localization of PCTAIRE-2 staining to 
the dense core of the amyloid plaques, as detected by co-
staining with 6E10 antibody (Figure 6C). Similar to the 
results from western blot analysis, PCTAIRE-3 staining 
was weaker in PS/APP mice as compared to PCTAIRE-2, 
and it showed punctate staining within the amyloid 
plaques in these brain sections (Figure 6D). Signifying the 
results from the cell lines, neurons and mouse models of 
AD, analysis of human brain samples from MCI and AD 
patients showed that PCTAIRE-2 and PCTAIRE-3 levels 
are significantly increased in AD individuals (Figure 6 E 
and 6F). PCTAIRE-2 expression was also significantly 
increased in MCI brain, suggesting that this particular cdk 
might play a relevant role in disease advancement.
dIscussIon
The results presented here show identification of 
novel downstream targets of APP and/or Aβ that might 
play a role in APP-dependent neurodegeneration in AD. 
The results from this study are summarized in a schematic 
shown in Figure 7. A comprehensive phosphoproteomic 
analysis of B103 and B103-695 cells resulted in the 
identification of both changes in phosphorylation and 
expression of proteins in response to APP expression. 
Selected, significant differentially phosphorylated proteins 
listed in Table 2 shows that several of these proteins are 
associated with cell division cycle. For example, AKAP12 
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has been shown to physically bind cyclin D1 in the 
cytoplasm and inhibit its nuclear translocation, which is 
necessary for its function in cell cycle progression [38, 
39]. AKAP12 is phosphorylated at Ser507/515 by protein 
kinase C (PKC) and this modification has been shown to 
disrupt the cyclin binding motifs present on AKAP12 [38]. 
Our finding that Ser507 phosphorylation on AKAP12 is 
enhanced upon APP expression implies that APP mediates 
inactivation of AKAP12, thereby allowing nuclear 
translocation of cyclin D1 and G1 progression. 
Phosphoproteome analysis of B103-695 cells also 
revealed increased phosphorylation of heat shock protein 
beta 1 (HspB1) at Ser15 (3.16-fold) and Ser86 (4.49-
fold). The HpsB1 protein is a molecular chaperone that 
belongs to a family of survival proteins that modulate 
cell proliferation and cytoskeletal reorganization [28-30]. 
The phosphorylation status of HspB1 is thought to dictate 
both its structure and function [40, 41] and has been 
shown to occur in response to activation of a number of 
kinases [40]. An in vitro study using dorsal root ganglion 
sensory neuron model has shown that phosphorylation 
of HspB1 can induce cytoskeletal reorganization and 
neurite outgrowth [42]. In another study, stress stimuli 
were shown to promote phosphorylation of HspB1 at 
Figure 7: Potential APP or Aβ-mediated mechanisms in neurodegeneration. The figure shows a schematic of the mechanism 
by which APP or Aβ may be inducing neuropathology development in AD. The results described here imply that APP or Aβ (in an APP-
dependent manner) induces phosphorylation and/or expression of proteins that play a role in cell cycle (PCTAIREs) or transcriptional 
(P-Histone H4) dysregulation in neurons. This could potentially lead to additional phosphorylation on Tau or APP, contributing to 
neurofibrillary tangle formation or plaque pathology development, or promote expression of genes that play a role in AD pathology 
development. Interfering with these signaling cascades might prevent APP-dependent activation and promotion of neurodegeneration by 
these downstream targets of APP.
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Ser15 and Ser86 and influence its subcellular localization 
in hippocampal rat neurons, increasing its recruitment to 
dendrites and synaptic sites [43]. APP is known to induce 
neurite outgrowth in B103 cells [19] and it is possible that 
this is partly mediated through enhanced phosphorylation 
of HspB1. APP expression was not always associated 
with enhanced phosphorylation on proteins. For example, 
B103-695 cells showed a significant reduction in the 
phosphorylation of myristoylated alanine-rich C-kinase 
substrate (MARCKS) at multiple sites. MARCKS is 
phosphorylated by kinases such as PKC and CaM-
Kinases and has been shown to elicit cell type specific 
phosphorylation changes in the AD brains, where neurons 
showed a decrease and microglia showed an increase in 
phosphorylation [32]. The mechanism behind the reduced 
phosphorylation of MARCKS observed in B103-APP cells 
is unclear at this point. 
Phosphorylation of Histone H4 at Ser47, which 
was significantly increased in B103-695 cells compared 
to B103 cells is novel, has not previously been reported 
in AD, and this was confirmed by western blot analysis. 
Histone H4 Ser47 phosphorylation has been shown to 
regulate nucleosome assembly, promoting assembly 
of H3.3-H4 by the histone chaperone HIRA, while 
inhibiting CAF-1 mediated assembly of H3.1-H4 [34]. 
While Histone variant H3.3 differs from H3.1 by only 
5 amino acids, the functions of H3.3 are unique and 
cannot be substituted by H3.1 [44-46]. H3.3 is localized 
to gene bodies of actively transcribed genes, and this 
positively correlates with gene expression [47, 48]. Ser47 
on Histone H4 is phosphorylated by Pak2, a member of 
the p21-activated serine/threonine kinase (Pak) family 
[34]. Additionally, phosphatases PP1α, PP1β, and Wip1 
also regulate P-Ser47-Histone H4 levels [49] through 
activation of Pak2; depletion of PP1α and PP1β result 
in increased Pak2 phosphorylation at Ser141 [35, 49]. 
Pak2 phosphorylation at Ser141 was identified in our 
phosphoproteomic dataset but it was not significantly 
increased in B103-695 cells, suggesting that additional 
mechanisms are involved in the observed increase in 
P-Ser47 Histone H4. LAD human brain samples showed 
a significant increase in phosphorylation of Histone H4 at 
Ser47, whereas NAD showed no specific phosphorylation 
and MCI showed slightly enhanced phosphorylation. 
Furthermore, increased phosphorylation was also observed 
in Aβ-mediated signaling is treated primary neurons, 
which provides strong evidence that APP and/or Aβ are 
involved promotion of Histone H4-Ser47 phosphorylation. 
While the significance of this in AD progression has not 
been determined, this data suggests that APP and its 
metabolites may influence Histone H4-associated gene 
function, which may have consequences in AD.
PCTAIRE-2 and PCTAIRE-3 were also 
differentially phosphorylated in B103-695 cells compared 
to APP-null B103 cells, and this was confirmed by 
western blot analysis. Phosphorylation of PCTAIRE-2 
at Ser146 and Ser180 has been identified in previous 
phosphoproteomic studies of human tissue [50-52]. 
Phosphorylation of PCTAIRE-3 at Ser66 has been shown 
previously in rats [53]. Additionally, phosphorylation of 
PCTAIRE-3 at Ser12, Ser66, and Ser109 has been shown 
in HEK293T human cells [54]. We did not confirm the 
changes in levels of phosphorylation at these residues due 
to lack of phospho-specific antibodies, only total protein 
expression was examined.
PCTAIRE-2 expression was significantly increased 
in PS/APP transgenic mice, while PCTAIRE-3 showed 
only slight increase. Immunostaining analysis of the Tg-
AD mouse brain slices showed that both PCTAIRE-2 and 
3 were localized to the dense, amyloid plaques suggesting 
a possible role for these kinases in Aβ-dependent 
pathology development. This is supported by the results 
from the primary neurons treated with oligomeric Aβ42, 
which showed an increase in expression of these two 
proteins, upon both immunostaining and western blot 
analyses. Furthermore, the finding that the changes 
in PCTAIRE expression and localization were more 
prominent in Aβ-treated APP expressing B103 cells imply 
that APP might act as a receptor for Aβ mediated signaling 
and deregulation of these less characterized Cdk family 
members. The findings that MCI brains show increased 
expression of both PCTAIRE-2 and PCTAIRE-3 and 
LAD brains show an increase in both PCSTAIRE-2 and 
PCSTIARE-3 may imply that PCSTAIRE-2 may act early 
in the development of the disease and persists through the 
progression while PCTAIRE-3 is associated with the late 
stage pathological changes in AD. 
PCTAIRE kinases are categorized by a serine 
to cysteine mutation in the PSTAIRE cyclin binding 
consensus motif of the cell cycle associated well known 
CDKs [55]. PCTAIRE-2 and PCTAIRE-3 are Cdc-2-
related serine/threonine kinases; however their functions 
remain to be discovered. Whether PCTAIREs are involved 
in cell cycle regulation or are regulated by the cell cycle 
is yet to be determined. A study by Meek and colleagues 
(2004) identified PCTAIRE-2 and PCTAIRE-3 as 14-3-3 
binding partners, and furthermore PCTAIRE-2 interacted 
with 14-3-3 in a cell cycle-regulated manner. Other 
studies, however, indicate that PCTAIREs may function 
independently of the cell cycle [56, 57]. PCTAIRE-2 is 
expressed in terminally differentiated neurons and has 
been found to phosphorylate Ser and Thr residues of 
Histone H1 [58]. PCTAIRE-3 is expressed in the brain 
and testis. A study by Herskovits and Davies (2006) 
found increased levels of PCTAIRE-3 in the temporal 
cortex of AD brains compared with control brains, where 
it co-localized with paired helical filaments (PHFs). 
Furthermore, they showed that PCTAIRE-3 is indirectly 
involved in promoting phosphorylation of tau at residues 
T231 and S235, early modifications in AD pathogenesis. 
A separate study recently found that PCTAIRE-3 can 
be activated through association with Cyclin A and/or 
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phosphorylation by Protein Kinase A (PKA) [54]. PKA 
increased phosphorylation of PCTAIRE-3 at Ser12, 
Ser66, and Ser109, though only phosphorylation of 
Ser12 appeared to increase kinase activity; the function 
of PCTAIRE-3 phosphorylation at S109 and S66 by 
PKA is still unknown [54]. Interestingly, PKA was also 
found by Herskovits and Davies (2006) in the same PHF 
fractions that PCTAIRE-3 was present. Bioinformatic 
analysis of our previous proteomic study of B103 and 
B103-695 cells have shown increased PKA signaling in 
B103-695 cells [18] and the increased phosphorylation of 
PCTAIRE-3 at S109 and S66 in B103-695 cells in this 
phosphoproteomic dataset, imply a role for PKA in the 
observed phosphorylations on PCTAIRE. 
While further investigation is required to determine 
the functional role of the specific phosphorylations or 
expression changes in proteins described here to AD 
neurodegeneration and pathology development, the 
comprehensive phosphoproteomic dataset, together with 
the validation studies, provide insights into pathways that 
may be affected by APP expression, thereby providing a 
foundation for future mechanistic studies. Based on the 
results from A-β treated neurons, AD transgenic mice, and 
brain samples from AD and MCI patients, we hypothesize 
that the increased expression or posttranslational 
modifications of these identified proteins may play a 
relevant role in AD pathogenesis and timely inference with 
these modifications could prevent further progression of 
AD. 
MAterIAls And MetHods
Materials
B103 and B103-695 rat neuroblastoma cells were 
obtained from Dr. David Schubert (Salk Institute, La 
Jolla, CA). Tissue culture reagents, Hoechst 33258, and 
Alexa Fluor 488 and 594 dyes were purchased from Life 
Technologies (Carlsbad, CA). Amino acids for SILAC 
labeling were purchased from Cambridge Isotopes 
(Tewksbury, MA). Protein assay 660 reagent, ionic 
detergent compatibility reagent (IDCR), Halt Protease 
Cocktail Inhibitor, and chemiluminescence reagents were 
purchased from Pierce (Rockford, IL). Poly-L-Lysine 
(PLL) and antibodies against α-tubulin and β-actin were 
purchased from Sigma-Aldrich (St. Louis, MO). Anti-APP 
antibody (6E10) was from Covance (Princeton, NJ). Anti-
Tau1 antibody and FASP 30kDa regenerated cellulose 
filters were purchased from Millipore (Billerica, MA). 
Antibodies against PCTAIRE-2 and PCTAIRE-3 were 
purchased from Santa Cruz (Dallas, TX), anti-GAPDH 
and anti-histone H4 antibodies were purchased from Cell 
Signaling (Danbers, MA), and anti-phosphoSer47-histone 
H4 antibody was purchased from Abcam (Cambridge, 
MA). Recombinant Aβ (1-42) peptide was purchased from 
American Peptide Company (Sunnyvale, CA). Sprague 
Dawley E16 time-pregnant rats were obtained from Harlan 
Laboratories (Indianapolis, IN). Anti-PHF-1 (phospho-tau 
Ser396/Ser404) antibody was kindly provided by Dr. Peter 
Davies (Albert Einstein College of Medicine, Manhasset, 
NY). Trypsin/Lys-C was purchased from Promega 
(Madison, WI) and PolyMAC phosphoenrichment kits 
were from Expedeon (San Diego, CA). C18 SPE desalting 
columns were purchased from Thermo Fisher (Waltham, 
MA) and strong cation exchange columns were from 
PolyLC Inc (Columbia, MD).
cell culture and sIlAc labeling
B103 and B103-695 cells were grown in SILAC 
DMEM:F12 SILAC media supplemented with 10% 
dialyzed FBS, Pen-Strep-Glutamine, and either unlabeled 
L-arginine and L-lysine for B103 or heavy labelled 13C
6
-
L-lysine 2HCl and 13C
6
-15N
4
-arginine HCl for B103-
695 cells. Cells were grown for 5 doublings to achieve 
>99% incorporation of labeled amino acids before being 
collected.
sample preparation and phosphopeptide 
enrichment
Cells were lysed in 100mM Tris-HCl (pH 7.6), 4% 
SDS, 100mM DTT and Halt Protease Cocktail Inhibitor 
and incubated at 95˚C for 5 minutes, followed by 
sonication at 20% amplitude. Protein was quantified using 
the Pierce 660 assay supplemented with ionic-detergent 
compatibility reagent. Experiments were performed in 
triplicate. A total of 1.2mg B103 and 1.2mg B103-695 
lysate were combined and processed by filter-aided sample 
preparation (FASP) [59], followed by digestion with 
Trypsin/Lys-C at 1:50 (w:w; protease:protein) overnight at 
37˚C. Peptides were desalted using C18 SPE columns with 
a Supelco vacuum manifold and dried before resuspension 
in mobile phase A prior to fractionation. Peptides were 
fractionated on a Dionex U3000 HPLC system with a 
200 x 4.6mm i.d. strong cation-exchange (SCX) column 
packed with 5µm 200Å polySULFOETHYL A-SCX 
material. One minute fractions were collected using a 
45 minute gradient (15-200mM ammonium formate, pH 
3-6.5, 25% acetonitrile) at a flow rate of 1ml/minute.
Peptide fractions were enriched for phosphopeptides 
using PolyMAC, a nanopolymer titanium-based 
enrichment, as described by the manufacturer. Following 
PolyMAC enrichment the samples were dried and 
resuspended in 0.25% formic acid for LC-MS/MS 
analysis.
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lc-Ms/Ms
Peptides were analyzed on a Q-Exactive Plus 
(Thermo Fisher Scientific) following with a 75µm x 
50cm C18 reversed-phase(RP)-UPLC column (Dionex) 
using a 90 minute gradient on an EASY-nLC 1000 system 
(Thermo Fisher Scientific). Full MS survey scans used 
a resolving power of 60,000, selecting the top ten most 
abundant ions for MS/MS fragmentation and analysis.
database searching and consensus motif analysis
Raw data files were processed in MaxQuant (version 
1.5.0.30, http://www.maxquant.org) and searched against 
the UniprotKB Rattus norvegicus protein sequence 
database. The search parameters included a constant 
modification of cysteine by carbamidomethylation and 
variable modifications of methionine oxidation and 
phosphorylation of serine, threonine, and tyrosine.
Statistical analysis was carried out using Perseus 
software (version 1.5.0.31, http://141.61.102.17/
perseus_doku). Statistically significant changes in 
phosphopeptide abundance were determined using 
Significance A, an outlier test with a threshold p-value 
of 0.05. Only phosphopeptides identified in at least 2 
biological replicates with a minimum ratio count of 2 
were used for statistical analyses. Phosphopeptide ratios 
were normalized against total protein ratios from our 
previous SILAC-based proteomic analysis of B103 and 
B103-695 cells. Both non-normalized and normalized 
median phosphopeptide ratios were analyzed to account 
for potential changes in phosphorylation of proteins that 
were not identified in our initial proteomic analysis.
Consensus motif analysis was performed using 
Scaffold PTM (version 2.1.3) to determine overrepresented 
kinase motifs surrounding phosphorylation sites, using the 
method developed by Gygi and Schwartz [20], as well as 
potential enzyme recognition sites.
transgenic mouse tissue
Heterozygous PDGF-hAPP (V717F) mice (Swiss-
Webster x C57BL/6) were crossed with PDGF-hPS1 
(M146L) heterozygotes (Swiss-Webster x C57BL/6) 
to generate APP+/-/PS1+/- genotyped mice. In this study 
we used these transgenic mice with age-matched non-
transgenic (Ntg) mice to serve as control. Mice were 
anesthetized at 9 months with pentobarbital (10mg/kg 
body weight) and perfused with a saline solution. Brains 
were dissected out and half of each brain was fixed with 
4% paraformaldehyde and the other half was used for 
protein extraction using RIPA lysis buffer. Brains were 
processed prior to immunohistochemical analysis as 
previously described [60]. Brain sections were prepared 
using a freezing stage microtome and then stored at 4°C in 
phosphate buffered saline (PBS) containing 0.02% sodium 
azide.
Oligomeric Aβ42 preparation
1mg of monomeric Aβ42 was dissolved in 1ml 
trifluoroacetic acid and lyophilized in 100μg aliquots. 
Lyophilized Aβ42 was solubilized in sterile DMSO to 
a concentration of 5mM and then diluted to 100μM in 
DMEM media and left a 4°C overnight.
b103 culture and treatment
B103 and B103-695 cells were cultured in 
Advanced DMEM/F12 supplemented with 10% FBS 
and 1% Penicillin/Streptomycin at 37°C and 5% CO2 as 
previously described [61]. Cells were plated on 8-chamber 
slides coated with PLL at a density of approximately 5x104 
cells per well. After 24 hours, cells were treated with either 
5μM Aβ42 or DMSO, which served as a vehicle control.
Primary neuron culture and treatment
Primary neurons were cultured in Neurobasal 
Medium supplemented with 2X B-27, 1% Penicillin/
Streptomycin and 2mM glutamine. Neurons were 
cultured in 8-chamber glass slides and 100mm cell culture 
dishes coated with PLL. Briefly, E18 pregnant rats were 
euthanized by phentobarbital injection and feti excised 
and placed in isotonic solution. The meninges were then 
removed and cortices separated. Cortices were triturated 
into a single cell suspension in isotonic buffer and spun 
down at 1500 RPM for 5 mins at 4°C. The neuronal pellet 
was resuspended in 2ml Neurobasal media and filtered 
through a cell strainer. 8-chamber slides were plated with 
~5X104 neurons per well and 100mm dishes were plated 
with ~6X106 neurons. Neurons were fed every third day 
and grown for 5 days prior to treatment. Neurons grown 
on 100mm dishes were treated with either DMSO vehicle 
or 5μM Aβ42 and harvested after 24 hrs. Neurons grown 
on 8-chamber were treated with wither DMSO vehicle or 
incremental concentrations of Aβ42 ranging from 1μM to 
5μM and used for immunostaining analysis.
nuclear fractionation
B103 and B103-695 cells were grown in 
DMEM:F12 as described above, collected and pelleted 
by centrifugation at 500 x g for 15 minutes at 4˚C. Cells 
were resuspended in 1ml of 10mM Tris-HCl (pH 7.4), 
1mM EDTA, 200mM sucrose, and Halt Protease Inhibitor 
Cocktail and subjected to gentle dounce homogenization. 
Nuclei and cell debris were pelleted by centrifugation at 
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900 x g for 10 minutes at 4˚C. The nuclei containing pellet 
was lysed in 100mM Tris-HCl (pH 7.6), 4% SDS, 100mM 
DTT and Halt Protease Cocktail Inhibitor as described 
above. Protein was quantified using the Pierce 660 assay 
supplemented with ionic-detergent compatibility reagent 
before preparing 1μg/µl samples in Laemmli Buffer for 
western blot analysis.
Western blotting
Proteins were selected for validation by western 
blot analysis based on significance as well as function. 
Proteins were separated on an AnyKD SDS-PAGE gel 
(BioRad) and transferred to a PVDF membrane using 
the Trans Turboblot system (BioRad). Membranes were 
blocked in 5% non-fat milk in TBS for 1 hour at room 
temperature. Primary antibodies specific for phospho-
Serine47-Histone H4 (rabbit polyclonal, 1:500), Histone 
H4 (mouse monoclonal, 1:1000), PCTAIRE-2 and 
PCTAIRE-3 (rabbit polyclonal, 1:1000), actin (mouse 
monoclonal, 1:7000) and GAPDH (rabbit monoclonal, 
1:5000) were diluted in 5% BSA-TBS, containing 0.05% 
sodium azide and incubated overnight at 4˚C. Membranes 
were washed and then incubated with appropriate 
corresponding secondary antibodies, donkey anti-rabbit 
HRP-conjugated or goat anti-mouse HRP-conjugated 
for 1.5 hours at room temperature. After further washes, 
all blots were developed with Pico Chemiluminescence 
reagents, with the exception of pS47-Histone H4 which 
was developed using Femto Chemiluminescence reagents, 
using an Amersham Imager 600RGB (GE Healthcare).
Immunostaining
For immunostaining analysis of mouse brain 
sections, sections were mounted onto superfrost slides 
and rehydrated with TBS for 5 minutes. For antigen 
retrieval, sections were incubated in 10mM citrate 
buffer, pH 6.0 for 10mins at 95°C and cooled to room 
temperature. After washing with PBS, sections were 
incubated with blocking buffer (10% normal goat serum 
(NGS) in TBST with 0.02% sodium azide) for 2hrs at 
room temperature. Sections were then incubated with APP 
(6E10) primary antibody (mouse monoclonal 1:500) and 
either PCTAIRE-2 (1:50) or PCTAIRE-3 (1:50) primary 
antibody diluted in 1% BSA-TBST at 4°C in a humidified 
chamber overnight. Next, sections were washed and 
incubated for 2hrs at room temperature with goat anti-
mouse IgG Alexa Fluor 488 (1:1000) and goat anti-rabbit 
IgG Alexa Fluor 594 (1:4000) diluted in blocking buffer. 
After washing, slides were incubated with 1μg/ml Hoechst 
33342 DNA dye in PBS for 3mins. After thorough 
washing, the slides were coverslipped with Fluoro-Gel 
mounting media and analyzed with a Zeiss Fluorescence 
Axio Imager using AxioVision Rel 4.8 software.
For immunostaining analysis of cultured cells, 
they (either B103, B103-695 or primary neurons) were 
fixed with 4% paraformaldehyde for 10mins at room 
temperature and washed with PBS. Following this, 
cells were blocked in blocking buffer for 1hr. B103 
and B103-695 cells were then incubated overnight at 
4°C with α-tubulin (mouse monoclonal, 1:1000) and 
either PCTAIRE-2 (1:50) or PCTAIRE-3 (1:50) primary 
antibodies diluted in 1%BSA-TBST containing 0.02% 
sodium azide. Neurons were incubated with Tau 1 (mouse 
monoclonal, 1:500) and either PCTAIRE-2 (1:50) or 
PCTAIRE-3 (1:50) primary antibodies. After incubation, 
cells were washed and incubated in goat anti-mouse IgG 
Alexa Fluor 488 (1:1000) and goat anti-rabbit IgG Alexa 
Fluor 594 (1:4000) diluted in blocking buffer. After brief 
washing, cells were incubated for 3mins with 1μg/ml 
Hoechst 33342 DNA dye. Cells were thoroughly washed 
and mounted using Fluoro-Gel before being visualized and 
analyzed as mentioned above.
Human brain tissue
Human brain tissue was obtained from Dr. David 
Cribbs at the University of California Irvine Alzheimer’s 
Disease Research Center. Brain samples were de-
identified and categorized based on post-mortem Braak 
stage and pre-mortem clinical MMSE score. Additional 
information on this brain material is detailed in Table 1. 
Samples were categorized based on disease stage; Non-
AD (NAD), Mild Cognitive Impaired (MCI) or late-AD 
(LAD). Tissue was homogenized in 100mM Tris-HCl (pH 
7.6) containing 4% SDS, 100mM DTT and Halt protease 
inhibitor cocktail, heated at 100°C for 5mins, briefly 
sonicated and centrifuged for 15mins at 14,000 RPM. The 
soluble supernatant fraction was then separated from the 
insoluble pellet, protein concentrations were determined 
using Pierce 660 reagent and equal amounts of proteins 
were used for sample analysis by western blot.
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